{"8e70bc1eeb4aa9cf3920f62c9624f46846335558": [["Dear editor,Since December 2019, a novel disease COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) rapidly spread to over 200 countries and infected over 1.50 million people including 92,798 deaths (data as of April 10, 2020).", [["acute respiratory syndrome coronavirus", "DISEASE", 75, 113], ["deaths", "DISEASE", 221, 227], ["SARS-CoV-2", "ORGANISM", 117, 127], ["people", "ORGANISM", 197, 203], ["people", "SPECIES", 197, 203], ["severe acute respiratory syndrome coronavirus", "SPECIES", 68, 113], ["SARS-CoV-2", "SPECIES", 117, 127], ["a novel disease COVID", "PROBLEM", 33, 54], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 68, 113], ["SARS", "TEST", 117, 121], ["CoV", "TEST", 122, 125], ["severe", "OBSERVATION_MODIFIER", 68, 74], ["acute", "OBSERVATION_MODIFIER", 75, 80], ["respiratory syndrome", "OBSERVATION", 81, 101]]], ["On March 11, the World Health Organization (WHO) characterized COVID-19 as a pandemic, and called for accelerating diagnostics, vaccines, and drugs developments to combat this novel disease.", [["COVID", "TEST", 63, 68], ["vaccines", "TREATMENT", 128, 136], ["drugs", "TREATMENT", 142, 147], ["this novel disease", "PROBLEM", 171, 189]]], ["Apart of the new coronavirus, influenza virus infections have been a consistent threat to the global public health over the years.", [["coronavirus", "DISEASE", 17, 28], ["influenza virus infections", "DISEASE", 30, 56], ["coronavirus", "ORGANISM", 17, 28], ["influenza virus", "ORGANISM", 30, 45], ["influenza virus", "SPECIES", 30, 45], ["influenza virus", "SPECIES", 30, 45], ["the new coronavirus", "PROBLEM", 9, 28], ["influenza virus infections", "PROBLEM", 30, 56], ["new", "OBSERVATION_MODIFIER", 13, 16], ["coronavirus", "OBSERVATION", 17, 28], ["influenza virus", "OBSERVATION", 30, 45], ["global", "OBSERVATION_MODIFIER", 94, 100]]], ["In the United States alone, the Centers for Disease Control and Prevention (CDC) estimates that, so far during the 2019-2020 winter season, there have been at least 39 million illnesses, 400,000 hospitalizations and 24,000 deaths from influenza (https://www.cdc.gov/flu/weekly/index.htm).", [["deaths", "DISEASE", 223, 229], ["influenza", "DISEASE", 235, 244], ["Disease Control", "TREATMENT", 44, 59], ["influenza", "PROBLEM", 235, 244]]], ["Considering the current concomitant circulation of SARS-CoV-2 and influenza virus infections, the exploration of available and viable anti-influenza drugs to treat both diseases is of great interest.Dear editor,Actually, in the early stages of the outbreak of COVID-19, some anti-flu drugs (for example, oseltamivir) have been applied for the treatment of COVID-19 patients 1,2 .", [["SARS", "DISEASE", 51, 55], ["influenza virus infections", "DISEASE", 66, 92], ["COVID-19", "CHEMICAL", 260, 268], ["oseltamivir", "CHEMICAL", 304, 315], ["COVID", "DISEASE", 356, 361], ["COVID-19", "CHEMICAL", 260, 268], ["oseltamivir", "CHEMICAL", 304, 315], ["SARS-CoV-2", "ORGANISM", 51, 61], ["influenza virus", "ORGANISM", 66, 81], ["anti-flu drugs", "SIMPLE_CHEMICAL", 275, 289], ["oseltamivir", "SIMPLE_CHEMICAL", 304, 315], ["patients", "ORGANISM", 365, 373], ["CoV-2", "SPECIES", 56, 61], ["influenza virus", "SPECIES", 66, 81], ["patients", "SPECIES", 365, 373], ["SARS-CoV-2", "SPECIES", 51, 61], ["influenza virus", "SPECIES", 66, 81], ["SARS", "PROBLEM", 51, 55], ["CoV", "TEST", 56, 59], ["influenza virus infections", "PROBLEM", 66, 92], ["the exploration", "TEST", 94, 109], ["viable anti-influenza drugs", "TREATMENT", 127, 154], ["both diseases", "PROBLEM", 164, 177], ["COVID", "TEST", 260, 265], ["some anti-flu drugs", "TREATMENT", 270, 289], ["oseltamivir", "TREATMENT", 304, 315], ["COVID", "TEST", 356, 361]]], ["Previously, we reported that favipiravir (T705), an antiinfluenza drug approved in Japan and China, showed a certain efficacy against SARS-CoV-2 in vitro 3 .", [["favipiravir", "CHEMICAL", 29, 40], ["T705", "CHEMICAL", 42, 46], ["favipiravir", "CHEMICAL", 29, 40], ["T705", "CHEMICAL", 42, 46], ["favipiravir", "SIMPLE_CHEMICAL", 29, 40], ["T705", "SIMPLE_CHEMICAL", 42, 46], ["SARS-CoV-2", "ORGANISM", 134, 144], ["SARS-CoV", "SPECIES", 134, 142], ["an antiinfluenza drug", "TREATMENT", 49, 70], ["SARS", "PROBLEM", 134, 138], ["CoV", "TEST", 139, 142]]], ["In addition, arbidol, an anti-influenza drug targeting the viral hemagglutinin (HA) is being used in a clinical trial against COVID-19 (ChiCTR2000029573) and has been recently added to the Guidelines for the Diagnosis and Treatment of COVID-19 (sixth and seventh editions) in China.", [["arbidol", "CHEMICAL", 13, 20], ["arbidol", "CHEMICAL", 13, 20], ["arbidol", "SIMPLE_CHEMICAL", 13, 20], ["viral hemagglutinin", "ORGANISM", 59, 78], ["arbidol", "TREATMENT", 13, 20], ["an anti-influenza drug", "TREATMENT", 22, 44], ["the viral hemagglutinin (HA)", "TREATMENT", 55, 83], ["COVID", "TEST", 126, 131], ["COVID", "TEST", 235, 240]]], ["A recent retrospective study suggested that arbidol treatment showed tendency to improve the discharging rate and decrease the mortality rate of COVID-19 patients 4 .", [["arbidol", "CHEMICAL", 44, 51], ["arbidol", "CHEMICAL", 44, 51], ["arbidol", "SIMPLE_CHEMICAL", 44, 51], ["patients", "ORGANISM", 154, 162], ["patients", "SPECIES", 154, 162], ["A recent retrospective study", "TEST", 0, 28], ["arbidol treatment", "TREATMENT", 44, 61], ["tendency", "PROBLEM", 69, 77], ["COVID", "TEST", 145, 150]]], ["However, to our knowledge, there has been no systematical analysis about the efficacy of anti-influenza drugs against SARS-CoV-2.Dear editor,In this study, we evaluated six currently available and licensed anti-influenza drugs against SARS-CoV-2.", [["SARS", "DISEASE", 118, 122], ["SARS", "DISEASE", 235, 239], ["SARS-CoV-2", "ORGANISM", 118, 128], ["SARS-CoV-2", "ORGANISM", 235, 245], ["SARS-CoV", "SPECIES", 118, 126], ["SARS-CoV", "SPECIES", 235, 243], ["systematical analysis", "TEST", 45, 66], ["anti-influenza drugs", "TREATMENT", 89, 109], ["SARS", "PROBLEM", 118, 122], ["this study", "TEST", 144, 154], ["anti-influenza drugs", "TREATMENT", 206, 226]]], ["The drugs include arbidol, baloxavir, laninamivir, oseltamivir, peramivir, and zanamivir 5, 6 .", [["arbidol", "CHEMICAL", 18, 25], ["baloxavir", "CHEMICAL", 27, 36], ["laninamivir", "CHEMICAL", 38, 49], ["oseltamivir", "CHEMICAL", 51, 62], ["peramivir", "CHEMICAL", 64, 73], ["zanamivir", "CHEMICAL", 79, 88], ["arbidol", "CHEMICAL", 18, 25], ["baloxavir", "CHEMICAL", 27, 36], ["laninamivir", "CHEMICAL", 38, 49], ["oseltamivir", "CHEMICAL", 51, 62], ["peramivir", "CHEMICAL", 64, 73], ["zanamivir", "CHEMICAL", 79, 88], ["arbidol", "SIMPLE_CHEMICAL", 18, 25], ["baloxavir", "SIMPLE_CHEMICAL", 27, 36], ["laninamivir", "SIMPLE_CHEMICAL", 38, 49], ["oseltamivir", "SIMPLE_CHEMICAL", 51, 62], ["peramivir", "SIMPLE_CHEMICAL", 64, 73], ["zanamivir", "SIMPLE_CHEMICAL", 79, 88], ["The drugs", "TREATMENT", 0, 9], ["arbidol", "TREATMENT", 18, 25], ["baloxavir", "TREATMENT", 27, 36], ["laninamivir", "TREATMENT", 38, 49], ["oseltamivir", "TREATMENT", 51, 62], ["peramivir", "TREATMENT", 64, 73], ["zanamivir", "TREATMENT", 79, 88]]], ["The M2 inhibitors (amantadine and rimantadine) were not considered in this study since they were not recommended for treating influenza by WHO due to drug resistance.", [["amantadine", "CHEMICAL", 19, 29], ["rimantadine", "CHEMICAL", 34, 45], ["influenza", "DISEASE", 126, 135], ["amantadine", "CHEMICAL", 19, 29], ["rimantadine", "CHEMICAL", 34, 45], ["M2", "GENE_OR_GENE_PRODUCT", 4, 6], ["amantadine", "SIMPLE_CHEMICAL", 19, 29], ["rimantadine", "SIMPLE_CHEMICAL", 34, 45], ["The M2 inhibitors", "TREATMENT", 0, 17], ["amantadine", "TREATMENT", 19, 29], ["rimantadine", "TREATMENT", 34, 45], ["this study", "TEST", 70, 80], ["influenza", "PROBLEM", 126, 135], ["drug resistance", "PROBLEM", 150, 165]]], ["First, the cytotoxicity of the compounds in African green monkey kidney cells, Vero E6 (ATCC-1586) was measured by a standard cell counting kit-8 (CCK8) assay.", [["kidney cells", "ANATOMY", 65, 77], ["cell", "ANATOMY", 126, 130], ["ATCC-1586", "CHEMICAL", 88, 97], ["monkey", "ORGANISM", 58, 64], ["kidney cells", "CELL", 65, 77], ["Vero E6", "CELL", 79, 86], ["ATCC-1586", "CELL", 88, 97], ["cell", "CELL", 126, 130], ["kit-8", "GENE_OR_GENE_PRODUCT", 140, 145], ["CCK8", "GENE_OR_GENE_PRODUCT", 147, 151], ["African green monkey kidney cells", "CELL_LINE", 44, 77], ["green monkey", "SPECIES", 52, 64], ["African green monkey", "SPECIES", 44, 64], ["Vero E6 (ATCC-1586", "SPECIES", 79, 97], ["African green monkey kidney cells", "TEST", 44, 77], ["Vero E6 (ATCC", "TEST", 79, 92], ["a standard cell counting kit", "TEST", 115, 143], ["kidney cells", "ANATOMY", 65, 77]]], ["Then, the cells were infected with SARS-CoV-2 at a multiplicity of infection (MOI) of 0.05 in the presence of either compound or dimethyl sulfoxide (DMSO) control.", [["cells", "ANATOMY", 10, 15], ["multiplicity of infection", "DISEASE", 51, 76], ["dimethyl sulfoxide", "CHEMICAL", 129, 147], ["DMSO", "CHEMICAL", 149, 153], ["dimethyl sulfoxide", "CHEMICAL", 129, 147], ["DMSO", "CHEMICAL", 149, 153], ["cells", "CELL", 10, 15], ["CoV-2", "ORGANISM", 40, 45], ["dimethyl sulfoxide", "SIMPLE_CHEMICAL", 129, 147], ["DMSO", "SIMPLE_CHEMICAL", 149, 153], ["SARS-CoV", "SPECIES", 35, 43], ["the cells", "PROBLEM", 6, 15], ["SARS", "PROBLEM", 35, 39], ["CoV", "TEST", 40, 43], ["infection", "PROBLEM", 67, 76], ["dimethyl sulfoxide (DMSO) control", "TREATMENT", 129, 162], ["infected", "OBSERVATION_MODIFIER", 21, 29], ["infection", "OBSERVATION", 67, 76]]], ["The dose-response curves were determined by quantification of viral RNA copy numbers in the supernatant of infected cell at 48 h post infection (p.i.).", [["supernatant", "ANATOMY", 92, 103], ["cell", "ANATOMY", 116, 120], ["cell", "CELL", 116, 120], ["infected cell", "CELL_TYPE", 107, 120], ["response curves", "TEST", 9, 24], ["viral RNA copy numbers", "PROBLEM", 62, 84], ["infected cell", "PROBLEM", 107, 120], ["infection", "PROBLEM", 134, 143], ["viral RNA", "OBSERVATION", 62, 71], ["infected cell", "OBSERVATION", 107, 120], ["infection", "OBSERVATION", 134, 143]]], ["As demonstrated in Fig. 1a , arbidol efficiently inhibited virus infection in vitro.", [["arbidol", "CHEMICAL", 29, 36], ["infection", "DISEASE", 65, 74], ["arbidol", "CHEMICAL", 29, 36], ["arbidol", "SIMPLE_CHEMICAL", 29, 36], ["arbidol", "TREATMENT", 29, 36], ["virus infection in vitro", "PROBLEM", 59, 83], ["Fig", "OBSERVATION_MODIFIER", 19, 22], ["infection", "OBSERVATION", 65, 74]]], ["The 50% maximal effective concentration (EC 50 ) and the 50% cytotoxic concentration (CC 50 ) of arbidol was 4.11 (3.55-4.73) and 31.79 (29.89-33.81) \u03bcM, respectively, and the selectivity index (SI = CC 50 /EC 50 ) was 7.73.", [["CC", "CHEMICAL", 86, 88], ["arbidol", "CHEMICAL", 97, 104], ["arbidol", "CHEMICAL", 97, 104], ["arbidol", "SIMPLE_CHEMICAL", 97, 104], ["The 50% maximal effective concentration (EC", "TREATMENT", 0, 43], ["arbidol", "TEST", 97, 104], ["the selectivity index", "TEST", 172, 193], ["SI", "TEST", 195, 197], ["CC", "TEST", 200, 202], ["EC", "TEST", 207, 209]]], ["Baloxavir partially inhibited SARS-CoV-2 infection (~29%) at a high concentration of 50 \u03bcM (Fig. 1a) .", [["Baloxavir", "CHEMICAL", 0, 9], ["infection", "DISEASE", 41, 50], ["Baloxavir", "CHEMICAL", 0, 9], ["Baloxavir", "SIMPLE_CHEMICAL", 0, 9], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 30, 40], ["SARS-CoV-2", "SPECIES", 30, 40], ["Baloxavir", "TREATMENT", 0, 9], ["SARS", "PROBLEM", 30, 34], ["2 infection", "PROBLEM", 39, 50]]], ["In contrast, laninamivir, oseltamivir, peramivir, and zanamivir did not exhibit anti-SARS-CoV-2 activity even at the highest drug concentrations (Fig. 1a) .", [["laninamivir", "CHEMICAL", 13, 24], ["oseltamivir", "CHEMICAL", 26, 37], ["peramivir", "CHEMICAL", 39, 48], ["zanamivir", "CHEMICAL", 54, 63], ["laninamivir", "CHEMICAL", 13, 24], ["oseltamivir", "CHEMICAL", 26, 37], ["peramivir", "CHEMICAL", 39, 48], ["zanamivir", "CHEMICAL", 54, 63], ["laninamivir", "SIMPLE_CHEMICAL", 13, 24], ["oseltamivir", "SIMPLE_CHEMICAL", 26, 37], ["peramivir", "SIMPLE_CHEMICAL", 39, 48], ["zanamivir", "SIMPLE_CHEMICAL", 54, 63], ["anti-SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 80, 95], ["contrast", "TREATMENT", 3, 11], ["laninamivir", "TREATMENT", 13, 24], ["oseltamivir", "TREATMENT", 26, 37], ["peramivir", "TREATMENT", 39, 48], ["zanamivir", "TREATMENT", 54, 63], ["anti-SARS", "TEST", 80, 89]]], ["The antiviral effect of the compounds was also evaluated by observing cytopathic effects \u00a9 The Author(s) 2020Dear editor,Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.", [["antiviral effect", "OBSERVATION", 4, 20]]], ["The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material.", [["The images", "TEST", 0, 10]]], ["(CPE) and immunofluorescence staining of infected cells.", [["cells", "ANATOMY", 50, 55], ["cells", "CELL", 50, 55], ["infected cells", "CELL_TYPE", 41, 55], ["CPE", "PROBLEM", 1, 4], ["immunofluorescence staining", "TEST", 10, 37], ["infected cells", "PROBLEM", 41, 55], ["infected cells", "OBSERVATION", 41, 55]]], ["As shown in Supplementary Fig. S1 , at 48 h p.i. only in cells treated with arbidol, but not with the other five drugs, viral NP expression and CPE due to SARS-CoV-2 was substantially reduced.", [["cells", "ANATOMY", 57, 62], ["arbidol", "CHEMICAL", 76, 83], ["SARS", "DISEASE", 155, 159], ["arbidol", "CHEMICAL", 76, 83], ["S1", "GENE_OR_GENE_PRODUCT", 31, 33], ["cells", "CELL", 57, 62], ["arbidol", "SIMPLE_CHEMICAL", 76, 83], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 155, 165], ["S1", "PROTEIN", 31, 33], ["SARS-CoV", "SPECIES", 155, 163], ["arbidol", "TREATMENT", 76, 83], ["viral NP expression", "TREATMENT", 120, 139], ["CPE", "PROBLEM", 144, 147], ["SARS", "PROBLEM", 155, 159], ["CoV", "TEST", 160, 163], ["reduced", "OBSERVATION_MODIFIER", 184, 191]]], ["To be noted, we also tried some human lung cell lines, for example human embryo lung fibroblasts MRC-5 and lung cancer cell line Calu-3, however, they were not very efficient for SARS-CoV-2 replication, and therefore were not used for this study.Dear editor,Apart from influenza virus, arbidol was reported to inhibit a wide array of viruses by interfering with multiple steps of the virus replication cycle 7 .", [["lung cell lines", "ANATOMY", 38, 53], ["embryo lung fibroblasts MRC-5", "ANATOMY", 73, 102], ["lung cancer cell line Calu-3", "ANATOMY", 107, 135], ["lung cancer", "DISEASE", 107, 118], ["influenza virus", "DISEASE", 269, 284], ["arbidol", "CHEMICAL", 286, 293], ["arbidol", "CHEMICAL", 286, 293], ["human", "ORGANISM", 32, 37], ["lung cell lines", "CELL", 38, 53], ["human", "ORGANISM", 67, 72], ["embryo lung fibroblasts MRC-5", "CELL", 73, 102], ["lung cancer cell line Calu-3", "CELL", 107, 135], ["CoV-2", "ORGANISM", 184, 189], ["influenza virus", "ORGANISM", 269, 284], ["arbidol", "SIMPLE_CHEMICAL", 286, 293], ["human lung cell lines", "CELL_LINE", 32, 53], ["human embryo lung fibroblasts MRC-5", "CELL_LINE", 67, 102], ["lung cancer cell line", "CELL_LINE", 107, 128], ["Calu-3", "CELL_LINE", 129, 135], ["human", "SPECIES", 32, 37], ["human", "SPECIES", 67, 72], ["influenza virus", "SPECIES", 269, 284], ["human", "SPECIES", 32, 37], ["human", "SPECIES", 67, 72], ["SARS-CoV", "SPECIES", 179, 187], ["influenza virus", "SPECIES", 269, 284], ["some human lung cell lines", "TREATMENT", 27, 53], ["example human embryo lung fibroblasts MRC", "TEST", 59, 100], ["lung cancer cell line Calu", "TEST", 107, 133], ["SARS", "PROBLEM", 179, 183], ["CoV-2 replication", "TREATMENT", 184, 201], ["this study", "TEST", 235, 245], ["influenza virus", "PROBLEM", 269, 284], ["arbidol", "TREATMENT", 286, 293], ["viruses", "PROBLEM", 334, 341], ["the virus replication cycle", "TREATMENT", 380, 407], ["lung", "ANATOMY", 38, 42], ["cell lines", "OBSERVATION", 43, 53], ["lung", "ANATOMY", 80, 84], ["fibroblasts", "OBSERVATION", 85, 96], ["lung", "ANATOMY", 107, 111], ["cancer", "OBSERVATION", 112, 118], ["cell line", "OBSERVATION", 119, 128], ["influenza virus", "OBSERVATION", 269, 284], ["viruses", "OBSERVATION", 334, 341]]], ["The stage of SARS-CoV-2 replication targeted by arbidol was explored by conducting a preliminary time-of-addition experiment using virus at an MOI of 0.05.", [["SARS", "DISEASE", 13, 17], ["arbidol", "CHEMICAL", 48, 55], ["arbidol", "CHEMICAL", 48, 55], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 13, 23], ["arbidol", "SIMPLE_CHEMICAL", 48, 55], ["SARS", "PROBLEM", 13, 17], ["CoV-2 replication", "TREATMENT", 18, 35], ["virus", "TREATMENT", 131, 136]]], ["Arbidol was incubated with cells during the virus entry process (Entry), the post-entry stages (Post-entry), or the entire process of infection (Full-time) and progeny virus yield was quantified by qRT-PCR.", [["cells", "ANATOMY", 27, 32], ["Arbidol", "CHEMICAL", 0, 7], ["infection", "DISEASE", 134, 143], ["Arbidol", "CHEMICAL", 0, 7], ["Arbidol", "SIMPLE_CHEMICAL", 0, 7], ["cells", "CELL", 27, 32], ["Arbidol", "TREATMENT", 0, 7], ["infection", "PROBLEM", 134, 143], ["progeny virus yield", "PROBLEM", 160, 179], ["infection", "OBSERVATION", 134, 143]]], ["The data revealed that arbidol efficiently blocked both viral entry and post-entry stages.", [["arbidol", "CHEMICAL", 23, 30], ["arbidol", "CHEMICAL", 23, 30], ["arbidol", "SIMPLE_CHEMICAL", 23, 30], ["The data", "TEST", 0, 8], ["arbidol", "TREATMENT", 23, 30], ["viral entry", "OBSERVATION", 56, 67]]], ["It had a profound impact on virus Entry (~75% inhibition) with a lesser effect on Post-entry events (~55% inhibition rate) (Fig. 1b) .", [["virus Entry", "TREATMENT", 28, 39], ["Post-entry events", "PROBLEM", 82, 99], ["inhibition rate", "TEST", 106, 121], ["profound", "OBSERVATION_MODIFIER", 9, 17], ["impact", "OBSERVATION_MODIFIER", 18, 24], ["lesser", "OBSERVATION_MODIFIER", 65, 71], ["effect", "OBSERVATION_MODIFIER", 72, 78]]], ["In addition, western blot analysis (Fig. 1c) and immunofluorescence microscopy ( Supplementary Fig. S2) confirmed that the expression level of viral NP was reduced drastically at Full-time (13% of the DMSO group, Fig. 1c) , and showed more inhibitory effect at the Entry stage (41%) than at the Post-entry stage (61%).Dear editor,The details of how arbidol blocks the entry of SARS-CoV-2 into cells were further investigated.", [["cells", "ANATOMY", 393, 398], ["arbidol", "CHEMICAL", 349, 356], ["SARS", "DISEASE", 377, 381], ["DMSO", "CHEMICAL", 201, 205], ["arbidol", "CHEMICAL", 349, 356], ["arbidol", "SIMPLE_CHEMICAL", 349, 356], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 377, 387], ["cells", "CELL", 393, 398], ["S2", "PROTEIN", 100, 102], ["western blot analysis", "TEST", 13, 34], ["immunofluorescence microscopy", "TEST", 49, 78], ["viral NP", "PROBLEM", 143, 151], ["the DMSO group", "TREATMENT", 197, 211], ["CoV", "TEST", 382, 385]]], ["Virus (MOI = 0.05) was allowed to bind to Vero E6 cells at 4\u00b0C for 1 h in the presence of arbidol (10 \u03bcM) or DMSO control.", [["Vero E6 cells", "ANATOMY", 42, 55], ["arbidol", "CHEMICAL", 90, 97], ["DMSO", "CHEMICAL", 109, 113], ["arbidol", "CHEMICAL", 90, 97], ["DMSO", "CHEMICAL", 109, 113], ["Virus", "ORGANISM", 0, 5], ["Vero E6 cells", "CELL", 42, 55], ["arbidol", "SIMPLE_CHEMICAL", 90, 97], ["DMSO", "SIMPLE_CHEMICAL", 109, 113], ["Vero E6 cells", "CELL_LINE", 42, 55], ["Vero E6", "SPECIES", 42, 49], ["Virus", "PROBLEM", 0, 5], ["MOI", "TEST", 7, 10], ["Vero E6 cells", "TREATMENT", 42, 55], ["arbidol", "TREATMENT", 90, 97], ["DMSO control", "TREATMENT", 109, 121]]], ["Virus particles bound to the cell (bound virions) and those in the supernatant (unbound virions) were analyzed by qRT-PCR.", [["cell", "ANATOMY", 29, 33], ["virions", "ANATOMY", 41, 48], ["supernatant", "ANATOMY", 67, 78], ["virions", "ANATOMY", 88, 95], ["Virus", "ORGANISM", 0, 5], ["cell", "CELL", 29, 33], ["Virus particles", "PROBLEM", 0, 15]]], ["The results showed that arbidol treatment led to a significantly decreased binding efficiency (67%) compared with the control group (P < 0.05) (Fig. 1d) .", [["arbidol", "CHEMICAL", 24, 31], ["arbidol", "CHEMICAL", 24, 31], ["arbidol", "SIMPLE_CHEMICAL", 24, 31], ["arbidol treatment", "TREATMENT", 24, 41], ["a significantly decreased binding efficiency", "PROBLEM", 49, 93], ["decreased", "OBSERVATION_MODIFIER", 65, 74], ["binding efficiency", "OBSERVATION", 75, 93]]], ["Correspondingly, the portion of unbound virions increased significantly to 156% of the control group after arbidol treatment (P < 0.001) (Fig. 1d) .Dear editor,Next, we analyzed viral intracellular trafficking.", [["virions", "ANATOMY", 40, 47], ["intracellular", "ANATOMY", 184, 197], ["arbidol", "CHEMICAL", 107, 114], ["arbidol", "CHEMICAL", 107, 114], ["arbidol", "SIMPLE_CHEMICAL", 107, 114], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 184, 197], ["unbound virions", "PROBLEM", 32, 47], ["arbidol treatment", "TREATMENT", 107, 124], ["portion", "OBSERVATION_MODIFIER", 21, 28], ["unbound", "OBSERVATION_MODIFIER", 32, 39], ["virions", "OBSERVATION_MODIFIER", 40, 47], ["increased", "OBSERVATION_MODIFIER", 48, 57], ["significantly", "OBSERVATION_MODIFIER", 58, 71]]], ["As we reported recently, within infected cells, SARS-CoV-2 underwent vesicle transportation, which was first carried out by early endosomes (EEs) then further transported to endolysosomes (ELs) 8 Fig. 1e and Supplementary Fig. S3 , in each tracked time points, there was no significant difference in the amounts of virions co-localized with EEs when comparing the DMSO-and arbidol-treated groups, although as time of infection went on (30, 60, and 90 min p.i.), the levels of colocalization considerably decreased in both DMSO-(24.0%, 5.1%, and 3.2%) and arbidol-(21.4%, 4.1%, and 2.8%) treated groups, suggesting that some virions were already transported from EEs to the next stage of vesicle transportation.", [["cells", "ANATOMY", 41, 46], ["vesicle", "ANATOMY", 69, 76], ["early endosomes", "ANATOMY", 124, 139], ["EEs", "ANATOMY", 141, 144], ["virions", "ANATOMY", 315, 322], ["virions", "ANATOMY", 624, 631], ["vesicle", "ANATOMY", 687, 694], ["DMSO", "CHEMICAL", 364, 368], ["arbidol", "CHEMICAL", 373, 380], ["infection", "DISEASE", 417, 426], ["DMSO", "CHEMICAL", 522, 526], ["arbidol", "CHEMICAL", 555, 562], ["DMSO", "CHEMICAL", 364, 368], ["arbidol", "CHEMICAL", 373, 380], ["DMSO", "CHEMICAL", 522, 526], ["arbidol", "CHEMICAL", 555, 562], ["cells", "CELL", 41, 46], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 48, 58], ["vesicle", "CELLULAR_COMPONENT", 69, 76], ["early endosomes", "CELLULAR_COMPONENT", 124, 139], ["S3", "GENE_OR_GENE_PRODUCT", 227, 229], ["EEs", "SIMPLE_CHEMICAL", 341, 344], ["DMSO", "SIMPLE_CHEMICAL", 364, 368], ["arbidol", "SIMPLE_CHEMICAL", 373, 380], ["DMSO", "SIMPLE_CHEMICAL", 522, 526], ["arbidol", "SIMPLE_CHEMICAL", 555, 562], ["vesicle", "CELLULAR_COMPONENT", 687, 694], ["infected cells", "CELL_TYPE", 32, 46], ["EEs", "PROTEIN", 141, 144], ["infected cells", "PROBLEM", 32, 46], ["SARS", "PROBLEM", 48, 52], ["vesicle transportation", "TEST", 69, 91], ["Supplementary Fig", "TREATMENT", 208, 225], ["the DMSO", "TEST", 360, 368], ["arbidol", "TREATMENT", 373, 380], ["infection", "PROBLEM", 417, 426], ["the levels", "TEST", 462, 472], ["DMSO", "TEST", 522, 526], ["arbidol", "TEST", 555, 562], ["some virions", "PROBLEM", 619, 631], ["infected cells", "OBSERVATION", 32, 46], ["no", "UNCERTAINTY", 271, 273], ["significant", "OBSERVATION_MODIFIER", 274, 285], ["difference", "OBSERVATION", 286, 296], ["infection", "OBSERVATION", 417, 426], ["considerably", "OBSERVATION_MODIFIER", 491, 503], ["decreased", "OBSERVATION_MODIFIER", 504, 513], ["vesicle transportation", "OBSERVATION", 687, 709]]], ["By contrast, at 60 min p.i., a slightly higher percentage of virions were transported to ELs in the arbidol-treated group (22.4%) than in the DMSO group (18.3%) (P < 0.05) (Fig. 1e, f) .", [["virions", "ANATOMY", 61, 68], ["ELs", "ANATOMY", 89, 92], ["arbidol", "CHEMICAL", 100, 107], ["DMSO", "CHEMICAL", 142, 146], ["arbidol", "CHEMICAL", 100, 107], ["DMSO", "CHEMICAL", 142, 146], ["ELs", "GENE_OR_GENE_PRODUCT", 89, 92], ["arbidol", "SIMPLE_CHEMICAL", 100, 107], ["DMSO", "SIMPLE_CHEMICAL", 142, 146], ["a slightly higher percentage of virions", "PROBLEM", 29, 68], ["the DMSO group", "TEST", 138, 152]]], ["At 90 min p.i., significantly fewer virions (~13.5%) were detected in ELs in the DMSO group; whereas significantly higher proportions of virions (~23.6%) remained within ELs in the arbidol-treated group, suggesting the drug trapped the virus in the ELs (P < 0.001) (Fig. 1e, f) .", [["virions", "ANATOMY", 36, 43], ["ELs", "ANATOMY", 70, 73], ["virions", "ANATOMY", 137, 144], ["ELs", "ANATOMY", 170, 173], ["ELs", "ANATOMY", 249, 252], ["DMSO", "CHEMICAL", 81, 85], ["arbidol", "CHEMICAL", 181, 188], ["DMSO", "CHEMICAL", 81, 85], ["arbidol", "CHEMICAL", 181, 188], ["ELs", "PATHOLOGICAL_FORMATION", 70, 73], ["DMSO", "SIMPLE_CHEMICAL", 81, 85], ["ELs", "PATHOLOGICAL_FORMATION", 170, 173], ["arbidol", "SIMPLE_CHEMICAL", 181, 188], ["ELs", "CELL_TYPE", 70, 73], ["significantly fewer virions", "PROBLEM", 16, 43], ["virions", "TEST", 137, 144], ["the drug trapped the virus", "PROBLEM", 215, 241], ["virus", "OBSERVATION", 236, 241]]], ["Taken together, these results suggested that arbidol impeded not only viral attachment, but also release of SARS-CoV-2 from intracellular vesicles (ELs)..", [["intracellular vesicles", "ANATOMY", 124, 146], ["ELs", "ANATOMY", 148, 151], ["arbidol", "CHEMICAL", 45, 52], ["arbidol", "CHEMICAL", 45, 52], ["arbidol", "SIMPLE_CHEMICAL", 45, 52], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 108, 118], ["intracellular vesicles", "CELLULAR_COMPONENT", 124, 146], ["arbidol", "TREATMENT", 45, 52], ["viral attachment", "PROBLEM", 70, 86], ["SARS", "PROBLEM", 108, 112], ["CoV", "TEST", 113, 116], ["intracellular vesicles", "ANATOMY", 124, 146]]], ["Co-localization of virions with EEs or ELs was visualized by immunofluorescence microscopy and statistically analyzed (n > 150 cells).", [["virions", "ANATOMY", 19, 26], ["EEs", "ANATOMY", 32, 35], ["cells", "ANATOMY", 127, 132], ["EEs", "GENE_OR_GENE_PRODUCT", 32, 35], ["ELs", "GENE_OR_GENE_PRODUCT", 39, 42], ["cells", "CELL", 127, 132], ["EEs", "PROTEIN", 32, 35], ["ELs", "PROTEIN", 39, 42], ["immunofluorescence microscopy", "TEST", 61, 90], ["virions", "OBSERVATION", 19, 26]]], ["As shown inAmong the drugs tested, laninamivir, oseltamivir, peramivir, and zanamivir are neuraminidase (NA) inhibitors, which are most widely prescribed for prophylaxis and treatment of influenza.", [["laninamivir", "CHEMICAL", 35, 46], ["oseltamivir", "CHEMICAL", 48, 59], ["peramivir", "CHEMICAL", 61, 70], ["zanamivir", "CHEMICAL", 76, 85], ["NA", "CHEMICAL", 105, 107], ["influenza", "DISEASE", 187, 196], ["laninamivir", "CHEMICAL", 35, 46], ["oseltamivir", "CHEMICAL", 48, 59], ["peramivir", "CHEMICAL", 61, 70], ["zanamivir", "CHEMICAL", 76, 85], ["laninamivir", "SIMPLE_CHEMICAL", 35, 46], ["oseltamivir", "SIMPLE_CHEMICAL", 48, 59], ["peramivir", "SIMPLE_CHEMICAL", 61, 70], ["zanamivir", "SIMPLE_CHEMICAL", 76, 85], ["neuraminidase", "SIMPLE_CHEMICAL", 90, 103], ["NA", "SIMPLE_CHEMICAL", 105, 107], ["the drugs", "TREATMENT", 17, 26], ["laninamivir", "TREATMENT", 35, 46], ["oseltamivir", "TREATMENT", 48, 59], ["peramivir", "TREATMENT", 61, 70], ["zanamivir", "TREATMENT", 76, 85], ["neuraminidase (NA) inhibitors", "TREATMENT", 90, 119], ["prophylaxis", "TREATMENT", 158, 169], ["treatment", "TREATMENT", 174, 183], ["influenza", "PROBLEM", 187, 196], ["influenza", "OBSERVATION", 187, 196]]], ["Although no NA analog exists in SARS-CoV-2, NA inhibitors such as oseltamivir nevertheless are being used clinically in treating COVID-19 patients 1, 2 .", [["NA", "CHEMICAL", 12, 14], ["oseltamivir", "CHEMICAL", 66, 77], ["COVID", "DISEASE", 129, 134], ["oseltamivir", "CHEMICAL", 66, 77], ["NA", "SIMPLE_CHEMICAL", 12, 14], ["SARS-CoV-2", "ORGANISM", 32, 42], ["NA inhibitors", "SIMPLE_CHEMICAL", 44, 57], ["oseltamivir", "SIMPLE_CHEMICAL", 66, 77], ["patients", "ORGANISM", 138, 146], ["patients", "SPECIES", 138, 146], ["SARS-CoV", "SPECIES", 32, 40], ["NA analog", "PROBLEM", 12, 21], ["SARS", "TEST", 32, 36], ["CoV", "TEST", 37, 40], ["NA inhibitors", "TREATMENT", 44, 57], ["oseltamivir", "TREATMENT", 66, 77], ["COVID", "TEST", 129, 134], ["no", "UNCERTAINTY", 9, 11]]], ["Our data showed these NA inhibitors were not active against SARS-CoV-2 (Fig. 1a) , which is consistent with the finding that oseltamivir and zanamivir were (see figure on previous page) Fig. 1 Comparative antiviral efficacy of anti-influenza drugs and the mode of actions of arbidol against SARS-CoV-2 infection in vitro. a Antiviral activities of the drugs.", [["oseltamivir", "CHEMICAL", 125, 136], ["zanamivir", "CHEMICAL", 141, 150], ["arbidol", "CHEMICAL", 275, 282], ["SARS", "DISEASE", 291, 295], ["infection", "DISEASE", 302, 311], ["oseltamivir", "CHEMICAL", 125, 136], ["zanamivir", "CHEMICAL", 141, 150], ["arbidol", "CHEMICAL", 275, 282], ["NA", "SIMPLE_CHEMICAL", 22, 24], ["SARS-CoV-2", "ORGANISM", 60, 70], ["Fig. 1a", "ORGANISM", 72, 79], ["oseltamivir", "SIMPLE_CHEMICAL", 125, 136], ["zanamivir", "SIMPLE_CHEMICAL", 141, 150], ["arbidol", "SIMPLE_CHEMICAL", 275, 282], ["SARS-CoV-2", "ORGANISM", 291, 301], ["CoV-2", "SPECIES", 296, 301], ["SARS-CoV", "SPECIES", 60, 68], ["SARS-CoV-2", "SPECIES", 291, 301], ["Our data", "TEST", 0, 8], ["these NA inhibitors", "TEST", 16, 35], ["SARS", "PROBLEM", 60, 64], ["CoV", "TEST", 65, 68], ["oseltamivir", "TREATMENT", 125, 136], ["zanamivir", "TREATMENT", 141, 150], ["anti-influenza drugs", "TREATMENT", 227, 247], ["arbidol", "TREATMENT", 275, 282], ["SARS", "PROBLEM", 291, 295], ["CoV", "PROBLEM", 296, 299], ["2 infection", "PROBLEM", 300, 311], ["the drugs", "TREATMENT", 348, 357], ["consistent with", "UNCERTAINTY", 92, 107], ["infection", "OBSERVATION", 302, 311]]], ["The antiviral efficacy was evaluated in Vero E6 cells by qRT-PCR analysis of virus yield at 48 h p.i.", [["Vero E6 cells", "ANATOMY", 40, 53], ["Vero E6 cells", "CELL", 40, 53], ["Vero E6 cells", "CELL_LINE", 40, 53], ["Vero E6", "SPECIES", 40, 47], ["The antiviral efficacy", "TREATMENT", 0, 22], ["Vero E6 cells", "TREATMENT", 40, 53], ["qRT", "TEST", 57, 60], ["PCR analysis", "TEST", 61, 73], ["antiviral efficacy", "OBSERVATION", 4, 22]]], ["Data represent the mean \u00b1 standard deviation (SD) from two independent repeats. b, c Time-of-addition experiment of arbidol.", [["arbidol", "CHEMICAL", 116, 123], ["arbidol", "CHEMICAL", 116, 123], ["arbidol", "SIMPLE_CHEMICAL", 116, 123], ["arbidol", "TREATMENT", 116, 123]]], ["At 16 h p.i., virus yield in the cell supernatant was quantified by qRT-PCR (b), and the expression of NP in infected cells was analyzed by western blots (c).", [["cell supernatant", "ANATOMY", 33, 49], ["cells", "ANATOMY", 118, 123], ["cell", "CELL", 33, 37], ["NP", "GENE_OR_GENE_PRODUCT", 103, 105], ["cells", "CELL", 118, 123], ["NP", "PROTEIN", 103, 105], ["infected cells", "CELL_TYPE", 109, 123], ["virus", "PROBLEM", 14, 19], ["the cell supernatant", "TEST", 29, 49], ["qRT", "TEST", 68, 71], ["PCR", "TEST", 72, 75], ["NP in infected cells", "TREATMENT", 103, 123], ["infected cells", "OBSERVATION", 109, 123]]], ["The values below the blot represent the relative band intensity (NP/GAPDH) normalized to that of the DMSO group. d Impact of arbidol on SARS-CoV-2 binding.", [["DMSO", "CHEMICAL", 101, 105], ["arbidol", "CHEMICAL", 125, 132], ["SARS", "DISEASE", 136, 140], ["DMSO", "CHEMICAL", 101, 105], ["arbidol", "CHEMICAL", 125, 132], ["DMSO", "SIMPLE_CHEMICAL", 101, 105], ["arbidol", "SIMPLE_CHEMICAL", 125, 132], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 136, 146], ["GAPDH", "PROTEIN", 68, 73], ["The values", "TEST", 0, 10], ["the blot", "TEST", 17, 25], ["the relative band intensity", "PROBLEM", 36, 63], ["NP/GAPDH", "TEST", 65, 73], ["the DMSO group", "TREATMENT", 97, 111], ["arbidol", "TREATMENT", 125, 132]]], ["Vero E6 cells were treated with arbidol (10 \u03bcM) or DMSO for 1 h prior to infection with SARS-CoV-2 at 4\u00b0C for 1 h.", [["Vero E6 cells", "ANATOMY", 0, 13], ["arbidol", "CHEMICAL", 32, 39], ["DMSO", "CHEMICAL", 51, 55], ["infection", "DISEASE", 73, 82], ["arbidol", "CHEMICAL", 32, 39], ["DMSO", "CHEMICAL", 51, 55], ["Vero E6 cells", "CELL", 0, 13], ["arbidol", "SIMPLE_CHEMICAL", 32, 39], ["DMSO", "SIMPLE_CHEMICAL", 51, 55], ["Vero E6 cells", "CELL_LINE", 0, 13], ["Vero E6", "SPECIES", 0, 7], ["SARS-CoV", "SPECIES", 88, 96], ["Vero E6 cells", "TREATMENT", 0, 13], ["arbidol", "TREATMENT", 32, 39], ["DMSO", "TREATMENT", 51, 55], ["infection", "PROBLEM", 73, 82], ["SARS", "PROBLEM", 88, 92], ["E6 cells", "OBSERVATION", 5, 13], ["infection", "OBSERVATION", 73, 82]]], ["The supernatant (unbound virions) and the cells containing bound virions (bound virions) were collected for quantification of viral RNA copies by qRT-PCR. e, f Effect of arbidol on intracellular trafficking of SARS-CoV-2.", [["supernatant", "ANATOMY", 4, 15], ["virions", "ANATOMY", 25, 32], ["cells", "ANATOMY", 42, 47], ["virions", "ANATOMY", 65, 72], ["virions", "ANATOMY", 80, 87], ["intracellular", "ANATOMY", 181, 194], ["arbidol", "CHEMICAL", 170, 177], ["arbidol", "CHEMICAL", 170, 177], ["cells", "CELL", 42, 47], ["virions", "CELLULAR_COMPONENT", 65, 72], ["arbidol", "SIMPLE_CHEMICAL", 170, 177], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 181, 194], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 210, 220], ["viral RNA copies", "RNA", 126, 142], ["The supernatant (unbound virions", "TREATMENT", 0, 32], ["the cells containing bound virions (bound virions", "TREATMENT", 38, 87], ["viral RNA copies", "TEST", 126, 142], ["qRT", "TEST", 146, 149], ["arbidol", "TREATMENT", 170, 177]]], ["The colocalization of virions with EEs or LEs was analyzed by immunofluorescence assays as described in the Supplementary Methods. e The portion of virions that co-localized with EEs or ELs in each group (n > 150 cells) was quantified by Image J. f Representative confocal microscopic images of virions (red) and LAMP1 + ELs (green) in each group.", [["virions", "ANATOMY", 22, 29], ["virions", "ANATOMY", 148, 155], ["EEs", "ANATOMY", 179, 182], ["ELs", "ANATOMY", 186, 189], ["cells", "ANATOMY", 213, 218], ["virions", "ANATOMY", 295, 302], ["LAMP1 + ELs", "ANATOMY", 313, 324], ["EEs", "GENE_OR_GENE_PRODUCT", 35, 38], ["LEs", "GENE_OR_GENE_PRODUCT", 42, 45], ["EEs", "GENE_OR_GENE_PRODUCT", 179, 182], ["ELs", "GENE_OR_GENE_PRODUCT", 186, 189], ["cells", "CELL", 213, 218], ["LAMP1", "GENE_OR_GENE_PRODUCT", 313, 318], ["EEs", "PROTEIN", 35, 38], ["LEs", "PROTEIN", 42, 45], ["EEs", "PROTEIN", 179, 182], ["ELs", "PROTEIN", 186, 189], ["LAMP1", "PROTEIN", 313, 318], ["ELs", "PROTEIN", 321, 324], ["immunofluorescence assays", "TEST", 62, 87], ["virions", "OBSERVATION", 22, 29], ["virions", "OBSERVATION", 148, 155], ["virions", "ANATOMY", 295, 302]]], ["The nuclei (blue) were stained with Hoechst 33258 dye.", [["nuclei", "ANATOMY", 4, 10], ["Hoechst 33258", "CHEMICAL", 36, 49], ["Hoechst 33258", "CHEMICAL", 36, 49], ["nuclei", "CELLULAR_COMPONENT", 4, 10], ["Hoechst 33258 dye", "SIMPLE_CHEMICAL", 36, 53], ["nuclei", "ANATOMY", 4, 10]]], ["White arrows: virions co-localized with ELs; bars: 10 \u03bcm.", [["virions", "ANATOMY", 14, 21], ["ELs", "PROTEIN", 40, 43]]], ["For (b) and (e), statistical analysis was performed using a one-way analysis of variance (ANOVA) with GraphPad Prism.", [["statistical analysis", "TEST", 17, 37], ["GraphPad Prism", "TREATMENT", 102, 116]]], ["For (d), statistical analysis was performed and calculated by unpaired two-tailed t test. **P < 0.001; ns, not significant..", [["statistical analysis", "TEST", 9, 29], ["tailed t test", "TEST", 75, 88], ["ns", "TREATMENT", 103, 105]]], ["Co-localization of virions with EEs or ELs was visualized by immunofluorescence microscopy and statistically analyzed (n > 150 cells).", [["virions", "ANATOMY", 19, 26], ["EEs", "ANATOMY", 32, 35], ["cells", "ANATOMY", 127, 132], ["EEs", "GENE_OR_GENE_PRODUCT", 32, 35], ["ELs", "GENE_OR_GENE_PRODUCT", 39, 42], ["cells", "CELL", 127, 132], ["EEs", "PROTEIN", 32, 35], ["ELs", "PROTEIN", 39, 42], ["immunofluorescence microscopy", "TEST", 61, 90], ["virions", "OBSERVATION", 19, 26]]], ["As shown inineffective in inhibiting SARS-CoV 9 .", [["SARS-CoV 9", "GENE_OR_GENE_PRODUCT", 37, 47], ["SARS-CoV", "SPECIES", 37, 45]]], ["Baloxavir marboxil is a new anti-influenza drug, which selectively inhibits the endonuclease activity of the viral polymerase responsible for snatching capped primers from host mRNAs to initiate viral mRNA transcription.", [["Baloxavir marboxil", "CHEMICAL", 0, 18], ["Baloxavir marboxil", "CHEMICAL", 0, 18], ["Baloxavir", "SIMPLE_CHEMICAL", 0, 9], ["marboxil", "SIMPLE_CHEMICAL", 10, 18], ["endonuclease", "PROTEIN", 80, 92], ["viral polymerase", "PROTEIN", 109, 125], ["host mRNAs", "RNA", 172, 182], ["viral mRNA", "RNA", 195, 205], ["Baloxavir marboxil", "TREATMENT", 0, 18], ["a new anti-influenza drug", "TREATMENT", 22, 47], ["the viral polymerase", "PROBLEM", 105, 125], ["snatching capped primers", "TREATMENT", 142, 166], ["viral mRNA transcription", "TREATMENT", 195, 219], ["viral polymerase", "OBSERVATION", 109, 125]]], ["However, this \"capsnatching\" mechanism of the endonuclease is not shared by coronaviruses that encode their own enzymes to form 5\u02b9-mRNA cap structures 10 .", [["endonuclease", "PROTEIN", 46, 58], ["enzymes", "PROTEIN", 112, 119], ["5\u02b9", "PROTEIN", 128, 130], ["the endonuclease", "PROBLEM", 42, 58], ["their own enzymes", "TEST", 102, 119]]], ["This may explain why baloxavir failed to block SARS-CoV-2 infection (Fig. 1a) .", [["baloxavir", "CHEMICAL", 21, 30], ["infection", "DISEASE", 58, 67], ["baloxavir", "CHEMICAL", 21, 30], ["baloxavir", "SIMPLE_CHEMICAL", 21, 30], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 47, 57], ["baloxavir", "TREATMENT", 21, 30], ["block SARS", "PROBLEM", 41, 51], ["CoV-2 infection", "PROBLEM", 52, 67]]], ["During the review process of this study, Choy et al. also showed that oseltamivir and baloxavir failed to inhibit SARS-CoV-2 in vitro 11 ..", [["oseltamivir", "CHEMICAL", 70, 81], ["baloxavir", "CHEMICAL", 86, 95], ["oseltamivir", "CHEMICAL", 70, 81], ["baloxavir", "CHEMICAL", 86, 95], ["oseltamivir", "SIMPLE_CHEMICAL", 70, 81], ["baloxavir", "SIMPLE_CHEMICAL", 86, 95], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 114, 124], ["this study", "TEST", 29, 39], ["oseltamivir", "TREATMENT", 70, 81], ["baloxavir", "TREATMENT", 86, 95], ["SARS", "TEST", 114, 118], ["CoV", "TEST", 119, 122]]], ["Co-localization of virions with EEs or ELs was visualized by immunofluorescence microscopy and statistically analyzed (n > 150 cells).", [["virions", "ANATOMY", 19, 26], ["EEs", "ANATOMY", 32, 35], ["cells", "ANATOMY", 127, 132], ["EEs", "GENE_OR_GENE_PRODUCT", 32, 35], ["ELs", "GENE_OR_GENE_PRODUCT", 39, 42], ["cells", "CELL", 127, 132], ["EEs", "PROTEIN", 32, 35], ["ELs", "PROTEIN", 39, 42], ["immunofluorescence microscopy", "TEST", 61, 90], ["virions", "OBSERVATION", 19, 26]]], ["As shown inArbidol, an indole-derivative, has been licensed for decades in Russia and China against influenza.", [["inArbidol", "CHEMICAL", 9, 18], ["influenza", "DISEASE", 100, 109], ["inArbidol", "CHEMICAL", 9, 18], ["indole", "CHEMICAL", 23, 29], ["inArbidol", "SIMPLE_CHEMICAL", 9, 18], ["indole-derivative", "SIMPLE_CHEMICAL", 23, 40], ["an indole-derivative", "TREATMENT", 20, 40], ["influenza", "PROBLEM", 100, 109]]], ["It is a broad-spectrum drug against a wide range of enveloped and non-enveloped viruses.", [["a broad-spectrum drug", "TREATMENT", 6, 27], ["non-enveloped viruses", "PROBLEM", 66, 87], ["non-enveloped viruses", "OBSERVATION", 66, 87]]], ["Arbidol interacts preferentially with aromatic amino acids, and it affects multiple stages of the virus life cycle, either by direct targeting viral proteins or virus-associated host factors 7 .", [["Arbidol", "CHEMICAL", 0, 7], ["amino acids", "CHEMICAL", 47, 58], ["Arbidol", "CHEMICAL", 0, 7], ["amino acids", "CHEMICAL", 47, 58], ["Arbidol", "SIMPLE_CHEMICAL", 0, 7], ["amino acids", "AMINO_ACID", 47, 58], ["viral proteins", "PROTEIN", 143, 157], ["virus-associated host factors 7", "PROTEIN", 161, 192], ["Arbidol", "TREATMENT", 0, 7], ["aromatic amino acids", "TREATMENT", 38, 58], ["direct targeting viral proteins", "PROBLEM", 126, 157], ["virus", "PROBLEM", 161, 166], ["aromatic amino acids", "OBSERVATION", 38, 58]]], ["For example, in influenza virus, crystal structures showed that arbidol inserted into a hydrophobic pocket of the fusion subunit of HA, thus hindering low-pH conformational change of HA and blocking the fusion process 12 .", [["arbidol", "CHEMICAL", 64, 71], ["arbidol", "CHEMICAL", 64, 71], ["influenza virus", "ORGANISM", 16, 31], ["arbidol", "SIMPLE_CHEMICAL", 64, 71], ["HA", "GENE_OR_GENE_PRODUCT", 132, 134], ["fusion subunit", "PROTEIN", 114, 128], ["HA", "PROTEIN", 132, 134], ["influenza virus", "SPECIES", 16, 31], ["influenza virus", "SPECIES", 16, 31], ["influenza virus, crystal structures", "PROBLEM", 16, 51], ["arbidol", "TREATMENT", 64, 71], ["a hydrophobic pocket", "PROBLEM", 86, 106], ["HA", "PROBLEM", 132, 134], ["hindering low-pH conformational change of HA", "PROBLEM", 141, 185], ["blocking the fusion process", "PROBLEM", 190, 217], ["influenza virus", "OBSERVATION", 16, 31], ["hydrophobic pocket", "OBSERVATION", 88, 106], ["fusion", "OBSERVATION", 114, 120], ["pH conformational", "OBSERVATION", 155, 172], ["fusion", "OBSERVATION", 203, 209]]], ["In hepatitis C virus, arbidol impaired both virus attachment and intracellular vesicle trafficking 13 .", [["intracellular vesicle", "ANATOMY", 65, 86], ["hepatitis C", "DISEASE", 3, 14], ["arbidol", "CHEMICAL", 22, 29], ["arbidol", "CHEMICAL", 22, 29], ["hepatitis C virus", "ORGANISM", 3, 20], ["arbidol", "SIMPLE_CHEMICAL", 22, 29], ["intracellular vesicle", "CELLULAR_COMPONENT", 65, 86], ["hepatitis C virus", "SPECIES", 3, 20], ["hepatitis C virus", "SPECIES", 3, 20], ["hepatitis C virus", "PROBLEM", 3, 20], ["arbidol impaired both virus attachment", "PROBLEM", 22, 60], ["intracellular vesicle trafficking", "TEST", 65, 98], ["hepatitis", "OBSERVATION", 3, 12], ["both virus", "OBSERVATION", 39, 49], ["vesicle trafficking", "OBSERVATION", 79, 98]]], ["Likewise, we found arbidol plays a role in interfering SAS-CoV-2 binding (Fig. 1d ) and intracellular vesicle trafficking (Fig. 1e, f) .", [["intracellular vesicle", "ANATOMY", 88, 109], ["arbidol", "CHEMICAL", 19, 26], ["arbidol", "CHEMICAL", 19, 26], ["arbidol", "SIMPLE_CHEMICAL", 19, 26], ["SAS-CoV-2", "GENE_OR_GENE_PRODUCT", 55, 64], ["Fig. 1d", "GENE_OR_GENE_PRODUCT", 74, 81], ["intracellular vesicle", "CELLULAR_COMPONENT", 88, 109], ["arbidol", "PROTEIN", 19, 26], ["interfering SAS", "PROBLEM", 43, 58], ["intracellular vesicle trafficking", "TREATMENT", 88, 121]]], ["Arbidol can also bind to lipid membranes and may alter membrane configuration of the cytoplasm or the endosome, which are crucial for viral attachment and fusion 7 .", [["lipid membranes", "ANATOMY", 25, 40], ["membrane", "ANATOMY", 55, 63], ["cytoplasm", "ANATOMY", 85, 94], ["endosome", "ANATOMY", 102, 110], ["Arbidol", "CHEMICAL", 0, 7], ["Arbidol", "CHEMICAL", 0, 7], ["Arbidol", "SIMPLE_CHEMICAL", 0, 7], ["lipid membranes", "CELLULAR_COMPONENT", 25, 40], ["membrane", "CELLULAR_COMPONENT", 55, 63], ["cytoplasm", "ORGANISM_SUBSTANCE", 85, 94], ["endosome", "CELLULAR_COMPONENT", 102, 110], ["Arbidol", "TREATMENT", 0, 7], ["viral attachment and fusion", "TREATMENT", 134, 161], ["lipid membranes", "OBSERVATION", 25, 40], ["membrane configuration", "OBSERVATION", 55, 77], ["cytoplasm", "OBSERVATION", 85, 94]]], ["It could be further investigated whether arbidol targets virus or/ and cells by using published method 14 ..", [["cells", "ANATOMY", 71, 76], ["arbidol", "CHEMICAL", 41, 48], ["arbidol", "CHEMICAL", 41, 48], ["arbidol", "SIMPLE_CHEMICAL", 41, 48], ["cells", "CELL", 71, 76], ["arbidol targets virus", "PROBLEM", 41, 62], ["published method", "TEST", 86, 102]]], ["Co-localization of virions with EEs or ELs was visualized by immunofluorescence microscopy and statistically analyzed (n > 150 cells).", [["virions", "ANATOMY", 19, 26], ["EEs", "ANATOMY", 32, 35], ["cells", "ANATOMY", 127, 132], ["EEs", "GENE_OR_GENE_PRODUCT", 32, 35], ["ELs", "GENE_OR_GENE_PRODUCT", 39, 42], ["cells", "CELL", 127, 132], ["EEs", "PROTEIN", 32, 35], ["ELs", "PROTEIN", 39, 42], ["immunofluorescence microscopy", "TEST", 61, 90], ["virions", "OBSERVATION", 19, 26]]], ["As shown inIn summary, among the six anti-influenza drugs, only arbidol efficiently inhibited SARS-CoV-2 infection.", [["arbidol", "CHEMICAL", 64, 71], ["SARS-CoV-2 infection", "DISEASE", 94, 114], ["arbidol", "CHEMICAL", 64, 71], ["arbidol", "SIMPLE_CHEMICAL", 64, 71], ["SARS-CoV-2", "ORGANISM", 94, 104], ["SARS-CoV-2", "SPECIES", 94, 104], ["the six anti-influenza drugs", "TREATMENT", 29, 57], ["SARS", "PROBLEM", 94, 98], ["CoV-2 infection", "PROBLEM", 99, 114], ["infection", "OBSERVATION", 105, 114]]], ["Functionally, it appears to block virus entry by impeding viral attachment and release from the ELs.", [["ELs", "ANATOMY", 96, 99], ["ELs", "PATHOLOGICAL_FORMATION", 96, 99], ["ELs", "CELL_TYPE", 96, 99], ["block virus entry", "PROBLEM", 28, 45], ["impeding viral attachment", "PROBLEM", 49, 74], ["viral attachment", "OBSERVATION", 58, 74]]], ["Although the SI of arbidol is relatively low (SI = 7.73), as a repurposed drug, its pharmacokinetics profile such as maximal concentration (Cmax) is more important for predicting efficacy.", [["arbidol", "CHEMICAL", 19, 26], ["arbidol", "CHEMICAL", 19, 26], ["arbidol", "SIMPLE_CHEMICAL", 19, 26], ["a repurposed drug", "TREATMENT", 61, 78], ["its pharmacokinetics profile", "TREATMENT", 80, 108], ["low", "OBSERVATION_MODIFIER", 41, 44]]], ["It is generally believed that if the Cmax achieves EC 90 , the drug is very likely to be effective; while if the Cmax achieves EC 50 , the drug is possibly effective in vivo.", [["Cmax", "CHEMICAL", 37, 41], ["Cmax", "CHEMICAL", 113, 117], ["Cmax", "SIMPLE_CHEMICAL", 37, 41], ["EC", "CELL", 51, 53], ["Cmax", "SIMPLE_CHEMICAL", 113, 117], ["EC", "CELL", 127, 129], ["the Cmax", "TEST", 33, 41], ["the Cmax", "TEST", 109, 117]]], ["In humans, a single oral administration of 800 mg of arbidol results in Cmax of~4.1 \u03bcM 15 , and this dosage is efficacious and safe against different influenza viruses with EC 50 values ranging from 2.5-20 \u03bcM 7, 16 .", [["oral", "ANATOMY", 20, 24], ["arbidol", "CHEMICAL", 53, 60], ["Cmax", "CHEMICAL", 72, 76], ["influenza", "DISEASE", 150, 159], ["arbidol", "CHEMICAL", 53, 60], ["humans", "ORGANISM", 3, 9], ["oral", "ORGANISM_SUBDIVISION", 20, 24], ["arbidol", "SIMPLE_CHEMICAL", 53, 60], ["Cmax", "SIMPLE_CHEMICAL", 72, 76], ["EC", "CELL", 173, 175], ["humans", "SPECIES", 3, 9], ["humans", "SPECIES", 3, 9], ["arbidol", "TREATMENT", 53, 60], ["Cmax", "TEST", 72, 76], ["different influenza viruses", "PROBLEM", 140, 167], ["EC", "TEST", 173, 175]]], ["Arbidol also showed anti-inflammatory activity, which may enhance its efficacy in vivo 16 .", [["Arbidol", "CHEMICAL", 0, 7], ["Arbidol", "CHEMICAL", 0, 7], ["Arbidol", "SIMPLE_CHEMICAL", 0, 7], ["Arbidol", "TREATMENT", 0, 7], ["anti-inflammatory activity", "PROBLEM", 20, 46], ["anti-inflammatory activity", "OBSERVATION", 20, 46]]], ["Considering the EC 50 (4.11 \u03bcM) of arbidol against SARS-CoV-2 is comparable to, or even lower than those of influenza viruses, we, therefore, suggest that arbidol is potentially effective to treat COVID-19 patients.", [["EC", "ANATOMY", 16, 18], ["arbidol", "CHEMICAL", 35, 42], ["SARS", "DISEASE", 51, 55], ["influenza viruses", "DISEASE", 108, 125], ["arbidol", "CHEMICAL", 155, 162], ["COVID", "DISEASE", 197, 202], ["arbidol", "CHEMICAL", 35, 42], ["arbidol", "CHEMICAL", 155, 162], ["EC", "CELL", 16, 18], ["arbidol", "SIMPLE_CHEMICAL", 35, 42], ["SARS-CoV-2", "ORGANISM", 51, 61], ["influenza viruses", "ORGANISM", 108, 125], ["arbidol", "SIMPLE_CHEMICAL", 155, 162], ["patients", "ORGANISM", 206, 214], ["patients", "SPECIES", 206, 214], ["SARS-CoV", "SPECIES", 51, 59], ["the EC", "TEST", 12, 18], ["arbidol", "TREATMENT", 35, 42], ["SARS", "PROBLEM", 51, 55], ["CoV", "TEST", 56, 59], ["influenza viruses", "PROBLEM", 108, 125], ["arbidol", "TREATMENT", 155, 162], ["COVID", "TEST", 197, 202], ["influenza viruses", "OBSERVATION", 108, 125]]], ["However, the current dose of arbidol (200 mg, 3 times/day) recommended by the Chinese Guidelines may not be able to achieve an ideal therapeutic efficacy to inhibit SARS-CoV-2 infection, and should be elevated.", [["arbidol", "CHEMICAL", 29, 36], ["infection", "DISEASE", 176, 185], ["arbidol", "CHEMICAL", 29, 36], ["arbidol", "SIMPLE_CHEMICAL", 29, 36], ["SARS-CoV-2", "ORGANISM", 165, 175], ["SARS-CoV", "SPECIES", 165, 173], ["arbidol", "TREATMENT", 29, 36], ["SARS", "PROBLEM", 165, 169], ["CoV-2 infection", "PROBLEM", 170, 185], ["infection", "OBSERVATION", 176, 185]]]], "cb1087c0ca9a8eb73028fbdf71f6ca5914a82f8a": [["IntroductionThe spread of Coronavirus Disease 2019 across the United States confirms that not all Americans are equally at risk of infection, severe disease, or mortality.", [["infection", "DISEASE", 131, 140], ["Coronavirus Disease", "PROBLEM", 26, 45], ["infection", "PROBLEM", 131, 140], ["severe disease", "PROBLEM", 142, 156], ["mortality", "PROBLEM", 161, 170], ["spread", "OBSERVATION_MODIFIER", 16, 22], ["Coronavirus Disease", "OBSERVATION", 26, 45], ["infection", "OBSERVATION", 131, 140], ["severe", "OBSERVATION_MODIFIER", 142, 148], ["disease", "OBSERVATION", 149, 156]]], ["Researchers have noted geographic disparities in critical medical resources, such as ventilators, hospital beds, and intensive care unit beds (1) (2) (3) (4) , which are important determinants of COVID-19 survival.", [["COVID-19 survival", "TREATMENT", 196, 213]]], ["Preliminary data from the epidemic in the US is exposing a convergence of demographic and socioeconomic issues that make low-income communities and people of color more vulnerable than others.", [["people", "ORGANISM", 148, 154], ["people", "SPECIES", 148, 154], ["Preliminary data", "TEST", 0, 16], ["demographic and socioeconomic issues", "PROBLEM", 74, 110]]], ["Reports from Detroit, Milwaukee, New Orleans, and Chicago suggest that blacks comprise a disproportionate proportion of COVID-19 cases and deaths relative to their share of the population (5, 6) .IntroductionAge and pre-existing health conditions are recognized as important biological risk factors for serious disease and mortality from COVID-19 (7, 8) .", [["deaths", "DISEASE", 139, 145], ["COVID-19", "CHEMICAL", 338, 346], ["pre-existing health conditions", "PROBLEM", 216, 246], ["serious disease", "PROBLEM", 303, 318], ["COVID", "TEST", 338, 343]]], ["Demographic factors including population density; living arrangements, such as group quarters ( e.g. , adult living facilities, nursing homes, or prisons), household size, household composition ( e.g., grandparents living with grandchildren); or the number of educational institutions, for example, affect contact patterns and transmission rates at the county level (9) (10) (11) (12) (13) .", [["transmission rates", "TEST", 327, 345]]], ["Socioeconomic factors like poverty, job insecurity, and lack of health insurance will determine the ability of populations to work-from-home and \"shelter in place\" (14) (15) (16) , at a time when such non-pharmaceutical interventions are considered a primary defense against the outbreak (17, 18) .IntroductionUnderstanding the distribution of these county-specific characteristics is therefore critical to mounting an adequate, timely, and comprehensive response.", [["such non-pharmaceutical interventions", "TREATMENT", 196, 233]]], ["These structural issues must also be considered as we look ahead to possible scenarios for ending the epidemic, and to ways in which we can reconfigure health systems to be resilient to pandemic risks.Introduction3 .", [["pandemic", "DISEASE", 186, 194]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 11, 2020. . https://doi.org/10.1101/2020.04.08.20058248 doi: medRxiv preprint(which was not certified by peer review)To assess each county's level of risk of high COVID-19 medical burden, we examine available data for a range of characteristics for all U.S. counties, or county equivalents.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["high COVID-19 medical burden", "PROBLEM", 424, 452], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["We have made available an online tool for planners to explore the burden of these risk factors and others in their counties (Supplemental Materials Text S1).MethodsUsing publicly available county-specific data from the Area Health Resources Files (19) , American Community Survey (20) , Centers for Disease Control and Prevention Atlas file (21) , National Center for Health Statistics (22), and RWJF Community Health Rankings (23), we identified key biological, demographic, and socioeconomic characteristics influencing susceptibility to COVID-19, guided by international experiences, and consideration of epidemiological parameters of importance.", [["these risk factors", "PROBLEM", 76, 94], ["Disease Control", "TREATMENT", 299, 314], ["COVID", "TEST", 540, 545]]], ["We created five bivariate county-level maps to illustrate examples of key relationships across these categories grouping age and poverty; comorbidities and lack of health insurance; proximity, density and bed capacity; and race and ethnicity, and premature mortality.", [["premature mortality", "DISEASE", 247, 266], ["proximity, density and bed capacity", "PROBLEM", 182, 217], ["premature mortality", "PROBLEM", 247, 266], ["density", "OBSERVATION", 193, 200], ["bed capacity", "OBSERVATION", 205, 217]]], ["Bivariate maps show the risk in a county across independent axes, highlighting both the convergence and divergence of factors.MethodsWe have purposefully avoided weighting these risk factors relative to each other, since there is no strong evidence to rigorously assign importance across categories.", [["Bivariate maps", "TEST", 0, 14], ["Methods", "TREATMENT", 126, 133], ["no strong", "UNCERTAINTY", 230, 239]]], ["The included univariate maps demonstrate the vast heterogeneity in risks across the United States (Supplemental Materials).", [["univariate maps", "TEST", 13, 28], ["Supplemental Materials", "TREATMENT", 99, 121], ["vast", "OBSERVATION_MODIFIER", 45, 49], ["heterogeneity", "OBSERVATION", 50, 63]]], ["The bivariate maps may assist county-and state-level policymakers in their response to COVID-19 by exemplifying how different risk factors together contribute to counties' overall level of COVID-19Methodsburden.MethodsAn online dashboard (Supplemental Materials Text S1) allows querying of these risk factors to create other bivariate maps that may be more informative to a given locality.", [["The bivariate maps", "TEST", 0, 18], ["COVID", "TEST", 87, 92], ["COVID", "TEST", 189, 194], ["these risk factors", "PROBLEM", 290, 308], ["bivariate maps", "TEST", 325, 339]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)MethodsThe copyright holder for this preprint this version posted April 11, 2020. . https://doi.org/10.1101/2020.04.08.20058248 doi: medRxiv preprint option to show counties above different population thresholds.", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["medRxiv preprint option", "TREATMENT", 335, 358], ["med", "ANATOMY", 105, 108]]], ["Moreover, the appropriate covariate threshold for any state or county will depend on the context of that count; therefore, the online dashboard allows interested readers to change the threshold for each covariate.", [["that count", "TEST", 100, 110]]], ["(Supplemental Materials Text S1).Age and povertyAge ( Figure S1 ) is an important biological risk factor for severe disease and mortality from COVID-19.Age and povertyIn a study of 44,672 confirmed cases of COVID-19 from China, the case-fatality rate was highest among the elderly (7).", [["severe disease", "PROBLEM", 109, 123], ["COVID", "TEST", 143, 148], ["a study", "TEST", 170, 177], ["COVID", "TEST", 207, 212], ["fatality rate", "TEST", 237, 250], ["severe", "OBSERVATION_MODIFIER", 109, 115], ["disease", "OBSERVATION", 116, 123]]], ["In the United States, among 2,449 cases from February 12 to March 16, 2020, 53% of ICU admissions and 80% of deaths occurred among adults aged \u226565, with the highest percentage of severe outcomes among adults aged \u226585 years (8) .", [["deaths", "DISEASE", 109, 115], ["severe", "OBSERVATION_MODIFIER", 179, 185]]], ["Poverty ( Figure S2 ), independently, heightens vulnerability to COVID-19, due to its association with higher risk of comorbidities, decreased access to care (15, 16, 24) , and reduced ability to practice social distancing (25) .", [["COVID", "TEST", 65, 70], ["comorbidities", "PROBLEM", 118, 131], ["comorbidities", "OBSERVATION", 118, 131]]], ["We are already beginning to see the differential effects of COVID-19 across communities, with higher burden found in high poverty areas in the United States (27, 28) .Age and povertyOverall, 10% of the US population is over the age of 70 (29), and 12% of the population lives below the poverty line , (30) .", [["COVID", "TEST", 60, 65], ["higher burden", "PROBLEM", 94, 107], ["the US population", "TEST", 198, 215], ["high poverty", "OBSERVATION_MODIFIER", 117, 129]]], ["In 667 of 3,106 counties, more than 20% of households live below the poverty line.", [["poverty line", "OBSERVATION", 69, 81]]], ["111 of 3,106 counties, accounting for about 1.6 million people, have both a high number of 5 .", [["people", "ORGANISM", 56, 62], ["people", "SPECIES", 56, 62], ["high number", "OBSERVATION_MODIFIER", 76, 87]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)Age and povertyThe copyright holder for this preprint this version posted April 11, 2020. . https://doi.org/10.1101/2020.04.08.20058248 doi: medRxiv preprint households below the poverty line and a high proportion of elderly residents.", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 217, 237], ["medRxiv preprint households", "TREATMENT", 343, 370], ["the poverty line", "TREATMENT", 377, 393], ["med", "ANATOMY", 105, 108]]], ["Georgia, Texas, and Arkansas are the states with the largest number of such counties.", [["largest", "OBSERVATION_MODIFIER", 53, 60]]], ["We discuss the compounding effect of poverty on age in subsequent sections.", [["sections", "ANATOMY", 66, 74]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)Age and povertyThe copyright holder for this preprint this version posted April 11, 2020. . https://doi.org/10.1101/2020.04.08.20058248 doi: medRxiv preprint Comorbidities and lack of health insurance Pre-existing health conditions, including hypertension, diabetes, and coronary heart disease, increase the likelihood of severe disease and mortality from COVID-19.", [["coronary", "ANATOMY", 473, 481], ["heart", "ANATOMY", 482, 487], ["CC", "CHEMICAL", 0, 2], ["hypertension", "DISEASE", 445, 457], ["diabetes", "DISEASE", 459, 467], ["coronary heart disease", "DISEASE", 473, 495], ["COVID-19", "CHEMICAL", 558, 566], ["heart", "ORGAN", 482, 487], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 217, 237], ["Pre-existing health conditions", "PROBLEM", 403, 433], ["hypertension", "PROBLEM", 445, 457], ["diabetes", "PROBLEM", 459, 467], ["coronary heart disease", "PROBLEM", 473, 495], ["severe disease", "PROBLEM", 524, 538], ["COVID", "TEST", 558, 563], ["med", "ANATOMY", 105, 108], ["hypertension", "OBSERVATION", 445, 457], ["diabetes", "OBSERVATION", 459, 467], ["coronary heart", "ANATOMY", 473, 487], ["disease", "OBSERVATION", 488, 495], ["severe", "OBSERVATION_MODIFIER", 524, 530], ["disease", "OBSERVATION", 531, 538]]], ["In a study from China, the overall case-fatality rate was estimated at 2.4%, but was markedly higher for those with cardiovascular disease (10.5%), diabetes (7.3%), chronic respiratory disease (6.3%), and hypertension (6.0%) (7) .", [["cardiovascular", "ANATOMY", 116, 130], ["respiratory", "ANATOMY", 173, 184], ["cardiovascular disease", "DISEASE", 116, 138], ["diabetes", "DISEASE", 148, 156], ["chronic respiratory disease", "DISEASE", 165, 192], ["hypertension", "DISEASE", 205, 217], ["a study", "TEST", 3, 10], ["fatality rate", "TEST", 40, 53], ["cardiovascular disease", "PROBLEM", 116, 138], ["diabetes", "PROBLEM", 148, 156], ["chronic respiratory disease", "PROBLEM", 165, 192], ["hypertension", "PROBLEM", 205, 217], ["chronic", "OBSERVATION_MODIFIER", 165, 172], ["respiratory disease", "OBSERVATION", 173, 192], ["hypertension", "OBSERVATION", 205, 217]]], ["The prevalence of non-communicable diseases varies across the US.", [["non-communicable diseases", "DISEASE", 18, 43], ["non-communicable diseases", "PROBLEM", 18, 43], ["the US", "TEST", 58, 64], ["non-communicable diseases", "OBSERVATION", 18, 43]]], ["The 55 of 3,106 counties, where at least 20% of the population over 20 years old carries a diagnosis of diabetes, are primarily concentrated in the Southeast US, with the most in Georgia, Texas, and Alabama, consistent with previous research ( Figure S3 ) (31, 32) .Age and povertyIndividuals without health insurance ( Figure S4 ) have limited access to hospital care (33) .", [["diabetes", "DISEASE", 104, 112], ["diabetes", "PROBLEM", 104, 112], ["diabetes", "OBSERVATION", 104, 112], ["concentrated", "OBSERVATION_MODIFIER", 128, 140], ["consistent with", "UNCERTAINTY", 208, 223]]], ["Those without health insurance are also more likely to work in service-oriented industries with decreased ability to work from home (34) , putting them at higher risk of infection.", [["infection", "DISEASE", 170, 179], ["infection", "PROBLEM", 170, 179], ["infection", "OBSERVATION", 170, 179]]], ["Within weeks of implementing social distancing measures, and closures of schools and non-essential businesses, unemployment in the United States rose from 282,000 to 3.3 million (35) .", [["social distancing measures", "TREATMENT", 29, 55]]], ["The consequence of these unemployment rates on health insurance are not captured in our data.Age and povertyWe examine hospitalization rates of coronary heart disease (CHD) and hypertension (HTN) among Medicare beneficiaries, and the health insurance status of adults 18-64 years old ( Figure 2 ).", [["coronary", "ANATOMY", 144, 152], ["heart", "ANATOMY", 153, 158], ["coronary heart disease", "DISEASE", 144, 166], ["CHD", "DISEASE", 168, 171], ["hypertension", "DISEASE", 177, 189], ["HTN", "DISEASE", 191, 194], ["coronary heart", "MULTI-TISSUE_STRUCTURE", 144, 158], ["coronary heart disease", "PROBLEM", 144, 166], ["CHD", "PROBLEM", 168, 171], ["hypertension", "PROBLEM", 177, 189], ["HTN", "PROBLEM", 191, 194], ["coronary heart", "ANATOMY", 144, 158], ["disease", "OBSERVATION", 159, 166], ["hypertension", "OBSERVATION", 177, 189]]], ["In addition to increasing the burden of severe disease and mortality from COVID-19 in a county, high baseline rates of hospitalization for CHD and HTN among the elderly affect availability of hospital and ICU beds.", [["CHD", "DISEASE", 139, 142], ["HTN", "DISEASE", 147, 150], ["severe disease", "PROBLEM", 40, 54], ["COVID", "TEST", 74, 79], ["CHD", "PROBLEM", 139, 142], ["HTN", "PROBLEM", 147, 150], ["increasing", "OBSERVATION_MODIFIER", 15, 25], ["severe", "OBSERVATION_MODIFIER", 40, 46], ["disease", "OBSERVATION", 47, 54]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 11, 2020.Proximity, density and bed capacityHousehold size and characteristics like the number of generations living together ( Figure S5 ), will affect transmission rates, household vulnerability, and the feasibility of social distancing measures.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["Proximity, density and bed capacity", "PROBLEM", 275, 310], ["social distancing measures", "TREATMENT", 487, 513], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108], ["density", "OBSERVATION", 286, 293], ["bed capacity", "OBSERVATION_MODIFIER", 298, 310], ["size", "OBSERVATION_MODIFIER", 320, 324]]], ["A study looking at transmission among close contacts in Shenzhen, China estimated a secondary attack rate of approximately 15% among household contacts (36) .", [["A study", "TEST", 0, 7]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 11, 2020. . https://doi.org/10.1101/2020.04.08.20058248 doi: medRxiv preprint increases the risk of transmission for members of these communities.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["medRxiv", "TREATMENT", 327, 334], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["527 of 3,111 counties have greater than 5% of their population living in group quarters ( Figure S6 ).(which was not certified by peer review)Additionally, high population density increases risk of rapid transmission, especially in the absence of adequate or timely social distancing measures, as evidenced by the current scale of the outbreak in New York City (38) .", [["high population density", "PROBLEM", 156, 179], ["rapid transmission", "PROBLEM", 198, 216], ["high", "OBSERVATION_MODIFIER", 156, 160], ["population", "OBSERVATION_MODIFIER", 161, 171], ["density", "OBSERVATION", 172, 179], ["rapid", "OBSERVATION_MODIFIER", 198, 203]]], ["425 of 3,111 counties, mostly concentrated in the eastern United States and on the West coast, have greater than 100 people living per square mile, compared to the national median of 45 people per square mile ( Figure S7 ).(which was not certified by peer review)The ability of counties to respond to these additional risks will partly depend on local bed capacity.(which was not certified by peer review)Several studies examining hospital capacity in the U.S. predict substantial shortages in hospital-and ICU-beds (1-4).", [["people", "ORGANISM", 186, 192], ["people", "SPECIES", 117, 123], ["people", "SPECIES", 186, 192], ["Several studies", "TEST", 405, 420], ["mostly", "OBSERVATION_MODIFIER", 23, 29], ["concentrated", "OBSERVATION_MODIFIER", 30, 42]]], ["949 of 3,111 counties have fewer than 100 hospital beds per 100,000 people, as compared to the national median of 185 ( Figure S8 ).", [["people", "SPECIES", 68, 74]]], ["1,939 of 3,111 counties have fewer than 10 ICU beds per 100,000 population ( Figure S9 ).(which was not certified by peer review)In Figure 3 we examine the overlapping risks of group quarters, population density, and hospital bed capacity.", [["population density", "PROBLEM", 193, 211], ["population", "OBSERVATION_MODIFIER", 193, 203], ["density", "OBSERVATION", 204, 211]]], ["155 of 3,111 counties across the United States are both densely populated and have low hospital bed capacity per capita, and are home to over 17 million people ( Figure 3B ).", [["people", "ORGANISM", 153, 159], ["people", "SPECIES", 153, 159], ["densely", "OBSERVATION_MODIFIER", 56, 63], ["populated", "OBSERVATION", 64, 73], ["low", "OBSERVATION_MODIFIER", 83, 86]]], ["More than 40% of these counties are concentrated in Georgia, Virginia, Ohio, Kentucky, and Michigan, and are at higher risk of being overwhelmed in the event of an outbreak ( Figure 3B ).9.", [["concentrated", "OBSERVATION_MODIFIER", 36, 48]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 11, 2020. .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["Intensive care unit beds are defined as medical/surgical, cardiac, and other intensive care beds (Source: Area Health Resources Files).", [["cardiac", "ANATOMY", 58, 65], ["cardiac", "ANATOMY", 58, 65]]], ["There is high heterogeneity across the US: some counties have a substantial proportion of their population living in group quarters (dark reds), others with low rates of ICU beds (dark blues) and some with high levels of both (dark purple).10.", [["high heterogeneity", "PROBLEM", 9, 27], ["high", "OBSERVATION_MODIFIER", 9, 13], ["heterogeneity", "OBSERVATION", 14, 27], ["substantial", "OBSERVATION_MODIFIER", 64, 75], ["proportion", "OBSERVATION_MODIFIER", 76, 86], ["low rates", "OBSERVATION_MODIFIER", 157, 166], ["high levels", "OBSERVATION_MODIFIER", 206, 217]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 11, 2020. . https://doi.org/10.1101/2020.04.08.20058248 doi: medRxiv preprint Race and ethnicity and premature death (YPLL) Persistent structural inequities in American society have resulted in health disparities that are closely associated with race and ethnicity in the United States (39) .", [["CC", "CHEMICAL", 0, 2], ["premature death", "DISEASE", 367, 382], ["YPLL", "DISEASE", 384, 388], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["medRxiv", "TREATMENT", 327, 334], ["premature death", "PROBLEM", 367, 382], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108], ["Persistent", "OBSERVATION_MODIFIER", 390, 400]]], ["Communities of color do not only have increased risk of chronic diseases (40) , which increase risk of COVID-19 infection, but also experience unequal access to health care (5, 41) .", [["chronic diseases", "DISEASE", 56, 72], ["infection", "DISEASE", 112, 121], ["COVID-19", "SPECIES", 103, 111], ["chronic diseases", "PROBLEM", 56, 72], ["COVID-19 infection", "PROBLEM", 103, 121], ["increased", "OBSERVATION_MODIFIER", 38, 47], ["chronic", "OBSERVATION_MODIFIER", 56, 63], ["diseases", "OBSERVATION", 64, 72], ["infection", "OBSERVATION", 112, 121]]], ["Populations of color are also disproportionately unemployed (42), incarcerated (43) , and without health insurance (14) -all independent risks, as we have discussed above.", [["disproportionately", "OBSERVATION_MODIFIER", 30, 48], ["incarcerated", "OBSERVATION_MODIFIER", 66, 78]]], ["These disparities contribute to higher age-adjusted death rates among non-Hispanic blacks relative to non-Hispanic whites (44) , Even within levels of chronological age, groups subjected to economic and social deprivation have a higher risk of comorbidities and premature mortality compared to people who are chronologically older but more privileged (45, 46) .11.", [["death", "DISEASE", 52, 57], ["people", "ORGANISM", 294, 300], ["people", "SPECIES", 294, 300], ["adjusted death rates", "PROBLEM", 43, 63], ["non-Hispanic blacks", "PROBLEM", 70, 89], ["comorbidities", "PROBLEM", 244, 257], ["premature mortality", "PROBLEM", 262, 281]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 11, 2020. .DiscussionOur findings demonstrate significant inter-county variation in the multiple, interconnected social determinants that will affect both the burden of COVID-19 disease and the ability of communities to effectively respond to it.", [["CC", "CHEMICAL", 0, 2], ["COVID", "DISEASE", 435, 440], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["significant inter-county variation", "PROBLEM", 312, 346], ["COVID-19 disease", "PROBLEM", 435, 451], ["med", "ANATOMY", 105, 108], ["significant", "OBSERVATION_MODIFIER", 312, 323], ["inter-county variation", "OBSERVATION", 324, 346], ["multiple", "OBSERVATION_MODIFIER", 354, 362]]], ["In more than 10% of all counties, more than half the population CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 11, 2020. . https://doi.org/10.1101/2020.04.08.20058248 doi: medRxiv preprint factors, many of which can be traced back to legacies of Jim Crow and race relations in the South (47, 48) .", [["CC", "CHEMICAL", 64, 66], ["The copyright holder", "TREATMENT", 265, 285], ["medRxiv preprint factors", "TREATMENT", 391, 415], ["med", "ANATOMY", 169, 172]]], ["Many Americans with chronic comorbidities, lack (and recent loss) of health insurance, inability to work from home, and poor access to care, are likely to be disproportionately affected by COVID-19, due to their increased risk of both infection and severe disease.", [["chronic comorbidities", "DISEASE", 20, 41], ["infection", "DISEASE", 235, 244], ["chronic comorbidities", "PROBLEM", 20, 41], ["COVID", "TEST", 189, 194], ["both infection", "PROBLEM", 230, 244], ["severe disease", "PROBLEM", 249, 263], ["chronic", "OBSERVATION_MODIFIER", 20, 27], ["comorbidities", "OBSERVATION", 28, 41], ["both", "OBSERVATION_MODIFIER", 230, 234], ["infection", "OBSERVATION", 235, 244], ["severe", "OBSERVATION_MODIFIER", 249, 255], ["disease", "OBSERVATION", 256, 263]]], ["The majority of counties that carry these multiple burdens, however, are also located in states that have been tepid in their social-distancing response (49) .", [["multiple", "OBSERVATION_MODIFIER", 42, 50], ["burdens", "OBSERVATION", 51, 58]]], ["Our analysis provides insights into how communities of color may likely continue to bear disproportionately high burden of infection, severe disease, and mortality (5, 50) .(which was not certified by peer review)Collecting and sharing data on COVID-19 outcomes by race/ethnicity, which surveillance systems hitherto have not been systematically reporting (51, 52) , will be crucial to understanding and rectifying inequities in the distribution of COVID-19 outcomes.(which was not certified by peer review)Attempts to avert the high burden among these populations will require a concerted strategy to ameliorate the conditions that compound their vulnerability, beyond merely ramping up bed capacity.(which was not certified by peer review)These counties and states, in particular, will benefit from implementing measures that make it possible for individuals and families to practice social distancing, for example, through financial aid and expanded healthcare.", [["infection", "DISEASE", 123, 132], ["Our analysis", "TEST", 0, 12], ["infection", "PROBLEM", 123, 132], ["severe disease", "PROBLEM", 134, 148], ["COVID", "TEST", 244, 249], ["surveillance systems", "TEST", 287, 307], ["the high burden", "PROBLEM", 525, 540], ["a concerted strategy", "TREATMENT", 578, 598], ["infection", "OBSERVATION", 123, 132], ["severe", "OBSERVATION_MODIFIER", 134, 140], ["disease", "OBSERVATION", 141, 148]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 11, 2020. . https://doi.org/10.1101/2020.04.08.20058248 doi: medRxiv preprint immigration status, numbers of incarcerated and homeless persons, measures of inequality like the Gini coefficient and Index of Concentration at the Extremes (ICE), and density of residential drug treatment programs and residential mental health facilities, may all contribute to how counties are affected and respond.", [["CC", "CHEMICAL", 0, 2], ["persons", "SPECIES", 401, 408], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["residential drug treatment programs", "TREATMENT", 524, 559], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108], ["incarcerated", "OBSERVATION_MODIFIER", 375, 387]]], ["There currently is insufficient evidence to justify assigning weights to different risk factors, but as more data become available, future research may expand on our analysis by constructing a polysocial risk score (54) .ConclusionAt a time when the US continues to inadequately test its population or protect healthcare providers, the need for actionable, contextually relevant data that allows for judicious distribution of our limited resources becomes imperative.", [["different risk factors", "PROBLEM", 73, 95], ["our analysis", "TEST", 162, 174], ["the US", "TEST", 246, 252]]], ["The morbidity and mortality toll, as early numbers indicate, will likely be disproportionately borne by communities of color in the absence of concerted, aggressive, and proactive responses across administrative boundaries that account for the vast inter-county variability in risks across populations.AcknowledgementsWe thank Ayesha S. Mahmud, Nishant Kishore, and Tori Cowger for their valuable input and feedback.Competing InterestsNone to declare 14 .", [["morbidity", "OBSERVATION", 4, 13]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 11, 2020.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 11, 2020. . https://doi.org/10.1101/2020.04.08.20058248 doi: medRxiv preprint .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["medRxiv preprint", "TREATMENT", 327, 343], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 11, 2020. . https://doi.org/10.1101/2020.04.08.20058248 doi: medRxiv preprint .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["medRxiv preprint", "TREATMENT", 327, 343], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 11, 2020. . .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 11, 2020. . https://doi.org/10.1101/2020.04.08.20058248 doi: medRxiv preprintSupplemental MaterialsSupplemental Text S1.", [["CC", "CHEMICAL", 0, 2], ["Supplemental MaterialsSupplemental Text S1", "PROTEIN", 343, 385], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["medRxiv", "TREATMENT", 327, 334], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["For interested readers, we provide an interactive results viewer at https://mkiang.shinyapps.io/county_risks / which allows readers to select any combination of covariates discussed in this paper as well as a range of thresholds.", [["covariates", "TREATMENT", 161, 171]]], ["Age-adjusted percent of adults over 20 years old who are diagnosed with diabetes, 2016 4.", [["diabetes", "DISEASE", 72, 80], ["diabetes", "PROBLEM", 72, 80], ["diabetes", "OBSERVATION", 72, 80]]], ["Figure S6 .", [["S6", "PROTEIN", 7, 9]]], ["Population per square mile of land mass (log 10), 2010 8.", [["land mass", "PROBLEM", 30, 39], ["mass", "OBSERVATION", 35, 39]]], ["Coronary heart disease-related hospitalizations per 1,000 Medicare beneficiaries (65+), 2014-2016 11.", [["Coronary", "ANATOMY", 0, 8], ["heart", "ANATOMY", 9, 14], ["Coronary heart disease", "DISEASE", 0, 22], ["heart", "ORGAN", 9, 14], ["Coronary heart disease", "PROBLEM", 0, 22], ["heart", "ANATOMY", 9, 14], ["disease", "OBSERVATION", 15, 22]]], ["Hypertension hospitalization rate per 1,000 Medicare beneficiaries (65+), 2014-2016 12.", [["Hypertension", "DISEASE", 0, 12], ["Hypertension", "PROBLEM", 0, 12]]], ["Average household size, 2018 13.", [["size", "OBSERVATION_MODIFIER", 18, 22]]], ["Figure S15 .", [["S15", "GENE_OR_GENE_PRODUCT", 7, 10]]], ["Population estimates (log 10), 2018 17.", [["Population estimates", "TEST", 0, 20]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 11, 2020.22.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 11, 2020. .23.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 11, 2020. .24.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 11, 2020. .25.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 11, 2020. .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["Figure S6 .", [["S6", "PROTEIN", 7, 9]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 11, 2020.27.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 11, 2020. .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 11, 2020. .29.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 11, 2020.30.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 11, 2020.31.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 11, 2020.32.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 11, 2020.33.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)33The copyright holder for this preprint this version posted April 11, 2020. . https://doi.org/10.1101/2020.04.08.20058248 doi: medRxiv preprint Figure S14 .", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)34The copyright holder for this preprint this version posted April 11, 2020.35.", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)35The copyright holder for this preprint this version posted April 11, 2020.", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)35The copyright holder for this preprint this version posted April 11, 2020.", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)35The copyright holder for this preprint this version posted April 11, 2020.38.", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)38The copyright holder for this preprint this version posted April 11, 2020. . https://doi.org/10.1101/2020.04.08.20058248 doi: medRxiv preprint", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["medRxiv", "TREATMENT", 330, 337], ["med", "ANATOMY", 105, 108]]]], "9fee13458c2afb3c9dac6c04c0ccf070d703f54d": [["IntroductionAcute lung injury (ALI), and its more severe form, acute respiratory distress syndrome (ARDS), are important causes of morbidity and mortality in critically ill patients [1] .", [["lung", "ANATOMY", 18, 22], ["respiratory", "ANATOMY", 69, 80], ["IntroductionAcute lung injury", "DISEASE", 0, 29], ["ALI", "DISEASE", 31, 34], ["acute respiratory distress syndrome", "DISEASE", 63, 98], ["ARDS", "DISEASE", 100, 104], ["critically ill", "DISEASE", 158, 172], ["lung", "ORGAN", 18, 22], ["patients", "ORGANISM", 173, 181], ["patients", "SPECIES", 173, 181], ["IntroductionAcute lung injury (ALI)", "PROBLEM", 0, 35], ["acute respiratory distress syndrome", "PROBLEM", 63, 98], ["ARDS", "PROBLEM", 100, 104], ["morbidity", "PROBLEM", 131, 140], ["lung", "ANATOMY", 18, 22], ["injury", "OBSERVATION", 23, 29], ["ALI", "OBSERVATION", 31, 34], ["more severe", "OBSERVATION_MODIFIER", 45, 56], ["acute", "OBSERVATION_MODIFIER", 63, 68], ["respiratory distress", "OBSERVATION", 69, 89]]], ["One of the hallmarks of ALI/ARDS is the accumulation of protein-rich edema fluid in the alveolar compartment of the lung [1] , caused by increased fluid influx into the airspaces, and decreased fluid transport out of these airspaces.", [["edema fluid", "ANATOMY", 69, 80], ["alveolar compartment", "ANATOMY", 88, 108], ["lung", "ANATOMY", 116, 120], ["fluid", "ANATOMY", 147, 152], ["airspaces", "ANATOMY", 169, 178], ["fluid", "ANATOMY", 194, 199], ["airspaces", "ANATOMY", 223, 232], ["ALI", "DISEASE", 24, 27], ["ARDS", "DISEASE", 28, 32], ["edema", "DISEASE", 69, 74], ["edema", "PATHOLOGICAL_FORMATION", 69, 74], ["fluid", "ORGANISM_SUBSTANCE", 75, 80], ["alveolar compartment", "MULTI-TISSUE_STRUCTURE", 88, 108], ["lung", "ORGAN", 116, 120], ["fluid", "ORGANISM_SUBSTANCE", 147, 152], ["airspaces", "MULTI-TISSUE_STRUCTURE", 169, 178], ["airspaces", "MULTI-TISSUE_STRUCTURE", 223, 232], ["ALI", "PROBLEM", 24, 27], ["ARDS", "PROBLEM", 28, 32], ["protein-rich edema fluid", "PROBLEM", 56, 80], ["increased fluid influx into the airspaces", "PROBLEM", 137, 178], ["decreased fluid transport", "PROBLEM", 184, 209], ["ALI", "OBSERVATION", 24, 27], ["ARDS", "OBSERVATION", 28, 32], ["accumulation", "OBSERVATION_MODIFIER", 40, 52], ["protein", "OBSERVATION_MODIFIER", 56, 63], ["rich", "OBSERVATION_MODIFIER", 64, 68], ["edema", "OBSERVATION_MODIFIER", 69, 74], ["fluid", "OBSERVATION", 75, 80], ["alveolar", "ANATOMY_MODIFIER", 88, 96], ["compartment", "ANATOMY_MODIFIER", 97, 108], ["lung", "ANATOMY", 116, 120], ["increased", "OBSERVATION_MODIFIER", 137, 146], ["fluid influx", "OBSERVATION", 147, 159], ["airspaces", "ANATOMY", 169, 178], ["decreased", "OBSERVATION_MODIFIER", 184, 193], ["fluid transport", "OBSERVATION", 194, 209], ["airspaces", "ANATOMY_MODIFIER", 223, 232]]], ["In the case of the latter, impaired alveolar fluid clearance (AFC) is a key underlying cause of alveolar edema persistence [2, 3] , and the ability of ALI/ARDS patients to clear edema fluid is correlated with a shorter stay in the intensive care unit, and reduced mortality [4] .", [["alveolar fluid", "ANATOMY", 36, 50], ["alveolar edema", "ANATOMY", 96, 110], ["edema fluid", "ANATOMY", 178, 189], ["edema", "DISEASE", 105, 110], ["ALI", "DISEASE", 151, 154], ["ARDS", "DISEASE", 155, 159], ["edema", "DISEASE", 178, 183], ["alveolar fluid", "MULTI-TISSUE_STRUCTURE", 36, 50], ["alveolar edema", "PATHOLOGICAL_FORMATION", 96, 110], ["patients", "ORGANISM", 160, 168], ["edema", "PATHOLOGICAL_FORMATION", 178, 183], ["patients", "SPECIES", 160, 168], ["impaired alveolar fluid clearance", "PROBLEM", 27, 60], ["alveolar edema persistence", "PROBLEM", 96, 122], ["ALI", "PROBLEM", 151, 154], ["ARDS", "PROBLEM", 155, 159], ["edema fluid", "PROBLEM", 178, 189], ["impaired", "OBSERVATION_MODIFIER", 27, 35], ["alveolar", "OBSERVATION", 36, 44], ["fluid clearance", "OBSERVATION", 45, 60], ["alveolar", "ANATOMY_MODIFIER", 96, 104], ["edema", "OBSERVATION", 105, 110], ["ARDS", "OBSERVATION", 155, 159], ["edema", "OBSERVATION", 178, 183]]], ["Much effort has therefore been focused on identifying pathogenic mechanisms underlying perturbed AFC in ALI/ARDS patients, and how we can potentiate AFC, which may form the basis of novel or improved therapeu-tic strategies.", [["ALI", "DISEASE", 104, 107], ["ARDS", "DISEASE", 108, 112], ["tic", "DISEASE", 209, 212], ["AFC", "GENE_OR_GENE_PRODUCT", 97, 100], ["patients", "ORGANISM", 113, 121], ["AFC", "GENE_OR_GENE_PRODUCT", 149, 152], ["patients", "SPECIES", 113, 121], ["ALI", "PROBLEM", 104, 107], ["ARDS", "PROBLEM", 108, 112], ["AFC", "PROBLEM", 149, 152], ["ARDS", "OBSERVATION", 108, 112]]], ["The accompanying review by Vad\u00e1sz et al. (http://dx.doi.org/10.1007/s00134-007-0661-8) details our current understanding of the signaling mechanisms that facilitate AFC.", [["AFC", "GENE_OR_GENE_PRODUCT", 165, 168], ["the signaling mechanisms", "PROBLEM", 124, 148]]], ["To complement that report this review focuses on how intact organ and animal models and clinical studies have facilitated our understanding of AFC in ALI/ARDS.", [["organ", "ANATOMY", 60, 65], ["ALI", "DISEASE", 150, 153], ["ARDS", "DISEASE", 154, 158], ["organ", "ORGAN", 60, 65], ["AFC", "GENE_OR_GENE_PRODUCT", 143, 146], ["clinical studies", "TEST", 88, 104], ["AFC", "PROBLEM", 143, 146], ["ALI", "PROBLEM", 150, 153], ["ARDS", "PROBLEM", 154, 158], ["ALI", "ANATOMY", 150, 153], ["ARDS", "OBSERVATION", 154, 158]]], ["We also discuss how some of these studies have led to novel therapeutic approaches.IntroductionEdema fluid is transported out of the alveolar airspaces into the interstitium, where it is cleared by the lymphatic drainage.", [["alveolar airspaces", "ANATOMY", 133, 151], ["interstitium", "ANATOMY", 161, 173], ["lymphatic", "ANATOMY", 202, 211], ["alveolar airspaces", "MULTI-TISSUE_STRUCTURE", 133, 151], ["interstitium", "TISSUE", 161, 173], ["lymphatic", "MULTI-TISSUE_STRUCTURE", 202, 211], ["these studies", "TEST", 28, 41], ["IntroductionEdema fluid", "PROBLEM", 83, 106], ["the lymphatic drainage", "PROBLEM", 198, 220], ["fluid", "OBSERVATION", 101, 106], ["alveolar", "ANATOMY_MODIFIER", 133, 141], ["airspaces", "ANATOMY_MODIFIER", 142, 151], ["interstitium", "ANATOMY_MODIFIER", 161, 173], ["cleared", "OBSERVATION_MODIFIER", 187, 194], ["lymphatic", "ANATOMY", 202, 211], ["drainage", "OBSERVATION", 212, 220]]], ["Alternatively, fluid can also be transported into the vasculature, where it is cleared by the circulation.", [["fluid", "ANATOMY", 15, 20], ["vasculature", "ANATOMY", 54, 65], ["fluid", "ORGANISM_SUBSTANCE", 15, 20], ["vasculature", "MULTI-TISSUE_STRUCTURE", 54, 65], ["fluid", "PROBLEM", 15, 20], ["fluid", "OBSERVATION", 15, 20], ["vasculature", "ANATOMY", 54, 65], ["circulation", "OBSERVATION_MODIFIER", 94, 105]]], ["Maintenance of an optimum alveolar fluid volume results from a finely balanced influx of fluid into the lung, and fluid clearance out of the lung; therefore, endothelial and epithelial barrier integrity is essential for optimal fluid balance [3] .", [["alveolar fluid", "ANATOMY", 26, 40], ["fluid", "ANATOMY", 89, 94], ["lung", "ANATOMY", 104, 108], ["fluid", "ANATOMY", 114, 119], ["lung", "ANATOMY", 141, 145], ["endothelial", "ANATOMY", 158, 169], ["epithelial barrier", "ANATOMY", 174, 192], ["fluid", "ANATOMY", 228, 233], ["alveolar fluid", "MULTI-TISSUE_STRUCTURE", 26, 40], ["lung", "ORGAN", 104, 108], ["fluid", "ORGANISM_SUBSTANCE", 114, 119], ["lung", "ORGAN", 141, 145], ["endothelial", "CELL", 158, 169], ["epithelial barrier", "TISSUE", 174, 192], ["fluid", "ORGANISM_SUBSTANCE", 228, 233], ["an optimum alveolar fluid volume", "TEST", 15, 47], ["a finely balanced influx of fluid into the lung", "PROBLEM", 61, 108], ["fluid clearance", "TEST", 114, 129], ["endothelial and epithelial barrier integrity", "TREATMENT", 158, 202], ["optimal fluid balance", "TEST", 220, 241], ["alveolar", "ANATOMY_MODIFIER", 26, 34], ["fluid volume", "OBSERVATION", 35, 47], ["fluid", "OBSERVATION", 89, 94], ["lung", "ANATOMY", 104, 108], ["fluid clearance", "OBSERVATION", 114, 129], ["lung", "ANATOMY", 141, 145], ["endothelial", "ANATOMY", 158, 169], ["epithelial", "ANATOMY_MODIFIER", 174, 184], ["barrier integrity", "OBSERVATION", 185, 202]]], ["In patients with ALI/ARDS, the integrity of both the endothelial and epithelial barriers may be compromised, leading to accelerated fluid influx into the alveolar compartment and impaired AFC [3] .", [["endothelial", "ANATOMY", 53, 64], ["epithelial", "ANATOMY", 69, 79], ["fluid", "ANATOMY", 132, 137], ["alveolar compartment", "ANATOMY", 154, 174], ["ALI", "DISEASE", 17, 20], ["ARDS", "DISEASE", 21, 25], ["patients", "ORGANISM", 3, 11], ["endothelial", "CELL", 53, 64], ["epithelial", "TISSUE", 69, 79], ["fluid", "ORGANISM_SUBSTANCE", 132, 137], ["alveolar compartment", "MULTI-TISSUE_STRUCTURE", 154, 174], ["patients", "SPECIES", 3, 11], ["ALI", "PROBLEM", 17, 20], ["ARDS", "PROBLEM", 21, 25], ["accelerated fluid influx into the alveolar compartment", "PROBLEM", 120, 174], ["impaired AFC", "PROBLEM", 179, 191], ["ARDS", "OBSERVATION", 21, 25], ["endothelial", "ANATOMY", 53, 64], ["epithelial", "ANATOMY", 69, 79], ["fluid influx", "OBSERVATION", 132, 144], ["alveolar compartment", "OBSERVATION", 154, 174], ["impaired", "OBSERVATION_MODIFIER", 179, 187], ["AFC", "OBSERVATION", 188, 191]]], ["In healthy lungs the alveolar epithelium is considerably less permeable than the endothelium [5] .", [["lungs", "ANATOMY", 11, 16], ["alveolar epithelium", "ANATOMY", 21, 40], ["endothelium", "ANATOMY", 81, 92], ["lungs", "ORGAN", 11, 16], ["alveolar epithelium", "TISSUE", 21, 40], ["endothelium", "TISSUE", 81, 92], ["lungs", "ANATOMY", 11, 16], ["alveolar", "ANATOMY_MODIFIER", 21, 29], ["epithelium", "ANATOMY_MODIFIER", 30, 40], ["considerably", "OBSERVATION_MODIFIER", 44, 56], ["less", "OBSERVATION_MODIFIER", 57, 61], ["permeable", "OBSERVATION_MODIFIER", 62, 71]]], ["Approximately 90% of the alveolar epithelium surface area is composed of flat alveolar type I cells, with the remaining 10% accounted for by cuboidal type II cells which produce surfactant and are progenitor cells that regenerate the epithelium after injury.", [["alveolar epithelium surface area", "ANATOMY", 25, 57], ["alveolar type I cells", "ANATOMY", 78, 99], ["cuboidal type II cells", "ANATOMY", 141, 163], ["progenitor cells", "ANATOMY", 197, 213], ["epithelium", "ANATOMY", 234, 244], ["alveolar epithelium", "TISSUE", 25, 44], ["alveolar type I cells", "CELL", 78, 99], ["cuboidal type II cells", "CELL", 141, 163], ["progenitor cells", "CELL", 197, 213], ["epithelium", "TISSUE", 234, 244], ["flat alveolar type I cells", "CELL_TYPE", 73, 99], ["cuboidal type II cells", "CELL_TYPE", 141, 163], ["progenitor cells", "CELL_TYPE", 197, 213], ["the alveolar epithelium surface area", "PROBLEM", 21, 57], ["flat alveolar type I cells", "PROBLEM", 73, 99], ["cuboidal type II cells", "PROBLEM", 141, 163], ["surfactant", "TREATMENT", 178, 188], ["progenitor cells", "PROBLEM", 197, 213], ["injury", "PROBLEM", 251, 257], ["alveolar", "ANATOMY_MODIFIER", 25, 33], ["epithelium", "ANATOMY_MODIFIER", 34, 44], ["surface", "ANATOMY_MODIFIER", 45, 52], ["flat", "OBSERVATION_MODIFIER", 73, 77], ["alveolar type I cells", "OBSERVATION", 78, 99], ["surfactant", "OBSERVATION", 178, 188], ["progenitor cells", "OBSERVATION", 197, 213], ["epithelium", "OBSERVATION_MODIFIER", 234, 244]]], ["Historically, type II cells are accredited with a key role in AFC.", [["type II cells", "ANATOMY", 14, 27], ["type II cells", "CELL", 14, 27], ["AFC", "CANCER", 62, 65], ["type II cells", "CELL_TYPE", 14, 27], ["type II cells", "PROBLEM", 14, 27]]], ["It is widely accepted that AFC is driven by sodium transport across the airway epithelium, which is affected by the concerted action of two sodium transport systems: the epithelial sodium channel (ENaC) [6] and the Na + , K + transporting adenosine-5 -triphosphatase (Na,K-ATPase) [7] as well as the cystic fibrosis transmembrane conductance regulator (CFTR; a chloride channel) [8] and other, as yet uncharacterized channels [9] .", [["airway epithelium", "ANATOMY", 72, 89], ["epithelial", "ANATOMY", 170, 180], ["sodium", "CHEMICAL", 44, 50], ["sodium", "CHEMICAL", 140, 146], ["sodium", "CHEMICAL", 181, 187], ["Na", "CHEMICAL", 215, 217], ["K", "CHEMICAL", 222, 223], ["adenosine", "CHEMICAL", 239, 248], ["Na", "CHEMICAL", 268, 270], ["K", "CHEMICAL", 271, 272], ["fibrosis", "DISEASE", 307, 315], ["chloride", "CHEMICAL", 361, 369], ["sodium", "CHEMICAL", 44, 50], ["sodium", "CHEMICAL", 140, 146], ["sodium", "CHEMICAL", 181, 187], ["Na +", "CHEMICAL", 215, 219], ["K +", "CHEMICAL", 222, 225], ["adenosine", "CHEMICAL", 239, 248], ["Na", "CHEMICAL", 268, 270], ["K", "CHEMICAL", 271, 272], ["chloride", "CHEMICAL", 361, 369], ["AFC", "GENE_OR_GENE_PRODUCT", 27, 30], ["sodium", "SIMPLE_CHEMICAL", 44, 50], ["airway epithelium", "TISSUE", 72, 89], ["sodium", "SIMPLE_CHEMICAL", 140, 146], ["epithelial sodium channel", "GENE_OR_GENE_PRODUCT", 170, 195], ["ENaC", "GENE_OR_GENE_PRODUCT", 197, 201], ["Na +", "SIMPLE_CHEMICAL", 215, 219], ["K + transporting adenosine-5 -triphosphatase", "GENE_OR_GENE_PRODUCT", 222, 266], ["Na,K-ATPase", "GENE_OR_GENE_PRODUCT", 268, 279], ["cystic fibrosis transmembrane conductance regulator", "GENE_OR_GENE_PRODUCT", 300, 351], ["CFTR", "GENE_OR_GENE_PRODUCT", 353, 357], ["epithelial sodium channel", "PROTEIN", 170, 195], ["ENaC", "PROTEIN", 197, 201], ["Na + , K + transporting adenosine-5 -triphosphatase", "PROTEIN", 215, 266], ["Na,K-ATPase", "PROTEIN", 268, 279], ["cystic fibrosis transmembrane conductance regulator", "PROTEIN", 300, 351], ["CFTR", "PROTEIN", 353, 357], ["chloride channel", "PROTEIN", 361, 377], ["the epithelial sodium channel", "TEST", 166, 195], ["the Na", "TEST", 211, 217], ["K", "TEST", 222, 223], ["adenosine", "TEST", 239, 248], ["triphosphatase", "TEST", 252, 266], ["Na", "TEST", 268, 270], ["the cystic fibrosis transmembrane conductance regulator", "PROBLEM", 296, 351], ["a chloride channel)", "TREATMENT", 359, 378], ["AFC", "OBSERVATION", 27, 30], ["airway", "ANATOMY", 72, 78], ["epithelium", "ANATOMY_MODIFIER", 79, 89], ["cystic", "OBSERVATION_MODIFIER", 300, 306], ["fibrosis", "OBSERVATION", 307, 315]]], ["Impaired function of any one of these ion transport systems can perturb AFC.", [["AFC", "GENE_OR_GENE_PRODUCT", 72, 75], ["AFC", "PROTEIN", 72, 75]]], ["Diffuse alveolar damage, including severe alveolar epithelial damage, is one of the hallmarks of ALI/ARDS [1, 10] , where extensive type I cell necrosis occurs, leaving an intact but denuded basement membrane which is repopulated by hyperplastic type II cells that regenerate the alveolar epithelium [11] .", [["alveolar", "ANATOMY", 8, 16], ["alveolar epithelial", "ANATOMY", 42, 61], ["cell", "ANATOMY", 139, 143], ["basement membrane", "ANATOMY", 191, 208], ["hyperplastic type II cells", "ANATOMY", 233, 259], ["alveolar epithelium", "ANATOMY", 280, 299], ["alveolar damage", "DISEASE", 8, 23], ["alveolar epithelial damage", "DISEASE", 42, 68], ["ALI", "DISEASE", 97, 100], ["ARDS", "DISEASE", 101, 105], ["necrosis", "DISEASE", 144, 152], ["alveolar", "MULTI-TISSUE_STRUCTURE", 8, 16], ["alveolar epithelial", "TISSUE", 42, 61], ["cell", "CELL", 139, 143], ["basement membrane", "CELLULAR_COMPONENT", 191, 208], ["hyperplastic type II cells", "CELL", 233, 259], ["alveolar epithelium", "TISSUE", 280, 299], ["hyperplastic type II cells", "CELL_TYPE", 233, 259], ["Diffuse alveolar damage", "PROBLEM", 0, 23], ["severe alveolar epithelial damage", "PROBLEM", 35, 68], ["ALI", "PROBLEM", 97, 100], ["ARDS", "PROBLEM", 101, 105], ["extensive type I cell necrosis", "PROBLEM", 122, 152], ["hyperplastic type II cells", "PROBLEM", 233, 259], ["alveolar", "ANATOMY_MODIFIER", 8, 16], ["damage", "OBSERVATION", 17, 23], ["severe", "OBSERVATION_MODIFIER", 35, 41], ["alveolar", "ANATOMY_MODIFIER", 42, 50], ["epithelial", "ANATOMY_MODIFIER", 51, 61], ["damage", "OBSERVATION", 62, 68], ["ALI", "OBSERVATION", 97, 100], ["ARDS", "OBSERVATION", 101, 105], ["extensive", "OBSERVATION_MODIFIER", 122, 131], ["type I", "OBSERVATION_MODIFIER", 132, 138], ["cell necrosis", "OBSERVATION", 139, 152], ["intact", "OBSERVATION", 172, 178], ["denuded", "OBSERVATION_MODIFIER", 183, 190], ["basement membrane", "OBSERVATION_MODIFIER", 191, 208], ["repopulated", "OBSERVATION_MODIFIER", 218, 229], ["hyperplastic type II cells", "OBSERVATION", 233, 259], ["alveolar epithelium", "OBSERVATION", 280, 299]]], ["Given the established importance of the type II cell in AFC [6] and the emerging importance of the type I cell in AFC with the recent discovery that type I cells also contain functional sodium and chloride channels [12] , this epithelial damage Fig. 1 Factors that cause impaired alveolar fluid clearance in ALI/ARDS that have been investigated in animal and organ models and in clinical studies.", [["type II cell", "ANATOMY", 40, 52], ["type I cell", "ANATOMY", 99, 110], ["AFC", "ANATOMY", 114, 117], ["type I cells", "ANATOMY", 149, 161], ["epithelial", "ANATOMY", 227, 237], ["alveolar fluid", "ANATOMY", 280, 294], ["organ", "ANATOMY", 359, 364], ["sodium", "CHEMICAL", 186, 192], ["chloride", "CHEMICAL", 197, 205], ["ALI", "DISEASE", 308, 311], ["ARDS", "DISEASE", 312, 316], ["sodium", "CHEMICAL", 186, 192], ["chloride", "CHEMICAL", 197, 205], ["type II cell", "CELL", 40, 52], ["type I cell", "CELL", 99, 110], ["AFC", "CELL", 114, 117], ["type I cells", "CELL", 149, 161], ["sodium", "SIMPLE_CHEMICAL", 186, 192], ["chloride", "SIMPLE_CHEMICAL", 197, 205], ["epithelial", "TISSUE", 227, 237], ["alveolar fluid", "MULTI-TISSUE_STRUCTURE", 280, 294], ["organ", "ORGAN", 359, 364], ["type II cell", "CELL_TYPE", 40, 52], ["type I cell", "CELL_TYPE", 99, 110], ["type I cells", "CELL_TYPE", 149, 161], ["the type I cell", "PROBLEM", 95, 110], ["type I cells", "PROBLEM", 149, 161], ["functional sodium and chloride channels", "TREATMENT", 175, 214], ["this epithelial damage Fig", "PROBLEM", 222, 248], ["impaired alveolar fluid clearance", "PROBLEM", 271, 304], ["ALI", "PROBLEM", 308, 311], ["ARDS", "PROBLEM", 312, 316], ["clinical studies", "TEST", 379, 395], ["epithelial", "ANATOMY", 227, 237], ["damage Fig", "OBSERVATION", 238, 248], ["impaired", "OBSERVATION_MODIFIER", 271, 279], ["alveolar", "ANATOMY_MODIFIER", 280, 288], ["fluid clearance", "OBSERVATION", 289, 304], ["ALI", "ANATOMY", 308, 311], ["ARDS", "OBSERVATION", 312, 316]]], ["ANF, Atrial natriuretic factor; ENaC, epithelial sodium channel; Na,K-ATPase, Na + , K + transporting adenosine-5triphosphatase, TGF-\u03b2, transforming growth factor \u03b2 is likely to massively impact AFC in ALI/ARDS patients.", [["epithelial", "ANATOMY", 38, 48], ["sodium", "CHEMICAL", 49, 55], ["Na", "CHEMICAL", 65, 67], ["Na", "CHEMICAL", 78, 80], ["K", "CHEMICAL", 85, 86], ["adenosine", "CHEMICAL", 102, 111], ["ALI", "DISEASE", 202, 205], ["ARDS", "DISEASE", 206, 210], ["sodium", "CHEMICAL", 49, 55], ["Na", "CHEMICAL", 65, 67], ["K-", "CHEMICAL", 68, 70], ["Na +", "CHEMICAL", 78, 82], ["K +", "CHEMICAL", 85, 88], ["adenosine", "CHEMICAL", 102, 111], ["ANF", "GENE_OR_GENE_PRODUCT", 0, 3], ["Atrial natriuretic factor", "GENE_OR_GENE_PRODUCT", 5, 30], ["ENaC", "GENE_OR_GENE_PRODUCT", 32, 36], ["epithelial sodium channel", "GENE_OR_GENE_PRODUCT", 38, 63], ["Na,K-ATPase", "GENE_OR_GENE_PRODUCT", 65, 76], ["Na +", "SIMPLE_CHEMICAL", 78, 82], ["K + transporting adenosine-5triphosphatase", "GENE_OR_GENE_PRODUCT", 85, 127], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 129, 134], ["transforming growth factor \u03b2", "GENE_OR_GENE_PRODUCT", 136, 164], ["AFC", "GENE_OR_GENE_PRODUCT", 195, 198], ["patients", "ORGANISM", 211, 219], ["ANF", "PROTEIN", 0, 3], ["Atrial natriuretic factor", "PROTEIN", 5, 30], ["ENaC", "PROTEIN", 32, 36], ["epithelial sodium channel", "PROTEIN", 38, 63], ["Na,K-ATPase", "PROTEIN", 65, 76], ["Na + , K + transporting adenosine-5triphosphatase", "PROTEIN", 78, 127], ["TGF-\u03b2", "PROTEIN", 129, 134], ["transforming growth factor \u03b2", "PROTEIN", 136, 164], ["patients", "SPECIES", 211, 219], ["ANF", "TEST", 0, 3], ["Atrial natriuretic factor", "TEST", 5, 30], ["ENaC", "TEST", 32, 36], ["epithelial sodium channel", "TEST", 38, 63], ["Na", "TEST", 65, 67], ["ATPase", "TEST", 70, 76], ["Na", "TEST", 78, 80], ["K", "TEST", 85, 86], ["adenosine", "TEST", 102, 111], ["5triphosphatase", "TEST", 112, 127], ["TGF", "TEST", 129, 132], ["transforming growth factor", "PROBLEM", 136, 162], ["ALI", "PROBLEM", 202, 205], ["ARDS", "PROBLEM", 206, 210], ["Atrial", "ANATOMY", 5, 11], ["ARDS", "OBSERVATION", 206, 210]]], ["This idea is strengthened by the observation that in patients with hydrostatic pulmonary edema, which may result from congestive heart failure or acute myocardial infarction, both the alveolar epithelial barrier and AFC remain intact [13] .IntroductionAnimal and organ models have proved particularly useful to study AFC, because the three-compartment (alveolar airspace-interstitium-vasculature) structure of the lung is preserved [14] [15] [16] .", [["pulmonary", "ANATOMY", 79, 88], ["heart", "ANATOMY", 129, 134], ["myocardial", "ANATOMY", 152, 162], ["alveolar epithelial barrier", "ANATOMY", 184, 211], ["organ", "ANATOMY", 263, 268], ["alveolar airspace", "ANATOMY", 353, 370], ["interstitium", "ANATOMY", 371, 383], ["vasculature", "ANATOMY", 384, 395], ["lung", "ANATOMY", 414, 418], ["hydrostatic pulmonary edema", "DISEASE", 67, 94], ["congestive heart failure", "DISEASE", 118, 142], ["acute myocardial infarction", "DISEASE", 146, 173], ["patients", "ORGANISM", 53, 61], ["pulmonary", "ORGAN", 79, 88], ["heart", "ORGAN", 129, 134], ["myocardial", "MULTI-TISSUE_STRUCTURE", 152, 162], ["alveolar epithelial barrier", "TISSUE", 184, 211], ["organ", "ORGAN", 263, 268], ["AFC", "CANCER", 317, 320], ["alveolar airspace", "MULTI-TISSUE_STRUCTURE", 353, 370], ["interstitium-vasculature", "MULTI-TISSUE_STRUCTURE", 371, 395], ["lung", "ORGAN", 414, 418], ["patients", "SPECIES", 53, 61], ["hydrostatic pulmonary edema", "PROBLEM", 67, 94], ["congestive heart failure", "PROBLEM", 118, 142], ["acute myocardial infarction", "PROBLEM", 146, 173], ["the alveolar epithelial barrier", "TEST", 180, 211], ["study AFC", "TEST", 311, 320], ["pulmonary", "ANATOMY", 79, 88], ["edema", "OBSERVATION", 89, 94], ["congestive", "OBSERVATION_MODIFIER", 118, 128], ["heart", "ANATOMY", 129, 134], ["failure", "OBSERVATION", 135, 142], ["acute", "OBSERVATION_MODIFIER", 146, 151], ["myocardial", "ANATOMY", 152, 162], ["infarction", "OBSERVATION", 163, 173], ["alveolar", "ANATOMY_MODIFIER", 184, 192], ["epithelial", "ANATOMY_MODIFIER", 193, 203], ["intact", "OBSERVATION", 227, 233], ["alveolar", "ANATOMY_MODIFIER", 353, 361], ["airspace", "ANATOMY_MODIFIER", 362, 370], ["interstitium", "ANATOMY_MODIFIER", 371, 383], ["vasculature", "ANATOMY", 384, 395], ["lung", "ANATOMY", 414, 418]]], ["Studies in humans have relied heavily on the assessment of extravascular lung water (EVLW) [17] .", [["extravascular lung", "ANATOMY", 59, 77], ["humans", "ORGANISM", 11, 17], ["extravascular lung", "MULTI-TISSUE_STRUCTURE", 59, 77], ["humans", "SPECIES", 11, 17], ["humans", "SPECIES", 11, 17], ["the assessment", "TEST", 41, 55], ["extravascular", "ANATOMY_MODIFIER", 59, 72], ["lung", "ANATOMY", 73, 77]]], ["More recently, nasal potential difference (NPD) has been employed as a surrogate measurement for transepithelial ion transport [18] , although this measurement is clearly limited in its usefulness when studying diseases that exclusively impair alveolar ion transport.", [["nasal", "ANATOMY", 15, 20], ["transepithelial", "ANATOMY", 97, 112], ["alveolar", "ANATOMY", 244, 252], ["alveolar ion", "MULTI-TISSUE_STRUCTURE", 244, 256], ["transepithelial ion transport", "TEST", 97, 126], ["this measurement", "TEST", 143, 159], ["studying diseases", "PROBLEM", 202, 219], ["nasal", "ANATOMY", 15, 20]]], ["The aspects of impaired AFC in ALI/ARDS that have been examined in animal or organ models and clinical studies are summarized in Fig. 1 .IntroductionStudies in live, anesthetized, ventilated sheep provided the first evidence that alveolar fluid relied on active ion transport, where clearance of salt and water occurred against an increase protein concentration in the alveolar lining fluid [19] .", [["organ", "ANATOMY", 77, 82], ["alveolar fluid", "ANATOMY", 230, 244], ["alveolar lining fluid", "ANATOMY", 369, 390], ["ALI", "DISEASE", 31, 34], ["ARDS", "DISEASE", 35, 39], ["AFC", "GENE_OR_GENE_PRODUCT", 24, 27], ["organ", "ORGAN", 77, 82], ["sheep", "ORGANISM", 191, 196], ["alveolar fluid", "MULTI-TISSUE_STRUCTURE", 230, 244], ["ion", "SIMPLE_CHEMICAL", 262, 265], ["salt", "SIMPLE_CHEMICAL", 296, 300], ["water", "SIMPLE_CHEMICAL", 305, 310], ["alveolar lining", "TISSUE", 369, 384], ["sheep", "SPECIES", 191, 196], ["sheep", "SPECIES", 191, 196], ["impaired AFC", "PROBLEM", 15, 27], ["ALI", "PROBLEM", 31, 34], ["ARDS", "PROBLEM", 35, 39], ["clinical studies", "TEST", 94, 110], ["alveolar fluid", "PROBLEM", 230, 244], ["active ion transport", "TREATMENT", 255, 275], ["salt and water", "TREATMENT", 296, 310], ["an increase protein concentration", "PROBLEM", 328, 361], ["impaired", "OBSERVATION_MODIFIER", 15, 23], ["AFC", "OBSERVATION", 24, 27], ["ALI", "ANATOMY", 31, 34], ["ARDS", "OBSERVATION", 35, 39], ["alveolar", "ANATOMY", 230, 238], ["fluid", "OBSERVATION", 239, 244], ["increase", "OBSERVATION_MODIFIER", 331, 339], ["protein concentration", "OBSERVATION", 340, 361], ["alveolar", "ANATOMY_MODIFIER", 369, 377]]], ["Supporting these data, fluid clearance was impeded at low temperature in in situ perfused goat lungs (maintained at 18\u00b0C) [20] , and in isolated, perfused liquid-filled rat lungs [21] consistent with the inhibition of an active transport process.IntroductionActive sodium transport in particular was implicated in AFC, since amiloride, a potent and specific inhibitor ENaC inhibited 40-70% of basal fluid clearance in sheep, rabbits, rats, mice, and in the human lung [3] .", [["fluid", "ANATOMY", 23, 28], ["lungs", "ANATOMY", 95, 100], ["lungs", "ANATOMY", 173, 178], ["basal fluid", "ANATOMY", 393, 404], ["lung", "ANATOMY", 463, 467], ["sodium", "CHEMICAL", 265, 271], ["amiloride", "CHEMICAL", 325, 334], ["sodium", "CHEMICAL", 265, 271], ["amiloride", "CHEMICAL", 325, 334], ["fluid", "ORGANISM_SUBSTANCE", 23, 28], ["goat", "ORGANISM", 90, 94], ["lungs", "ORGAN", 95, 100], ["rat", "ORGANISM", 169, 172], ["lungs", "ORGAN", 173, 178], ["sodium", "SIMPLE_CHEMICAL", 265, 271], ["AFC", "SIMPLE_CHEMICAL", 314, 317], ["amiloride", "SIMPLE_CHEMICAL", 325, 334], ["ENaC", "GENE_OR_GENE_PRODUCT", 368, 372], ["fluid", "ORGANISM_SUBSTANCE", 399, 404], ["sheep", "ORGANISM", 418, 423], ["rabbits", "ORGANISM", 425, 432], ["rats", "ORGANISM", 434, 438], ["mice", "ORGANISM", 440, 444], ["human", "ORGANISM", 457, 462], ["lung", "ORGAN", 463, 467], ["goat", "SPECIES", 90, 94], ["rat", "SPECIES", 169, 172], ["sheep", "SPECIES", 418, 423], ["rabbits", "SPECIES", 425, 432], ["rats", "SPECIES", 434, 438], ["mice", "SPECIES", 440, 444], ["human", "SPECIES", 457, 462], ["goat", "SPECIES", 90, 94], ["sheep", "SPECIES", 418, 423], ["mice", "SPECIES", 440, 444], ["human", "SPECIES", 457, 462], ["fluid clearance", "TEST", 23, 38], ["an active transport process", "PROBLEM", 218, 245], ["IntroductionActive sodium transport", "TREATMENT", 246, 281], ["amiloride", "TREATMENT", 325, 334], ["a potent and specific inhibitor ENaC", "TREATMENT", 336, 372], ["basal fluid clearance in sheep", "TREATMENT", 393, 423], ["low temperature", "OBSERVATION_MODIFIER", 54, 69], ["lungs", "ANATOMY", 95, 100], ["lungs", "ANATOMY", 173, 178], ["active", "OBSERVATION", 221, 227], ["human lung", "ANATOMY", 457, 467]]], ["O'Brodovich and colleagues [22] have further demonstrated that application of amiloride to newborn guinea pig lungs caused respiratory distress, hypoxemia and elevated extravascular lung water, implicating active sodium transport in AFC in neonates.", [["lungs", "ANATOMY", 110, 115], ["respiratory", "ANATOMY", 123, 134], ["extravascular lung", "ANATOMY", 168, 186], ["amiloride", "CHEMICAL", 78, 87], ["respiratory distress", "DISEASE", 123, 143], ["hypoxemia", "DISEASE", 145, 154], ["sodium", "CHEMICAL", 213, 219], ["amiloride", "CHEMICAL", 78, 87], ["sodium", "CHEMICAL", 213, 219], ["amiloride", "SIMPLE_CHEMICAL", 78, 87], ["pig", "ORGANISM", 106, 109], ["lungs", "ORGAN", 110, 115], ["lung", "ORGAN", 182, 186], ["sodium", "SIMPLE_CHEMICAL", 213, 219], ["AFC", "SIMPLE_CHEMICAL", 233, 236], ["neonates", "ORGANISM", 240, 248], ["guinea pig", "SPECIES", 99, 109], ["pig", "SPECIES", 106, 109], ["amiloride", "TREATMENT", 78, 87], ["respiratory distress", "PROBLEM", 123, 143], ["hypoxemia", "PROBLEM", 145, 154], ["elevated extravascular lung water", "PROBLEM", 159, 192], ["active sodium transport", "PROBLEM", 206, 229], ["AFC in neonates", "PROBLEM", 233, 248], ["lungs", "ANATOMY", 110, 115], ["respiratory distress", "OBSERVATION", 123, 143], ["hypoxemia", "OBSERVATION", 145, 154], ["elevated", "OBSERVATION_MODIFIER", 159, 167], ["extravascular", "ANATOMY_MODIFIER", 168, 181], ["lung", "ANATOMY", 182, 186], ["active", "OBSERVATION_MODIFIER", 206, 212]]], ["Consistent with this idea, targeted deletion of both ENaC\u03b1 alleles in mice caused death within 40 h of birth as a consequence of impaired AFC [23] .", [["death", "DISEASE", 82, 87], ["ENaC\u03b1", "GENE_OR_GENE_PRODUCT", 53, 58], ["mice", "ORGANISM", 70, 74], ["ENaC\u03b1 alleles", "DNA", 53, 66], ["mice", "SPECIES", 70, 74], ["mice", "SPECIES", 70, 74], ["death", "PROBLEM", 82, 87], ["impaired AFC", "PROBLEM", 129, 141]]], ["Transgenic overexpression of the ENaC\u03b1 gene in an ENaC\u03b1 -/null mouse background rescued this pulmonary phenotype [24] .", [["pulmonary", "ANATOMY", 93, 102], ["ENaC\u03b1", "GENE_OR_GENE_PRODUCT", 33, 38], ["ENaC\u03b1", "GENE_OR_GENE_PRODUCT", 50, 55], ["pulmonary", "ORGAN", 93, 102], ["ENaC\u03b1 gene", "DNA", 33, 43], ["ENaC\u03b1", "PROTEIN", 50, 55], ["mouse", "SPECIES", 63, 68], ["mouse", "SPECIES", 63, 68], ["an ENaC\u03b1", "TEST", 47, 55], ["this pulmonary phenotype", "PROBLEM", 88, 112], ["pulmonary", "ANATOMY", 93, 102]]], ["Conversely, overexpression of ENaC in the mouse lower airways accelerated sodium absorption, and depleted the volume of fluid coating the airway epithelium [25] .", [["lower airways", "ANATOMY", 48, 61], ["fluid", "ANATOMY", 120, 125], ["airway epithelium", "ANATOMY", 138, 155], ["sodium", "CHEMICAL", 74, 80], ["sodium", "CHEMICAL", 74, 80], ["ENaC", "GENE_OR_GENE_PRODUCT", 30, 34], ["mouse", "ORGANISM", 42, 47], ["lower", "ORGANISM_SUBDIVISION", 48, 53], ["airways", "MULTI-TISSUE_STRUCTURE", 54, 61], ["sodium", "SIMPLE_CHEMICAL", 74, 80], ["airway epithelium", "TISSUE", 138, 155], ["ENaC", "PROTEIN", 30, 34], ["mouse", "SPECIES", 42, 47], ["mouse", "SPECIES", 42, 47], ["ENaC in the mouse lower airways accelerated sodium absorption", "PROBLEM", 30, 91], ["lower", "ANATOMY_MODIFIER", 48, 53], ["airways", "ANATOMY", 54, 61], ["sodium absorption", "OBSERVATION", 74, 91], ["fluid coating", "OBSERVATION", 120, 133], ["airway", "ANATOMY", 138, 144]]], ["Together, these data implicate both active transepithelial sodium transport and ENaC itself in AFC.", [["transepithelial", "ANATOMY", 43, 58], ["sodium", "CHEMICAL", 59, 65], ["sodium", "CHEMICAL", 59, 65], ["transepithelial", "MULTI-TISSUE_STRUCTURE", 43, 58], ["sodium", "SIMPLE_CHEMICAL", 59, 65], ["ENaC", "GENE_OR_GENE_PRODUCT", 80, 84], ["ENaC", "PROTEIN", 80, 84], ["active transepithelial sodium transport", "TREATMENT", 36, 75], ["active", "OBSERVATION_MODIFIER", 36, 42], ["transepithelial sodium", "OBSERVATION", 43, 65]]], ["Using small interfering RNA directed against ENaC\u03b1 applied to the airways of live rats, other non-ENaC type ion channels are also likely to play an important role in transepithelial sodium transport and fluid reabsorption, particularly baseline fluid reabsorption [9] .IntroductionWhile ENaC located on the apical surface of alveolar epithelial cells acts as a sodium channel, investigations in live animals and isolated organ models have revealed that the driving force behind ENaC-mediated sodium uptake is the Na,K-ATPase [7] .", [["airways", "ANATOMY", 66, 73], ["transepithelial", "ANATOMY", 166, 181], ["fluid", "ANATOMY", 203, 208], ["fluid", "ANATOMY", 245, 250], ["apical surface", "ANATOMY", 307, 321], ["alveolar epithelial cells", "ANATOMY", 325, 350], ["organ", "ANATOMY", 421, 426], ["sodium", "CHEMICAL", 182, 188], ["sodium", "CHEMICAL", 361, 367], ["sodium", "CHEMICAL", 492, 498], ["Na", "CHEMICAL", 513, 515], ["sodium", "CHEMICAL", 182, 188], ["sodium", "CHEMICAL", 361, 367], ["sodium", "CHEMICAL", 492, 498], ["Na", "CHEMICAL", 513, 515], ["K-", "CHEMICAL", 516, 518], ["ENaC\u03b1", "GENE_OR_GENE_PRODUCT", 45, 50], ["airways", "MULTI-TISSUE_STRUCTURE", 66, 73], ["rats", "ORGANISM", 82, 86], ["transepithelial", "IMMATERIAL_ANATOMICAL_ENTITY", 166, 181], ["sodium", "SIMPLE_CHEMICAL", 182, 188], ["ENaC", "GENE_OR_GENE_PRODUCT", 287, 291], ["apical surface", "CELLULAR_COMPONENT", 307, 321], ["alveolar epithelial cells", "CELL", 325, 350], ["sodium", "SIMPLE_CHEMICAL", 361, 367], ["organ", "ORGAN", 421, 426], ["ENaC", "GENE_OR_GENE_PRODUCT", 478, 482], ["sodium", "SIMPLE_CHEMICAL", 492, 498], ["Na,K-ATPase", "GENE_OR_GENE_PRODUCT", 513, 524], ["small interfering RNA", "RNA", 6, 27], ["ENaC\u03b1", "PROTEIN", 45, 50], ["non-ENaC type ion channels", "PROTEIN", 94, 120], ["ENaC", "PROTEIN", 287, 291], ["alveolar epithelial cells", "CELL_TYPE", 325, 350], ["ENaC", "PROTEIN", 478, 482], ["Na,K-ATPase", "PROTEIN", 513, 524], ["rats", "SPECIES", 82, 86], ["small interfering RNA", "TREATMENT", 6, 27], ["ENaC\u03b1", "TREATMENT", 45, 50], ["other non-ENaC type ion channels", "TREATMENT", 88, 120], ["transepithelial sodium transport", "TREATMENT", 166, 198], ["fluid reabsorption", "TREATMENT", 203, 221], ["baseline fluid reabsorption", "TREATMENT", 236, 263], ["ENaC", "TREATMENT", 287, 291], ["a sodium channel", "TEST", 359, 375], ["isolated organ models", "TEST", 412, 433], ["ENaC", "TEST", 478, 482], ["sodium uptake", "TEST", 492, 505], ["the Na", "TEST", 509, 515], ["airways", "ANATOMY", 66, 73], ["apical", "ANATOMY_MODIFIER", 307, 313], ["surface", "ANATOMY_MODIFIER", 314, 321], ["alveolar", "ANATOMY_MODIFIER", 325, 333], ["epithelial cells", "OBSERVATION", 334, 350]]], ["Ouabain, a potent and specific inhibitor of the Na,K-ATPase, inhibited AFC in isolated, perfused fluid-filled mouse lungs [26] .", [["fluid", "ANATOMY", 97, 102], ["lungs", "ANATOMY", 116, 121], ["Ouabain", "CHEMICAL", 0, 7], ["Na", "CHEMICAL", 48, 50], ["Ouabain", "CHEMICAL", 0, 7], ["Na", "CHEMICAL", 48, 50], ["K-", "CHEMICAL", 51, 53], ["Ouabain", "SIMPLE_CHEMICAL", 0, 7], ["Na", "GENE_OR_GENE_PRODUCT", 48, 50], ["K-ATPase", "GENE_OR_GENE_PRODUCT", 51, 59], ["AFC", "SIMPLE_CHEMICAL", 71, 74], ["mouse", "ORGANISM", 110, 115], ["lungs", "ORGAN", 116, 121], ["Na,K-ATPase", "PROTEIN", 48, 59], ["AFC", "PROTEIN", 71, 74], ["mouse", "SPECIES", 110, 115], ["mouse", "SPECIES", 110, 115], ["Ouabain", "TREATMENT", 0, 7], ["the Na", "TEST", 44, 50], ["AFC", "PROBLEM", 71, 74], ["perfused", "OBSERVATION_MODIFIER", 88, 96], ["fluid", "OBSERVATION", 97, 102], ["lungs", "ANATOMY", 116, 121]]], ["Furthermore, adenoviral-mediated gene transfer of the Na,K-ATPase \u03b21 subunit into the lungs of rats augmented AFC [27] .", [["lungs", "ANATOMY", 86, 91], ["Na", "CHEMICAL", 54, 56], ["Na", "CHEMICAL", 54, 56], ["K-", "CHEMICAL", 57, 59], ["adenoviral", "ORGANISM", 13, 23], ["Na", "GENE_OR_GENE_PRODUCT", 54, 56], ["K-ATPase \u03b21", "GENE_OR_GENE_PRODUCT", 57, 68], ["lungs", "ORGAN", 86, 91], ["rats", "ORGANISM", 95, 99], ["Na,K-ATPase \u03b21 subunit", "PROTEIN", 54, 76], ["rats", "SPECIES", 95, 99], ["adenoviral", "TREATMENT", 13, 23], ["the Na", "TEST", 50, 56], ["K-ATPase \u03b21 subunit", "TREATMENT", 57, 76], ["lungs", "ANATOMY", 86, 91]]], ["Furthermore, overexpression of the Na,K-ATPase \u03b21 subunit in the alveolar epithelium restored active transepithelial sodium transport and AFC in a rat model of acute hydrostatic pulmonary edema [28] .", [["alveolar epithelium", "ANATOMY", 65, 84], ["transepithelial", "ANATOMY", 101, 116], ["pulmonary", "ANATOMY", 178, 187], ["Na", "CHEMICAL", 35, 37], ["sodium", "CHEMICAL", 117, 123], ["hydrostatic pulmonary edema", "DISEASE", 166, 193], ["Na", "CHEMICAL", 35, 37], ["sodium", "CHEMICAL", 117, 123], ["Na,K-ATPase \u03b21", "GENE_OR_GENE_PRODUCT", 35, 49], ["alveolar epithelium", "TISSUE", 65, 84], ["transepithelial", "MULTI-TISSUE_STRUCTURE", 101, 116], ["sodium", "SIMPLE_CHEMICAL", 117, 123], ["rat", "ORGANISM", 147, 150], ["Na,K-ATPase \u03b21 subunit", "PROTEIN", 35, 57], ["rat", "SPECIES", 147, 150], ["rat", "SPECIES", 147, 150], ["the Na", "TEST", 31, 37], ["ATPase", "TEST", 40, 46], ["active transepithelial sodium transport", "TREATMENT", 94, 133], ["acute hydrostatic pulmonary edema", "PROBLEM", 160, 193], ["alveolar", "ANATOMY_MODIFIER", 65, 73], ["epithelium", "ANATOMY_MODIFIER", 74, 84], ["transepithelial sodium", "OBSERVATION", 101, 123], ["acute", "OBSERVATION_MODIFIER", 160, 165], ["hydrostatic", "OBSERVATION_MODIFIER", 166, 177], ["pulmonary", "ANATOMY", 178, 187], ["edema", "OBSERVATION", 188, 193]]], ["Gene knockout strategies have also addressed a role for the two Na,K-ATPase \u03b1 subunits in AFC, where mice heterozygous for each of the Na,K-ATPase \u03b1 subunits (\u03b1 1 +/-/\u03b1 2 +/-) exhibit reduced cyclic-adenosine monophosphate (cAMP) dependent AFC [29] .IntroductionIn addition to a role for sodium transport, it has recently emerged that chloride transport via the CFTR channel also plays a role in AFC.", [["Na", "CHEMICAL", 64, 66], ["Na", "CHEMICAL", 135, 137], ["K", "CHEMICAL", 138, 139], ["cyclic-adenosine monophosphate", "CHEMICAL", 192, 222], ["cAMP", "CHEMICAL", 224, 228], ["sodium", "CHEMICAL", 288, 294], ["chloride", "CHEMICAL", 335, 343], ["Na", "CHEMICAL", 64, 66], ["K-", "CHEMICAL", 67, 69], ["Na", "CHEMICAL", 135, 137], ["K", "CHEMICAL", 138, 139], ["cyclic-adenosine monophosphate", "CHEMICAL", 192, 222], ["cAMP", "CHEMICAL", 224, 228], ["sodium", "CHEMICAL", 288, 294], ["chloride", "CHEMICAL", 335, 343], ["Na", "GENE_OR_GENE_PRODUCT", 64, 66], ["K-ATPase \u03b1 subunits", "GENE_OR_GENE_PRODUCT", 67, 86], ["AFC", "GENE_OR_GENE_PRODUCT", 90, 93], ["mice", "ORGANISM", 101, 105], ["Na,K-ATPase \u03b1 subunits", "GENE_OR_GENE_PRODUCT", 135, 157], ["\u03b1 1", "GENE_OR_GENE_PRODUCT", 159, 162], ["cyclic-adenosine monophosphate", "SIMPLE_CHEMICAL", 192, 222], ["cAMP", "SIMPLE_CHEMICAL", 224, 228], ["sodium", "SIMPLE_CHEMICAL", 288, 294], ["chloride", "SIMPLE_CHEMICAL", 335, 343], ["CFTR", "GENE_OR_GENE_PRODUCT", 362, 366], ["AFC", "CANCER", 396, 399], ["Na,K-ATPase \u03b1 subunits", "PROTEIN", 64, 86], ["AFC", "PROTEIN", 90, 93], ["Na,K-ATPase \u03b1 subunits", "PROTEIN", 135, 157], ["\u03b1 1", "PROTEIN", 159, 162], ["\u03b1 2", "PROTEIN", 167, 170], ["CFTR channel", "PROTEIN", 362, 374], ["mice", "SPECIES", 101, 105], ["mice", "SPECIES", 101, 105], ["Gene knockout strategies", "TREATMENT", 0, 24], ["K-ATPase \u03b1 subunits", "TREATMENT", 67, 86], ["the Na", "TEST", 131, 137], ["K", "TEST", 138, 139], ["ATPase", "TEST", 140, 146], ["subunits", "TEST", 149, 157], ["reduced cyclic-adenosine monophosphate (cAMP) dependent AFC", "PROBLEM", 184, 243], ["sodium transport", "TREATMENT", 288, 304], ["chloride transport", "TREATMENT", 335, 353]]], ["Using glibenclamide, an inhibitor of potassium and CFTR channels, fluid clearance from in situ perused and unperfused mouse lungs and ex vivo human lungs was impaired [8] .", [["fluid", "ANATOMY", 66, 71], ["lungs", "ANATOMY", 124, 129], ["lungs", "ANATOMY", 148, 153], ["glibenclamide", "CHEMICAL", 6, 19], ["potassium", "CHEMICAL", 37, 46], ["glibenclamide", "CHEMICAL", 6, 19], ["potassium", "CHEMICAL", 37, 46], ["glibenclamide", "SIMPLE_CHEMICAL", 6, 19], ["potassium", "SIMPLE_CHEMICAL", 37, 46], ["CFTR", "GENE_OR_GENE_PRODUCT", 51, 55], ["mouse", "ORGANISM", 118, 123], ["lungs", "ORGAN", 124, 129], ["human", "ORGANISM", 142, 147], ["lungs", "ORGAN", 148, 153], ["potassium and CFTR channels", "PROTEIN", 37, 64], ["mouse", "SPECIES", 118, 123], ["human", "SPECIES", 142, 147], ["mouse", "SPECIES", 118, 123], ["human", "SPECIES", 142, 147], ["glibenclamide", "TREATMENT", 6, 19], ["an inhibitor of potassium and CFTR channels", "TREATMENT", 21, 64], ["fluid clearance", "TEST", 66, 81], ["lungs", "ANATOMY", 124, 129], ["lungs", "ANATOMY", 148, 153]]], ["These data were supported using a cystic fibrosis (\u2206F508) mouse in a model of acute hydrostatic edema, where chloride transport by the CFTR channel was demonstrated to play a major role in AFC [8] .", [["fibrosis", "DISEASE", 41, 49], ["edema", "DISEASE", 96, 101], ["chloride", "CHEMICAL", 109, 117], ["chloride", "CHEMICAL", 109, 117], ["mouse", "ORGANISM", 58, 63], ["edema", "PATHOLOGICAL_FORMATION", 96, 101], ["chloride", "SIMPLE_CHEMICAL", 109, 117], ["CFTR", "GENE_OR_GENE_PRODUCT", 135, 139], ["CFTR channel", "PROTEIN", 135, 147], ["mouse", "SPECIES", 58, 63], ["mouse", "SPECIES", 58, 63], ["These data", "TEST", 0, 10], ["a cystic fibrosis", "PROBLEM", 32, 49], ["acute hydrostatic edema", "PROBLEM", 78, 101], ["chloride transport", "TREATMENT", 109, 127], ["the CFTR channel", "TREATMENT", 131, 147], ["cystic", "OBSERVATION_MODIFIER", 34, 40], ["fibrosis", "OBSERVATION", 41, 49], ["acute", "OBSERVATION_MODIFIER", 78, 83], ["hydrostatic", "OBSERVATION_MODIFIER", 84, 95], ["edema", "OBSERVATION", 96, 101]]], ["Further supporting this idea, adenoviral-mediated transfer of the CFTR gene into the lungs of live rats and mice significantly increased AFC, an effect that was blocked in the presence the chloride channel blockers 5-nitro-2-(3phenylpropylamino) benzoic acid, bumetanide, and gliben-clamide [30] .", [["lungs", "ANATOMY", 85, 90], ["chloride", "CHEMICAL", 189, 197], ["5-nitro-2-(3phenylpropylamino) benzoic acid", "CHEMICAL", 215, 258], ["bumetanide", "CHEMICAL", 260, 270], ["gliben-clamide", "CHEMICAL", 276, 290], ["chloride", "CHEMICAL", 189, 197], ["5-nitro-2-(3phenylpropylamino) benzoic acid", "CHEMICAL", 215, 258], ["bumetanide", "CHEMICAL", 260, 270], ["gliben-clamide", "CHEMICAL", 276, 290], ["adenoviral", "ORGANISM", 30, 40], ["CFTR", "GENE_OR_GENE_PRODUCT", 66, 70], ["lungs", "ORGAN", 85, 90], ["rats", "ORGANISM", 99, 103], ["mice", "ORGANISM", 108, 112], ["AFC", "SIMPLE_CHEMICAL", 137, 140], ["chloride", "SIMPLE_CHEMICAL", 189, 197], ["5-nitro-2-(3phenylpropylamino) benzoic acid", "SIMPLE_CHEMICAL", 215, 258], ["bumetanide", "SIMPLE_CHEMICAL", 260, 270], ["gliben-clamide [30]", "SIMPLE_CHEMICAL", 276, 295], ["CFTR gene", "DNA", 66, 75], ["rats", "SPECIES", 99, 103], ["mice", "SPECIES", 108, 112], ["mice", "SPECIES", 108, 112], ["mice significantly increased AFC", "PROBLEM", 108, 140], ["the chloride channel blockers", "TREATMENT", 185, 214], ["nitro", "TREATMENT", 217, 222], ["3phenylpropylamino) benzoic acid", "TREATMENT", 226, 258], ["bumetanide", "TREATMENT", 260, 270], ["gliben-clamide", "TREATMENT", 276, 290], ["lungs", "ANATOMY", 85, 90]]], ["Animal and organ models have thus confirmed invaluable in the identification of transepithelial active sodium transport as the basis of AFC, and in the validation of ENaC and other channels and the Na,K-ATPase, as key components that drive this process.IntroductionMechanisms of impaired fluid clearance in ALI/ARDS: what we have learned from intact organ and animal models, and clinical studiesHypoxia and hyperoxiaHypoxia is a feature of both ARDS and high-altitude pulmonary edema (HAPE).", [["organ", "ANATOMY", 11, 16], ["transepithelial", "ANATOMY", 80, 95], ["fluid", "ANATOMY", 288, 293], ["organ", "ANATOMY", 350, 355], ["pulmonary", "ANATOMY", 468, 477], ["sodium", "CHEMICAL", 103, 109], ["Na", "CHEMICAL", 198, 200], ["impaired fluid clearance", "DISEASE", 279, 303], ["ALI", "DISEASE", 307, 310], ["ARDS", "DISEASE", 311, 315], ["Hypoxia", "DISEASE", 395, 402], ["hyperoxiaHypoxia", "DISEASE", 407, 423], ["ARDS", "DISEASE", 445, 449], ["high-altitude pulmonary edema", "DISEASE", 454, 483], ["HAPE", "DISEASE", 485, 489], ["sodium", "CHEMICAL", 103, 109], ["Na", "CHEMICAL", 198, 200], ["organ", "ORGAN", 11, 16], ["transepithelial", "MULTI-TISSUE_STRUCTURE", 80, 95], ["sodium", "SIMPLE_CHEMICAL", 103, 109], ["AFC", "GENE_OR_GENE_PRODUCT", 136, 139], ["ENaC", "GENE_OR_GENE_PRODUCT", 166, 170], ["Na,K-ATPase", "GENE_OR_GENE_PRODUCT", 198, 209], ["fluid", "ORGANISM_SUBSTANCE", 288, 293], ["organ", "ORGAN", 350, 355], ["pulmonary edema", "PATHOLOGICAL_FORMATION", 468, 483], ["ENaC", "PROTEIN", 166, 170], ["Na,K-ATPase", "PROTEIN", 198, 209], ["transepithelial active sodium transport", "TREATMENT", 80, 119], ["AFC", "TEST", 136, 139], ["the Na,K-ATPase", "TEST", 194, 209], ["impaired fluid clearance", "PROBLEM", 279, 303], ["ALI", "PROBLEM", 307, 310], ["ARDS", "PROBLEM", 311, 315], ["clinical studies", "TEST", 379, 395], ["Hypoxia", "PROBLEM", 395, 402], ["hyperoxiaHypoxia", "PROBLEM", 407, 423], ["both ARDS", "PROBLEM", 440, 449], ["high-altitude pulmonary edema", "PROBLEM", 454, 483], ["AFC", "OBSERVATION", 136, 139], ["impaired", "OBSERVATION_MODIFIER", 279, 287], ["fluid clearance", "OBSERVATION", 288, 303], ["ARDS", "OBSERVATION", 311, 315], ["ARDS", "OBSERVATION", 445, 449], ["high", "OBSERVATION_MODIFIER", 454, 458], ["altitude", "OBSERVATION_MODIFIER", 459, 467], ["pulmonary", "ANATOMY", 468, 477], ["edema", "OBSERVATION", 478, 483]]], ["In isolated, ventilated rat lungs perfused at constant pressure (therefore independent of pressure changes caused by adaptation to hypoxic pulmonary vasoconstriction), exposure to hypoxia (1. .", [["lungs", "ANATOMY", 28, 33], ["pulmonary", "ANATOMY", 139, 148], ["hypoxia", "DISEASE", 180, 187], ["rat", "ORGANISM", 24, 27], ["lungs", "ORGAN", 28, 33], ["pulmonary", "ORGAN", 139, 148], ["rat", "SPECIES", 24, 27], ["rat", "SPECIES", 24, 27], ["pressure changes", "PROBLEM", 90, 106], ["hypoxic pulmonary vasoconstriction", "PROBLEM", 131, 165], ["hypoxia", "PROBLEM", 180, 187], ["ventilated", "OBSERVATION", 13, 23], ["lungs", "ANATOMY", 28, 33], ["perfused", "OBSERVATION", 34, 42], ["pressure", "OBSERVATION_MODIFIER", 55, 63], ["pulmonary vasoconstriction", "ANATOMY", 139, 165], ["hypoxia", "OBSERVATION", 180, 187]]], ["These and other observations introduced the possibility of using gene therapy to augment AFC and treat ALI/ARDS.Mechanical ventilationPatients with ALI/ARDS frequently require mechanical ventilation to facilitate breathing.", [["ALI", "DISEASE", 103, 106], ["ARDS", "DISEASE", 107, 111], ["ALI", "DISEASE", 148, 151], ["ARDS", "DISEASE", 152, 156], ["gene therapy", "TREATMENT", 65, 77], ["augment AFC", "TREATMENT", 81, 92], ["ALI", "PROBLEM", 103, 106], ["ARDS", "PROBLEM", 107, 111], ["Mechanical ventilationPatients", "TREATMENT", 112, 142], ["ALI/ARDS", "TREATMENT", 148, 156], ["mechanical ventilation", "TREATMENT", 176, 198], ["ARDS", "OBSERVATION", 107, 111], ["ALI", "OBSERVATION", 148, 151], ["ARDS", "OBSERVATION", 152, 156], ["mechanical ventilation", "OBSERVATION", 176, 198]]], ["However, mechanical ventilation can directly induce ALI (ventilator-induced lung injury, VILI), by promoting alveolo-capillary barrier permeability [1, 45] , inducing proinflammatory cytokines [46], or by directly inhibiting AFC.", [["lung", "ANATOMY", 76, 80], ["alveolo-capillary barrier", "ANATOMY", 109, 134], ["ALI", "DISEASE", 52, 55], ["ventilator-induced lung injury", "DISEASE", 57, 87], ["VILI", "DISEASE", 89, 93], ["lung", "ORGAN", 76, 80], ["alveolo-capillary barrier", "TISSUE", 109, 134], ["AFC", "GENE_OR_GENE_PRODUCT", 225, 228], ["proinflammatory cytokines", "PROTEIN", 167, 192], ["AFC", "PROTEIN", 225, 228], ["mechanical ventilation", "TREATMENT", 9, 31], ["ALI", "PROBLEM", 52, 55], ["lung injury", "PROBLEM", 76, 87], ["VILI", "PROBLEM", 89, 93], ["proinflammatory cytokines", "TEST", 167, 192], ["mechanical ventilation", "OBSERVATION", 9, 31], ["lung", "ANATOMY", 76, 80], ["injury", "OBSERVATION", 81, 87], ["VILI", "OBSERVATION", 89, 93]]], ["Supporting the latter idea, Lecuona et al. [47] demonstrated that ventilation of rats with high tidal volumes (V T ) of 40 ml/kg and a peak airway pressure of 35 cmH 2 O rapidly impaired AFC, accompanied by a significant decrease in activity (but not expression) of Na,K-ATPase.", [["airway", "ANATOMY", 140, 146], ["cmH 2 O", "CHEMICAL", 162, 169], ["Na", "CHEMICAL", 266, 268], ["cmH 2 O", "CHEMICAL", 162, 169], ["Na", "CHEMICAL", 266, 268], ["rats", "ORGANISM", 81, 85], ["airway", "MULTI-TISSUE_STRUCTURE", 140, 146], ["Na", "GENE_OR_GENE_PRODUCT", 266, 268], ["K-ATPase", "GENE_OR_GENE_PRODUCT", 269, 277], ["Na", "PROTEIN", 266, 268], ["K-ATPase", "PROTEIN", 269, 277], ["rats", "SPECIES", 81, 85], ["ventilation of rats", "TREATMENT", 66, 85], ["high tidal volumes", "TREATMENT", 91, 109], ["a peak airway pressure", "TEST", 133, 155], ["rapidly impaired AFC", "PROBLEM", 170, 190], ["a significant decrease in activity", "PROBLEM", 207, 241], ["Na", "TEST", 266, 268], ["airway", "ANATOMY", 140, 146], ["pressure", "OBSERVATION_MODIFIER", 147, 155], ["impaired", "OBSERVATION_MODIFIER", 178, 186], ["AFC", "OBSERVATION", 187, 190], ["significant", "OBSERVATION_MODIFIER", 209, 220], ["decrease", "OBSERVATION_MODIFIER", 221, 229]]], ["Thus high V T ventilation can directly block AFC by inhibiting Na,K-ATPase-driven sodium transport, and hence AFC.Mechanical ventilationMechanical ventilation can also worsen preexisting ALI (ventilator-associated lung injury, VALI).", [["lung", "ANATOMY", 214, 218], ["Na", "CHEMICAL", 63, 65], ["sodium", "CHEMICAL", 82, 88], ["ALI", "DISEASE", 187, 190], ["ventilator-associated lung injury", "DISEASE", 192, 225], ["VALI", "DISEASE", 227, 231], ["Na", "CHEMICAL", 63, 65], ["K-", "CHEMICAL", 66, 68], ["sodium", "CHEMICAL", 82, 88], ["V T", "GENE_OR_GENE_PRODUCT", 10, 13], ["AFC", "GENE_OR_GENE_PRODUCT", 45, 48], ["Na", "SIMPLE_CHEMICAL", 63, 65], ["K-ATPase", "GENE_OR_GENE_PRODUCT", 66, 74], ["sodium", "SIMPLE_CHEMICAL", 82, 88], ["AFC", "GENE_OR_GENE_PRODUCT", 110, 113], ["lung", "ORGAN", 214, 218], ["Na,K-ATPase", "PROTEIN", 63, 74], ["high V T ventilation", "TREATMENT", 5, 25], ["Na", "TEST", 63, 65], ["K-ATPase", "TEST", 66, 74], ["sodium transport", "TREATMENT", 82, 98], ["AFC", "TEST", 110, 113], ["Mechanical ventilation", "TREATMENT", 114, 136], ["Mechanical ventilation", "TREATMENT", 136, 158], ["preexisting ALI", "PROBLEM", 175, 190], ["lung injury", "PROBLEM", 214, 225], ["high V", "OBSERVATION_MODIFIER", 5, 11], ["ventilation", "OBSERVATION", 125, 136], ["Mechanical ventilation", "OBSERVATION", 136, 158], ["ALI", "OBSERVATION", 187, 190], ["lung", "ANATOMY", 214, 218], ["injury", "OBSERVATION", 219, 225]]], ["In a canine model of acid aspiration-induced ALI Corbridge et al. [45] demonstrated that ventilation with high V T (30 ml/kg) but a fixed, low positive end-expiratory pressure (PEEP; 3 cmH 2 O) increased EVLW to a greater extent than did ventilation with lower V T (15 ml/kg) but a fixed, higher PEEP (12 cmH 2 O).", [["ALI", "DISEASE", 45, 48], ["canine", "ORGANISM", 5, 11], ["canine", "SPECIES", 5, 11], ["acid aspiration", "TREATMENT", 21, 36], ["ventilation", "TREATMENT", 89, 100], ["high V T", "TREATMENT", 106, 114], ["PEEP", "TREATMENT", 177, 181], ["increased EVLW", "PROBLEM", 194, 208], ["lower V T", "TREATMENT", 255, 264], ["higher PEEP", "TREATMENT", 289, 300], ["expiratory pressure", "OBSERVATION", 156, 175], ["greater extent", "OBSERVATION_MODIFIER", 214, 228]]], ["Similar trends were observed in an acid aspiration-induced model of ALI in rats, where a progressive reduction in V T from 12 to 6 to 3 ml/kg, keeping PEEP fixed at 10 to 12 cm H 2 O, was accompanied by a progressive decrease in EVLW accumulation [48] .", [["ALI", "DISEASE", 68, 71], ["H 2 O", "CHEMICAL", 177, 182], ["rats", "ORGANISM", 75, 79], ["V T", "GENE_OR_GENE_PRODUCT", 114, 117], ["rats", "SPECIES", 75, 79], ["an acid aspiration", "TEST", 32, 50], ["ALI in rats", "PROBLEM", 68, 79], ["a progressive reduction in V T", "TREATMENT", 87, 117], ["PEEP", "TREATMENT", 151, 155], ["a progressive decrease in EVLW accumulation", "PROBLEM", 203, 246], ["aspiration", "OBSERVATION", 40, 50], ["ALI", "OBSERVATION", 68, 71], ["progressive", "OBSERVATION_MODIFIER", 89, 100], ["reduction", "OBSERVATION_MODIFIER", 101, 110], ["progressive", "OBSERVATION_MODIFIER", 205, 216], ["decrease", "OBSERVATION_MODIFIER", 217, 225], ["EVLW accumulation", "OBSERVATION", 229, 246]]], ["In both instances a low V T /high PEEP strategy proved beneficial.", [["V T", "GENE_OR_GENE_PRODUCT", 24, 27], ["a low V T /high PEEP strategy", "TREATMENT", 18, 47], ["low V", "OBSERVATION_MODIFIER", 20, 25]]], ["Thus in addition to reducing both permeability and proinflammatory cytokine release, a low V T /high PEEP ventilation strategy might also promote AFC and has formed the basis of important advances in ventilation strategies for ALI/ARDS patients that are in routine use today.Hypocapnia and hypocapnic alkalosisHyperventilation and hypocapnic alkalosis are often found together in patients with ALI/ARDS [49] .", [["ALI", "DISEASE", 227, 230], ["ARDS", "DISEASE", 231, 235], ["Hypocapnia", "DISEASE", 275, 285], ["Hyperventilation", "DISEASE", 310, 326], ["alkalosis", "DISEASE", 342, 351], ["ALI", "DISEASE", 394, 397], ["ARDS", "DISEASE", 398, 402], ["V T", "GENE_OR_GENE_PRODUCT", 91, 94], ["patients", "ORGANISM", 236, 244], ["patients", "ORGANISM", 380, 388], ["proinflammatory cytokine", "PROTEIN", 51, 75], ["patients", "SPECIES", 236, 244], ["patients", "SPECIES", 380, 388], ["proinflammatory cytokine release", "TREATMENT", 51, 83], ["a low V T /high PEEP ventilation strategy", "TREATMENT", 85, 126], ["ventilation strategies", "TREATMENT", 200, 222], ["ALI", "PROBLEM", 227, 230], ["ARDS", "PROBLEM", 231, 235], ["Hypocapnia", "PROBLEM", 275, 285], ["hypocapnic alkalosis", "PROBLEM", 290, 310], ["Hyperventilation", "PROBLEM", 310, 326], ["hypocapnic alkalosis", "PROBLEM", 331, 351], ["ALI", "PROBLEM", 394, 397], ["ARDS", "PROBLEM", 398, 402], ["low V", "OBSERVATION_MODIFIER", 87, 92], ["ARDS", "OBSERVATION", 231, 235], ["hypocapnic", "OBSERVATION", 290, 300], ["alkalosisHyperventilation", "OBSERVATION", 301, 326], ["hypocapnic alkalosis", "OBSERVATION", 331, 351], ["ARDS", "OBSERVATION", 398, 402]]], ["In an isolated, buffer-perfused ventilated rabbit lung, exposure to hypocapnia (> 3 h) increased vascular permeability, and hence promoted alveolar edema [50] .", [["lung", "ANATOMY", 50, 54], ["vascular", "ANATOMY", 97, 105], ["alveolar edema", "ANATOMY", 139, 153], ["hypocapnia", "DISEASE", 68, 78], ["alveolar edema", "DISEASE", 139, 153], ["rabbit", "ORGANISM", 43, 49], ["lung", "ORGAN", 50, 54], ["vascular", "MULTI-TISSUE_STRUCTURE", 97, 105], ["rabbit", "SPECIES", 43, 49], ["rabbit", "SPECIES", 43, 49], ["hypocapnia", "PROBLEM", 68, 78], ["increased vascular permeability", "PROBLEM", 87, 118], ["alveolar edema", "PROBLEM", 139, 153], ["isolated", "OBSERVATION", 6, 14], ["perfused", "OBSERVATION_MODIFIER", 23, 31], ["ventilated rabbit", "OBSERVATION", 32, 49], ["lung", "ANATOMY", 50, 54], ["hypocapnia", "OBSERVATION", 68, 78], ["vascular", "ANATOMY", 97, 105], ["permeability", "OBSERVATION_MODIFIER", 106, 118], ["alveolar", "ANATOMY", 139, 147], ["edema", "OBSERVATION", 148, 153]]], ["Further to this, using an isolated, perfused, fluid-filled rat lung, Myrianthefs et al.Hypocapnia and hypocapnic alkalosis[51] demonstrated that hypocapnia dramatically impaired AFC.", [["lung", "ANATOMY", 63, 67], ["Hypocapnia", "DISEASE", 87, 97], ["alkalosis", "DISEASE", 113, 122], ["hypocapnia", "DISEASE", 145, 155], ["rat", "ORGANISM", 59, 62], ["lung", "ORGAN", 63, 67], ["rat", "SPECIES", 59, 62], ["an isolated, perfused, fluid-filled rat lung", "PROBLEM", 23, 67], ["Hypocapnia", "PROBLEM", 87, 97], ["hypocapnic alkalosis", "PROBLEM", 102, 122], ["hypocapnia dramatically impaired AFC", "PROBLEM", 145, 181], ["perfused", "OBSERVATION_MODIFIER", 36, 44], ["fluid", "OBSERVATION", 46, 51], ["filled", "OBSERVATION", 52, 58], ["lung", "ANATOMY", 63, 67], ["hypocapnic alkalosis", "OBSERVATION", 102, 122], ["hypocapnia", "OBSERVATION_MODIFIER", 145, 155], ["dramatically", "OBSERVATION_MODIFIER", 156, 168], ["impaired", "OBSERVATION_MODIFIER", 169, 177], ["AFC", "OBSERVATION", 178, 181]]], ["This block was reversible upon restoration of normal CO 2 levels and was not induced by metabolic alkalosis.", [["metabolic alkalosis", "DISEASE", 88, 107], ["CO 2", "CHEMICAL", 53, 57], ["CO 2", "GENE_OR_GENE_PRODUCT", 53, 57], ["This block", "PROBLEM", 0, 10], ["metabolic alkalosis", "PROBLEM", 88, 107], ["normal", "OBSERVATION", 46, 52], ["metabolic alkalosis", "OBSERVATION", 88, 107]]], ["The AFC block was attributed to impaired sodium transport resulting from decreased membrane abundance of the Na,K-ATPase in rat lungs [51] .", [["membrane", "ANATOMY", 83, 91], ["lungs", "ANATOMY", 128, 133], ["sodium", "CHEMICAL", 41, 47], ["Na", "CHEMICAL", 109, 111], ["sodium", "CHEMICAL", 41, 47], ["Na", "CHEMICAL", 109, 111], ["K-", "CHEMICAL", 112, 114], ["sodium", "SIMPLE_CHEMICAL", 41, 47], ["membrane", "CELLULAR_COMPONENT", 83, 91], ["Na,K-ATPase", "GENE_OR_GENE_PRODUCT", 109, 120], ["rat", "ORGANISM", 124, 127], ["lungs", "ORGAN", 128, 133], ["Na,K-ATPase", "PROTEIN", 109, 120], ["rat", "SPECIES", 124, 127], ["The AFC block", "PROBLEM", 0, 13], ["impaired sodium transport", "PROBLEM", 32, 57], ["decreased membrane abundance", "PROBLEM", 73, 101], ["the Na", "TEST", 105, 111], ["decreased", "OBSERVATION_MODIFIER", 73, 82], ["membrane", "OBSERVATION_MODIFIER", 83, 91], ["abundance", "OBSERVATION_MODIFIER", 92, 101], ["lungs", "ANATOMY", 128, 133]]], ["Hypocapnia can therefore promote both the formation of alveolar edema and impair the resolution of this edema by blocking transepithelial sodium transport, and hence AFC.CoagulationProcoagulant pathways are upregulated in ALI/ARDS, while fibrinolysis is suppressed [1] .", [["alveolar edema", "ANATOMY", 55, 69], ["edema", "ANATOMY", 104, 109], ["transepithelial", "ANATOMY", 122, 137], ["Hypocapnia", "DISEASE", 0, 10], ["alveolar edema", "DISEASE", 55, 69], ["edema", "DISEASE", 104, 109], ["sodium", "CHEMICAL", 138, 144], ["ALI", "DISEASE", 222, 225], ["ARDS", "DISEASE", 226, 230], ["sodium", "CHEMICAL", 138, 144], ["alveolar edema", "PATHOLOGICAL_FORMATION", 55, 69], ["edema", "PATHOLOGICAL_FORMATION", 104, 109], ["transepithelial sodium", "SIMPLE_CHEMICAL", 122, 144], ["Hypocapnia", "PROBLEM", 0, 10], ["alveolar edema", "PROBLEM", 55, 69], ["this edema", "PROBLEM", 99, 109], ["blocking transepithelial sodium transport", "TREATMENT", 113, 154], ["AFC", "TEST", 166, 169], ["ARDS", "PROBLEM", 226, 230], ["alveolar", "ANATOMY", 55, 63], ["edema", "OBSERVATION", 64, 69], ["resolution", "OBSERVATION_MODIFIER", 85, 95], ["edema", "OBSERVATION", 104, 109], ["ARDS", "OBSERVATION", 226, 230]]], ["Coagulation proteases such as thrombin have well documented roles in the development of ALI/ARDS where thrombin can directly increase vascular permeability and promote alveolar flooding [1] .", [["vascular", "ANATOMY", 134, 142], ["alveolar", "ANATOMY", 168, 176], ["ALI", "DISEASE", 88, 91], ["ARDS", "DISEASE", 92, 96], ["thrombin", "GENE_OR_GENE_PRODUCT", 30, 38], ["thrombin", "GENE_OR_GENE_PRODUCT", 103, 111], ["vascular", "MULTI-TISSUE_STRUCTURE", 134, 142], ["alveolar", "MULTI-TISSUE_STRUCTURE", 168, 176], ["Coagulation proteases", "PROTEIN", 0, 21], ["thrombin", "PROTEIN", 30, 38], ["thrombin", "PROTEIN", 103, 111], ["Coagulation proteases", "TEST", 0, 21], ["thrombin", "PROBLEM", 30, 38], ["ALI", "PROBLEM", 88, 91], ["ARDS", "PROBLEM", 92, 96], ["thrombin", "TREATMENT", 103, 111], ["ALI", "OBSERVATION", 88, 91], ["ARDS", "OBSERVATION", 92, 96], ["vascular", "ANATOMY", 134, 142], ["alveolar flooding", "OBSERVATION", 168, 185]]], ["Recent work by Vad\u00e1sz et al. [52] demonstrated that thrombin applied to the vascular compartment of isolated, ventilated and perfused rabbit lungs also impaired AFC.", [["vascular compartment", "ANATOMY", 76, 96], ["lungs", "ANATOMY", 141, 146], ["thrombin", "GENE_OR_GENE_PRODUCT", 52, 60], ["vascular compartment", "MULTI-TISSUE_STRUCTURE", 76, 96], ["rabbit", "ORGANISM", 134, 140], ["lungs", "ORGAN", 141, 146], ["thrombin", "PROTEIN", 52, 60], ["rabbit", "SPECIES", 134, 140], ["rabbit", "SPECIES", 134, 140], ["thrombin", "TREATMENT", 52, 60], ["impaired AFC", "PROBLEM", 152, 164], ["thrombin", "OBSERVATION", 52, 60], ["vascular", "ANATOMY", 76, 84], ["ventilated", "OBSERVATION", 110, 120], ["lungs", "ANATOMY", 141, 146], ["impaired", "OBSERVATION_MODIFIER", 152, 160], ["AFC", "OBSERVATION", 161, 164]]], ["This was attributed to a block in transepithelial sodium and hence fluid transport across the alveolocapillary barrier.", [["transepithelial", "ANATOMY", 34, 49], ["fluid", "ANATOMY", 67, 72], ["alveolocapillary barrier", "ANATOMY", 94, 118], ["sodium", "CHEMICAL", 50, 56], ["sodium", "CHEMICAL", 50, 56], ["transepithelial sodium", "SIMPLE_CHEMICAL", 34, 56], ["alveolocapillary barrier", "TISSUE", 94, 118], ["a block in transepithelial sodium", "PROBLEM", 23, 56], ["fluid transport", "TREATMENT", 67, 82], ["the alveolocapillary barrier", "TREATMENT", 90, 118], ["transepithelial sodium", "OBSERVATION", 34, 56], ["fluid", "OBSERVATION", 67, 72]]], ["It was subsequently demonstrated that thrombin promoted the endocytosis of the Na,K-ATPase, thereby reducing Na,K-ATPase activity (see the accompanying review by Vad\u00e1sz et al.Coagulation(http://dx.doi.org/10.1007/s00134-007-0661-8).", [["Na", "CHEMICAL", 79, 81], ["Na", "CHEMICAL", 109, 111], ["K", "CHEMICAL", 112, 113], ["Na", "CHEMICAL", 79, 81], ["K-", "CHEMICAL", 82, 84], ["Na", "CHEMICAL", 109, 111], ["K", "CHEMICAL", 112, 113], ["thrombin", "GENE_OR_GENE_PRODUCT", 38, 46], ["Na", "GENE_OR_GENE_PRODUCT", 79, 81], ["K-ATPase", "GENE_OR_GENE_PRODUCT", 82, 90], ["Na", "SIMPLE_CHEMICAL", 109, 111], ["K-ATPase", "GENE_OR_GENE_PRODUCT", 112, 120], ["thrombin", "PROTEIN", 38, 46], ["Na,K-ATPase", "PROTEIN", 79, 90], ["Na,K-ATPase", "PROTEIN", 109, 120], ["thrombin", "PROBLEM", 38, 46], ["the Na", "TEST", 75, 81], ["Na", "TEST", 109, 111], ["K", "TEST", 112, 113], ["Coagulation", "TEST", 175, 186], ["thrombin", "OBSERVATION", 38, 46]]], ["Thus coagulation proteases play a dual role in impaired AFC.", [["AFC", "ANATOMY", 56, 59], ["AFC", "GENE_OR_GENE_PRODUCT", 56, 59], ["coagulation proteases", "PROTEIN", 5, 26], ["coagulation proteases", "TREATMENT", 5, 26], ["impaired AFC", "PROBLEM", 47, 59], ["impaired", "OBSERVATION_MODIFIER", 47, 55], ["AFC", "OBSERVATION", 56, 59]]], ["In addition to causing a permeability edema, thrombin, by virtue of its signaling properties, directly blocks fluid reabsorption.", [["fluid", "ANATOMY", 110, 115], ["edema", "DISEASE", 38, 43], ["edema", "PATHOLOGICAL_FORMATION", 38, 43], ["thrombin", "GENE_OR_GENE_PRODUCT", 45, 53], ["fluid", "ORGANISM_SUBSTANCE", 110, 115], ["thrombin", "PROTEIN", 45, 53], ["a permeability edema", "PROBLEM", 23, 43], ["thrombin", "TREATMENT", 45, 53], ["directly blocks fluid reabsorption", "PROBLEM", 94, 128], ["permeability", "OBSERVATION_MODIFIER", 25, 37], ["edema", "OBSERVATION", 38, 43], ["thrombin", "OBSERVATION", 45, 53], ["fluid reabsorption", "OBSERVATION", 110, 128]]], ["In contrast to the thrombin-signaling effects on Na,K-ATPase trafficking, serine proteases can directly enhance \u03b2-adrenergic-stimulated ENaC activity in alveolar epithelial cells and enhance \u03b2-adrenergic-stimulated AFC in live mice [53] .", [["alveolar epithelial cells", "ANATOMY", 153, 178], ["Na", "CHEMICAL", 49, 51], ["Na", "CHEMICAL", 49, 51], ["K-", "CHEMICAL", 52, 54], ["serine", "CHEMICAL", 74, 80], ["thrombin", "GENE_OR_GENE_PRODUCT", 19, 27], ["Na", "SIMPLE_CHEMICAL", 49, 51], ["K-ATPase", "GENE_OR_GENE_PRODUCT", 52, 60], ["serine", "AMINO_ACID", 74, 80], ["\u03b2-adrenergic", "SIMPLE_CHEMICAL", 112, 124], ["ENaC", "GENE_OR_GENE_PRODUCT", 136, 140], ["alveolar epithelial cells", "CELL", 153, 178], ["\u03b2-adrenergic", "SIMPLE_CHEMICAL", 191, 203], ["AFC", "GENE_OR_GENE_PRODUCT", 215, 218], ["mice", "ORGANISM", 227, 231], ["thrombin", "PROTEIN", 19, 27], ["Na,K-ATPase", "PROTEIN", 49, 60], ["serine proteases", "PROTEIN", 74, 90], ["ENaC", "PROTEIN", 136, 140], ["alveolar epithelial cells", "CELL_TYPE", 153, 178], ["\u03b2-adrenergic-stimulated AFC", "PROTEIN", 191, 218], ["mice", "SPECIES", 227, 231], ["Na", "TEST", 49, 51], ["K-ATPase trafficking", "TEST", 52, 72], ["serine proteases", "TEST", 74, 90], ["\u03b2-adrenergic", "TEST", 112, 124], ["alveolar epithelial cells", "PROBLEM", 153, 178], ["\u03b2-adrenergic", "TEST", 191, 203], ["thrombin", "OBSERVATION", 19, 27], ["alveolar epithelial cells", "OBSERVATION", 153, 178]]], ["Thus serine proteases appear to have opposing effects on different components of the sodium transport machinery.Infection and inflammatory mediatorsInfection and purified endotoxin promote vascular permeability and pulmonary edema by inflammatory mechanisms involving granulocytes [14] .", [["vascular", "ANATOMY", 189, 197], ["pulmonary", "ANATOMY", 215, 224], ["granulocytes", "ANATOMY", 268, 280], ["sodium", "CHEMICAL", 85, 91], ["Infection", "DISEASE", 112, 121], ["endotoxin", "CHEMICAL", 171, 180], ["edema", "DISEASE", 225, 230], ["serine", "CHEMICAL", 5, 11], ["sodium", "CHEMICAL", 85, 91], ["serine", "AMINO_ACID", 5, 11], ["sodium", "SIMPLE_CHEMICAL", 85, 91], ["endotoxin", "SIMPLE_CHEMICAL", 171, 180], ["vascular", "MULTI-TISSUE_STRUCTURE", 189, 197], ["pulmonary edema", "PATHOLOGICAL_FORMATION", 215, 230], ["granulocytes", "CELL", 268, 280], ["serine proteases", "PROTEIN", 5, 21], ["inflammatory mediators", "PROTEIN", 126, 148], ["granulocytes", "CELL_TYPE", 268, 280], ["serine proteases", "TREATMENT", 5, 21], ["the sodium transport machinery", "TREATMENT", 81, 111], ["Infection", "PROBLEM", 112, 121], ["inflammatory mediators", "PROBLEM", 126, 148], ["Infection", "PROBLEM", 148, 157], ["purified endotoxin promote vascular permeability", "PROBLEM", 162, 210], ["pulmonary edema", "PROBLEM", 215, 230], ["inflammatory mechanisms involving granulocytes", "PROBLEM", 234, 280], ["inflammatory", "OBSERVATION_MODIFIER", 126, 138], ["endotoxin", "OBSERVATION_MODIFIER", 171, 180], ["vascular", "ANATOMY", 189, 197], ["permeability", "OBSERVATION_MODIFIER", 198, 210], ["pulmonary", "ANATOMY", 215, 224], ["edema", "OBSERVATION", 225, 230], ["inflammatory", "OBSERVATION_MODIFIER", 234, 246]]], ["Interestingly, AFC was upregulated after intratracheal administration of endotoxin to live rats and in a rat model of septic shock [54], possibly as a protective mechanism induced during septic shock to overcome alveolar flooding.", [["intratracheal", "ANATOMY", 41, 54], ["alveolar", "ANATOMY", 212, 220], ["endotoxin", "CHEMICAL", 73, 82], ["septic shock", "DISEASE", 118, 130], ["septic shock", "DISEASE", 187, 199], ["AFC", "GENE_OR_GENE_PRODUCT", 15, 18], ["intratracheal", "IMMATERIAL_ANATOMICAL_ENTITY", 41, 54], ["endotoxin", "SIMPLE_CHEMICAL", 73, 82], ["rats", "ORGANISM", 91, 95], ["rat", "ORGANISM", 105, 108], ["alveolar", "MULTI-TISSUE_STRUCTURE", 212, 220], ["AFC", "PROTEIN", 15, 18], ["rats", "SPECIES", 91, 95], ["rat", "SPECIES", 105, 108], ["rat", "SPECIES", 105, 108], ["AFC", "TEST", 15, 18], ["endotoxin", "TREATMENT", 73, 82], ["septic shock", "PROBLEM", 118, 130], ["septic shock", "PROBLEM", 187, 199], ["alveolar flooding", "PROBLEM", 212, 229], ["septic shock", "OBSERVATION", 118, 130], ["septic shock", "OBSERVATION", 187, 199], ["alveolar flooding", "OBSERVATION", 212, 229]]], ["However, both cell-surface ENaC expression and AFC were downregulated in an experimental Mycoplasma pneumoniae infection in live mice, an effect mediated by reactive oxygen-nitrogen intermediates [55].", [["cell", "ANATOMY", 14, 18], ["surface", "ANATOMY", 19, 26], ["Mycoplasma pneumoniae infection", "DISEASE", 89, 120], ["oxygen", "CHEMICAL", 166, 172], ["oxygen", "CHEMICAL", 166, 172], ["nitrogen", "CHEMICAL", 173, 181], ["cell", "CELL", 14, 18], ["ENaC", "GENE_OR_GENE_PRODUCT", 27, 31], ["AFC", "GENE_OR_GENE_PRODUCT", 47, 50], ["Mycoplasma pneumoniae", "ORGANISM", 89, 110], ["mice", "ORGANISM", 129, 133], ["oxygen", "SIMPLE_CHEMICAL", 166, 172], ["ENaC", "PROTEIN", 27, 31], ["AFC", "PROTEIN", 47, 50], ["Mycoplasma pneumoniae", "SPECIES", 89, 110], ["mice", "SPECIES", 129, 133], ["Mycoplasma pneumoniae", "SPECIES", 89, 110], ["mice", "SPECIES", 129, 133], ["AFC", "TEST", 47, 50], ["an experimental Mycoplasma pneumoniae infection", "PROBLEM", 73, 120], ["reactive oxygen-nitrogen intermediates", "TREATMENT", 157, 195], ["Mycoplasma pneumoniae", "OBSERVATION", 89, 110], ["reactive", "OBSERVATION_MODIFIER", 157, 165]]], ["This phenomenon is not limited to bacterial pathogens, since in live rats, the influenza virus can directly impair ENaC activity by reducing the open probability (P o ) of the channel, and thus downregulate AFC, independently of viral entry into the epithelium [56] .", [["epithelium", "ANATOMY", 250, 260], ["rats", "ORGANISM", 69, 73], ["influenza virus", "ORGANISM", 79, 94], ["ENaC", "GENE_OR_GENE_PRODUCT", 115, 119], ["AFC", "GENE_OR_GENE_PRODUCT", 207, 210], ["epithelium", "TISSUE", 250, 260], ["ENaC", "PROTEIN", 115, 119], ["AFC", "PROTEIN", 207, 210], ["rats", "SPECIES", 69, 73], ["influenza virus", "SPECIES", 79, 94], ["This phenomenon", "PROBLEM", 0, 15], ["bacterial pathogens", "PROBLEM", 34, 53], ["the influenza virus", "PROBLEM", 75, 94], ["not limited to", "UNCERTAINTY", 19, 33], ["bacterial", "OBSERVATION_MODIFIER", 34, 43], ["pathogens", "OBSERVATION", 44, 53], ["ENaC activity", "OBSERVATION", 115, 128]]], ["Thus it appears that lung infections can impair AFC, although there appear to be multiple underlying causes.Infection and inflammatory mediatorsAcute lung injury may develop rapidly in recipients of transfused whole plasma [1] .", [["lung", "ANATOMY", 21, 25], ["lung", "ANATOMY", 150, 154], ["plasma", "ANATOMY", 216, 222], ["lung infections", "DISEASE", 21, 36], ["Infection", "DISEASE", 108, 117], ["lung injury", "DISEASE", 150, 161], ["lung", "ORGAN", 21, 25], ["AFC", "GENE_OR_GENE_PRODUCT", 48, 51], ["lung", "ORGAN", 150, 154], ["plasma", "ORGANISM_SUBSTANCE", 216, 222], ["inflammatory mediators", "PROTEIN", 122, 144], ["lung infections", "PROBLEM", 21, 36], ["AFC", "PROBLEM", 48, 51], ["multiple underlying causes", "PROBLEM", 81, 107], ["Infection", "PROBLEM", 108, 117], ["inflammatory mediators", "PROBLEM", 122, 144], ["Acute lung injury", "PROBLEM", 144, 161], ["lung", "ANATOMY", 21, 25], ["infections", "OBSERVATION", 26, 36], ["appear to be", "UNCERTAINTY", 68, 80], ["multiple", "OBSERVATION_MODIFIER", 81, 89], ["inflammatory", "OBSERVATION_MODIFIER", 122, 134], ["lung", "ANATOMY", 150, 154], ["injury", "OBSERVATION", 155, 161], ["rapidly", "OBSERVATION_MODIFIER", 174, 181]]], ["This transfusion-associated acute lung injury (TRALI) is caused by biologically active lipids, and antileukocyte antibodies, which cause a pronounced vascular leak [1] .", [["lung", "ANATOMY", 34, 38], ["vascular", "ANATOMY", 150, 158], ["acute lung injury", "DISEASE", 28, 45], ["TRALI", "DISEASE", 47, 52], ["lung", "ORGAN", 34, 38], ["lipids", "SIMPLE_CHEMICAL", 87, 93], ["antileukocyte antibodies", "GENE_OR_GENE_PRODUCT", 99, 123], ["vascular", "MULTI-TISSUE_STRUCTURE", 150, 158], ["antileukocyte antibodies", "PROTEIN", 99, 123], ["This transfusion", "TREATMENT", 0, 16], ["acute lung injury", "PROBLEM", 28, 45], ["TRALI", "PROBLEM", 47, 52], ["biologically active lipids", "PROBLEM", 67, 93], ["antileukocyte antibodies", "TEST", 99, 123], ["a pronounced vascular leak", "PROBLEM", 137, 163], ["acute", "OBSERVATION_MODIFIER", 28, 33], ["lung", "ANATOMY", 34, 38], ["injury", "OBSERVATION", 39, 45], ["TRALI", "OBSERVATION", 47, 52], ["pronounced", "OBSERVATION_MODIFIER", 139, 149], ["vascular", "ANATOMY", 150, 158], ["leak", "OBSERVATION", 159, 163]]], ["In a new mouse model of TRALI Looney et al. [57] have demonstrated that AFC is also impaired in TRALI, although the molecular mechanism has not been described.Infection and inflammatory mediatorsLevels of proinflammatory factors are elevated in bronchoalveolar lavage fluids from ALI/ARDS patients, including interleukin (IL) 1\u03b2, IL-6, IL-8, tumor necrosis factor (TNF)-\u03b1, and transforming growth factor (TGF) \u03b2 [58].", [["bronchoalveolar lavage fluids", "ANATOMY", 245, 274], ["TRALI", "DISEASE", 24, 29], ["TRALI", "DISEASE", 96, 101], ["ALI", "DISEASE", 280, 283], ["ARDS", "DISEASE", 284, 288], ["necrosis", "DISEASE", 348, 356], ["mouse", "ORGANISM", 9, 14], ["AFC", "GENE_OR_GENE_PRODUCT", 72, 75], ["bronchoalveolar lavage fluids", "ORGANISM_SUBSTANCE", 245, 274], ["patients", "ORGANISM", 289, 297], ["interleukin (IL) 1\u03b2", "GENE_OR_GENE_PRODUCT", 309, 328], ["IL-6", "GENE_OR_GENE_PRODUCT", 330, 334], ["IL-8", "GENE_OR_GENE_PRODUCT", 336, 340], ["tumor necrosis factor (TNF)-\u03b1", "GENE_OR_GENE_PRODUCT", 342, 371], ["transforming growth factor (TGF) \u03b2", "GENE_OR_GENE_PRODUCT", 377, 411], ["AFC", "PROTEIN", 72, 75], ["proinflammatory factors", "PROTEIN", 205, 228], ["interleukin (IL) 1\u03b2", "PROTEIN", 309, 328], ["IL-8", "PROTEIN", 336, 340], ["tumor necrosis factor (TNF)-\u03b1", "PROTEIN", 342, 371], ["TGF", "PROTEIN", 405, 408], ["mouse", "SPECIES", 9, 14], ["patients", "SPECIES", 289, 297], ["mouse", "SPECIES", 9, 14], ["AFC", "PROBLEM", 72, 75], ["TRALI", "PROBLEM", 96, 101], ["Infection", "PROBLEM", 159, 168], ["inflammatory mediators", "PROBLEM", 173, 195], ["proinflammatory factors", "PROBLEM", 205, 228], ["bronchoalveolar lavage fluids", "TREATMENT", 245, 274], ["ALI", "PROBLEM", 280, 283], ["ARDS", "PROBLEM", 284, 288], ["interleukin (IL)", "TREATMENT", 309, 325], ["IL", "TEST", 330, 332], ["IL", "TEST", 336, 338], ["tumor necrosis factor", "PROBLEM", 342, 363], ["TNF", "TEST", 365, 368], ["AFC", "OBSERVATION", 72, 75], ["impaired", "OBSERVATION_MODIFIER", 84, 92], ["TRALI", "OBSERVATION", 96, 101], ["inflammatory", "OBSERVATION_MODIFIER", 173, 185], ["proinflammatory", "OBSERVATION_MODIFIER", 205, 220], ["elevated", "OBSERVATION_MODIFIER", 233, 241], ["bronchoalveolar lavage", "OBSERVATION", 245, 267], ["ARDS", "OBSERVATION", 284, 288], ["tumor", "OBSERVATION_MODIFIER", 342, 347], ["necrosis", "OBSERVATION", 348, 356]]], ["Based on studies in rats Fukuda et al. [59] demonstrated that different domains of TNF-\u03b1 have opposing effects on sodium transport and AFC, where interaction with the TNF-\u03b1 receptor caused inflammation and increased permeability, while the TNF-\u03b1 lectin-like domain directly activated ENaC and potentiated AFC.", [["sodium", "CHEMICAL", 114, 120], ["inflammation", "DISEASE", 189, 201], ["sodium", "CHEMICAL", 114, 120], ["rats", "ORGANISM", 20, 24], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 83, 88], ["sodium", "SIMPLE_CHEMICAL", 114, 120], ["AFC", "SIMPLE_CHEMICAL", 135, 138], ["TNF-\u03b1 receptor", "GENE_OR_GENE_PRODUCT", 167, 181], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 240, 245], ["ENaC", "GENE_OR_GENE_PRODUCT", 284, 288], ["AFC", "GENE_OR_GENE_PRODUCT", 305, 308], ["TNF", "PROTEIN", 83, 86], ["TNF-\u03b1 receptor", "PROTEIN", 167, 181], ["TNF", "PROTEIN", 240, 243], ["\u03b1 lectin", "PROTEIN", 244, 252], ["ENaC", "PROTEIN", 284, 288], ["AFC", "PROTEIN", 305, 308], ["rats", "SPECIES", 20, 24], ["studies", "TEST", 9, 16], ["TNF", "TEST", 83, 86], ["sodium transport", "TREATMENT", 114, 130], ["AFC", "TEST", 135, 138], ["the TNF", "TEST", 163, 170], ["inflammation", "PROBLEM", 189, 201], ["increased permeability", "PROBLEM", 206, 228], ["the TNF", "TEST", 236, 243], ["lectin", "TEST", 246, 252], ["inflammation", "OBSERVATION", 189, 201], ["increased", "OBSERVATION_MODIFIER", 206, 215], ["permeability", "OBSERVATION_MODIFIER", 216, 228]]], ["In contrast, atrial natriuretic factor applied to the vasculature of isolated, perfused lungs [60], and TGF-\u03b2 applied intratracheally to live rats [61] impaired transepithelial sodium transport and blocked AFC.", [["vasculature", "ANATOMY", 54, 65], ["lungs", "ANATOMY", 88, 93], ["transepithelial", "ANATOMY", 161, 176], ["sodium", "CHEMICAL", 177, 183], ["sodium", "CHEMICAL", 177, 183], ["atrial natriuretic factor", "GENE_OR_GENE_PRODUCT", 13, 38], ["vasculature", "MULTI-TISSUE_STRUCTURE", 54, 65], ["lungs", "ORGAN", 88, 93], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 104, 109], ["rats", "ORGANISM", 142, 146], ["transepithelial sodium", "SIMPLE_CHEMICAL", 161, 183], ["atrial natriuretic factor", "PROTEIN", 13, 38], ["TGF-\u03b2", "PROTEIN", 104, 109], ["AFC", "PROTEIN", 206, 209], ["rats", "SPECIES", 142, 146], ["atrial natriuretic factor", "TREATMENT", 13, 38], ["TGF", "TEST", 104, 107], ["impaired transepithelial sodium transport", "TREATMENT", 152, 193], ["atrial", "ANATOMY", 13, 19], ["vasculature", "ANATOMY", 54, 65], ["lungs", "ANATOMY", 88, 93]]], ["It was subsequently demonstrated that TGF-\u03b2 downregulated ENaC gene expression [61] .", [["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 38, 43], ["ENaC", "GENE_OR_GENE_PRODUCT", 58, 62], ["TGF-\u03b2", "PROTEIN", 38, 43], ["ENaC gene", "DNA", 58, 67], ["TGF", "TEST", 38, 41]]], ["Together these data indicate new and emerging roles for polypeptide growth factors and other hormones in the regulation of AFC.Infection and inflammatory mediatorsTargeting fluid clearance in ALI/ARDS: what we have learned from intact organ and animal models, and clinical studiesVentilation strategiesStudies in animal models demonstrated that low V T and high PEEP ventilation strategies potentiated AFC in acid aspiration-induced ALI [45, 48], suggesting a therapeutic benefit of this ventilation strategy in the management of ALI/ARDS.", [["fluid", "ANATOMY", 173, 178], ["organ", "ANATOMY", 235, 240], ["Infection", "DISEASE", 127, 136], ["ALI", "DISEASE", 192, 195], ["ARDS", "DISEASE", 196, 200], ["ALI", "DISEASE", 433, 436], ["ALI", "DISEASE", 530, 533], ["ARDS", "DISEASE", 534, 538], ["polypeptide growth factors", "GENE_OR_GENE_PRODUCT", 56, 82], ["AFC", "GENE_OR_GENE_PRODUCT", 123, 126], ["fluid", "ORGANISM_SUBSTANCE", 173, 178], ["organ", "ORGAN", 235, 240], ["V T", "GENE_OR_GENE_PRODUCT", 349, 352], ["AFC", "SIMPLE_CHEMICAL", 402, 405], ["polypeptide growth factors", "PROTEIN", 56, 82], ["inflammatory mediators", "PROTEIN", 141, 163], ["these data", "TEST", 9, 19], ["polypeptide growth factors", "PROBLEM", 56, 82], ["Infection", "PROBLEM", 127, 136], ["inflammatory mediators", "PROBLEM", 141, 163], ["fluid clearance", "TEST", 173, 188], ["ALI", "PROBLEM", 192, 195], ["ARDS", "PROBLEM", 196, 200], ["clinical studies", "TEST", 264, 280], ["Ventilation strategies", "TREATMENT", 280, 302], ["animal models", "TEST", 313, 326], ["low V T", "PROBLEM", 345, 352], ["high PEEP ventilation strategies", "TREATMENT", 357, 389], ["AFC in acid aspiration", "PROBLEM", 402, 424], ["this ventilation strategy", "TREATMENT", 483, 508], ["ALI", "PROBLEM", 530, 533], ["ARDS", "PROBLEM", 534, 538], ["new", "OBSERVATION_MODIFIER", 29, 32], ["inflammatory", "OBSERVATION_MODIFIER", 141, 153], ["fluid clearance", "OBSERVATION", 173, 188], ["ALI", "ANATOMY", 192, 195], ["ARDS", "OBSERVATION", 196, 200], ["low V", "OBSERVATION_MODIFIER", 345, 350], ["ALI", "OBSERVATION", 530, 533], ["ARDS", "OBSERVATION", 534, 538]]], ["Several small phase III clinical trials addressing the potential benefit of low V T (which is lung protective) vs. traditional higher V T (providing better oxygenation) yielded conflicting results (reviewed in [62] ).", [["lung", "ANATOMY", 94, 98], ["V T", "GENE_OR_GENE_PRODUCT", 80, 83], ["lung", "ORGAN", 94, 98], ["low V T", "PROBLEM", 76, 83], ["traditional higher V T", "TREATMENT", 115, 137], ["small", "OBSERVATION_MODIFIER", 8, 13], ["phase", "OBSERVATION_MODIFIER", 14, 19], ["low V", "OBSERVATION_MODIFIER", 76, 81], ["lung", "ANATOMY", 94, 98]]], ["A subsequent multicenter, randomized, controlled trial of 861 patients conducted under the auspices of the National Heart, Lung and Blood Institute ARDS Network demonstrated that a 6 ml/kg V T ventilation strategy yielded a significant reduction in mortality compared with a 12 ml/kg V T ventilation strategy (with a plateau pressure of < 30 cmH 2 O) [63] .", [["Lung", "ANATOMY", 123, 127], ["ARDS", "DISEASE", 148, 152], ["cmH 2 O", "CHEMICAL", 342, 349], ["patients", "ORGANISM", 62, 70], ["Lung", "ORGAN", 123, 127], ["Blood", "ORGANISM_SUBSTANCE", 132, 137], ["patients", "SPECIES", 62, 70], ["a 6 ml/kg V T ventilation strategy", "TREATMENT", 179, 213], ["a significant reduction in mortality", "PROBLEM", 222, 258], ["V T ventilation strategy", "TREATMENT", 284, 308], ["a plateau pressure", "TEST", 315, 333], ["Heart", "ANATOMY", 116, 121], ["Lung", "ANATOMY", 123, 127], ["significant", "OBSERVATION_MODIFIER", 224, 235], ["reduction", "OBSERVATION_MODIFIER", 236, 245]]], ["While EVLW was not assessed in this trial, the 6 ml/kg V T ventilation strategy also increased the number of ventilator-free days, indicative of improved lung function.", [["lung", "ANATOMY", 154, 158], ["lung", "ORGAN", 154, 158], ["the 6 ml/kg V T ventilation strategy", "TREATMENT", 43, 79], ["improved lung function", "PROBLEM", 145, 167], ["increased", "OBSERVATION_MODIFIER", 85, 94], ["indicative of", "UNCERTAINTY", 131, 144], ["improved", "OBSERVATION_MODIFIER", 145, 153], ["lung", "ANATOMY", 154, 158], ["function", "OBSERVATION", 159, 167]]], ["To date this remains the only intervention with a confirmed benefit on clinical outcome, and clearly demonstrates how studies on ALI/ARDS in animal and organ models have translated into a successful therapeutic strategy.CatecholaminesCatecholamine-stimulated transepithelial sodium transport is the most intensely explored possibility of manipulating AFC in a therapeutic context.", [["organ", "ANATOMY", 152, 157], ["transepithelial", "ANATOMY", 259, 274], ["ALI", "DISEASE", 129, 132], ["ARDS", "DISEASE", 133, 137], ["Catecholamine", "CHEMICAL", 234, 247], ["sodium", "CHEMICAL", 275, 281], ["Catecholamines", "CHEMICAL", 220, 234], ["Catecholamine", "CHEMICAL", 234, 247], ["sodium", "CHEMICAL", 275, 281], ["organ", "ORGAN", 152, 157], ["Catecholamines", "SIMPLE_CHEMICAL", 220, 234], ["Catecholamine", "SIMPLE_CHEMICAL", 234, 247], ["transepithelial", "MULTI-TISSUE_STRUCTURE", 259, 274], ["sodium", "SIMPLE_CHEMICAL", 275, 281], ["AFC", "GENE_OR_GENE_PRODUCT", 351, 354], ["ALI", "PROBLEM", 129, 132], ["ARDS", "PROBLEM", 133, 137], ["a successful therapeutic strategy", "TREATMENT", 186, 219], ["CatecholaminesCatecholamine", "TREATMENT", 220, 247], ["stimulated transepithelial sodium transport", "TREATMENT", 248, 291], ["ARDS", "OBSERVATION", 133, 137]]], ["It was demonstrated in 1978 that epinephrine stimulated AFC from the airspaces of newborn mammals [64] , implicating \u03b2-adrenergic receptors in AFC.", [["airspaces", "ANATOMY", 69, 78], ["epinephrine", "CHEMICAL", 33, 44], ["epinephrine", "CHEMICAL", 33, 44], ["epinephrine", "SIMPLE_CHEMICAL", 33, 44], ["AFC", "GENE_OR_GENE_PRODUCT", 56, 59], ["airspaces", "MULTI-TISSUE_STRUCTURE", 69, 78], ["\u03b2-adrenergic receptors", "GENE_OR_GENE_PRODUCT", 117, 139], ["AFC", "CELL", 143, 146], ["\u03b2-adrenergic receptors", "PROTEIN", 117, 139], ["\u03b2-adrenergic receptors in AFC", "PROBLEM", 117, 146], ["airspaces", "ANATOMY_MODIFIER", 69, 78]]], ["Both epinephrine and terbutaline stimulated AFC in anesthetized sheep [65] , and terbutaline stimulated transepithelial sodium transport in an isolated, buffer-perfused rat lung [66] and dramatically enhanced alveolar fluid clearance in a resected human lung [67] . \u03b2-Adrenergic agonists also reduce high vascular pressureinduced vascular permeability in isolated rat lungs [68] , indicating that \u03b2-adrenergic agonsist may influence both reduce barrier permeability and potentiate AFC.", [["transepithelial", "ANATOMY", 104, 119], ["lung", "ANATOMY", 173, 177], ["alveolar fluid", "ANATOMY", 209, 223], ["lung", "ANATOMY", 254, 258], ["vascular", "ANATOMY", 305, 313], ["vascular", "ANATOMY", 330, 338], ["lungs", "ANATOMY", 368, 373], ["barrier", "ANATOMY", 445, 452], ["epinephrine", "CHEMICAL", 5, 16], ["terbutaline", "CHEMICAL", 21, 32], ["terbutaline", "CHEMICAL", 81, 92], ["sodium", "CHEMICAL", 120, 126], ["epinephrine", "CHEMICAL", 5, 16], ["terbutaline", "CHEMICAL", 21, 32], ["terbutaline", "CHEMICAL", 81, 92], ["sodium", "CHEMICAL", 120, 126], ["epinephrine", "SIMPLE_CHEMICAL", 5, 16], ["terbutaline", "SIMPLE_CHEMICAL", 21, 32], ["AFC", "SIMPLE_CHEMICAL", 44, 47], ["sheep", "ORGANISM", 64, 69], ["terbutaline", "SIMPLE_CHEMICAL", 81, 92], ["transepithelial sodium", "SIMPLE_CHEMICAL", 104, 126], ["rat", "ORGANISM", 169, 172], ["lung", "ORGAN", 173, 177], ["alveolar fluid", "MULTI-TISSUE_STRUCTURE", 209, 223], ["human", "ORGANISM", 248, 253], ["lung", "ORGAN", 254, 258], ["\u03b2-Adrenergic", "SIMPLE_CHEMICAL", 266, 278], ["vascular", "MULTI-TISSUE_STRUCTURE", 305, 313], ["vascular", "MULTI-TISSUE_STRUCTURE", 330, 338], ["rat", "ORGANISM", 364, 367], ["lungs", "ORGAN", 368, 373], ["\u03b2-adrenergic", "SIMPLE_CHEMICAL", 397, 409], ["barrier", "TISSUE", 445, 452], ["sheep", "SPECIES", 64, 69], ["rat", "SPECIES", 169, 172], ["human", "SPECIES", 248, 253], ["rat", "SPECIES", 364, 367], ["sheep", "SPECIES", 64, 69], ["human", "SPECIES", 248, 253], ["Both epinephrine", "TREATMENT", 0, 16], ["terbutaline", "TREATMENT", 21, 32], ["terbutaline stimulated transepithelial sodium transport", "TREATMENT", 81, 136], ["dramatically enhanced alveolar fluid clearance", "PROBLEM", 187, 233], ["\u03b2-Adrenergic agonists", "TREATMENT", 266, 287], ["high vascular pressureinduced vascular permeability in isolated rat lungs", "PROBLEM", 300, 373], ["\u03b2-adrenergic agonsist", "PROBLEM", 397, 418], ["barrier permeability", "TREATMENT", 445, 465], ["AFC", "PROBLEM", 481, 484], ["lung", "ANATOMY", 173, 177], ["dramatically", "OBSERVATION_MODIFIER", 187, 199], ["enhanced", "OBSERVATION_MODIFIER", 200, 208], ["alveolar", "OBSERVATION_MODIFIER", 209, 217], ["fluid clearance", "OBSERVATION", 218, 233], ["resected", "OBSERVATION", 239, 247], ["lung", "ANATOMY", 254, 258], ["high", "OBSERVATION_MODIFIER", 300, 304], ["vascular", "ANATOMY", 305, 313], ["pressureinduced", "ANATOMY_MODIFIER", 314, 329], ["vascular", "ANATOMY", 330, 338], ["permeability", "OBSERVATION_MODIFIER", 339, 351], ["lungs", "ANATOMY", 368, 373]]], ["The ability of \u03b2-adrenergic agonists to stimulate AFC is attributed in part to recruitment from intracellular pools (a) of Na,K-ATPase to the basolateral membrane [69] and (b) of ENaC to the apical membrane [70] of alveolar epithelial cells (reviewed in [71] ).", [["intracellular", "ANATOMY", 96, 109], ["basolateral membrane", "ANATOMY", 142, 162], ["apical membrane", "ANATOMY", 191, 206], ["alveolar epithelial cells", "ANATOMY", 215, 240], ["Na", "CHEMICAL", 123, 125], ["Na", "CHEMICAL", 123, 125], ["K-", "CHEMICAL", 126, 128], ["AFC", "GENE_OR_GENE_PRODUCT", 50, 53], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 96, 109], ["Na,K-ATPase", "GENE_OR_GENE_PRODUCT", 123, 134], ["basolateral membrane", "CELLULAR_COMPONENT", 142, 162], ["ENaC", "GENE_OR_GENE_PRODUCT", 179, 183], ["apical membrane", "CELLULAR_COMPONENT", 191, 206], ["alveolar epithelial cells", "CELL", 215, 240], ["AFC", "PROTEIN", 50, 53], ["Na,K-ATPase", "PROTEIN", 123, 134], ["ENaC", "PROTEIN", 179, 183], ["alveolar epithelial cells", "CELL_TYPE", 215, 240], ["\u03b2-adrenergic agonists", "TREATMENT", 15, 36], ["AFC", "PROBLEM", 50, 53], ["Na", "TEST", 123, 125], ["the basolateral membrane", "TEST", 138, 162], ["alveolar epithelial cells", "PROBLEM", 215, 240], ["basolateral", "ANATOMY_MODIFIER", 142, 153], ["apical membrane", "ANATOMY", 191, 206], ["alveolar epithelial cells", "OBSERVATION", 215, 240]]], ["Furthermore, \u03b2-adrenergic stimulation can clear edema in hypoxia-induced ALI [35] and ventilator-associated lung injury [72] in animals, suggesting a potentially exciting therapeutic potential for \u03b2-adrenergic agonists in the treatment of ALI/ARDS.", [["edema", "ANATOMY", 48, 53], ["lung", "ANATOMY", 108, 112], ["edema", "DISEASE", 48, 53], ["ALI", "DISEASE", 73, 76], ["lung injury", "DISEASE", 108, 119], ["ALI", "DISEASE", 239, 242], ["ARDS", "DISEASE", 243, 247], ["\u03b2-adrenergic", "SIMPLE_CHEMICAL", 13, 25], ["edema", "PATHOLOGICAL_FORMATION", 48, 53], ["lung", "ORGAN", 108, 112], ["\u03b2-adrenergic", "SIMPLE_CHEMICAL", 197, 209], ["\u03b2-adrenergic stimulation", "TREATMENT", 13, 37], ["edema", "PROBLEM", 48, 53], ["hypoxia-induced ALI", "PROBLEM", 57, 76], ["ventilator", "TREATMENT", 86, 96], ["lung injury", "PROBLEM", 108, 119], ["\u03b2-adrenergic agonists", "TREATMENT", 197, 218], ["ALI", "PROBLEM", 239, 242], ["ARDS", "PROBLEM", 243, 247], ["edema", "OBSERVATION", 48, 53], ["lung", "ANATOMY", 108, 112], ["injury", "OBSERVATION", 113, 119], ["ALI", "OBSERVATION", 239, 242], ["ARDS", "OBSERVATION", 243, 247]]], ["This idea was further supported by the observations that adenovirus-mediated transfer of \u03b2-adrenergic receptor genes to live rats improved AFC due to increased sensitivity to endogenous catecholamines and consequent upregulation of Na,K-ATPase activity and ENaC protein expression the lung [73] .", [["lung", "ANATOMY", 285, 289], ["catecholamines", "CHEMICAL", 186, 200], ["Na", "CHEMICAL", 232, 234], ["catecholamines", "CHEMICAL", 186, 200], ["Na", "CHEMICAL", 232, 234], ["K-", "CHEMICAL", 235, 237], ["adenovirus", "ORGANISM", 57, 67], ["\u03b2-adrenergic receptor", "GENE_OR_GENE_PRODUCT", 89, 110], ["rats", "ORGANISM", 125, 129], ["AFC", "GENE_OR_GENE_PRODUCT", 139, 142], ["catecholamines", "SIMPLE_CHEMICAL", 186, 200], ["Na", "GENE_OR_GENE_PRODUCT", 232, 234], ["K-ATPase", "GENE_OR_GENE_PRODUCT", 235, 243], ["ENaC", "GENE_OR_GENE_PRODUCT", 257, 261], ["lung", "ORGAN", 285, 289], ["\u03b2-adrenergic receptor genes", "DNA", 89, 116], ["K-ATPase", "PROTEIN", 235, 243], ["ENaC", "PROTEIN", 257, 261], ["rats", "SPECIES", 125, 129], ["adenovirus", "PROBLEM", 57, 67], ["\u03b2-adrenergic receptor genes", "TREATMENT", 89, 116], ["increased sensitivity", "PROBLEM", 150, 171], ["endogenous catecholamines", "PROBLEM", 175, 200], ["Na", "TEST", 232, 234], ["K-ATPase activity", "TEST", 235, 252], ["ENaC protein expression the lung", "PROBLEM", 257, 289], ["protein expression", "OBSERVATION", 262, 280], ["lung", "ANATOMY", 285, 289]]], ["More recently a role for the CFTR channel in cAMP-stimulated AFC has been proposed since AFC in cystic fibrosis (\u2206F508) mice, which lack CFTR activity was not stimulated with \u03b2-adrenergic agonists [8] .", [["cAMP", "CHEMICAL", 45, 49], ["fibrosis", "DISEASE", 103, 111], ["cAMP", "CHEMICAL", 45, 49], ["CFTR", "GENE_OR_GENE_PRODUCT", 29, 33], ["cAMP", "SIMPLE_CHEMICAL", 45, 49], ["AFC", "GENE_OR_GENE_PRODUCT", 61, 64], ["AFC", "GENE_OR_GENE_PRODUCT", 89, 92], ["cystic fibrosis", "PATHOLOGICAL_FORMATION", 96, 111], ["CFTR", "GENE_OR_GENE_PRODUCT", 137, 141], ["CFTR channel", "PROTEIN", 29, 41], ["AFC", "PROTEIN", 61, 64], ["CFTR", "PROTEIN", 137, 141], ["mice", "SPECIES", 120, 124], ["the CFTR channel", "TREATMENT", 25, 41], ["cAMP-stimulated AFC", "TREATMENT", 45, 64], ["AFC", "PROBLEM", 89, 92], ["cystic fibrosis", "PROBLEM", 96, 111], ["\u03b2-adrenergic agonists", "TREATMENT", 175, 196], ["cystic", "OBSERVATION_MODIFIER", 96, 102], ["fibrosis", "OBSERVATION", 103, 111]]], ["Furthermore, administration of a CFTR inhibitor to live mice blocked cAMP-stimulated AFC [14] .", [["cAMP", "CHEMICAL", 69, 73], ["cAMP", "CHEMICAL", 69, 73], ["CFTR", "GENE_OR_GENE_PRODUCT", 33, 37], ["mice", "ORGANISM", 56, 60], ["cAMP", "SIMPLE_CHEMICAL", 69, 73], ["mice", "SPECIES", 56, 60], ["mice", "SPECIES", 56, 60], ["a CFTR inhibitor", "TREATMENT", 31, 47]]], ["These studies provide strong evidence of an important role for the CFTR channel, along with the transepithelial sodium transport system, in \u03b2-adrenergic-stimulated AFC.CatecholaminesAmong the neurotransmitter catecholamines, dopamine stimulated AFC in isolated, perfused rat lungs, by activation of the dopamine D 1 receptor, which stimulated exocytosis of the Na,K-ATPase [74] , and by activation of the D 2 receptor, which induced Na,K-ATPase gene expression [75] .", [["transepithelial", "ANATOMY", 96, 111], ["AFC", "ANATOMY", 164, 167], ["lungs", "ANATOMY", 275, 280], ["sodium", "CHEMICAL", 112, 118], ["Catecholamines", "CHEMICAL", 168, 182], ["catecholamines", "CHEMICAL", 209, 223], ["dopamine", "CHEMICAL", 225, 233], ["dopamine", "CHEMICAL", 303, 311], ["Na", "CHEMICAL", 361, 363], ["K", "CHEMICAL", 364, 365], ["Na", "CHEMICAL", 433, 435], ["sodium", "CHEMICAL", 112, 118], ["Catecholamines", "CHEMICAL", 168, 182], ["catecholamines", "CHEMICAL", 209, 223], ["dopamine", "CHEMICAL", 225, 233], ["dopamine", "CHEMICAL", 303, 311], ["Na", "CHEMICAL", 361, 363], ["K", "CHEMICAL", 364, 365], ["Na", "CHEMICAL", 433, 435], ["CFTR", "GENE_OR_GENE_PRODUCT", 67, 71], ["sodium", "SIMPLE_CHEMICAL", 112, 118], ["\u03b2-adrenergic", "SIMPLE_CHEMICAL", 140, 152], ["AFC", "CELL", 164, 167], ["Catecholamines", "GENE_OR_GENE_PRODUCT", 168, 182], ["catecholamines", "SIMPLE_CHEMICAL", 209, 223], ["dopamine", "SIMPLE_CHEMICAL", 225, 233], ["AFC", "SIMPLE_CHEMICAL", 245, 248], ["rat", "ORGANISM", 271, 274], ["lungs", "ORGAN", 275, 280], ["dopamine D 1 receptor", "GENE_OR_GENE_PRODUCT", 303, 324], ["Na,K-ATPase", "GENE_OR_GENE_PRODUCT", 361, 372], ["D 2 receptor", "GENE_OR_GENE_PRODUCT", 405, 417], ["Na", "GENE_OR_GENE_PRODUCT", 433, 435], ["K-ATPase", "GENE_OR_GENE_PRODUCT", 436, 444], ["CFTR channel", "PROTEIN", 67, 79], ["\u03b2-adrenergic-stimulated AFC", "CELL_LINE", 140, 167], ["AFC", "PROTEIN", 245, 248], ["dopamine D 1 receptor", "PROTEIN", 303, 324], ["Na,K-ATPase", "PROTEIN", 361, 372], ["D 2 receptor", "PROTEIN", 405, 417], ["rat", "SPECIES", 271, 274], ["These studies", "TEST", 0, 13], ["the CFTR channel", "TREATMENT", 63, 79], ["the transepithelial sodium transport system", "TREATMENT", 92, 135], ["Catecholamines", "TEST", 168, 182], ["the neurotransmitter catecholamines", "TREATMENT", 188, 223], ["dopamine stimulated AFC", "TREATMENT", 225, 248], ["the dopamine D 1 receptor", "TREATMENT", 299, 324], ["the Na", "TEST", 357, 363], ["K", "TEST", 364, 365], ["the D 2 receptor", "TREATMENT", 401, 417], ["lungs", "ANATOMY", 275, 280]]], ["Dopamine also promoted edema clearance in rats when ALI was induced either by hyperoxia or mechanical ventilation [74] .", [["edema", "ANATOMY", 23, 28], ["Dopamine", "CHEMICAL", 0, 8], ["edema", "DISEASE", 23, 28], ["ALI", "DISEASE", 52, 55], ["Dopamine", "CHEMICAL", 0, 8], ["Dopamine", "SIMPLE_CHEMICAL", 0, 8], ["edema", "PATHOLOGICAL_FORMATION", 23, 28], ["rats", "ORGANISM", 42, 46], ["rats", "SPECIES", 42, 46], ["Dopamine", "TREATMENT", 0, 8], ["edema clearance", "PROBLEM", 23, 38], ["ALI", "PROBLEM", 52, 55], ["mechanical ventilation", "TREATMENT", 91, 113], ["edema", "OBSERVATION", 23, 28], ["clearance", "OBSERVATION_MODIFIER", 29, 38], ["mechanical ventilation", "OBSERVATION", 91, 113]]], ["Although not assessed in animal or organ models, dopamine also exerted an enhancing effect on ENaC activity [76] , where dopamine increased the P o of ENaC, without altering ENaC density on the apical surface of L2 cells.", [["organ", "ANATOMY", 35, 40], ["apical surface", "ANATOMY", 194, 208], ["L2 cells", "ANATOMY", 212, 220], ["dopamine", "CHEMICAL", 49, 57], ["dopamine", "CHEMICAL", 121, 129], ["dopamine", "CHEMICAL", 49, 57], ["dopamine", "CHEMICAL", 121, 129], ["organ", "ORGAN", 35, 40], ["dopamine", "SIMPLE_CHEMICAL", 49, 57], ["ENaC", "GENE_OR_GENE_PRODUCT", 94, 98], ["dopamine", "SIMPLE_CHEMICAL", 121, 129], ["ENaC", "GENE_OR_GENE_PRODUCT", 151, 155], ["ENaC", "GENE_OR_GENE_PRODUCT", 174, 178], ["apical surface", "CELLULAR_COMPONENT", 194, 208], ["L2 cells", "CELL", 212, 220], ["ENaC", "PROTEIN", 94, 98], ["ENaC", "PROTEIN", 151, 155], ["ENaC", "PROTEIN", 174, 178], ["L2 cells", "CELL_LINE", 212, 220], ["dopamine", "TREATMENT", 49, 57], ["dopamine", "TREATMENT", 121, 129], ["altering ENaC density", "PROBLEM", 165, 186], ["enhancing", "OBSERVATION_MODIFIER", 74, 83], ["without", "UNCERTAINTY", 157, 164], ["ENaC", "OBSERVATION_MODIFIER", 174, 178], ["density", "OBSERVATION", 179, 186], ["apical", "ANATOMY_MODIFIER", 194, 200], ["surface", "ANATOMY_MODIFIER", 201, 208], ["L2 cells", "ANATOMY", 212, 220]]], ["Thus, separate from the \u03b2-adrenergic system, the dopamine system provides an alternative opportunity for the pharmacological manipulation of AFC.CatecholaminesSome \u03b2-adrenergic agonists, for example, albuterol, can be deposited into the lungs of patients with pulmonary edema at therapeutic concentrations by aerosolization [77] .", [["lungs", "ANATOMY", 237, 242], ["pulmonary", "ANATOMY", 260, 269], ["dopamine", "CHEMICAL", 49, 57], ["albuterol", "CHEMICAL", 200, 209], ["pulmonary edema", "DISEASE", 260, 275], ["dopamine", "CHEMICAL", 49, 57], ["Catecholamines", "CHEMICAL", 145, 159], ["albuterol", "CHEMICAL", 200, 209], ["dopamine", "SIMPLE_CHEMICAL", 49, 57], ["AFC", "GENE_OR_GENE_PRODUCT", 141, 144], ["Catecholamines", "SIMPLE_CHEMICAL", 145, 159], ["albuterol", "SIMPLE_CHEMICAL", 200, 209], ["lungs", "ORGAN", 237, 242], ["patients", "ORGANISM", 246, 254], ["pulmonary edema", "PATHOLOGICAL_FORMATION", 260, 275], ["patients", "SPECIES", 246, 254], ["the dopamine system", "TREATMENT", 45, 64], ["the pharmacological manipulation of AFC", "TREATMENT", 105, 144], ["Catecholamines", "TEST", 145, 159], ["albuterol", "TREATMENT", 200, 209], ["pulmonary edema", "PROBLEM", 260, 275], ["lungs", "ANATOMY", 237, 242], ["pulmonary", "ANATOMY", 260, 269], ["edema", "OBSERVATION", 270, 275]]], ["In a double-blind, randomized, placebo-controlled study Sartori et al. [78] assessed the effect of inhalation of the \u03b2-agonist salmeterol (125 \u00b5g every 12 h) on the incidence of pulmonary edema in 37 HAPE-prone subjects at high altitude.", [["pulmonary", "ANATOMY", 178, 187], ["salmeterol", "CHEMICAL", 127, 137], ["pulmonary edema", "DISEASE", 178, 193], ["HAPE", "DISEASE", 200, 204], ["salmeterol", "CHEMICAL", 127, 137], ["salmeterol", "SIMPLE_CHEMICAL", 127, 137], ["pulmonary edema", "PATHOLOGICAL_FORMATION", 178, 193], ["placebo", "TREATMENT", 31, 38], ["the \u03b2-agonist salmeterol", "TREATMENT", 113, 137], ["pulmonary edema", "PROBLEM", 178, 193], ["prone subjects", "PROBLEM", 205, 219], ["pulmonary", "ANATOMY", 178, 187], ["edema", "OBSERVATION", 188, 193], ["high altitude", "OBSERVATION_MODIFIER", 223, 236]]], ["Prophylactic salmeterol significantly reduced the incidence of HAPE by more than 50%, without any change in pulmonary hemodynamics.", [["pulmonary", "ANATOMY", 108, 117], ["salmeterol", "CHEMICAL", 13, 23], ["HAPE", "DISEASE", 63, 67], ["salmeterol", "CHEMICAL", 13, 23], ["salmeterol", "SIMPLE_CHEMICAL", 13, 23], ["pulmonary", "ORGAN", 108, 117], ["Prophylactic salmeterol", "TREATMENT", 0, 23], ["HAPE", "PROBLEM", 63, 67], ["any change in pulmonary hemodynamics", "PROBLEM", 94, 130], ["HAPE", "OBSERVATION", 63, 67], ["pulmonary", "ANATOMY", 108, 117], ["hemodynamics", "OBSERVATION", 118, 130]]], ["Furthermore, this study demonstrated that transepithelial sodium transport in the nasal epithelium was reduced in HAPE-prone subjects.", [["transepithelial", "ANATOMY", 42, 57], ["nasal epithelium", "ANATOMY", 82, 98], ["sodium", "CHEMICAL", 58, 64], ["HAPE", "DISEASE", 114, 118], ["sodium", "CHEMICAL", 58, 64], ["transepithelial sodium", "SIMPLE_CHEMICAL", 42, 64], ["nasal epithelium", "TISSUE", 82, 98], ["this study", "TEST", 13, 23], ["transepithelial sodium transport", "TEST", 42, 74], ["transepithelial sodium", "OBSERVATION", 42, 64], ["nasal epithelium", "ANATOMY", 82, 98], ["reduced", "OBSERVATION_MODIFIER", 103, 110], ["HAPE", "OBSERVATION", 114, 118]]], ["Together, these data suggest a therapeutic benefit of inhaled \u03b2-agonists in the treatment of HAPE.CatecholaminesThe \u03b2-Agonist Lung Injury Trial (BALTI), a singlecenter, double-blind, randomized controlled trial, assessed the effect of sustained infusion of a \u03b2-agonist (in this case, 15 \u00b5g/kg salbutamol per hour) on the resolution of pulmonary edema in 40 ALI/ARDS patients [79] , using EVLW as a primary endpoint.", [["Lung", "ANATOMY", 126, 130], ["pulmonary", "ANATOMY", 335, 344], ["HAPE", "DISEASE", 93, 97], ["Lung Injury", "DISEASE", 126, 137], ["salbutamol", "CHEMICAL", 293, 303], ["pulmonary edema", "DISEASE", 335, 350], ["ALI", "DISEASE", 357, 360], ["ARDS", "DISEASE", 361, 365], ["Catecholamines", "CHEMICAL", 98, 112], ["salbutamol", "CHEMICAL", 293, 303], ["Catecholamines", "SIMPLE_CHEMICAL", 98, 112], ["salbutamol", "SIMPLE_CHEMICAL", 293, 303], ["pulmonary edema", "PATHOLOGICAL_FORMATION", 335, 350], ["patients", "ORGANISM", 366, 374], ["patients", "SPECIES", 366, 374], ["inhaled \u03b2-agonists", "TREATMENT", 54, 72], ["HAPE", "PROBLEM", 93, 97], ["Catecholamines", "TEST", 98, 112], ["double-blind", "TREATMENT", 169, 181], ["a \u03b2-agonist", "TREATMENT", 257, 268], ["pulmonary edema", "PROBLEM", 335, 350], ["HAPE", "OBSERVATION", 93, 97], ["Lung", "ANATOMY", 126, 130], ["Injury", "OBSERVATION", 131, 137], ["pulmonary", "ANATOMY", 335, 344], ["edema", "OBSERVATION", 345, 350]]], ["The BALTI trial demonstrated that sustained treatment with intravenous \u03b2-agonists was generally well tolerated, although patients receiving salbutamol exhibited a trend towards higher heart rates, and patients in the salbutamol group exhibited higher incidence (26% vs. 10% in the placebo group) of supraventricular arrhythmias.", [["intravenous", "ANATOMY", 59, 70], ["heart", "ANATOMY", 184, 189], ["supraventricular", "ANATOMY", 299, 315], ["salbutamol", "CHEMICAL", 140, 150], ["salbutamol", "CHEMICAL", 217, 227], ["supraventricular arrhythmias", "DISEASE", 299, 327], ["salbutamol", "CHEMICAL", 140, 150], ["salbutamol", "CHEMICAL", 217, 227], ["intravenous \u03b2-agonists", "SIMPLE_CHEMICAL", 59, 81], ["patients", "ORGANISM", 121, 129], ["salbutamol", "SIMPLE_CHEMICAL", 140, 150], ["heart", "ORGAN", 184, 189], ["patients", "ORGANISM", 201, 209], ["salbutamol", "SIMPLE_CHEMICAL", 217, 227], ["patients", "SPECIES", 121, 129], ["patients", "SPECIES", 201, 209], ["The BALTI trial", "TEST", 0, 15], ["intravenous \u03b2-agonists", "TREATMENT", 59, 81], ["salbutamol", "TREATMENT", 140, 150], ["supraventricular arrhythmias", "PROBLEM", 299, 327], ["supraventricular arrhythmias", "OBSERVATION", 299, 327]]], ["Patients receiving salbutamol demonstrated a significant reduction in EVLW in comparison to placebo-treated patients.", [["salbutamol", "CHEMICAL", 19, 29], ["salbutamol", "CHEMICAL", 19, 29], ["Patients", "ORGANISM", 0, 8], ["salbutamol", "SIMPLE_CHEMICAL", 19, 29], ["patients", "ORGANISM", 108, 116], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 108, 116], ["salbutamol", "TREATMENT", 19, 29], ["a significant reduction in EVLW", "TREATMENT", 43, 74], ["placebo", "TREATMENT", 92, 99], ["significant", "OBSERVATION_MODIFIER", 45, 56], ["reduction", "OBSERVATION_MODIFIER", 57, 66], ["EVLW", "OBSERVATION", 70, 74]]], ["Therefore a second multicenter, randomized, double-blind, placebo-controlled trial (BALTI-2; International Standard Randomized Controlled Trial number 38366450) is currently underway to assess the influence of intravenous salbutamol in ARDS patients on 28-day mortality.Anti-inflammatory agentsAlthough glucocorticoids have been employed in the management of ARDS to reduce inflammation (in the early phase), and fibrosis (in the late phase) [1] , their use is controversial.", [["intravenous", "ANATOMY", 210, 221], ["salbutamol", "CHEMICAL", 222, 232], ["ARDS", "DISEASE", 236, 240], ["glucocorticoids", "CHEMICAL", 303, 318], ["ARDS", "DISEASE", 359, 363], ["inflammation", "DISEASE", 374, 386], ["fibrosis", "DISEASE", 413, 421], ["salbutamol", "CHEMICAL", 222, 232], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 210, 221], ["salbutamol", "SIMPLE_CHEMICAL", 222, 232], ["patients", "ORGANISM", 241, 249], ["glucocorticoids", "SIMPLE_CHEMICAL", 303, 318], ["patients", "SPECIES", 241, 249], ["a second multicenter", "TREATMENT", 10, 30], ["double-blind", "TREATMENT", 44, 56], ["placebo", "TREATMENT", 58, 65], ["BALTI", "TEST", 84, 89], ["International Standard Randomized Controlled Trial number", "TREATMENT", 93, 150], ["intravenous salbutamol", "TREATMENT", 210, 232], ["ARDS", "PROBLEM", 236, 240], ["Anti-inflammatory agents", "TREATMENT", 270, 294], ["glucocorticoids", "TREATMENT", 303, 318], ["ARDS", "PROBLEM", 359, 363], ["inflammation", "PROBLEM", 374, 386], ["fibrosis", "PROBLEM", 413, 421], ["ARDS", "OBSERVATION", 359, 363], ["inflammation", "OBSERVATION", 374, 386], ["early phase", "OBSERVATION_MODIFIER", 395, 406], ["fibrosis", "OBSERVATION", 413, 421]]], ["The potential beneficial effects of glucocorticoid use are attributed in part to the ability of glucocorticoids to influence AFC, by upregulating protein expression of the sodium transporting machinery.", [["sodium", "CHEMICAL", 172, 178], ["sodium", "CHEMICAL", 172, 178], ["glucocorticoid", "SIMPLE_CHEMICAL", 36, 50], ["glucocorticoids", "SIMPLE_CHEMICAL", 96, 111], ["AFC", "GENE_OR_GENE_PRODUCT", 125, 128], ["sodium", "SIMPLE_CHEMICAL", 172, 178], ["glucocorticoid use", "TREATMENT", 36, 54], ["glucocorticoids", "TREATMENT", 96, 111], ["AFC", "TREATMENT", 125, 128], ["the sodium transporting machinery", "TREATMENT", 168, 201], ["glucocorticoid use", "OBSERVATION", 36, 54]]], ["Preterm infants with respiratory distress exhibit reduced expression of ENaC relative to healthy, full-term infants [80] .", [["respiratory", "ANATOMY", 21, 32], ["respiratory distress", "DISEASE", 21, 41], ["infants", "ORGANISM", 8, 15], ["ENaC", "GENE_OR_GENE_PRODUCT", 72, 76], ["infants", "ORGANISM", 108, 115], ["ENaC", "PROTEIN", 72, 76], ["infants", "SPECIES", 8, 15], ["infants", "SPECIES", 108, 115], ["Preterm infants", "PROBLEM", 0, 15], ["respiratory distress", "PROBLEM", 21, 41], ["respiratory distress", "OBSERVATION", 21, 41]]], ["Administration of dexamethasone to these infants upregulated ENaC expression, restoring ENaC expression to levels observed in healthy infants [80] .", [["dexamethasone", "CHEMICAL", 18, 31], ["dexamethasone", "CHEMICAL", 18, 31], ["dexamethasone", "SIMPLE_CHEMICAL", 18, 31], ["infants", "ORGANISM", 41, 48], ["ENaC", "GENE_OR_GENE_PRODUCT", 61, 65], ["ENaC", "GENE_OR_GENE_PRODUCT", 88, 92], ["ENaC", "PROTEIN", 61, 65], ["ENaC", "PROTEIN", 88, 92], ["infants", "SPECIES", 41, 48], ["infants", "SPECIES", 134, 141], ["dexamethasone", "TREATMENT", 18, 31], ["these infants upregulated ENaC expression", "TREATMENT", 35, 76]]], ["Working in adult rats, Noda et al. [81] demonstrated that a single intraperitoneal injection of dexamethasone dramatically increased AFC and reversed hypoxemia induced by an intratracheal fluid challenge, 48-72 h after dexamethasone administration.Anti-inflammatory agentsThis was attributed to an increase in ENaC mRNA levels.", [["intraperitoneal", "ANATOMY", 67, 82], ["fluid", "ANATOMY", 188, 193], ["dexamethasone", "CHEMICAL", 96, 109], ["hypoxemia", "DISEASE", 150, 159], ["dexamethasone", "CHEMICAL", 219, 232], ["dexamethasone", "CHEMICAL", 96, 109], ["dexamethasone", "CHEMICAL", 219, 232], ["rats", "ORGANISM", 17, 21], ["intraperitoneal", "IMMATERIAL_ANATOMICAL_ENTITY", 67, 82], ["dexamethasone", "SIMPLE_CHEMICAL", 96, 109], ["AFC", "SIMPLE_CHEMICAL", 133, 136], ["dexamethasone", "SIMPLE_CHEMICAL", 219, 232], ["ENaC", "GENE_OR_GENE_PRODUCT", 310, 314], ["ENaC mRNA", "RNA", 310, 319], ["rats", "SPECIES", 17, 21], ["a single intraperitoneal injection of dexamethasone", "TREATMENT", 58, 109], ["increased AFC", "PROBLEM", 123, 136], ["reversed hypoxemia", "PROBLEM", 141, 159], ["an intratracheal fluid challenge", "TREATMENT", 171, 203], ["dexamethasone administration", "TREATMENT", 219, 247], ["Anti-inflammatory agents", "TREATMENT", 248, 272], ["an increase in ENaC mRNA levels", "PROBLEM", 295, 326], ["hypoxemia", "OBSERVATION", 150, 159], ["intratracheal", "ANATOMY", 174, 187], ["fluid", "OBSERVATION", 188, 193], ["increase", "OBSERVATION_MODIFIER", 298, 306], ["ENaC mRNA levels", "OBSERVATION", 310, 326]]], ["While Na,K-ATPase mRNA levels were not altered, Na,K-ATPase activity was increased.", [["Na", "CHEMICAL", 6, 8], ["Na", "CHEMICAL", 48, 50], ["K", "CHEMICAL", 51, 52], ["Na", "CHEMICAL", 6, 8], ["Na", "CHEMICAL", 48, 50], ["K", "CHEMICAL", 51, 52], ["Na,K-ATPase", "GENE_OR_GENE_PRODUCT", 6, 17], ["Na,K-ATPase", "GENE_OR_GENE_PRODUCT", 48, 59], ["Na,K-ATPase mRNA", "RNA", 6, 22], ["ATPase", "PROTEIN", 53, 59], ["Na", "TEST", 6, 8], ["ATPase mRNA levels", "TEST", 11, 29], ["Na", "TEST", 48, 50], ["K", "TEST", 51, 52], ["increased", "OBSERVATION_MODIFIER", 73, 82]]], ["These data suggest that glucocorticoids may be of use in the treatment of ARDS by potentiating AFC.Anti-inflammatory agentsA number of clinical trials have addressed the use of glucocorticoids in early and late phase ARDS.", [["glucocorticoids", "CHEMICAL", 24, 39], ["ARDS", "DISEASE", 74, 78], ["glucocorticoids", "CHEMICAL", 177, 192], ["ARDS", "DISEASE", 217, 221], ["glucocorticoids", "SIMPLE_CHEMICAL", 24, 39], ["glucocorticoids", "TREATMENT", 24, 39], ["ARDS", "PROBLEM", 74, 78], ["AFC", "TEST", 95, 98], ["Anti-inflammatory agents", "TREATMENT", 99, 123], ["clinical trials", "TREATMENT", 135, 150], ["glucocorticoids", "TREATMENT", 177, 192], ["ARDS", "PROBLEM", 217, 221], ["ARDS", "OBSERVATION", 74, 78]]], ["Notable among these, in a randomized, double-blind, placebocontrolled trial involving 24 patients with unresolving ARDS, Meduri et al. [82] demonstrated that prolonged methlyprednisolone administration significantly improved lung function and reduced mortality.", [["lung", "ANATOMY", 225, 229], ["ARDS", "DISEASE", 115, 119], ["methlyprednisolone", "CHEMICAL", 168, 186], ["methlyprednisolone", "CHEMICAL", 168, 186], ["patients", "ORGANISM", 89, 97], ["methlyprednisolone", "SIMPLE_CHEMICAL", 168, 186], ["lung", "ORGAN", 225, 229], ["patients", "SPECIES", 89, 97], ["double-blind", "TREATMENT", 38, 50], ["placebocontrolled trial", "TREATMENT", 52, 75], ["unresolving ARDS", "PROBLEM", 103, 119], ["prolonged methlyprednisolone administration", "TREATMENT", 158, 201], ["reduced mortality", "PROBLEM", 243, 260], ["ARDS", "OBSERVATION", 115, 119], ["lung", "ANATOMY", 225, 229], ["reduced", "OBSERVATION_MODIFIER", 243, 250], ["mortality", "OBSERVATION", 251, 260]]], ["A larger randomized, multicenter, placebo-controlled trial of 180 patients with unresolving ARDS (the \"Late Steroid Rescue Study\", LaSRS) that used 60-day mortality as the primary endpoint did not support the use of methylprednisolone for unresolving ARDS [83] .", [["ARDS", "DISEASE", 92, 96], ["methylprednisolone", "CHEMICAL", 216, 234], ["ARDS", "DISEASE", 251, 255], ["Steroid", "CHEMICAL", 108, 115], ["methylprednisolone", "CHEMICAL", 216, 234], ["patients", "ORGANISM", 66, 74], ["methylprednisolone", "SIMPLE_CHEMICAL", 216, 234], ["patients", "SPECIES", 66, 74], ["placebo", "TREATMENT", 34, 41], ["unresolving ARDS", "PROBLEM", 80, 96], ["methylprednisolone", "TREATMENT", 216, 234], ["unresolving ARDS", "PROBLEM", 239, 255], ["larger", "OBSERVATION_MODIFIER", 2, 8], ["ARDS", "OBSERVATION", 92, 96], ["ARDS", "OBSERVATION", 251, 255]]], ["However, methylprednisolone did increase the number of ventilator-free days during the first 28 days, accompanied by improved compliance and oxygenation.", [["methylprednisolone", "CHEMICAL", 9, 27], ["methylprednisolone", "CHEMICAL", 9, 27], ["methylprednisolone", "SIMPLE_CHEMICAL", 9, 27], ["methylprednisolone", "TREATMENT", 9, 27], ["improved", "OBSERVATION_MODIFIER", 117, 125], ["compliance", "OBSERVATION", 126, 136], ["oxygenation", "OBSERVATION_MODIFIER", 141, 152]]], ["The EVLW was not assessed in either study.Cytokines, growth factors, and hormonesSeveral polypeptide growth factors can potentiate AFC and protect against ALI induced in experimental animal models, notable among them, keratinocyte growth factor (reviewed in [84] ).", [["ALI", "DISEASE", 155, 158], ["AFC", "SIMPLE_CHEMICAL", 131, 134], ["keratinocyte growth factor", "GENE_OR_GENE_PRODUCT", 218, 244], ["Cytokines", "PROTEIN", 42, 51], ["growth factors", "PROTEIN", 53, 67], ["polypeptide growth factors", "PROTEIN", 89, 115], ["keratinocyte growth factor", "PROTEIN", 218, 244], ["The EVLW", "TEST", 0, 8], ["either study", "TEST", 29, 41], ["Cytokines", "PROBLEM", 42, 51], ["Several polypeptide growth factors", "PROBLEM", 81, 115], ["AFC", "PROBLEM", 131, 134], ["ALI", "PROBLEM", 155, 158], ["EVLW", "OBSERVATION", 4, 8]]], ["Keratinocyte growth factor upregulated alveolar fluid clearance in anesthetized, ventilated rats [85] , and upregulated transepithelial sodium transport in isolated, ventilated, and perfused lungs from healthy rats as well as in rats in which ALI has been induced with \u03b1-naphthylurea [86] .", [["alveolar fluid", "ANATOMY", 39, 53], ["transepithelial", "ANATOMY", 120, 135], ["lungs", "ANATOMY", 191, 196], ["sodium", "CHEMICAL", 136, 142], ["ALI", "DISEASE", 243, 246], ["\u03b1-naphthylurea", "CHEMICAL", 269, 283], ["sodium", "CHEMICAL", 136, 142], ["\u03b1-naphthylurea", "CHEMICAL", 269, 283], ["Keratinocyte growth factor", "GENE_OR_GENE_PRODUCT", 0, 26], ["alveolar fluid", "MULTI-TISSUE_STRUCTURE", 39, 53], ["rats", "ORGANISM", 92, 96], ["transepithelial sodium", "SIMPLE_CHEMICAL", 120, 142], ["lungs", "ORGAN", 191, 196], ["rats", "ORGANISM", 210, 214], ["rats", "ORGANISM", 229, 233], ["\u03b1-naphthylurea", "SIMPLE_CHEMICAL", 269, 283], ["Keratinocyte growth factor", "PROTEIN", 0, 26], ["rats", "SPECIES", 92, 96], ["rats", "SPECIES", 210, 214], ["rats", "SPECIES", 229, 233], ["Keratinocyte growth factor", "TEST", 0, 26], ["alveolar fluid clearance", "TEST", 39, 63], ["upregulated transepithelial sodium transport", "TREATMENT", 108, 152], ["alveolar", "ANATOMY_MODIFIER", 39, 47], ["fluid clearance", "OBSERVATION", 48, 63], ["ventilated", "OBSERVATION", 166, 176], ["perfused", "ANATOMY_MODIFIER", 182, 190], ["lungs", "ANATOMY", 191, 196]]], ["This protective effect has been attributed to the ability of keratinocyte growth factor (KGF) to upregulate expression of components of the sodium transporting machinery, primarily the Na,K-ATPase, as well as its mitogenic properties on alveolar type II cells, since the alveolar epithelium is may be denuded in ALI/ARDS.", [["alveolar type II cells", "ANATOMY", 237, 259], ["alveolar epithelium", "ANATOMY", 271, 290], ["sodium", "CHEMICAL", 140, 146], ["Na", "CHEMICAL", 185, 187], ["ALI", "DISEASE", 312, 315], ["ARDS", "DISEASE", 316, 320], ["sodium", "CHEMICAL", 140, 146], ["Na", "CHEMICAL", 185, 187], ["keratinocyte growth factor", "GENE_OR_GENE_PRODUCT", 61, 87], ["KGF", "GENE_OR_GENE_PRODUCT", 89, 92], ["sodium", "SIMPLE_CHEMICAL", 140, 146], ["Na,K-ATPase", "GENE_OR_GENE_PRODUCT", 185, 196], ["alveolar type II cells", "CELL", 237, 259], ["alveolar epithelium", "TISSUE", 271, 290], ["keratinocyte growth factor", "PROTEIN", 61, 87], ["KGF", "PROTEIN", 89, 92], ["Na,K-ATPase", "PROTEIN", 185, 196], ["alveolar type II cells", "CELL_TYPE", 237, 259], ["keratinocyte growth factor", "PROBLEM", 61, 87], ["the sodium transporting machinery", "TREATMENT", 136, 169], ["the Na,K-ATPase", "TEST", 181, 196], ["the alveolar epithelium", "PROBLEM", 267, 290], ["ALI", "PROBLEM", 312, 315], ["ARDS", "PROBLEM", 316, 320], ["alveolar type II cells", "OBSERVATION", 237, 259], ["alveolar epithelium", "ANATOMY", 271, 290], ["may be", "UNCERTAINTY", 294, 300], ["denuded", "OBSERVATION_MODIFIER", 301, 308], ["ALI", "OBSERVATION", 312, 315], ["ARDS", "OBSERVATION", 316, 320]]], ["An upregulation of AFC attributable to elevated Na,K-ATPase levels has also been reported for epidermal growth factor (EGF) instilled into lungs of live rats, where EGF was proposed to upregulate expression levels of Na,K-ATPase [87] .", [["lungs", "ANATOMY", 139, 144], ["Na", "CHEMICAL", 48, 50], ["K", "CHEMICAL", 51, 52], ["Na", "CHEMICAL", 217, 219], ["Na", "CHEMICAL", 48, 50], ["K", "CHEMICAL", 51, 52], ["Na", "CHEMICAL", 217, 219], ["K-", "CHEMICAL", 220, 222], ["AFC", "GENE_OR_GENE_PRODUCT", 19, 22], ["Na,K-ATPase", "GENE_OR_GENE_PRODUCT", 48, 59], ["epidermal growth factor", "GENE_OR_GENE_PRODUCT", 94, 117], ["EGF", "GENE_OR_GENE_PRODUCT", 119, 122], ["lungs", "ORGAN", 139, 144], ["rats", "ORGANISM", 153, 157], ["EGF", "GENE_OR_GENE_PRODUCT", 165, 168], ["Na,K-ATPase", "GENE_OR_GENE_PRODUCT", 217, 228], ["AFC", "PROTEIN", 19, 22], ["Na,K-ATPase", "PROTEIN", 48, 59], ["epidermal growth factor", "PROTEIN", 94, 117], ["EGF", "PROTEIN", 119, 122], ["EGF", "PROTEIN", 165, 168], ["Na", "PROTEIN", 217, 219], ["K-ATPase", "PROTEIN", 220, 228], ["rats", "SPECIES", 153, 157], ["AFC", "PROBLEM", 19, 22], ["elevated Na", "PROBLEM", 39, 50], ["K", "TEST", 51, 52], ["ATPase levels", "TEST", 53, 66], ["epidermal growth factor", "PROBLEM", 94, 117], ["Na", "TEST", 217, 219], ["K-ATPase", "TEST", 220, 228], ["AFC", "OBSERVATION", 19, 22], ["elevated", "OBSERVATION", 39, 47], ["lungs", "ANATOMY", 139, 144]]], ["Other nonpeptide hormones can also influence AFC.", [["AFC", "GENE_OR_GENE_PRODUCT", 45, 48], ["Other nonpeptide hormones", "PROBLEM", 0, 25]]], ["For example, 3,3 ,5-triiodo-Lthyronine upregulated AFC in live adult rats, apparently by upregulation of transepithelial sodium transport [88] .Cytokines, growth factors, and hormonesWhile no clinical trial has yet been initiated, recombinant human KGF and liposome-mediated KGF gene delivery into mouse lungs afforded significant protection against oleic acid induced lung injury by improving arterial oxygenation and lung compliance in comparison to the vehicle-treated group [89] .", [["transepithelial", "ANATOMY", 105, 120], ["lungs", "ANATOMY", 304, 309], ["lung", "ANATOMY", 369, 373], ["arterial", "ANATOMY", 394, 402], ["lung", "ANATOMY", 419, 423], ["3,3 ,5-triiodo-Lthyronine", "CHEMICAL", 13, 38], ["sodium", "CHEMICAL", 121, 127], ["liposome", "CHEMICAL", 257, 265], ["oleic acid", "CHEMICAL", 350, 360], ["lung injury", "DISEASE", 369, 380], ["3,3 ,5-triiodo-Lthyronine", "CHEMICAL", 13, 38], ["sodium", "CHEMICAL", 121, 127], ["oleic acid", "CHEMICAL", 350, 360], ["3,3 ,5-triiodo-Lthyronine", "SIMPLE_CHEMICAL", 13, 38], ["AFC", "GENE_OR_GENE_PRODUCT", 51, 54], ["rats", "ORGANISM", 69, 73], ["transepithelial sodium", "SIMPLE_CHEMICAL", 105, 127], ["human", "ORGANISM", 243, 248], ["KGF", "GENE_OR_GENE_PRODUCT", 249, 252], ["liposome", "SIMPLE_CHEMICAL", 257, 265], ["KGF", "GENE_OR_GENE_PRODUCT", 275, 278], ["mouse", "ORGANISM", 298, 303], ["lungs", "ORGAN", 304, 309], ["oleic acid", "SIMPLE_CHEMICAL", 350, 360], ["lung", "ORGAN", 369, 373], ["arterial", "MULTI-TISSUE_STRUCTURE", 394, 402], ["lung", "ORGAN", 419, 423], ["AFC", "PROTEIN", 51, 54], ["Cytokines", "PROTEIN", 144, 153], ["growth factors", "PROTEIN", 155, 169], ["recombinant human KGF", "PROTEIN", 231, 252], ["KGF", "PROTEIN", 275, 278], ["rats", "SPECIES", 69, 73], ["human", "SPECIES", 243, 248], ["mouse", "SPECIES", 298, 303], ["human", "SPECIES", 243, 248], ["mouse", "SPECIES", 298, 303], ["example", "TEST", 4, 11], ["triiodo", "TEST", 20, 27], ["transepithelial sodium transport", "TEST", 105, 137], ["Cytokines", "PROBLEM", 144, 153], ["recombinant human KGF", "TREATMENT", 231, 252], ["liposome-mediated KGF gene delivery", "TREATMENT", 257, 292], ["significant protection", "TREATMENT", 319, 341], ["oleic acid induced lung injury", "PROBLEM", 350, 380], ["improving arterial oxygenation", "TREATMENT", 384, 414], ["lung compliance", "TREATMENT", 419, 434], ["lungs", "ANATOMY", 304, 309], ["lung", "ANATOMY", 369, 373], ["injury", "OBSERVATION", 374, 380], ["arterial oxygenation", "OBSERVATION", 394, 414], ["lung", "ANATOMY", 419, 423], ["compliance", "OBSERVATION", 424, 434]]], ["It was not reported in that study, however, whether AFC was improved in the KGF-treated group.", [["KGF", "CHEMICAL", 76, 79], ["KGF", "GENE_OR_GENE_PRODUCT", 76, 79], ["KGF", "PROTEIN", 76, 79], ["that study", "TEST", 23, 33], ["AFC", "PROBLEM", 52, 55], ["improved", "OBSERVATION_MODIFIER", 60, 68]]], ["However, given the ability of KGF upregulate AFC in an isolated organ model, and to repop-ulate denuded areas of the alveolar epithelium by virtue of its mitogenic properties on type II cells, further evaluation of the therapeutic potential of KGF appears warranted.Cytokines, growth factors, and hormonesThe lectin-like domain of TNF-\u03b1 enhanced AFC in ventilated rats [59] .", [["organ", "ANATOMY", 64, 69], ["alveolar epithelium", "ANATOMY", 117, 136], ["type II cells", "ANATOMY", 178, 191], ["KGF", "GENE_OR_GENE_PRODUCT", 30, 33], ["AFC", "GENE_OR_GENE_PRODUCT", 45, 48], ["organ", "ORGAN", 64, 69], ["alveolar epithelium", "TISSUE", 117, 136], ["type II cells", "CELL", 178, 191], ["KGF", "GENE_OR_GENE_PRODUCT", 244, 247], ["lectin", "GENE_OR_GENE_PRODUCT", 309, 315], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 331, 336], ["AFC", "SIMPLE_CHEMICAL", 346, 349], ["rats", "ORGANISM", 364, 368], ["KGF", "PROTEIN", 30, 33], ["AFC", "PROTEIN", 45, 48], ["type II cells", "CELL_TYPE", 178, 191], ["KGF", "PROTEIN", 244, 247], ["Cytokines", "PROTEIN", 266, 275], ["growth factors", "PROTEIN", 277, 291], ["lectin", "PROTEIN", 309, 315], ["TNF-\u03b1", "PROTEIN", 331, 336], ["AFC", "PROTEIN", 346, 349], ["rats", "SPECIES", 364, 368], ["AFC", "PROBLEM", 45, 48], ["an isolated organ model", "TEST", 52, 75], ["the alveolar epithelium", "PROBLEM", 113, 136], ["type II cells", "PROBLEM", 178, 191], ["further evaluation", "TEST", 193, 211], ["KGF", "PROBLEM", 244, 247], ["Cytokines", "PROBLEM", 266, 275], ["The lectin", "TEST", 305, 315], ["TNF", "TEST", 331, 334], ["denuded", "OBSERVATION_MODIFIER", 96, 103], ["areas", "OBSERVATION", 104, 109], ["alveolar epithelium", "ANATOMY", 117, 136], ["lectin", "OBSERVATION", 309, 315], ["TNF", "ANATOMY", 331, 334]]], ["Mouse TNF-\u03b1 promoted fluid reabsorption in wild-type mice and in mice deficient in both TNF-\u03b1 receptors, indicating that the effect of TNF-\u03b1 on AFC was independent of both TNF-\u03b1 receptors [90] .", [["fluid", "ANATOMY", 21, 26], ["Mouse", "ORGANISM", 0, 5], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 6, 11], ["fluid", "ORGANISM_SUBSTANCE", 21, 26], ["mice", "ORGANISM", 53, 57], ["mice", "ORGANISM", 65, 69], ["TNF-\u03b1 receptors", "GENE_OR_GENE_PRODUCT", 88, 103], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 135, 140], ["AFC", "GENE_OR_GENE_PRODUCT", 144, 147], ["TNF-\u03b1 receptors", "GENE_OR_GENE_PRODUCT", 172, 187], ["Mouse TNF-\u03b1", "PROTEIN", 0, 11], ["TNF-\u03b1 receptors", "PROTEIN", 88, 103], ["TNF", "PROTEIN", 135, 138], ["TNF-\u03b1 receptors", "PROTEIN", 172, 187], ["Mouse", "SPECIES", 0, 5], ["mice", "SPECIES", 53, 57], ["mice", "SPECIES", 65, 69], ["Mouse", "SPECIES", 0, 5], ["mice", "SPECIES", 53, 57], ["mice", "SPECIES", 65, 69], ["Mouse TNF", "PROBLEM", 0, 9], ["fluid reabsorption", "PROBLEM", 21, 39], ["TNF", "TEST", 135, 138], ["AFC", "TEST", 144, 147], ["fluid reabsorption", "OBSERVATION", 21, 39]]], ["Intratracheal application of a synthetic peptide that was based on the lectinlike domain sequence to an isolated, ventilated, autologous blood-perfused rat lung model caused a significant reduction in lung water and improvement in lung compliance, in comparison to lungs treated with a scrambled peptide of the same length [90] .", [["blood", "ANATOMY", 137, 142], ["lung", "ANATOMY", 156, 160], ["lung", "ANATOMY", 201, 205], ["lung", "ANATOMY", 231, 235], ["lungs", "ANATOMY", 265, 270], ["Intratracheal", "IMMATERIAL_ANATOMICAL_ENTITY", 0, 13], ["blood", "ORGANISM_SUBSTANCE", 137, 142], ["rat", "ORGANISM", 152, 155], ["lung", "ORGAN", 156, 160], ["lung", "ORGAN", 201, 205], ["lung", "ORGAN", 231, 235], ["lungs", "ORGAN", 265, 270], ["lectinlike domain sequence", "PROTEIN", 71, 97], ["rat", "SPECIES", 152, 155], ["Intratracheal application", "TREATMENT", 0, 25], ["a synthetic peptide", "TREATMENT", 29, 48], ["the lectinlike domain sequence", "PROBLEM", 67, 97], ["autologous blood", "TEST", 126, 142], ["a significant reduction in lung water", "PROBLEM", 174, 211], ["a scrambled peptide", "TREATMENT", 284, 303], ["ventilated", "OBSERVATION", 114, 124], ["lung", "ANATOMY", 156, 160], ["significant", "OBSERVATION_MODIFIER", 176, 187], ["reduction", "OBSERVATION_MODIFIER", 188, 197], ["lung", "ANATOMY", 201, 205], ["water", "OBSERVATION_MODIFIER", 206, 211], ["improvement", "OBSERVATION_MODIFIER", 216, 227], ["lung", "ANATOMY", 231, 235], ["compliance", "OBSERVATION", 236, 246], ["lungs", "ANATOMY", 265, 270]]], ["Thus at least two growth factors, KGF and the lectin-like domain of TNF-\u03b1, present us with novel opportunities for augmentation of AFC.AntioxidantsGranulocyte-derived reactive oxygen and nitrogen species are believed to play an important role in ALI/ARDS (reviewed in [91] ), and increased levels of the stable byproducts of nitric oxide decomposition, nitrite, and nitrate are observed in edema fluid from patients with ALI/ARDS [92] .", [["edema fluid", "ANATOMY", 390, 401], ["oxygen", "CHEMICAL", 176, 182], ["nitrogen", "CHEMICAL", 187, 195], ["ALI", "DISEASE", 246, 249], ["ARDS", "DISEASE", 250, 254], ["nitric oxide", "CHEMICAL", 325, 337], ["nitrite", "CHEMICAL", 353, 360], ["nitrate", "CHEMICAL", 366, 373], ["edema", "DISEASE", 390, 395], ["ALI", "DISEASE", 421, 424], ["ARDS", "DISEASE", 425, 429], ["oxygen", "CHEMICAL", 176, 182], ["nitrogen", "CHEMICAL", 187, 195], ["nitric oxide", "CHEMICAL", 325, 337], ["nitrite", "CHEMICAL", 353, 360], ["nitrate", "CHEMICAL", 366, 373], ["KGF", "GENE_OR_GENE_PRODUCT", 34, 37], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 68, 73], ["AFC", "GENE_OR_GENE_PRODUCT", 131, 134], ["Granulocyte-derived reactive oxygen", "SIMPLE_CHEMICAL", 147, 182], ["nitrogen species", "SIMPLE_CHEMICAL", 187, 203], ["nitric oxide", "SIMPLE_CHEMICAL", 325, 337], ["nitrite", "SIMPLE_CHEMICAL", 353, 360], ["nitrate", "SIMPLE_CHEMICAL", 366, 373], ["edema fluid", "ORGANISM_SUBSTANCE", 390, 401], ["patients", "ORGANISM", 407, 415], ["growth factors", "PROTEIN", 18, 32], ["KGF", "PROTEIN", 34, 37], ["lectin-like domain", "PROTEIN", 46, 64], ["TNF-\u03b1", "PROTEIN", 68, 73], ["patients", "SPECIES", 407, 415], ["KGF", "TEST", 34, 37], ["the lectin", "TEST", 42, 52], ["TNF", "TEST", 68, 71], ["AFC", "PROBLEM", 131, 134], ["Antioxidants", "TREATMENT", 135, 147], ["Granulocyte", "TEST", 147, 158], ["reactive oxygen", "TREATMENT", 167, 182], ["nitrogen species", "TREATMENT", 187, 203], ["ARDS", "PROBLEM", 250, 254], ["nitric oxide decomposition", "TREATMENT", 325, 351], ["nitrite", "TREATMENT", 353, 360], ["nitrate", "TREATMENT", 366, 373], ["edema fluid", "PROBLEM", 390, 401], ["ALI", "PROBLEM", 421, 424], ["ARDS", "PROBLEM", 425, 429], ["growth", "OBSERVATION_MODIFIER", 18, 24], ["AFC", "OBSERVATION", 131, 134], ["reactive oxygen", "OBSERVATION", 167, 182], ["ARDS", "OBSERVATION", 250, 254], ["stable", "OBSERVATION_MODIFIER", 304, 310], ["nitric oxide", "OBSERVATION", 325, 337], ["edema", "OBSERVATION", 390, 395], ["ARDS", "OBSERVATION", 425, 429]]], ["These and other data have suggested a therapeutic benefit of antioxidants, including Nacetylcysteine (NAC), procysteine, and albumin [62] .", [["Nacetylcysteine", "CHEMICAL", 85, 100], ["NAC", "CHEMICAL", 102, 105], ["procysteine", "CHEMICAL", 108, 119], ["Nacetylcysteine", "CHEMICAL", 85, 100], ["NAC", "CHEMICAL", 102, 105], ["procysteine", "CHEMICAL", 108, 119], ["Nacetylcysteine", "SIMPLE_CHEMICAL", 85, 100], ["NAC", "SIMPLE_CHEMICAL", 102, 105], ["procysteine", "SIMPLE_CHEMICAL", 108, 119], ["albumin [62]", "SIMPLE_CHEMICAL", 125, 137], ["antioxidants", "TREATMENT", 61, 73], ["Nacetylcysteine (NAC)", "TREATMENT", 85, 106], ["procysteine", "TREATMENT", 108, 119], ["albumin", "TREATMENT", 125, 132]]], ["Antioxidant therapy could also augment AFC.", [["AFC", "CELL", 39, 42], ["Antioxidant therapy", "TREATMENT", 0, 19]]], ["Oxidants such as hydrogen peroxide suppress glucocorticoidinduced ENaC gene transcription, an effect reversed by reactive oxygen scavengers, including thioredoxin.", [["hydrogen peroxide", "CHEMICAL", 17, 34], ["oxygen", "CHEMICAL", 122, 128], ["hydrogen peroxide", "CHEMICAL", 17, 34], ["oxygen", "CHEMICAL", 122, 128], ["hydrogen peroxide", "SIMPLE_CHEMICAL", 17, 34], ["ENaC", "GENE_OR_GENE_PRODUCT", 66, 70], ["reactive oxygen scavengers", "SIMPLE_CHEMICAL", 113, 139], ["thioredoxin", "GENE_OR_GENE_PRODUCT", 151, 162], ["ENaC gene", "DNA", 66, 75], ["thioredoxin", "PROTEIN", 151, 162], ["Oxidants", "TREATMENT", 0, 8], ["hydrogen peroxide suppress glucocorticoidinduced ENaC gene transcription", "TREATMENT", 17, 89], ["reactive oxygen scavengers", "TREATMENT", 113, 139], ["thioredoxin", "TREATMENT", 151, 162], ["reactive", "OBSERVATION_MODIFIER", 113, 121], ["oxygen scavengers", "OBSERVATION", 122, 139]]], ["In a rat model of hemorrhagic shock Modelska et al. [93] demonstrated that catecholamines were ineffective at upregulating AFC.", [["hemorrhagic shock", "DISEASE", 18, 35], ["catecholamines", "CHEMICAL", 75, 89], ["catecholamines", "CHEMICAL", 75, 89], ["rat", "ORGANISM", 5, 8], ["catecholamines", "SIMPLE_CHEMICAL", 75, 89], ["AFC", "GENE_OR_GENE_PRODUCT", 123, 126], ["AFC", "PROTEIN", 123, 126], ["rat", "SPECIES", 5, 8], ["hemorrhagic shock", "PROBLEM", 18, 35], ["catecholamines", "TREATMENT", 75, 89], ["hemorrhagic", "OBSERVATION_MODIFIER", 18, 29], ["shock", "OBSERVATION", 30, 35]]], ["However, after either intravenous administration of NAC, intratracheal administration of reduced glutathione or neutrophil depletion with vinblastine, the effect of catecholamines was restored.", [["intravenous", "ANATOMY", 22, 33], ["neutrophil", "ANATOMY", 112, 122], ["NAC", "CHEMICAL", 52, 55], ["glutathione", "CHEMICAL", 97, 108], ["vinblastine", "CHEMICAL", 138, 149], ["catecholamines", "CHEMICAL", 165, 179], ["NAC", "CHEMICAL", 52, 55], ["glutathione", "CHEMICAL", 97, 108], ["vinblastine", "CHEMICAL", 138, 149], ["catecholamines", "CHEMICAL", 165, 179], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 22, 33], ["NAC", "SIMPLE_CHEMICAL", 52, 55], ["intratracheal", "IMMATERIAL_ANATOMICAL_ENTITY", 57, 70], ["glutathione", "SIMPLE_CHEMICAL", 97, 108], ["neutrophil", "CELL", 112, 122], ["vinblastine", "SIMPLE_CHEMICAL", 138, 149], ["catecholamines", "SIMPLE_CHEMICAL", 165, 179], ["neutrophil", "CELL_TYPE", 112, 122], ["NAC", "TREATMENT", 52, 55], ["intratracheal administration", "TREATMENT", 57, 85], ["reduced glutathione", "TREATMENT", 89, 108], ["neutrophil depletion", "TREATMENT", 112, 132], ["vinblastine", "TREATMENT", 138, 149], ["catecholamines", "TREATMENT", 165, 179], ["neutrophil depletion", "OBSERVATION", 112, 132]]], ["These data provided in vivo evidence that neutrophil-mediated oxidative injury impaired AFC in ALI.", [["neutrophil", "ANATOMY", 42, 52], ["ALI", "DISEASE", 95, 98], ["neutrophil", "CELL", 42, 52], ["neutrophil", "CELL_TYPE", 42, 52], ["These data", "TEST", 0, 10], ["neutrophil-mediated oxidative injury impaired AFC in ALI", "PROBLEM", 42, 98], ["neutrophil", "OBSERVATION", 42, 52], ["oxidative injury", "OBSERVATION", 62, 78], ["impaired", "OBSERVATION_MODIFIER", 79, 87], ["AFC", "OBSERVATION", 88, 91], ["ALI", "ANATOMY", 95, 98]]], ["Building on this study, Lee et al. [94] demonstrated that the induction of hemoxygenase I (HO-1), a potent antioxidant, restores normal AFC after hemorrhagic shock by blocking iNOS-mediated NO release.", [["hemorrhagic shock", "DISEASE", 146, 163], ["NO", "CHEMICAL", 190, 192], ["NO", "CHEMICAL", 190, 192], ["hemoxygenase I", "GENE_OR_GENE_PRODUCT", 75, 89], ["HO-1", "GENE_OR_GENE_PRODUCT", 91, 95], ["iNOS", "GENE_OR_GENE_PRODUCT", 176, 180], ["NO", "SIMPLE_CHEMICAL", 190, 192], ["hemoxygenase I", "PROTEIN", 75, 89], ["HO", "PROTEIN", 91, 93], ["iNOS", "PROTEIN", 176, 180], ["this study", "TEST", 12, 22], ["hemorrhagic shock", "PROBLEM", 146, 163], ["blocking iNOS", "TREATMENT", 167, 180]]], ["Therefore with regard to edema resolution antioxidant therapy would most likely augment glucocorticoid or catecholamine-based efforts to upregulate AFC.AntioxidantsClinical trials involving antioxidants in ARDS have yielded equivocal results.", [["edema", "ANATOMY", 25, 30], ["edema", "DISEASE", 25, 30], ["catecholamine", "CHEMICAL", 106, 119], ["ARDS", "DISEASE", 206, 210], ["catecholamine", "CHEMICAL", 106, 119], ["edema", "PATHOLOGICAL_FORMATION", 25, 30], ["glucocorticoid", "SIMPLE_CHEMICAL", 88, 102], ["catecholamine", "SIMPLE_CHEMICAL", 106, 119], ["AFC", "GENE_OR_GENE_PRODUCT", 148, 151], ["AFC", "PROTEIN", 148, 151], ["edema resolution antioxidant therapy", "TREATMENT", 25, 61], ["glucocorticoid", "TREATMENT", 88, 102], ["catecholamine", "TREATMENT", 106, 119], ["AFC", "TEST", 148, 151], ["Antioxidants", "TREATMENT", 152, 164], ["antioxidants", "TREATMENT", 190, 202], ["ARDS", "PROBLEM", 206, 210], ["edema", "OBSERVATION", 25, 30]]], ["In one randomized, placebocontrolled, double-blind trial of 61 ARDS patients Suter et al. [95] demonstrated that intravenous NAC (40 mg/kg per day) improved systemic oxygenation and reduced the need for ventilatory support.", [["intravenous", "ANATOMY", 113, 124], ["ARDS", "DISEASE", 63, 67], ["NAC", "CHEMICAL", 125, 128], ["NAC", "CHEMICAL", 125, 128], ["patients", "ORGANISM", 68, 76], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 113, 124], ["NAC", "SIMPLE_CHEMICAL", 125, 128], ["patients", "SPECIES", 68, 76], ["ARDS", "PROBLEM", 63, 67], ["intravenous NAC", "TREATMENT", 113, 128], ["ventilatory support", "TREATMENT", 203, 222], ["systemic oxygenation", "OBSERVATION", 157, 177]]], ["In contrast, Domenighetti et al. [96] in a comparable trial (although employing a higher dose: 190 mg/kg per day) demonstrated no improvement in systemic oxygenation or a reduction in the need for ventilatory support.", [["systemic oxygenation", "TREATMENT", 145, 165], ["a reduction", "TREATMENT", 169, 180], ["ventilatory support", "TREATMENT", 197, 216], ["no", "UNCERTAINTY", 127, 129], ["improvement", "OBSERVATION_MODIFIER", 130, 141], ["systemic oxygenation", "OBSERVATION", 145, 165], ["reduction", "OBSERVATION_MODIFIER", 171, 180]]], ["Neither study reported a survival benefit, nor was EVLW assessed.", [["EVLW", "TEST", 51, 55]]], ["Clearly additional trials are warranted, although a recent, much larger phase III double-blind, placebo-controlled, clinical trial evaluating procysteine in ALI/ARDS was prematurely discontinued due to mortality concerns in the intervention group [62] .AnticoagulationTo date, a single animal study has explored the effect of anticoagulation on AFC, where the natural anticoagulant, activated protein C (APC) was applied in a Pseudomonasinduced ALI model in rats [97] .", [["procysteine", "CHEMICAL", 142, 153], ["ALI", "DISEASE", 157, 160], ["ARDS", "DISEASE", 161, 165], ["ALI", "DISEASE", 445, 448], ["procysteine", "CHEMICAL", 142, 153], ["procysteine", "SIMPLE_CHEMICAL", 142, 153], ["protein C", "GENE_OR_GENE_PRODUCT", 393, 402], ["APC", "GENE_OR_GENE_PRODUCT", 404, 407], ["rats", "ORGANISM", 458, 462], ["activated protein C", "PROTEIN", 383, 402], ["APC", "PROTEIN", 404, 407], ["rats", "SPECIES", 458, 462], ["placebo", "TREATMENT", 96, 103], ["ALI", "PROBLEM", 157, 160], ["ARDS", "PROBLEM", 161, 165], ["Anticoagulation", "TREATMENT", 253, 268], ["a single animal study", "TEST", 277, 298], ["anticoagulation", "TREATMENT", 326, 341], ["AFC", "TREATMENT", 345, 348], ["the natural anticoagulant", "TREATMENT", 356, 381], ["activated protein C (APC)", "TREATMENT", 383, 408], ["a Pseudomonasinduced ALI model", "TREATMENT", 424, 454], ["ARDS", "OBSERVATION", 161, 165]]], ["In that study AFC was potentiated in a TNF\u03b1-dependent manner; however, activated protein C did not enhance AFC.", [["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 39, 43], ["protein C", "GENE_OR_GENE_PRODUCT", 81, 90], ["AFC", "GENE_OR_GENE_PRODUCT", 107, 110], ["TNF\u03b1", "PROTEIN", 39, 43], ["activated protein C", "PROTEIN", 71, 90], ["AFC", "PROTEIN", 107, 110], ["that study AFC", "TEST", 3, 17], ["activated protein C", "TEST", 71, 90], ["AFC", "TEST", 107, 110]]], ["Given the recent report of Vad\u00e1sz et al. [52] which demonstrated that thrombin impaired AFC by blocking transepithelial sodium transport mediated by Na,K-ATPase, it appears likely that anticoagulant therapy would improve edema resolution by upregulating Na,K-ATPase-mediated AFC.", [["transepithelial", "ANATOMY", 104, 119], ["edema", "ANATOMY", 221, 226], ["sodium", "CHEMICAL", 120, 126], ["Na", "CHEMICAL", 149, 151], ["edema", "DISEASE", 221, 226], ["Na", "CHEMICAL", 254, 256], ["sodium", "CHEMICAL", 120, 126], ["Na", "CHEMICAL", 149, 151], ["K-", "CHEMICAL", 152, 154], ["Na", "CHEMICAL", 254, 256], ["K-", "CHEMICAL", 257, 259], ["thrombin", "GENE_OR_GENE_PRODUCT", 70, 78], ["AFC", "GENE_OR_GENE_PRODUCT", 88, 91], ["transepithelial", "IMMATERIAL_ANATOMICAL_ENTITY", 104, 119], ["sodium", "SIMPLE_CHEMICAL", 120, 126], ["Na,K-ATPase", "GENE_OR_GENE_PRODUCT", 149, 160], ["edema", "PATHOLOGICAL_FORMATION", 221, 226], ["Na,K-ATPase", "GENE_OR_GENE_PRODUCT", 254, 265], ["AFC", "GENE_OR_GENE_PRODUCT", 275, 278], ["thrombin", "PROTEIN", 70, 78], ["Na,K-ATPase", "PROTEIN", 149, 160], ["Na,K-ATPase", "PROTEIN", 254, 265], ["AFC", "PROTEIN", 275, 278], ["thrombin impaired AFC", "PROBLEM", 70, 91], ["blocking transepithelial sodium transport", "TREATMENT", 95, 136], ["anticoagulant therapy", "TREATMENT", 185, 206], ["edema", "PROBLEM", 221, 226], ["upregulating Na", "TEST", 241, 256], ["thrombin", "OBSERVATION", 70, 78], ["appears likely", "UNCERTAINTY", 165, 179], ["edema", "OBSERVATION", 221, 226]]], ["To date, no randomized, placebo-controlled trials have been conducted with anticoagulants in ALI/ARDS patients, although a randomized, phase II clinical trial of APC is currently in progress at the University of California in San Fransisco (ClinicalTrials.gov Identifier NCT00112164), employing the number of ventilator-free days measured at day 28 as the primary end-point.Gene therapy to improve AFCThe lung is an organ that is particularly amenable to local delivery of DNA, making it an attractive target for gene therapy studies.", [["lung", "ANATOMY", 405, 409], ["organ", "ANATOMY", 416, 421], ["ALI", "DISEASE", 93, 96], ["ARDS", "DISEASE", 97, 101], ["APC", "CHEMICAL", 162, 165], ["patients", "ORGANISM", 102, 110], ["APC", "GENE_OR_GENE_PRODUCT", 162, 165], ["lung", "ORGAN", 405, 409], ["organ", "ORGAN", 416, 421], ["DNA", "CELLULAR_COMPONENT", 473, 476], ["APC", "CELL_TYPE", 162, 165], ["AFC", "CELL_TYPE", 398, 401], ["patients", "SPECIES", 102, 110], ["placebo", "TREATMENT", 24, 31], ["anticoagulants", "TREATMENT", 75, 89], ["ALI", "PROBLEM", 93, 96], ["ARDS", "PROBLEM", 97, 101], ["APC", "TREATMENT", 162, 165], ["Gene therapy", "TREATMENT", 374, 386], ["AFC", "TEST", 398, 401], ["local delivery of DNA", "TREATMENT", 455, 476], ["gene therapy studies", "TEST", 513, 533], ["ARDS", "OBSERVATION", 97, 101], ["lung", "ANATOMY", 405, 409], ["organ", "ANATOMY", 416, 421]]], ["In the context of ALI/ARDS this possibility is particularly attractive since ALI/ARDS does not impair virus-mediated gene delivery to the alveolar epithelium [98] .", [["alveolar epithelium", "ANATOMY", 138, 157], ["ALI", "DISEASE", 18, 21], ["ARDS", "DISEASE", 22, 26], ["ALI", "DISEASE", 77, 80], ["ARDS", "DISEASE", 81, 85], ["alveolar epithelium", "TISSUE", 138, 157], ["ALI", "PROBLEM", 18, 21], ["ARDS", "PROBLEM", 22, 26], ["ALI", "PROBLEM", 77, 80], ["ARDS", "PROBLEM", 81, 85], ["impair virus", "PROBLEM", 95, 107], ["ALI", "OBSERVATION", 18, 21], ["ARDS", "OBSERVATION", 22, 26], ["ARDS", "OBSERVATION", 81, 85], ["alveolar epithelium", "ANATOMY", 138, 157]]], ["Several studies have highlighted the potential benefit of augmenting AFC by local delivery of genes into the lungs of live animals.", [["lungs", "ANATOMY", 109, 114], ["AFC", "SIMPLE_CHEMICAL", 69, 72], ["lungs", "ORGAN", 109, 114], ["Several studies", "TEST", 0, 15], ["augmenting AFC", "TREATMENT", 58, 72], ["lungs", "ANATOMY", 109, 114]]], ["The potential therapeutic benefit of upregulating Na,K-ATPase and CFTR channels in the lung as well as the delivery of KGF and HO-1 to the lung have already been discussed.", [["lung", "ANATOMY", 87, 91], ["lung", "ANATOMY", 139, 143], ["Na", "CHEMICAL", 50, 52], ["Na", "CHEMICAL", 50, 52], ["Na,K-ATPase", "GENE_OR_GENE_PRODUCT", 50, 61], ["CFTR", "GENE_OR_GENE_PRODUCT", 66, 70], ["lung", "ORGAN", 87, 91], ["KGF", "GENE_OR_GENE_PRODUCT", 119, 122], ["HO-1", "GENE_OR_GENE_PRODUCT", 127, 131], ["lung", "ORGAN", 139, 143], ["Na,K-ATPase", "PROTEIN", 50, 61], ["CFTR channels", "PROTEIN", 66, 79], ["KGF", "PROTEIN", 119, 122], ["HO", "PROTEIN", 127, 129], ["upregulating Na", "TEST", 37, 52], ["K-ATPase and CFTR channels", "TREATMENT", 53, 79], ["the delivery of KGF", "TREATMENT", 103, 122], ["potential", "UNCERTAINTY", 4, 13], ["therapeutic", "OBSERVATION_MODIFIER", 14, 25], ["lung", "ANATOMY", 87, 91], ["lung", "ANATOMY", 139, 143]]], ["All four systems have been explored in the context of gene therapy for ALI.Gene therapy to improve AFCAdenovirus-mediated transfer of Na,K-ATPase genes to lungs of live rats increased AFC [27] .", [["lungs", "ANATOMY", 155, 160], ["ALI", "DISEASE", 71, 74], ["Na", "CHEMICAL", 134, 136], ["Na", "CHEMICAL", 134, 136], ["K-", "CHEMICAL", 137, 139], ["AFCAdenovirus", "GENE_OR_GENE_PRODUCT", 99, 112], ["Na,K-ATPase", "GENE_OR_GENE_PRODUCT", 134, 145], ["lungs", "ORGAN", 155, 160], ["rats", "ORGANISM", 169, 173], ["AFCAdenovirus", "PROTEIN", 99, 112], ["Na,K-ATPase genes", "DNA", 134, 151], ["rats", "SPECIES", 169, 173], ["gene therapy", "TREATMENT", 54, 66], ["ALI", "PROBLEM", 71, 74], ["Gene therapy", "TREATMENT", 75, 87], ["AFCAdenovirus", "TREATMENT", 99, 112], ["Na", "TEST", 134, 136], ["ALI", "OBSERVATION", 71, 74], ["lungs", "ANATOMY", 155, 160]]], ["Upregulation of Na,K-ATPase expression in the alveolar epithelium by gene transfer improved edema resolution in rat models of ALI induced by elevated left arterial pressure [28] and hyperoxia [43] .", [["alveolar epithelium", "ANATOMY", 46, 65], ["edema", "ANATOMY", 92, 97], ["left arterial", "ANATOMY", 150, 163], ["Na", "CHEMICAL", 16, 18], ["edema", "DISEASE", 92, 97], ["ALI", "DISEASE", 126, 129], ["Na", "CHEMICAL", 16, 18], ["Na,K-ATPase", "GENE_OR_GENE_PRODUCT", 16, 27], ["alveolar epithelium", "TISSUE", 46, 65], ["edema", "PATHOLOGICAL_FORMATION", 92, 97], ["rat", "ORGANISM", 112, 115], ["arterial", "MULTI-TISSUE_STRUCTURE", 155, 163], ["Na,K", "PROTEIN", 16, 20], ["ATPase", "PROTEIN", 21, 27], ["rat", "SPECIES", 112, 115], ["rat", "SPECIES", 112, 115], ["Na,K", "TEST", 16, 20], ["ATPase expression in the alveolar epithelium", "PROBLEM", 21, 65], ["edema", "PROBLEM", 92, 97], ["ALI", "PROBLEM", 126, 129], ["elevated left arterial pressure", "PROBLEM", 141, 172], ["hyperoxia", "TEST", 182, 191], ["alveolar epithelium", "ANATOMY", 46, 65], ["improved", "OBSERVATION_MODIFIER", 83, 91], ["edema", "OBSERVATION", 92, 97], ["elevated", "OBSERVATION", 141, 149], ["left", "ANATOMY_MODIFIER", 150, 154], ["arterial", "ANATOMY", 155, 163]]], ["Furthermore, transfer of \u03b2 2 -adrenergic receptor genes to the lungs of adult rats increased their sensitivity to exogenous catecholamines, and upregulated AFC due to increased delivery of both ENaC and Na,K-ATPase to epithelial cell membranes [73] .", [["lungs", "ANATOMY", 63, 68], ["epithelial cell membranes", "ANATOMY", 218, 243], ["catecholamines", "CHEMICAL", 124, 138], ["Na", "CHEMICAL", 203, 205], ["catecholamines", "CHEMICAL", 124, 138], ["Na", "CHEMICAL", 203, 205], ["K-", "CHEMICAL", 206, 208], ["\u03b2 2 -adrenergic receptor", "GENE_OR_GENE_PRODUCT", 25, 49], ["lungs", "ORGAN", 63, 68], ["rats", "ORGANISM", 78, 82], ["catecholamines", "SIMPLE_CHEMICAL", 124, 138], ["AFC", "GENE_OR_GENE_PRODUCT", 156, 159], ["ENaC", "GENE_OR_GENE_PRODUCT", 194, 198], ["Na,K-ATPase", "GENE_OR_GENE_PRODUCT", 203, 214], ["epithelial cell membranes", "CELLULAR_COMPONENT", 218, 243], ["\u03b2 2 -adrenergic receptor genes", "DNA", 25, 55], ["AFC", "PROTEIN", 156, 159], ["ENaC", "PROTEIN", 194, 198], ["Na,K-ATPase", "PROTEIN", 203, 214], ["rats", "SPECIES", 78, 82], ["\u03b2 2 -adrenergic receptor genes", "TREATMENT", 25, 55], ["exogenous catecholamines", "TREATMENT", 114, 138], ["upregulated AFC", "PROBLEM", 144, 159], ["increased delivery", "PROBLEM", 167, 185], ["Na", "TEST", 203, 205], ["epithelial cell membranes", "PROBLEM", 218, 243], ["lungs", "ANATOMY", 63, 68], ["increased", "OBSERVATION_MODIFIER", 167, 176], ["epithelial cell membranes", "OBSERVATION", 218, 243]]], ["Transfer of the CTFR gene to mouse and rat lungs also augmented AFC and appeared to affect the expression and function of components of the sodium transport machinery [30] .", [["lungs", "ANATOMY", 43, 48], ["sodium", "CHEMICAL", 140, 146], ["sodium", "CHEMICAL", 140, 146], ["CTFR", "GENE_OR_GENE_PRODUCT", 16, 20], ["mouse", "ORGANISM", 29, 34], ["rat", "ORGANISM", 39, 42], ["lungs", "ORGAN", 43, 48], ["AFC", "GENE_OR_GENE_PRODUCT", 64, 67], ["sodium", "SIMPLE_CHEMICAL", 140, 146], ["CTFR gene", "DNA", 16, 25], ["AFC", "PROTEIN", 64, 67], ["mouse", "SPECIES", 29, 34], ["rat", "SPECIES", 39, 42], ["mouse", "SPECIES", 29, 34], ["rat", "SPECIES", 39, 42], ["the sodium transport machinery", "TREATMENT", 136, 166], ["lungs", "ANATOMY", 43, 48], ["AFC", "OBSERVATION", 64, 67]]], ["These data together suggest that the sodium transporting and \u03b2-adrenergic signaling systems in the lung are candidate targets for intervention by gene therapy in ALI/ARDS.", [["lung", "ANATOMY", 99, 103], ["sodium", "CHEMICAL", 37, 43], ["ALI", "DISEASE", 162, 165], ["ARDS", "DISEASE", 166, 170], ["sodium", "CHEMICAL", 37, 43], ["sodium", "SIMPLE_CHEMICAL", 37, 43], ["\u03b2-adrenergic", "GENE_OR_GENE_PRODUCT", 61, 73], ["lung", "ORGAN", 99, 103], ["These data", "TEST", 0, 10], ["the sodium transporting and \u03b2-adrenergic signaling systems", "PROBLEM", 33, 91], ["intervention", "TREATMENT", 130, 142], ["gene therapy", "TREATMENT", 146, 158], ["ALI", "PROBLEM", 162, 165], ["ARDS", "PROBLEM", 166, 170], ["lung", "ANATOMY", 99, 103], ["ARDS", "OBSERVATION", 166, 170]]], ["Clearly, enough epithelial cells would have to be present in the damaged epithelium for gene therapy to be effective, therefore, regeneration of the damaged epithelium with growth factors such as KGF has also been addressed by gene therapy.", [["epithelial cells", "ANATOMY", 16, 32], ["epithelium", "ANATOMY", 73, 83], ["epithelium", "ANATOMY", 157, 167], ["epithelial cells", "CELL", 16, 32], ["epithelium", "TISSUE", 73, 83], ["epithelium", "TISSUE", 157, 167], ["KGF", "GENE_OR_GENE_PRODUCT", 196, 199], ["epithelial cells", "CELL_TYPE", 16, 32], ["growth factors", "PROTEIN", 173, 187], ["KGF", "PROTEIN", 196, 199], ["epithelial cells", "PROBLEM", 16, 32], ["gene therapy", "TREATMENT", 88, 100], ["the damaged epithelium", "PROBLEM", 145, 167], ["growth factors", "PROBLEM", 173, 187], ["gene therapy", "TREATMENT", 227, 239], ["epithelial cells", "OBSERVATION", 16, 32], ["damaged epithelium", "OBSERVATION", 149, 167]]], ["Liposome-mediated KGF gene delivery into mouse lungs afforded protection in an oleic-acid induced lung injury model [89] .", [["lungs", "ANATOMY", 47, 52], ["lung", "ANATOMY", 98, 102], ["oleic-acid", "CHEMICAL", 79, 89], ["lung injury", "DISEASE", 98, 109], ["oleic-acid", "CHEMICAL", 79, 89], ["Liposome", "SIMPLE_CHEMICAL", 0, 8], ["KGF", "GENE_OR_GENE_PRODUCT", 18, 21], ["mouse", "ORGANISM", 41, 46], ["lungs", "ORGAN", 47, 52], ["oleic-acid", "SIMPLE_CHEMICAL", 79, 89], ["lung", "ORGAN", 98, 102], ["KGF", "PROTEIN", 18, 21], ["mouse", "SPECIES", 41, 46], ["mouse", "SPECIES", 41, 46], ["Liposome-mediated KGF gene delivery", "TREATMENT", 0, 35], ["an oleic", "TREATMENT", 76, 84], ["lung injury model", "PROBLEM", 98, 115], ["lungs", "ANATOMY", 47, 52], ["lung", "ANATOMY", 98, 102], ["injury", "OBSERVATION", 103, 109]]], ["Similarly, in the case of antioxidants adenovirus-mediated gene delivery of HO-1 into the lungs of live mice afforded significant protection against influenza virus-and lipopolysaccharide-induced Methods of potentiating alveolar fluid clearance in ALI/ARDS that have been validated in animal and organ models or in clinical studies.", [["lungs", "ANATOMY", 90, 95], ["alveolar fluid", "ANATOMY", 220, 234], ["organ", "ANATOMY", 296, 301], ["lipopolysaccharide", "CHEMICAL", 169, 187], ["ALI", "DISEASE", 248, 251], ["ARDS", "DISEASE", 252, 256], ["adenovirus", "ORGANISM", 39, 49], ["HO-1", "GENE_OR_GENE_PRODUCT", 76, 80], ["lungs", "ORGAN", 90, 95], ["mice", "ORGANISM", 104, 108], ["influenza virus", "ORGANISM", 149, 164], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 169, 187], ["alveolar fluid", "MULTI-TISSUE_STRUCTURE", 220, 234], ["organ", "ORGAN", 296, 301], ["HO-1", "PROTEIN", 76, 80], ["mice", "SPECIES", 104, 108], ["influenza virus", "SPECIES", 149, 164], ["mice", "SPECIES", 104, 108], ["antioxidants adenovirus", "TREATMENT", 26, 49], ["influenza virus", "PROBLEM", 149, 164], ["lipopolysaccharide", "TREATMENT", 169, 187], ["potentiating alveolar fluid clearance", "PROBLEM", 207, 244], ["ALI", "PROBLEM", 248, 251], ["ARDS", "PROBLEM", 252, 256], ["clinical studies", "TEST", 315, 331], ["lungs", "ANATOMY", 90, 95], ["alveolar", "ANATOMY", 220, 228], ["fluid clearance", "OBSERVATION", 229, 244], ["ARDS", "OBSERVATION", 252, 256]]], ["Interventions involving gene therapy are indicated in the shaded box.", [["Interventions", "TREATMENT", 0, 13], ["gene therapy", "TREATMENT", 24, 36]]], ["CFTR, Cystic fibrosis transmembrane conductance regulator; D 1 , dopamine D 1 receptor; D 2 , dopamine D 2 receptor; EGF, epidermal growth factor; ENaC, epithelial sodium channel; KGF, keratinocyte growth factor; Na,K-ATPase, Na + , K + transporting adenosine -5 -triphosphatase; T 3 , 3,3 ,5-triiodo-L-thyronine; TNF-\u03b1, tumor necrosis factor \u03b1 ALI [99] .", [["epithelial", "ANATOMY", 153, 163], ["fibrosis", "DISEASE", 13, 21], ["dopamine", "CHEMICAL", 65, 73], ["dopamine", "CHEMICAL", 94, 102], ["sodium", "CHEMICAL", 164, 170], ["Na", "CHEMICAL", 213, 215], ["K", "CHEMICAL", 216, 217], ["Na", "CHEMICAL", 226, 228], ["K", "CHEMICAL", 233, 234], ["adenosine", "CHEMICAL", 250, 259], ["T 3 , 3,3 ,5-triiodo-L-thyronine", "CHEMICAL", 280, 312], ["necrosis", "DISEASE", 327, 335], ["ALI", "DISEASE", 345, 348], ["dopamine", "CHEMICAL", 65, 73], ["dopamine", "CHEMICAL", 94, 102], ["sodium", "CHEMICAL", 164, 170], ["Na", "CHEMICAL", 213, 215], ["K", "CHEMICAL", 216, 217], ["Na +", "CHEMICAL", 226, 230], ["K +", "CHEMICAL", 233, 236], ["adenosine", "CHEMICAL", 250, 259], ["T 3 , 3,3 ,5-triiodo-L-thyronine", "CHEMICAL", 280, 312], ["CFTR", "GENE_OR_GENE_PRODUCT", 0, 4], ["D 1", "GENE_OR_GENE_PRODUCT", 59, 62], ["dopamine D 1 receptor", "GENE_OR_GENE_PRODUCT", 65, 86], ["D 2", "GENE_OR_GENE_PRODUCT", 88, 91], ["dopamine D 2 receptor", "GENE_OR_GENE_PRODUCT", 94, 115], ["EGF", "GENE_OR_GENE_PRODUCT", 117, 120], ["epidermal growth factor", "GENE_OR_GENE_PRODUCT", 122, 145], ["ENaC", "GENE_OR_GENE_PRODUCT", 147, 151], ["epithelial sodium channel", "GENE_OR_GENE_PRODUCT", 153, 178], ["KGF", "GENE_OR_GENE_PRODUCT", 180, 183], ["keratinocyte growth factor", "GENE_OR_GENE_PRODUCT", 185, 211], ["Na,K-ATPase", "GENE_OR_GENE_PRODUCT", 213, 224], ["Na +", "SIMPLE_CHEMICAL", 226, 230], ["K + transporting adenosine -5 -triphosphatase", "SIMPLE_CHEMICAL", 233, 278], ["T 3 , 3,3 ,5-triiodo-L-thyronine", "SIMPLE_CHEMICAL", 280, 312], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 314, 319], ["tumor necrosis factor \u03b1", "GENE_OR_GENE_PRODUCT", 321, 344], ["CFTR", "PROTEIN", 0, 4], ["Cystic fibrosis transmembrane conductance regulator", "PROTEIN", 6, 57], ["D 1", "PROTEIN", 59, 62], ["dopamine D 1 receptor", "PROTEIN", 65, 86], ["D 2", "PROTEIN", 88, 91], ["dopamine D 2 receptor", "PROTEIN", 94, 115], ["EGF", "PROTEIN", 117, 120], ["epidermal growth factor", "PROTEIN", 122, 145], ["ENaC", "PROTEIN", 147, 151], ["epithelial sodium channel", "PROTEIN", 153, 178], ["KGF", "PROTEIN", 180, 183], ["keratinocyte growth factor", "PROTEIN", 185, 211], ["Na,K-ATPase", "PROTEIN", 213, 224], ["Na + , K + transporting adenosine -5 -triphosphatase", "PROTEIN", 226, 278], ["TNF", "PROTEIN", 314, 317], ["tumor necrosis factor", "PROTEIN", 321, 342], ["CFTR", "PROBLEM", 0, 4], ["Cystic fibrosis transmembrane conductance regulator", "PROBLEM", 6, 57], ["dopamine D 1 receptor", "TREATMENT", 65, 86], ["dopamine D 2 receptor", "TREATMENT", 94, 115], ["EGF", "TEST", 117, 120], ["epidermal growth factor", "TEST", 122, 145], ["ENaC", "TEST", 147, 151], ["epithelial sodium channel", "TEST", 153, 178], ["KGF", "TEST", 180, 183], ["keratinocyte growth factor", "TEST", 185, 211], ["Na", "TEST", 213, 215], ["K", "TEST", 216, 217], ["ATPase", "TEST", 218, 224], ["Na", "TEST", 226, 228], ["K", "TEST", 233, 234], ["adenosine", "TEST", 250, 259], ["triphosphatase", "TEST", 264, 278], ["T", "TEST", 280, 281], ["triiodo", "TEST", 293, 300], ["thyronine", "TREATMENT", 303, 312], ["TNF", "TEST", 314, 317], ["tumor necrosis factor", "PROBLEM", 321, 342], ["ALI", "PROBLEM", 345, 348], ["Cystic", "OBSERVATION_MODIFIER", 6, 12], ["fibrosis", "OBSERVATION", 13, 21], ["TNF", "ANATOMY", 314, 317], ["tumor necrosis", "OBSERVATION", 321, 335]]], ["While AFC was not specifically addressed in the KGF or HO-1 studies, the documented role of KGF and HO-1 in augmenting AFC suggests that this phenomenon contributed to the beneficial effect observed.ConclusionOrgan and animal models of ALI together with clinical studies have helped us understand the contribution of impaired AFC to the development and persistence of ALI/ARDS (Fig. 2) .", [["ALI", "DISEASE", 236, 239], ["ALI", "DISEASE", 368, 371], ["ARDS", "DISEASE", 372, 376], ["AFC", "SIMPLE_CHEMICAL", 6, 9], ["KGF", "GENE_OR_GENE_PRODUCT", 48, 51], ["HO-1", "GENE_OR_GENE_PRODUCT", 55, 59], ["KGF", "GENE_OR_GENE_PRODUCT", 92, 95], ["HO-1", "GENE_OR_GENE_PRODUCT", 100, 104], ["AFC", "GENE_OR_GENE_PRODUCT", 119, 122], ["AFC", "GENE_OR_GENE_PRODUCT", 326, 329], ["KGF", "PROTEIN", 48, 51], ["HO", "PROTEIN", 55, 57], ["KGF", "PROTEIN", 92, 95], ["HO-1", "PROTEIN", 100, 104], ["KGF", "TEST", 92, 95], ["HO", "TEST", 100, 102], ["this phenomenon", "PROBLEM", 137, 152], ["ALI", "PROBLEM", 236, 239], ["clinical studies", "TEST", 254, 270], ["impaired AFC", "PROBLEM", 317, 329], ["ALI", "PROBLEM", 368, 371], ["ARDS", "PROBLEM", 372, 376], ["ALI", "OBSERVATION", 236, 239], ["impaired", "OBSERVATION_MODIFIER", 317, 325], ["AFC", "OBSERVATION", 326, 329], ["ALI", "OBSERVATION", 368, 371], ["ARDS", "OBSERVATION", 372, 376]]], ["Perturbations to the alveolo-capillary barrier can both promote the formation and prevent the resolution of alveolar edema associated with ALI/ARDS.", [["alveolo-capillary barrier", "ANATOMY", 21, 46], ["alveolar", "ANATOMY", 108, 116], ["alveolar edema", "DISEASE", 108, 122], ["ALI", "DISEASE", 139, 142], ["ARDS", "DISEASE", 143, 147], ["alveolo-capillary barrier", "TISSUE", 21, 46], ["alveolar edema", "PATHOLOGICAL_FORMATION", 108, 122], ["the alveolo-capillary barrier", "TREATMENT", 17, 46], ["alveolar edema", "PROBLEM", 108, 122], ["ALI", "PROBLEM", 139, 142], ["ARDS", "PROBLEM", 143, 147], ["alveolar", "ANATOMY", 108, 116], ["edema", "OBSERVATION", 117, 122], ["ALI", "OBSERVATION", 139, 142], ["ARDS", "OBSERVATION", 143, 147]]], ["Indeed, edema resolution is critical for the ALI/ARDS patient to survive.", [["edema", "ANATOMY", 8, 13], ["edema", "DISEASE", 8, 13], ["ALI", "DISEASE", 45, 48], ["ARDS", "DISEASE", 49, 53], ["edema", "PATHOLOGICAL_FORMATION", 8, 13], ["patient", "ORGANISM", 54, 61], ["patient", "SPECIES", 54, 61], ["edema", "PROBLEM", 8, 13], ["the ALI", "PROBLEM", 41, 48], ["ARDS", "PROBLEM", 49, 53], ["edema", "OBSERVATION", 8, 13], ["ARDS", "OBSERVATION", 49, 53]]], ["Animal and organ models of edema resolution and ALI have proved irreplaceable in the development of novel therapeutic strategies that augment AFC, the most obvious case being the low tidal volume ventilation strategy for the management of ARDS, a strategy that has now been validated in a large multicenter, randomized, controlled clinical trial.", [["organ", "ANATOMY", 11, 16], ["edema", "ANATOMY", 27, 32], ["edema", "DISEASE", 27, 32], ["ALI", "DISEASE", 48, 51], ["ARDS", "DISEASE", 239, 243], ["organ", "ORGAN", 11, 16], ["edema", "PATHOLOGICAL_FORMATION", 27, 32], ["AFC", "SIMPLE_CHEMICAL", 142, 145], ["edema resolution", "PROBLEM", 27, 43], ["ALI", "PROBLEM", 48, 51], ["novel therapeutic strategies", "TREATMENT", 100, 128], ["the low tidal volume ventilation strategy", "TREATMENT", 175, 216], ["the management", "TREATMENT", 221, 235], ["ARDS", "PROBLEM", 239, 243], ["organ", "ANATOMY", 11, 16], ["edema", "OBSERVATION", 27, 32], ["resolution", "OBSERVATION_MODIFIER", 33, 43], ["ALI", "OBSERVATION", 48, 51], ["low", "OBSERVATION_MODIFIER", 179, 182], ["tidal volume", "OBSERVATION", 183, 195], ["ARDS", "OBSERVATION", 239, 243]]], ["Due to our focus on AFC several other important ALI/ARDS candidate therapies currently under evaluation have been omitted from this review, including other ventilation strategies, surfactant replacement, fluid management, inhaled vasodilators, and nonglucocorticoid anti-inflammatory agents.", [["fluid", "ANATOMY", 204, 209], ["ALI", "DISEASE", 48, 51], ["ARDS", "DISEASE", 52, 56], ["surfactant", "SIMPLE_CHEMICAL", 180, 190], ["nonglucocorticoid anti-inflammatory agents", "SIMPLE_CHEMICAL", 248, 290], ["AFC", "TREATMENT", 20, 23], ["ARDS candidate therapies", "TREATMENT", 52, 76], ["evaluation", "TEST", 93, 103], ["other ventilation strategies", "TREATMENT", 150, 178], ["surfactant replacement", "TREATMENT", 180, 202], ["fluid management", "TREATMENT", 204, 220], ["inhaled vasodilators", "TREATMENT", 222, 242], ["nonglucocorticoid anti-inflammatory agents", "TREATMENT", 248, 290], ["ARDS", "OBSERVATION", 52, 56], ["surfactant replacement", "OBSERVATION", 180, 202]]], ["Animal and organ models and clinical studies will no doubt continue to prove instrumental in the further development of several new and emerging ideas designed to augment AFC in ALI, notable among these are anticoagulation, stimulation of the \u03b2-adrenergic system, and local gene delivery to the alveolar epithelium.", [["organ", "ANATOMY", 11, 16], ["alveolar epithelium", "ANATOMY", 295, 314], ["ALI", "DISEASE", 178, 181], ["organ", "ORGAN", 11, 16], ["AFC", "CELL", 171, 174], ["alveolar epithelium", "TISSUE", 295, 314], ["clinical studies", "TEST", 28, 44], ["anticoagulation", "TREATMENT", 207, 222], ["stimulation of the \u03b2-adrenergic system", "TREATMENT", 224, 262], ["local gene delivery", "TREATMENT", 268, 287], ["several", "OBSERVATION_MODIFIER", 120, 127], ["new", "OBSERVATION_MODIFIER", 128, 131], ["anticoagulation", "OBSERVATION", 207, 222], ["alveolar epithelium", "ANATOMY", 295, 314]]]], "PMC7106019": [["Overview of CAPPneumonia is an infection of the lower respiratory tract caused by bacteria, viruses, fungi, protozoa, or parasites.5 Respiratory pathogens reach the lungs through inhalation of microorganisms, aspiration of oropharyngeal secretions, and hematogenous spread from other bodily sites of infection.5 CAP refers to pneumonia that is acquired outside health care organizations, including hospitals, nursing homes, and other long-term care facilities.", [["lower respiratory tract", "ANATOMY", 48, 71], ["lungs", "ANATOMY", 165, 170], ["oropharyngeal secretions", "ANATOMY", 223, 247], ["bodily sites", "ANATOMY", 284, 296], ["CAPPneumonia", "CHEMICAL", 12, 24], ["infection of the lower respiratory tract", "DISEASE", 31, 71], ["infection", "DISEASE", 300, 309], ["CAP", "DISEASE", 312, 315], ["pneumonia", "DISEASE", 326, 335], ["lower", "ORGANISM_SUBDIVISION", 48, 53], ["respiratory tract", "ORGANISM_SUBDIVISION", 54, 71], ["lungs", "ORGAN", 165, 170], ["oropharyngeal secretions", "ORGANISM_SUBDIVISION", 223, 247], ["an infection", "PROBLEM", 28, 40], ["the lower respiratory tract", "PROBLEM", 44, 71], ["bacteria", "PROBLEM", 82, 90], ["viruses", "PROBLEM", 92, 99], ["fungi", "PROBLEM", 101, 106], ["protozoa", "PROBLEM", 108, 116], ["parasites", "PROBLEM", 121, 130], ["Respiratory pathogens", "PROBLEM", 133, 154], ["microorganisms", "PROBLEM", 193, 207], ["aspiration of oropharyngeal secretions", "PROBLEM", 209, 247], ["hematogenous spread", "PROBLEM", 253, 272], ["infection", "PROBLEM", 300, 309], ["pneumonia", "PROBLEM", 326, 335], ["infection", "OBSERVATION", 31, 40], ["lower", "ANATOMY_MODIFIER", 48, 53], ["respiratory tract", "ANATOMY", 54, 71], ["bacteria", "OBSERVATION", 82, 90], ["lungs", "ANATOMY", 165, 170], ["oropharyngeal", "ANATOMY", 223, 236], ["secretions", "OBSERVATION", 237, 247], ["hematogenous", "OBSERVATION_MODIFIER", 253, 265], ["spread", "OBSERVATION_MODIFIER", 266, 272], ["bodily sites", "OBSERVATION_MODIFIER", 284, 296], ["infection", "OBSERVATION", 300, 309], ["pneumonia", "OBSERVATION", 326, 335]]], ["Although antibiotic resistance has increasingly become a recognized problem in pneumonia, older age and underlying disease, not antibiotic resistance, are more important factors in mortality.1", [["pneumonia", "DISEASE", 79, 88], ["antibiotic resistance", "TREATMENT", 9, 30], ["pneumonia", "PROBLEM", 79, 88], ["underlying disease", "PROBLEM", 104, 122], ["antibiotic resistance", "TREATMENT", 128, 149], ["antibiotic resistance", "OBSERVATION", 9, 30], ["pneumonia", "OBSERVATION", 79, 88], ["disease", "OBSERVATION", 115, 122], ["not", "UNCERTAINTY", 124, 127], ["antibiotic resistance", "OBSERVATION", 128, 149]]]], "bfd8dbd39a258f0a769375e64f7bd8df0e757266": [["INTRODUCTIONOnconase (ONC), a protein of amphibian origin, is a member of the vertebrate secreted ribonucleases (RNases) family that presents antitumor and antiviral activities.", [["antitumor", "ANATOMY", 142, 151], ["ONC", "CHEMICAL", 22, 25], ["INTRODUCTIONOnconase", "GENE_OR_GENE_PRODUCT", 0, 20], ["ONC", "GENE_OR_GENE_PRODUCT", 22, 25], ["ribonucleases", "GENE_OR_GENE_PRODUCT", 98, 111], ["RNases", "GENE_OR_GENE_PRODUCT", 113, 119], ["antitumor", "CANCER", 142, 151], ["INTRODUCTIONOnconase", "PROTEIN", 0, 20], ["ONC", "PROTEIN", 22, 25], ["vertebrate secreted ribonucleases (RNases) family", "PROTEIN", 78, 127], ["antiviral activities", "TREATMENT", 156, 176], ["amphibian origin", "OBSERVATION", 41, 57]]], ["Its structure endows it with unusual high conformation stability [1] and with the ability to evade the cytoplasmic ribonuclease inhibitor (RI), a 50kDa protein that tightly binds to some RNases and inhibits their activity [2] .", [["cytoplasmic", "ANATOMY", 103, 114], ["cytoplasmic", "ORGANISM_SUBSTANCE", 103, 114], ["ribonuclease", "GENE_OR_GENE_PRODUCT", 115, 127], ["RI", "GENE_OR_GENE_PRODUCT", 139, 141], ["cytoplasmic ribonuclease inhibitor", "PROTEIN", 103, 137], ["RI", "PROTEIN", 139, 141], ["50kDa protein", "PROTEIN", 146, 159], ["RNases", "PROTEIN", 187, 193], ["unusual high conformation stability", "PROBLEM", 29, 64], ["the cytoplasmic ribonuclease inhibitor", "TREATMENT", 99, 137], ["a 50kDa protein", "TREATMENT", 144, 159], ["unusual", "OBSERVATION_MODIFIER", 29, 36], ["high", "OBSERVATION_MODIFIER", 37, 41], ["conformation", "OBSERVATION_MODIFIER", 42, 54], ["stability", "OBSERVATION_MODIFIER", 55, 64]]], ["Both its conformational stability and its ability to evade the RI provide ONC with significant intracellular survival that is critical to its biological actions.INTRODUCTIONRegarding the antitumor activity, it has been shown that ONC exhibits selective cytostatic and cytotoxic activities [3] against many human tumor models (for a review see [4, 5] ).", [["intracellular", "ANATOMY", 95, 108], ["antitumor", "ANATOMY", 187, 196], ["tumor", "ANATOMY", 312, 317], ["ONC", "CHEMICAL", 230, 233], ["tumor", "DISEASE", 312, 317], ["RI", "GENE_OR_GENE_PRODUCT", 63, 65], ["ONC", "CANCER", 74, 77], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 95, 108], ["antitumor", "CANCER", 187, 196], ["ONC", "SIMPLE_CHEMICAL", 230, 233], ["human", "ORGANISM", 306, 311], ["tumor", "CANCER", 312, 317], ["RI", "PROTEIN", 63, 65], ["human", "SPECIES", 306, 311], ["human", "SPECIES", 306, 311], ["significant intracellular survival", "PROBLEM", 83, 117], ["selective cytostatic and cytotoxic activities", "PROBLEM", 243, 288], ["conformational stability", "OBSERVATION", 9, 33], ["antitumor activity", "OBSERVATION", 187, 205], ["selective", "OBSERVATION_MODIFIER", 243, 252], ["cytostatic", "OBSERVATION_MODIFIER", 253, 263], ["tumor", "OBSERVATION", 312, 317]]], ["In addition, ONC presents synergy with a significant number of anti-tumor drugs, such as tamoxifen, lovastatin, cisplatin, and vincristine, among others (for a review see [6] ).", [["anti-tumor", "ANATOMY", 63, 73], ["ONC", "CHEMICAL", 13, 16], ["tamoxifen", "CHEMICAL", 89, 98], ["lovastatin", "CHEMICAL", 100, 110], ["cisplatin", "CHEMICAL", 112, 121], ["vincristine", "CHEMICAL", 127, 138], ["tamoxifen", "CHEMICAL", 89, 98], ["lovastatin", "CHEMICAL", 100, 110], ["cisplatin", "CHEMICAL", 112, 121], ["vincristine", "CHEMICAL", 127, 138], ["ONC", "SIMPLE_CHEMICAL", 13, 16], ["anti-tumor", "CANCER", 63, 73], ["tamoxifen", "SIMPLE_CHEMICAL", 89, 98], ["lovastatin", "SIMPLE_CHEMICAL", 100, 110], ["cisplatin", "SIMPLE_CHEMICAL", 112, 121], ["vincristine", "SIMPLE_CHEMICAL", 127, 138], ["anti-tumor drugs", "TREATMENT", 63, 79], ["tamoxifen", "TREATMENT", 89, 98], ["lovastatin", "TREATMENT", 100, 110], ["cisplatin", "TREATMENT", 112, 121], ["vincristine", "TREATMENT", 127, 138], ["anti-tumor drugs", "OBSERVATION", 63, 79]]], ["More interestingly, it has entered clinical trials for the treatment of different types of cancer and has reached phase II/III for the treatment of malignant mesothelioma [7] [8] [9] .INTRODUCTIONThe ONC-induced apoptotic effects linked to its cell internalization mechanism are still not well understood.", [["cancer", "ANATOMY", 91, 97], ["malignant mesothelioma", "ANATOMY", 148, 170], ["cell", "ANATOMY", 244, 248], ["cancer", "DISEASE", 91, 97], ["malignant mesothelioma", "DISEASE", 148, 170], ["ONC", "CHEMICAL", 200, 203], ["cancer", "CANCER", 91, 97], ["malignant mesothelioma", "CANCER", 148, 170], ["ONC", "SIMPLE_CHEMICAL", 200, 203], ["cell", "CELL", 244, 248], ["the treatment", "TREATMENT", 55, 68], ["cancer", "PROBLEM", 91, 97], ["malignant mesothelioma", "PROBLEM", 148, 170], ["apoptotic effects", "PROBLEM", 212, 229], ["cancer", "OBSERVATION", 91, 97], ["malignant", "OBSERVATION_MODIFIER", 148, 157], ["mesothelioma", "OBSERVATION", 158, 170], ["apoptotic effects", "OBSERVATION", 212, 229]]], ["It is believed that the normal route for ONC to reach the cytosol is through an endosomal compartment, but controversy exists about the existence of a cellular receptor [6] .", [["cytosol", "ANATOMY", 58, 65], ["endosomal compartment", "ANATOMY", 80, 101], ["cellular", "ANATOMY", 151, 159], ["ONC", "GENE_OR_GENE_PRODUCT", 41, 44], ["cytosol", "CELLULAR_COMPONENT", 58, 65], ["endosomal compartment", "CELLULAR_COMPONENT", 80, 101], ["cellular", "CELL", 151, 159], ["ONC", "PROTEIN", 41, 44], ["cellular receptor", "PROTEIN", 151, 168]]], ["Once in the cytosol, ONC degrades RNA, thereby preventing protein synthesis and inducing cell cycle arrest and apoptosis.", [["cytosol", "ANATOMY", 12, 19], ["cell", "ANATOMY", 89, 93], ["cytosol", "CELLULAR_COMPONENT", 12, 19], ["ONC", "GENE_OR_GENE_PRODUCT", 21, 24], ["cell", "CELL", 89, 93], ["ONC", "PROTEIN", 21, 24], ["protein synthesis", "PROBLEM", 58, 75], ["inducing cell cycle arrest", "TREATMENT", 80, 106], ["apoptosis", "PROBLEM", 111, 120], ["cell cycle arrest", "OBSERVATION", 89, 106]]], ["However, ONC-induced apoptosis presents features different from those of indiscriminate protein synthesis arrest (for a review see [6] ).", [["ONC", "CHEMICAL", 9, 12], ["ONC", "SIMPLE_CHEMICAL", 9, 12], ["apoptosis", "PROBLEM", 21, 30], ["indiscriminate protein synthesis arrest", "PROBLEM", 73, 112]]], ["In this regard, it has been demonstrated that, besides rRNA, the initially proposed ONC target [10] , mRNAs [11, 12] , tRNAs [13] , and miRNAs or their precursors [14] [15] [16] are also ONC targets.", [["rRNA", "CELLULAR_COMPONENT", 55, 59], ["ONC", "GENE_OR_GENE_PRODUCT", 84, 87], ["[14] [15] [16]", "SIMPLE_CHEMICAL", 163, 177], ["ONC", "GENE_OR_GENE_PRODUCT", 187, 190], ["rRNA", "RNA", 55, 59], ["ONC target [10] ,", "RNA", 84, 101], ["mRNAs", "RNA", 102, 107], ["ONC targets", "DNA", 187, 198], ["mRNAs", "TEST", 102, 107], ["tRNAs", "TEST", 119, 124], ["miRNAs", "TEST", 136, 142], ["their precursors", "TEST", 146, 162]]], ["Accordingly, ONC up-and down-regulates genes that code for proteins involved in cell cycle progression or transcription factors involved in cell survival [11, 12, 17] .Research PaperIn addition, ONC may trigger cell death in several ways, depending on the cell type.", [["cell", "ANATOMY", 80, 84], ["cell", "ANATOMY", 140, 144], ["cell", "ANATOMY", 211, 215], ["cell", "ANATOMY", 256, 260], ["death", "DISEASE", 216, 221], ["ONC", "GENE_OR_GENE_PRODUCT", 13, 16], ["cell", "CELL", 80, 84], ["cell", "CELL", 140, 144], ["cell", "CELL", 211, 215], ["cell type", "CELL", 256, 265], ["ONC", "PROTEIN", 13, 16], ["transcription factors", "PROTEIN", 106, 127], ["ONC", "TEST", 13, 16], ["proteins", "PROBLEM", 59, 67], ["transcription factors", "PROBLEM", 106, 127], ["cell death", "PROBLEM", 211, 221]]], ["It may induce caspase-dependent apoptosis linked to the activation of the stress-activated protein kinase c-Jun NH2 [18] or intrinsic apoptosis together with the activation of Ser-proteases [19, 20] .", [["caspase", "GENE_OR_GENE_PRODUCT", 14, 21], ["c-Jun NH2 [18]", "GENE_OR_GENE_PRODUCT", 106, 120], ["Ser-proteases", "GENE_OR_GENE_PRODUCT", 176, 189], ["caspase", "PROTEIN", 14, 21], ["stress-activated protein kinase c", "PROTEIN", 74, 107], ["Jun NH2", "PROTEIN", 108, 115], ["Ser-proteases", "PROTEIN", 176, 189], ["caspase", "PROBLEM", 14, 21], ["dependent apoptosis", "PROBLEM", 22, 41], ["the stress", "TEST", 70, 80], ["activated protein kinase", "TEST", 81, 105], ["Jun NH2", "PROBLEM", 108, 115], ["intrinsic apoptosis", "PROBLEM", 124, 143], ["apoptosis", "OBSERVATION", 134, 143]]], ["It has been demonstrated that intrinsic apoptosis depends on Apaf-1 reversing the inhibitory effect of tRNAs on the association of cytochrome c with Apaf-1 [21] .", [["Apaf-1", "GENE_OR_GENE_PRODUCT", 61, 67], ["cytochrome c", "GENE_OR_GENE_PRODUCT", 131, 143], ["Apaf-1", "GENE_OR_GENE_PRODUCT", 149, 155], ["Apaf-1", "PROTEIN", 61, 67], ["cytochrome c", "PROTEIN", 131, 143], ["Apaf", "PROTEIN", 149, 153], ["intrinsic apoptosis", "PROBLEM", 30, 49], ["Apaf", "TREATMENT", 61, 65], ["tRNAs", "TREATMENT", 103, 108], ["Apaf", "TEST", 149, 153], ["intrinsic", "OBSERVATION_MODIFIER", 30, 39], ["apoptosis", "OBSERVATION", 40, 49]]], ["In addition, ONC may induce cell death by autophagy [22, 23] .Research PaperThe antiviral activity of ONC is of particular interest due to ONC's ability to degrade not only RNA but dsRNA [24] .", [["cell", "ANATOMY", 28, 32], ["ONC", "CHEMICAL", 13, 16], ["death", "DISEASE", 33, 38], ["ONC", "CHEMICAL", 102, 105], ["ONC", "CHEMICAL", 139, 142], ["ONC", "SIMPLE_CHEMICAL", 13, 16], ["cell", "CELL", 28, 32], ["ONC", "SIMPLE_CHEMICAL", 102, 105], ["ONC", "SIMPLE_CHEMICAL", 139, 142], ["ONC", "PROTEIN", 13, 16], ["cell death", "PROBLEM", 28, 38]]], ["Antiviral drugs that destroy viral genomes not only suppress virus production but are likely to abolish latent virus infection.", [["latent virus infection", "DISEASE", 104, 126], ["latent virus", "ORGANISM", 104, 116], ["viral genomes", "DNA", 29, 42], ["Antiviral drugs", "TREATMENT", 0, 15], ["destroy viral genomes", "PROBLEM", 21, 42], ["suppress virus production", "PROBLEM", 52, 77], ["latent virus infection", "PROBLEM", 104, 126], ["likely to", "UNCERTAINTY", 86, 95], ["latent", "OBSERVATION_MODIFIER", 104, 110], ["virus", "OBSERVATION_MODIFIER", 111, 116], ["infection", "OBSERVATION", 117, 126]]], ["It has been described that ONC exhibits efficacy in suppressing the replication of HIV-1, leaving non-infected cells unharmed [25] .", [["cells", "ANATOMY", 111, 116], ["ONC", "CHEMICAL", 27, 30], ["ONC", "SIMPLE_CHEMICAL", 27, 30], ["HIV-1", "ORGANISM", 83, 88], ["cells", "CELL", 111, 116], ["non-infected cells", "CELL_TYPE", 98, 116], ["HIV-1", "SPECIES", 83, 88], ["HIV-1", "SPECIES", 83, 88], ["HIV", "PROBLEM", 83, 86], ["non-infected cells", "PROBLEM", 98, 116]]], ["Recently, several patents have been obtained by Tamir Biotechnology, Inc. (San Diego, CA) (http://tamirbio.com/) to use wild type ONC and variants as antiviral agents.", [["ONC", "CANCER", 130, 133], ["antiviral agents", "TREATMENT", 150, 166]]], ["The most success has been obtained with human papilloma virus (HPV) [26] , although other viral infections, such as those of the Herpesviridae family, are also being treated [27] .", [["human papilloma virus (HPV)", "DISEASE", 40, 67], ["viral infections", "DISEASE", 90, 106], ["human papilloma virus", "ORGANISM", 40, 61], ["HPV", "ORGANISM", 63, 66], ["human papilloma virus", "SPECIES", 40, 61], ["human papilloma virus", "SPECIES", 40, 61], ["HPV", "SPECIES", 63, 66], ["human papilloma virus", "PROBLEM", 40, 61], ["other viral infections", "PROBLEM", 84, 106], ["viral", "OBSERVATION_MODIFIER", 90, 95], ["infections", "OBSERVATION", 96, 106]]], ["ONC is now in clinical trial to study its safety and efficacy by topical administration to treat genital warts (clinical trial identifier: NCT02535104 at https://clinicaltrials. gov/).", [["genital warts", "ANATOMY", 97, 110], ["genital warts", "DISEASE", 97, 110], ["topical administration", "TREATMENT", 65, 87], ["genital warts", "PROBLEM", 97, 110]]], ["What is more, ONC is being considered alone or as adjuvant therapy in an effort to fight Ebola, orthomyxoviruses (influenza), Middle East Respiratory Syndrome (MERS-CoV), the Hepatitis C virus (HCV), the cytomegalovirus (CMV), the respiratory syncytial virus (RVS), and rhabodviruses (rabies) (http://tamirbio.com/).Research PaperTaking into account the large number of diseases with high social impact that are or can be treated with ONC, we have used microarray technology to identify significant altered gene expression in the treatment of two ovarian carcinoma cell lines, NCI/ADR-RES and its parental OVCAR-8, with this enzyme.", [["ovarian carcinoma cell lines", "ANATOMY", 547, 575], ["NCI", "ANATOMY", 577, 580], ["Ebola, orthomyxoviruses", "DISEASE", 89, 112], ["influenza", "DISEASE", 114, 123], ["Middle East Respiratory Syndrome (MERS-CoV)", "DISEASE", 126, 169], ["Hepatitis C virus (HCV), the cytomegalovirus (CMV)", "DISEASE", 175, 225], ["respiratory syncytial virus", "DISEASE", 231, 258], ["rabies", "DISEASE", 285, 291], ["ovarian carcinoma", "DISEASE", 547, 564], ["ADR", "CHEMICAL", 581, 584], ["ONC", "SIMPLE_CHEMICAL", 14, 17], ["Ebola", "ORGANISM", 89, 94], ["Middle East Respiratory Syndrome", "ORGANISM", 126, 158], ["MERS-CoV", "ORGANISM", 160, 168], ["Hepatitis C virus", "ORGANISM", 175, 192], ["HCV", "ORGANISM", 194, 197], ["cytomegalovirus", "ORGANISM", 204, 219], ["CMV", "ORGANISM", 221, 224], ["respiratory syncytial virus", "ORGANISM", 231, 258], ["RVS", "CANCER", 260, 263], ["ovarian carcinoma cell lines", "CELL", 547, 575], ["NCI", "CELL", 577, 580], ["ADR-RES", "CELL", 581, 588], ["OVCAR-8", "CELL", 606, 613], ["ovarian carcinoma cell lines", "CELL_LINE", 547, 575], ["NCI/ADR-RES", "CELL_LINE", 577, 588], ["Hepatitis C virus", "SPECIES", 175, 192], ["respiratory syncytial virus", "SPECIES", 231, 258], ["Middle East Respiratory Syndrome (MERS-CoV", "SPECIES", 126, 168], ["Hepatitis C virus", "SPECIES", 175, 192], ["HCV", "SPECIES", 194, 197], ["CMV", "SPECIES", 221, 224], ["respiratory syncytial virus", "SPECIES", 231, 258], ["adjuvant therapy", "TREATMENT", 50, 66], ["Ebola", "PROBLEM", 89, 94], ["orthomyxoviruses (influenza)", "PROBLEM", 96, 124], ["Middle East Respiratory Syndrome", "PROBLEM", 126, 158], ["the Hepatitis C virus", "PROBLEM", 171, 192], ["HCV", "PROBLEM", 194, 197], ["the cytomegalovirus (CMV", "PROBLEM", 200, 224], ["the respiratory syncytial virus", "PROBLEM", 227, 258], ["diseases", "PROBLEM", 370, 378], ["microarray technology", "TREATMENT", 453, 474], ["significant altered gene expression", "PROBLEM", 487, 522], ["the treatment", "TREATMENT", 526, 539], ["two ovarian carcinoma cell lines", "PROBLEM", 543, 575], ["its parental OVCAR", "TEST", 593, 611], ["this enzyme", "TEST", 620, 631], ["Respiratory Syndrome", "OBSERVATION", 138, 158], ["respiratory syncytial", "ANATOMY", 231, 252], ["large", "OBSERVATION_MODIFIER", 354, 359], ["number", "OBSERVATION_MODIFIER", 360, 366], ["diseases", "OBSERVATION", 370, 378], ["gene expression", "OBSERVATION", 507, 522], ["ovarian", "ANATOMY", 547, 554], ["carcinoma cell lines", "OBSERVATION", 555, 575]]], ["The present work is the second to use microarray-derived transcriptional profiling to identify ONC-regulated genes in order to understand the cytotoxic mechanism of this RNase.", [["ONC", "GENE_OR_GENE_PRODUCT", 95, 98], ["RNase", "GENE_OR_GENE_PRODUCT", 170, 175], ["ONC-regulated genes", "DNA", 95, 114], ["RNase", "PROTEIN", 170, 175], ["microarray", "TEST", 38, 48], ["transcriptional profiling", "TEST", 57, 82]]], ["In a previous work, Altomare et al. [12] investigated the effect of ONC on different human malignant mesothelioma (hMM) cell lines and showed that this RNase alters the expression of genes that control the cell cycle and apoptosis.Research PaperOur results show that the ONC up-regulated activating transcription factor 3 (ATF3) is a cell-type independent key factor of ONC antitumor activity.", [["malignant mesothelioma (hMM) cell lines", "ANATOMY", 91, 130], ["cell", "ANATOMY", 206, 210], ["cell", "ANATOMY", 334, 338], ["antitumor", "ANATOMY", 374, 383], ["ONC", "CHEMICAL", 68, 71], ["malignant mesothelioma", "DISEASE", 91, 113], ["ONC", "SIMPLE_CHEMICAL", 68, 71], ["human", "ORGANISM", 85, 90], ["malignant mesothelioma (hMM) cell lines", "CELL", 91, 130], ["RNase", "GENE_OR_GENE_PRODUCT", 152, 157], ["cell", "CELL", 206, 210], ["ONC", "GENE_OR_GENE_PRODUCT", 271, 274], ["activating transcription factor 3", "GENE_OR_GENE_PRODUCT", 288, 321], ["ATF3", "GENE_OR_GENE_PRODUCT", 323, 327], ["cell", "CELL", 334, 338], ["ONC", "CANCER", 370, 373], ["antitumor", "CANCER", 374, 383], ["human malignant mesothelioma (hMM) cell lines", "CELL_LINE", 85, 130], ["RNase", "PROTEIN", 152, 157], ["ONC", "PROTEIN", 271, 274], ["activating transcription factor 3", "PROTEIN", 288, 321], ["ATF3", "PROTEIN", 323, 327], ["human", "SPECIES", 85, 90], ["human", "SPECIES", 85, 90], ["different human malignant mesothelioma (hMM) cell lines", "TREATMENT", 75, 130], ["this RNase", "PROBLEM", 147, 157], ["apoptosis", "PROBLEM", 221, 230], ["ONC antitumor activity", "TREATMENT", 370, 392], ["malignant", "OBSERVATION_MODIFIER", 91, 100], ["mesothelioma", "OBSERVATION", 101, 113], ["cell lines", "OBSERVATION", 120, 130], ["cell cycle", "OBSERVATION", 206, 216]]], ["ATF3 activates other transcription factors that control different signaling pathways.", [["ATF3", "GENE_OR_GENE_PRODUCT", 0, 4], ["ATF3", "PROTEIN", 0, 4], ["transcription factors", "PROTEIN", 21, 42], ["transcription factors", "TREATMENT", 21, 42]]], ["This explains the effects observed in the cell cycle and the induction of apoptosis in cells treated with ONC.", [["cell", "ANATOMY", 42, 46], ["cells", "ANATOMY", 87, 92], ["ONC", "CHEMICAL", 106, 109], ["ONC", "CHEMICAL", 106, 109], ["cell", "CELL", 42, 46], ["cells", "CELL", 87, 92], ["ONC", "SIMPLE_CHEMICAL", 106, 109], ["the cell cycle", "TREATMENT", 38, 52], ["apoptosis in cells", "PROBLEM", 74, 92], ["ONC", "TREATMENT", 106, 109]]], ["Interestingly, it has been described that ATF3 and some of its regulated genes help to preclude viral genome replication, to maintain virus latency, or to prevent viral oncogenesis.", [["ATF3", "GENE_OR_GENE_PRODUCT", 42, 46], ["ATF3", "PROTEIN", 42, 46], ["ATF3", "TREATMENT", 42, 46], ["viral genome replication", "TREATMENT", 96, 120], ["virus latency", "PROBLEM", 134, 147], ["viral oncogenesis", "PROBLEM", 163, 180], ["viral oncogenesis", "OBSERVATION", 163, 180]]], ["Finally, our results also show that the pleiotropic effects caused by ONC, derived from its ribonucleolytic activity in the cytosol, are completely different from those promoted by nuclear-directed RNases (ND-RNases) [28] .RESULTSONC is a paradigmatic antitumor RNase whose cytotoxic mechanism has been studied by different means [6] .", [["cytosol", "ANATOMY", 124, 131], ["nuclear", "ANATOMY", 181, 188], ["antitumor", "ANATOMY", 252, 261], ["ONC", "CHEMICAL", 70, 73], ["ONC", "SIMPLE_CHEMICAL", 70, 73], ["cytosol", "CELLULAR_COMPONENT", 124, 131], ["ND-RNases", "GENE_OR_GENE_PRODUCT", 206, 215], ["antitumor", "CANCER", 252, 261], ["RNase", "GENE_OR_GENE_PRODUCT", 262, 267], ["ONC", "PROTEIN", 70, 73], ["nuclear-directed RNases", "PROTEIN", 181, 204], ["ND", "PROTEIN", 206, 208], ["RNases", "PROTEIN", 209, 215], ["RNase", "PROTEIN", 262, 267], ["a paradigmatic antitumor RNase", "TREATMENT", 237, 267], ["cytosol", "ANATOMY", 124, 131], ["completely", "OBSERVATION_MODIFIER", 137, 147], ["different", "OBSERVATION_MODIFIER", 148, 157]]], ["Nevertheless, microarray profiling to broadly analyze the genes affected by this drug has only been done in hMM cell lines [12] .", [["hMM cell lines", "ANATOMY", 108, 122], ["hMM cell lines", "CELL", 108, 122], ["hMM cell lines", "CELL_LINE", 108, 122], ["microarray profiling", "TEST", 14, 34], ["cell lines", "OBSERVATION", 112, 122]]], ["We have used the same approach to study the effects of ONC in two ovarian carcinoma cell lines, NCI/ADR-RES and its parental OVCAR-8.", [["ovarian carcinoma cell lines", "ANATOMY", 66, 94], ["NCI/ADR-RES", "ANATOMY", 96, 107], ["ONC", "CHEMICAL", 55, 58], ["ovarian carcinoma", "DISEASE", 66, 83], ["ONC", "SIMPLE_CHEMICAL", 55, 58], ["ovarian carcinoma cell lines", "CELL", 66, 94], ["NCI", "CELL", 96, 99], ["ADR-RES", "CELL", 100, 107], ["OVCAR-8", "CELL", 125, 132], ["ovarian carcinoma cell lines", "CELL_LINE", 66, 94], ["NCI/ADR-RES", "CELL_LINE", 96, 107], ["parental OVCAR-8", "CELL_LINE", 116, 132], ["ONC in two ovarian carcinoma cell lines", "TREATMENT", 55, 94], ["its parental OVCAR", "TEST", 112, 130], ["ovarian", "ANATOMY", 66, 73], ["carcinoma cell lines", "OBSERVATION", 74, 94]]], ["In addition, our results allow us to compare the effects on gene expression promoted by two different RNases in cancer cells: ONC, an RNase that exerts its action in the cytosol, and PE5, an ND-RNase [29] .Cell proliferation and RNase sensitivitySince ONC has ribonucleolytic activity, an unbiased approach to examine gene expression by microarray technology requires searching for optimal cell treatment conditions.", [["cancer cells", "ANATOMY", 112, 124], ["cytosol", "ANATOMY", 170, 177], ["Cell", "ANATOMY", 206, 210], ["cell", "ANATOMY", 390, 394], ["cancer", "DISEASE", 112, 118], ["ONC", "CHEMICAL", 252, 255], ["cancer cells", "CELL", 112, 124], ["ONC", "CELL", 126, 129], ["RNase", "GENE_OR_GENE_PRODUCT", 134, 139], ["cytosol", "CELLULAR_COMPONENT", 170, 177], ["PE5", "GENE_OR_GENE_PRODUCT", 183, 186], ["ND-RNase", "GENE_OR_GENE_PRODUCT", 191, 199], ["Cell", "CELL", 206, 210], ["RNase", "GENE_OR_GENE_PRODUCT", 229, 234], ["ONC", "GENE_OR_GENE_PRODUCT", 252, 255], ["cell", "CELL", 390, 394], ["RNases", "PROTEIN", 102, 108], ["cancer cells", "CELL_TYPE", 112, 124], ["ONC", "PROTEIN", 126, 129], ["RNase", "PROTEIN", 134, 139], ["PE5", "PROTEIN", 183, 186], ["RNase", "PROTEIN", 194, 199], ["RNase", "PROTEIN", 229, 234], ["ONC", "PROTEIN", 252, 255], ["gene expression", "TREATMENT", 60, 75], ["two different RNases in cancer cells", "PROBLEM", 88, 124], ["Cell proliferation", "PROBLEM", 206, 224], ["RNase sensitivity", "TEST", 229, 246], ["microarray technology", "TEST", 337, 358], ["optimal cell treatment conditions", "TREATMENT", 382, 415], ["cancer cells", "OBSERVATION", 112, 124], ["RNase sensitivity", "OBSERVATION_MODIFIER", 229, 246]]], ["An RNA population representative of the actual drug effect must be obtained, not one that results from an extensive RNA degradation caused by the apoptosis process [30] .", [["An RNA population", "PROBLEM", 0, 17], ["the actual drug effect", "PROBLEM", 36, 58], ["an extensive RNA degradation", "PROBLEM", 103, 131], ["the apoptosis process", "PROBLEM", 142, 163], ["RNA population", "OBSERVATION", 3, 17], ["extensive", "OBSERVATION_MODIFIER", 106, 115], ["RNA degradation", "OBSERVATION", 116, 131]]], ["Therefore, we investigated the cytotoxic effect of ONC on NCI/ADR-RES and OVCAR-8 cells at different ONC concentrations and incubation times, as we had previously done with PE5 [28] .", [["NCI/ADR-RES", "ANATOMY", 58, 69], ["OVCAR-8 cells", "ANATOMY", 74, 87], ["ONC", "ANATOMY", 101, 104], ["ONC", "CHEMICAL", 51, 54], ["ONC", "CHEMICAL", 51, 54], ["PE5 [28]", "CHEMICAL", 173, 181], ["ONC", "SIMPLE_CHEMICAL", 51, 54], ["NCI/ADR-RES", "CELL", 58, 69], ["OVCAR-8 cells", "CELL", 74, 87], ["ONC", "SIMPLE_CHEMICAL", 101, 104], ["NCI/ADR-RES and OVCAR-8 cells", "CELL_LINE", 58, 87], ["OVCAR", "TEST", 74, 79], ["cytotoxic", "OBSERVATION_MODIFIER", 31, 40]]], ["A dose-dependent cytotoxic effect was apparent after 24 h of incubation with ONC and increased with time ( Supplementary Figure 1 Supplementary Data).", [["ONC", "CHEMICAL", 77, 80], ["dependent cytotoxic effect", "PROBLEM", 7, 33], ["ONC", "TREATMENT", 77, 80], ["dependent", "OBSERVATION_MODIFIER", 7, 16], ["cytotoxic effect", "OBSERVATION", 17, 33]]], ["As expected [31] , the cytotoxic effect of ONC was greater than that of PE5 [28] , and the MDR cell line, NCI/ADR-RES, was less sensitive to both RNases than its parental cell line OVCAR-8.Cell proliferation and RNase sensitivityNext, we analyzed the RNA degradation caused by different doses of ONC.", [["MDR cell line", "ANATOMY", 91, 104], ["NCI", "ANATOMY", 106, 109], ["cell line", "ANATOMY", 171, 180], ["Cell", "ANATOMY", 189, 193], ["ONC", "CHEMICAL", 43, 46], ["ADR", "CHEMICAL", 110, 113], ["ONC", "CHEMICAL", 296, 299], ["ONC", "CHEMICAL", 43, 46], ["RES", "CHEMICAL", 114, 117], ["ONC", "SIMPLE_CHEMICAL", 43, 46], ["MDR cell line", "CELL", 91, 104], ["NCI", "CELL", 106, 109], ["ADR-RES", "CELL", 110, 117], ["cell line OVCAR-8", "CELL", 171, 188], ["Cell", "CELL", 189, 193], ["RNase", "GENE_OR_GENE_PRODUCT", 212, 217], ["ONC", "SIMPLE_CHEMICAL", 296, 299], ["MDR cell line", "CELL_LINE", 91, 104], ["RNases", "PROTEIN", 146, 152], ["parental cell line", "CELL_LINE", 162, 180], ["OVCAR-8", "CELL_LINE", 181, 188], ["RNase", "PROTEIN", 212, 217], ["ONC", "TEST", 43, 46], ["PE5", "TEST", 72, 75], ["the MDR cell line", "TEST", 87, 104], ["NCI/ADR", "TEST", 106, 113], ["Cell proliferation", "PROBLEM", 189, 207], ["RNase sensitivity", "TEST", 212, 229], ["the RNA degradation", "PROBLEM", 247, 266], ["ONC", "TREATMENT", 296, 299], ["cytotoxic", "OBSERVATION_MODIFIER", 23, 32], ["MDR cell line", "OBSERVATION", 91, 104], ["cell line", "OBSERVATION", 171, 180], ["RNase sensitivity", "OBSERVATION_MODIFIER", 212, 229]]], ["We incubated NCI/ADR-RES and OVCAR-8 cells with ONC concentrations that induced a decrease in cell proliferation of 5%, 10%, and 15% (IC 5 , IC 10 , and IC 15 ).", [["NCI/ADR-RES", "ANATOMY", 13, 24], ["OVCAR-8 cells", "ANATOMY", 29, 42], ["cell", "ANATOMY", 94, 98], ["ONC", "CHEMICAL", 48, 51], ["RES", "CHEMICAL", 21, 24], ["ONC", "CHEMICAL", 48, 51], ["NCI/ADR-RES", "CELL", 13, 24], ["OVCAR-8 cells", "CELL", 29, 42], ["ONC", "SIMPLE_CHEMICAL", 48, 51], ["cell", "CELL", 94, 98], ["NCI/ADR-RES and OVCAR-8 cells", "CELL_LINE", 13, 42], ["OVCAR", "TEST", 29, 34], ["ONC concentrations", "TREATMENT", 48, 66], ["a decrease in cell proliferation", "PROBLEM", 80, 112], ["IC", "TEST", 134, 136], ["IC", "TEST", 141, 143], ["IC", "TEST", 153, 155], ["decrease", "OBSERVATION_MODIFIER", 82, 90], ["cell proliferation", "OBSERVATION", 94, 112]]], ["After 36 h of incubation, the RNA degradation of treated and untreated cells was quantified using a bioanalyzer.", [["cells", "ANATOMY", 71, 76], ["cells", "CELL", 71, 76], ["incubation", "TREATMENT", 14, 24], ["the RNA degradation", "TREATMENT", 26, 45], ["untreated cells", "PROBLEM", 61, 76], ["a bioanalyzer", "TREATMENT", 98, 111]]], ["The RNA integrity number (RIN) values obtained for all samples were higher than 9.3.", [["samples", "ANATOMY", 55, 62], ["The RNA integrity", "TEST", 0, 17], ["all samples", "TEST", 51, 62], ["RNA", "OBSERVATION_MODIFIER", 4, 7], ["integrity", "OBSERVATION_MODIFIER", 8, 17]]], ["For a good comparison of the effects of ONC and PE5 on the NCI/ADR-RES cell line, we decided to carry out the microarray experiments at that concentration of ONC that triggered the same decrease in cell viability (10%) observed with PE5 [28] after 36 h of treatment (i.e. 0.5 \u03bcM).", [["NCI/ADR-RES cell line", "ANATOMY", 59, 80], ["cell", "ANATOMY", 198, 202], ["ONC", "CHEMICAL", 40, 43], ["PE5", "CHEMICAL", 48, 51], ["ONC", "CHEMICAL", 158, 161], ["PE5", "CHEMICAL", 233, 236], ["ONC", "CHEMICAL", 40, 43], ["PE5", "CHEMICAL", 48, 51], ["RES", "CHEMICAL", 67, 70], ["ONC", "CHEMICAL", 158, 161], ["PE5 [28]", "CHEMICAL", 233, 241], ["ONC", "SIMPLE_CHEMICAL", 40, 43], ["PE5", "SIMPLE_CHEMICAL", 48, 51], ["NCI/ADR-RES cell line", "CELL", 59, 80], ["ONC", "SIMPLE_CHEMICAL", 158, 161], ["cell", "CELL", 198, 202], ["NCI/ADR-RES cell line", "CELL_LINE", 59, 80], ["ADR-RES cell line", "TREATMENT", 63, 80], ["the same decrease in cell viability", "PROBLEM", 177, 212], ["treatment", "TREATMENT", 256, 265], ["cell line", "OBSERVATION", 71, 80], ["decrease", "OBSERVATION_MODIFIER", 186, 194], ["cell viability", "OBSERVATION", 198, 212]]], ["Likewise, we chose an ONC concentration for the OVCAR-8 cell line of 0.06 \u03bcM, which also produced a 10% decrease in cell proliferation.Gene expression changes in ONC-treated cellsONC-treated and untreated NCI/ADR-RES cells revealed 56 differentially expressed genes out of 35,377 present in the microarray (1.6 x 10 -3 %).", [["OVCAR-8 cell line", "ANATOMY", 48, 65], ["cell", "ANATOMY", 116, 120], ["ONC", "ANATOMY", 162, 165], ["cellsONC", "ANATOMY", 174, 182], ["NCI/ADR-RES cells", "ANATOMY", 205, 222], ["ONC", "CHEMICAL", 162, 165], ["cellsONC", "CHEMICAL", 174, 182], ["ONC", "SIMPLE_CHEMICAL", 22, 25], ["OVCAR-8 cell line", "CELL", 48, 65], ["cell", "CELL", 116, 120], ["ONC", "SIMPLE_CHEMICAL", 162, 165], ["cellsONC", "CELL", 174, 182], ["NCI/ADR-RES cells", "CELL", 205, 222], ["OVCAR-8 cell line", "CELL_LINE", 48, 65], ["ONC-treated cellsONC", "CELL_LINE", 162, 182], ["NCI/ADR-RES cells", "CELL_LINE", 205, 222], ["an ONC concentration", "TREATMENT", 19, 39], ["the OVCAR-8 cell line", "TREATMENT", 44, 65], ["a 10% decrease in cell proliferation", "PROBLEM", 98, 134], ["Gene expression changes in ONC", "PROBLEM", 135, 165], ["cellsONC", "TREATMENT", 174, 182], ["RES cells", "TEST", 213, 222], ["the microarray", "TEST", 291, 305], ["decrease", "OBSERVATION_MODIFIER", 104, 112], ["cell proliferation", "OBSERVATION", 116, 134]]], ["Among them, 89% were up-regulated (the increase from untreated cells ranged from 2-to 6.5-fold), whereas 11% were down-regulated (the decrease from untreated cells ranged from 2-to 2.5-fold).", [["cells", "ANATOMY", 63, 68], ["cells", "ANATOMY", 158, 163], ["cells", "CELL", 63, 68], ["cells", "CELL", 158, 163], ["untreated cells", "CELL_TYPE", 53, 68], ["untreated cells", "CELL_TYPE", 148, 163], ["untreated cells", "PROBLEM", 53, 68], ["the decrease from untreated cells", "PROBLEM", 130, 163], ["decrease", "OBSERVATION_MODIFIER", 134, 142]]], ["Table 1 shows the top 20 ONC upregulated genes as well as all the ONC down-regulated genes.", [["ONC", "CANCER", 25, 28], ["ONC", "GENE_OR_GENE_PRODUCT", 66, 69], ["ONC upregulated genes", "DNA", 25, 46], ["ONC down-regulated genes", "DNA", 66, 90]]], ["The results indicate that the primary effect of ONC in NCI/ADR-RES cells is the activation of gene expression.", [["NCI/ADR-RES cells", "ANATOMY", 55, 72], ["ONC", "CHEMICAL", 48, 51], ["ADR", "CHEMICAL", 59, 62], ["RES", "CHEMICAL", 63, 66], ["ONC", "SIMPLE_CHEMICAL", 48, 51], ["NCI/ADR-RES cells", "CELL", 55, 72], ["NCI/ADR-RES cells", "CELL_LINE", 55, 72], ["ONC in NCI/ADR-RES cells", "TREATMENT", 48, 72]]], ["ONC up-regulated genes are involved in transcription regulation (ATF3, CREB5, EGR1), cell cycle and apoptosis (GADD45A, PPP1R15A), immune response (IL6, IL33, IL1RL1, IL23A), and stress response (TXNIP), among other processes.", [["cell", "ANATOMY", 85, 89], ["ONC", "GENE_OR_GENE_PRODUCT", 0, 3], ["ATF3", "GENE_OR_GENE_PRODUCT", 65, 69], ["CREB5", "GENE_OR_GENE_PRODUCT", 71, 76], ["EGR1", "GENE_OR_GENE_PRODUCT", 78, 82], ["cell", "CELL", 85, 89], ["GADD45A", "GENE_OR_GENE_PRODUCT", 111, 118], ["PPP1R15A", "GENE_OR_GENE_PRODUCT", 120, 128], ["IL6", "GENE_OR_GENE_PRODUCT", 148, 151], ["IL33", "GENE_OR_GENE_PRODUCT", 153, 157], ["IL1RL1", "GENE_OR_GENE_PRODUCT", 159, 165], ["IL23A", "GENE_OR_GENE_PRODUCT", 167, 172], ["TXNIP", "GENE_OR_GENE_PRODUCT", 196, 201], ["ONC up-regulated genes", "DNA", 0, 22], ["ATF3", "PROTEIN", 65, 69], ["CREB5", "PROTEIN", 71, 76], ["EGR1", "PROTEIN", 78, 82], ["GADD45A", "PROTEIN", 111, 118], ["PPP1R15A", "PROTEIN", 120, 128], ["IL6", "PROTEIN", 148, 151], ["IL33", "PROTEIN", 153, 157], ["IL1RL1", "PROTEIN", 159, 165], ["IL23A", "PROTEIN", 167, 172], ["TXNIP", "PROTEIN", 196, 201], ["ATF3", "TEST", 65, 69], ["cell cycle", "TEST", 85, 95], ["apoptosis", "PROBLEM", 100, 109], ["PPP1R15A", "TEST", 120, 128], ["IL6", "TEST", 148, 151], ["IL33", "TEST", 153, 157], ["IL1RL1", "TREATMENT", 159, 165]]], ["Some of the upregulated genes act as tumor suppressors (TXNIP, EGR1, and PPP1R15A).", [["tumor", "ANATOMY", 37, 42], ["tumor", "DISEASE", 37, 42], ["tumor", "CANCER", 37, 42], ["TXNIP", "GENE_OR_GENE_PRODUCT", 56, 61], ["EGR1", "GENE_OR_GENE_PRODUCT", 63, 67], ["PPP1R15A", "GENE_OR_GENE_PRODUCT", 73, 81], ["upregulated genes", "DNA", 12, 29], ["TXNIP", "DNA", 56, 61], ["EGR1", "DNA", 63, 67], ["PPP1R15A", "DNA", 73, 81], ["tumor suppressors", "TREATMENT", 37, 54], ["TXNIP", "TEST", 56, 61], ["EGR1", "TEST", 63, 67]]], ["ONC down-regulated genes are also associated with transcription regulation (RDBP, XBP1), amino acid metabolism (PHGDH, ASNS), and protein folding (HSPA1A, HSPA8).Gene expression changes in ONC-treated cellsONC-treated and untreated OVCAR-8 cells revealed seven differentially expressed genes out of 35,377 present in the microarray (1.8 x 10 -4 %).", [["ONC", "ANATOMY", 189, 192], ["cellsONC", "ANATOMY", 201, 209], ["OVCAR-8 cells", "ANATOMY", 232, 245], ["amino acid", "CHEMICAL", 89, 99], ["ONC", "CHEMICAL", 189, 192], ["cellsONC", "CHEMICAL", 201, 209], ["amino acid", "CHEMICAL", 89, 99], ["ONC", "GENE_OR_GENE_PRODUCT", 0, 3], ["RDBP", "GENE_OR_GENE_PRODUCT", 76, 80], ["XBP1", "GENE_OR_GENE_PRODUCT", 82, 86], ["amino acid", "AMINO_ACID", 89, 99], ["PHGDH", "GENE_OR_GENE_PRODUCT", 112, 117], ["ASNS", "GENE_OR_GENE_PRODUCT", 119, 123], ["HSPA1A", "GENE_OR_GENE_PRODUCT", 147, 153], ["HSPA8", "GENE_OR_GENE_PRODUCT", 155, 160], ["ONC", "SIMPLE_CHEMICAL", 189, 192], ["cellsONC", "CELL", 201, 209], ["OVCAR-8 cells", "CELL", 232, 245], ["ONC down-regulated genes", "DNA", 0, 24], ["RDBP", "PROTEIN", 76, 80], ["XBP1", "PROTEIN", 82, 86], ["PHGDH", "PROTEIN", 112, 117], ["ASNS", "PROTEIN", 119, 123], ["HSPA1A", "PROTEIN", 147, 153], ["HSPA8", "PROTEIN", 155, 160], ["ONC-treated cellsONC", "CELL_LINE", 189, 209], ["OVCAR-8 cells", "CELL_LINE", 232, 245], ["transcription regulation", "TEST", 50, 74], ["RDBP", "TEST", 76, 80], ["amino acid metabolism", "TEST", 89, 110], ["PHGDH", "TEST", 112, 117], ["ASNS", "TEST", 119, 123], ["protein folding", "PROBLEM", 130, 145], ["HSPA1A", "TEST", 147, 153], ["HSPA8", "TEST", 155, 160], ["Gene expression changes", "PROBLEM", 162, 185], ["ONC", "TEST", 189, 192], ["cellsONC", "TEST", 201, 209], ["OVCAR", "TEST", 232, 237], ["the microarray", "TEST", 317, 331]]], ["All of them were upregulated (the increase from untreated cells ranged from 2-to 4-fold) ( Table 2 ), indicating that the primary effect of ONC is also gene expression activation.", [["cells", "ANATOMY", 58, 63], ["ONC", "CHEMICAL", 140, 143], ["cells", "CELL", 58, 63], ["ONC", "GENE_OR_GENE_PRODUCT", 140, 143], ["untreated cells", "CELL_TYPE", 48, 63], ["untreated cells", "PROBLEM", 48, 63], ["upregulated", "OBSERVATION_MODIFIER", 17, 28], ["increase", "OBSERVATION_MODIFIER", 34, 42]]], ["Again, some of the up-regulated genes are related to transcription regulation (ATF3, NEURL3, ZNF750), while others are involved in stress response (TXNIP).", [["ATF3", "GENE_OR_GENE_PRODUCT", 79, 83], ["NEURL3", "GENE_OR_GENE_PRODUCT", 85, 91], ["ZNF750", "GENE_OR_GENE_PRODUCT", 93, 99], ["TXNIP", "GENE_OR_GENE_PRODUCT", 148, 153], ["up-regulated genes", "DNA", 19, 37], ["ATF3", "PROTEIN", 79, 83], ["NEURL3", "PROTEIN", 85, 91], ["ZNF750", "PROTEIN", 93, 99], ["TXNIP", "PROTEIN", 148, 153]]], ["Six out of the seven ONC differentially expressed genes in the OVCAR-8 cell line were also differentially expressed in the NCI/ADR-RES cell line (TXNIP, ATF3, HIST1H2AC, NEURL3, DHRS2, and NPPB).Gene expression changes in ONC-treated cellsAmong the ONC and PE5 differentially expressed genes in the NCI/ADR-RES cell line, we identified only 10 that were common for both RNase treatments (i.e. 1.5% and 18% of the PE5 [28] and ONC differentially expressed genes, respectively).", [["OVCAR-8 cell line", "ANATOMY", 63, 80], ["NCI/ADR-RES cell line", "ANATOMY", 123, 144], ["ONC", "ANATOMY", 222, 225], ["cells", "ANATOMY", 234, 239], ["NCI/ADR-RES cell line", "ANATOMY", 299, 320], ["NPPB", "CHEMICAL", 189, 193], ["ONC", "CHEMICAL", 222, 225], ["NPPB", "CHEMICAL", 189, 193], ["ONC", "CANCER", 21, 24], ["OVCAR-8 cell line", "CELL", 63, 80], ["NCI/ADR-RES cell line", "CELL", 123, 144], ["TXNIP", "GENE_OR_GENE_PRODUCT", 146, 151], ["ATF3", "GENE_OR_GENE_PRODUCT", 153, 157], ["HIST1H2AC", "GENE_OR_GENE_PRODUCT", 159, 168], ["NEURL3", "GENE_OR_GENE_PRODUCT", 170, 176], ["DHRS2", "GENE_OR_GENE_PRODUCT", 178, 183], ["NPPB", "SIMPLE_CHEMICAL", 189, 193], ["ONC", "SIMPLE_CHEMICAL", 222, 225], ["cells", "CELL", 234, 239], ["ONC", "CANCER", 249, 252], ["PE5", "GENE_OR_GENE_PRODUCT", 257, 260], ["NCI/ADR-RES cell line", "CELL", 299, 320], ["RNase", "GENE_OR_GENE_PRODUCT", 370, 375], ["ONC differentially expressed genes", "DNA", 21, 55], ["OVCAR-8 cell line", "CELL_LINE", 63, 80], ["RES cell line", "CELL_LINE", 131, 144], ["TXNIP", "PROTEIN", 146, 151], ["ATF3", "PROTEIN", 153, 157], ["HIST1H2AC", "PROTEIN", 159, 168], ["NEURL3", "PROTEIN", 170, 176], ["DHRS2", "PROTEIN", 178, 183], ["ONC-treated cells", "CELL_LINE", 222, 239], ["ONC and PE5 differentially expressed genes", "DNA", 249, 291], ["NCI/ADR-RES cell line", "CELL_LINE", 299, 320], ["RNase", "PROTEIN", 370, 375], ["ONC differentially expressed genes", "DNA", 426, 460], ["TXNIP", "TEST", 146, 151], ["ATF3", "TEST", 153, 157], ["HIST1H2AC", "TEST", 159, 168], ["NEURL3", "TREATMENT", 170, 176], ["DHRS2", "TREATMENT", 178, 183], ["NPPB", "TREATMENT", 189, 193], ["Gene expression changes in ONC-treated cells", "PROBLEM", 195, 239], ["RES cell line", "TREATMENT", 307, 320], ["both RNase treatments", "TREATMENT", 365, 386], ["the PE5", "TREATMENT", 409, 416], ["genes", "OBSERVATION_MODIFIER", 50, 55], ["cell line", "OBSERVATION", 71, 80], ["cell line", "OBSERVATION", 135, 144], ["cell line", "OBSERVATION", 311, 320]]], ["Eight of them were up-regulated in RNase-treated cells respective to untreated cells, whereas the other two were down-regulated.", [["cells", "ANATOMY", 49, 54], ["cells", "ANATOMY", 79, 84], ["RNase", "GENE_OR_GENE_PRODUCT", 35, 40], ["cells", "CELL", 49, 54], ["cells", "CELL", 79, 84], ["RNase", "PROTEIN", 35, 40], ["untreated cells", "CELL_TYPE", 69, 84], ["RNase-treated cells respective", "TREATMENT", 35, 65], ["untreated cells", "PROBLEM", 69, 84]]], ["Common up-regulated genes are related to transcription regulation (HMBOX1, LINC00340, NEXN-AS1), immune response (CD86, IL6, IFIT2) and the last two are potential tumor suppressors (LRRC2 and SPINK6 [32, 33] ).", [["tumor", "ANATOMY", 163, 168], ["tumor", "DISEASE", 163, 168], ["HMBOX1", "GENE_OR_GENE_PRODUCT", 67, 73], ["LINC00340", "GENE_OR_GENE_PRODUCT", 75, 84], ["NEXN-AS1", "GENE_OR_GENE_PRODUCT", 86, 94], ["CD86", "GENE_OR_GENE_PRODUCT", 114, 118], ["IL6", "GENE_OR_GENE_PRODUCT", 120, 123], ["IFIT2", "GENE_OR_GENE_PRODUCT", 125, 130], ["tumor", "CANCER", 163, 168], ["LRRC2", "GENE_OR_GENE_PRODUCT", 182, 187], ["-regulated genes", "DNA", 9, 25], ["HMBOX1", "PROTEIN", 67, 73], ["LINC00340", "PROTEIN", 75, 84], ["NEXN", "PROTEIN", 86, 90], ["AS1", "DNA", 91, 94], ["CD86", "PROTEIN", 114, 118], ["IL6", "PROTEIN", 120, 123], ["IFIT2", "PROTEIN", 125, 130], ["LRRC2", "DNA", 182, 187], ["SPINK6", "DNA", 192, 198], ["Common up-regulated genes", "PROBLEM", 0, 25], ["transcription regulation", "TEST", 41, 65], ["HMBOX1", "TEST", 67, 73], ["LINC00340", "TEST", 75, 84], ["immune response", "PROBLEM", 97, 112], ["CD86", "TEST", 114, 118], ["IL6", "TEST", 120, 123], ["potential tumor suppressors", "PROBLEM", 153, 180], ["-regulated genes", "OBSERVATION", 9, 25], ["tumor suppressors", "OBSERVATION", 163, 180]]], ["Common down-regulated genes participate in amino acid metabolism (PHGDH, ASNS).Gene ontology analysis and KEGG pathway annotationTo better understand the functional relevance of ONC-regulated genes in NCI/ADR-RES cells, we performed a gene ontology analysis.", [["NCI/ADR-RES cells", "ANATOMY", 201, 218], ["amino acid", "CHEMICAL", 43, 53], ["amino acid", "CHEMICAL", 43, 53], ["amino acid", "AMINO_ACID", 43, 53], ["ONC", "GENE_OR_GENE_PRODUCT", 178, 181], ["NCI/ADR-RES cells", "CELL", 201, 218], ["down-regulated genes", "DNA", 7, 27], ["ONC-regulated genes", "DNA", 178, 197], ["NCI/ADR-RES cells", "CELL_LINE", 201, 218], ["amino acid metabolism", "TEST", 43, 64], ["Gene ontology analysis", "TEST", 79, 101], ["KEGG pathway annotation", "TEST", 106, 129], ["a gene ontology analysis", "TEST", 233, 257]]], ["To the same end, ONC differentially expressed genes were mapped to the KEGG database to find over-represented known metabolic and regulatory pathways.", [["ONC differentially expressed genes", "DNA", 17, 51], ["KEGG database", "DNA", 71, 84]]], ["These analyses were not done for the OVCAR-8 cell line because ONC-treatment gave only 10 differentially expressed genes.", [["OVCAR-8 cell line", "ANATOMY", 37, 54], ["ONC", "CHEMICAL", 63, 66], ["OVCAR-8 cell line", "CELL", 37, 54], ["ONC", "SIMPLE_CHEMICAL", 63, 66], ["OVCAR-8 cell line", "CELL_LINE", 37, 54], ["These analyses", "TEST", 0, 14], ["the OVCAR-8 cell line", "TREATMENT", 33, 54], ["treatment", "TREATMENT", 67, 76]]], ["The NCI/ ADR-RES differentially expressed genes were used to find over-represented gene ontology terms in the three broad ontology categories: \"molecular function\", which captures knowledge about the functional activity of gene products, the larger \"biological process\", as part of which these specific functions collectively act, and \"cellular component\", where all this occurs.", [["cellular", "ANATOMY", 336, 344], ["ADR", "CHEMICAL", 9, 12], ["NCI", "CANCER", 4, 7], ["cellular", "CELL", 336, 344], ["NCI/ ADR-RES differentially expressed genes", "DNA", 4, 47], ["gene products", "PROTEIN", 223, 236], ["gene products", "TREATMENT", 223, 236], ["larger", "OBSERVATION_MODIFIER", 242, 248]]], ["Gene ontology analysis shows that ONC differentially expressed genes (Table 3) are involved in a diversity of cellular events.", [["cellular", "ANATOMY", 110, 118], ["ONC", "GENE_OR_GENE_PRODUCT", 34, 37], ["Table 3", "GENE_OR_GENE_PRODUCT", 70, 77], ["cellular", "CELL", 110, 118], ["ONC differentially expressed genes", "DNA", 34, 68], ["Gene ontology analysis", "TEST", 0, 22], ["cellular events", "PROBLEM", 110, 125]]], ["The same was found for PE5, showing that these RNA-damaging drugs have pleiotropic effects [28] .Gene ontology analysis and KEGG pathway annotationThe most ONC-affected biological processes were cell proliferation, response to stress, signal transduction, cell differentiation, and apoptosis.", [["cell", "ANATOMY", 195, 199], ["cell", "ANATOMY", 256, 260], ["PE5", "SIMPLE_CHEMICAL", 23, 26], ["ONC", "CANCER", 156, 159], ["cell", "CELL", 195, 199], ["cell", "CELL", 256, 260], ["PE5", "PROTEIN", 23, 26], ["PE5", "PROBLEM", 23, 26], ["these RNA", "PROBLEM", 41, 50], ["damaging drugs", "TREATMENT", 51, 65], ["pleiotropic effects", "PROBLEM", 71, 90], ["Gene ontology analysis", "TEST", 97, 119], ["KEGG pathway", "TEST", 124, 136], ["affected biological processes", "PROBLEM", 160, 189], ["cell proliferation", "PROBLEM", 195, 213], ["apoptosis", "PROBLEM", 282, 291], ["cell proliferation", "OBSERVATION", 195, 213], ["cell differentiation", "OBSERVATION", 256, 276], ["apoptosis", "OBSERVATION_MODIFIER", 282, 291]]], ["The individual function of ONC-regulated genes favored cytokine activity, nucleic acid binding transcription factor activity, and growth factor activity, and were mainly associated with the extracellular region, the cell surface, and the nucleus.Gene ontology analysis and KEGG pathway annotationAnalysis of the over-represented pathways collected in the KEGG database showed that ONCaffected pathways (Table 3) were involved in growth and development processes, like JAK-STAT or the MAPK signaling pathway, which affect basic cellular functions such as cell growth, proliferation, differentiation, and death, as well as stress response.", [["extracellular region", "ANATOMY", 190, 210], ["cell surface", "ANATOMY", 216, 228], ["nucleus", "ANATOMY", 238, 245], ["cellular", "ANATOMY", 527, 535], ["cell", "ANATOMY", 554, 558], ["nucleic acid", "CHEMICAL", 74, 86], ["death", "DISEASE", 603, 608], ["ONC", "GENE_OR_GENE_PRODUCT", 27, 30], ["extracellular region", "CELLULAR_COMPONENT", 190, 210], ["cell surface", "CELLULAR_COMPONENT", 216, 228], ["nucleus", "CELLULAR_COMPONENT", 238, 245], ["Table 3", "GENE_OR_GENE_PRODUCT", 403, 410], ["JAK-STAT", "GENE_OR_GENE_PRODUCT", 468, 476], ["MAPK", "GENE_OR_GENE_PRODUCT", 484, 488], ["cellular", "CELL", 527, 535], ["cell", "CELL", 554, 558], ["ONC-regulated genes", "DNA", 27, 46], ["cytokine", "PROTEIN", 55, 63], ["nucleic acid binding transcription factor", "PROTEIN", 74, 115], ["growth factor", "PROTEIN", 130, 143], ["JAK", "PROTEIN", 468, 471], ["STAT", "PROTEIN", 472, 476], ["MAPK", "PROTEIN", 484, 488], ["cytokine activity", "PROBLEM", 55, 72], ["nucleic acid binding transcription factor activity", "PROBLEM", 74, 124], ["growth factor activity", "PROBLEM", 130, 152], ["Gene ontology analysis", "TEST", 246, 268], ["KEGG pathway", "TEST", 273, 285], ["annotationAnalysis", "TEST", 286, 304], ["the KEGG database", "TEST", 351, 368], ["JAK", "TEST", 468, 471], ["the MAPK signaling pathway", "TEST", 480, 506], ["cell growth", "PROBLEM", 554, 565], ["death", "PROBLEM", 603, 608], ["stress response", "PROBLEM", 621, 636], ["cytokine activity", "OBSERVATION", 55, 72], ["extracellular", "ANATOMY_MODIFIER", 190, 203], ["region", "ANATOMY_MODIFIER", 204, 210], ["cell surface", "OBSERVATION", 216, 228], ["nucleus", "ANATOMY", 238, 245], ["cell", "OBSERVATION", 554, 558], ["growth", "OBSERVATION_MODIFIER", 559, 565]]], ["Some pathways related to infection or immunological diseases were also affected.ONC cytotoxic mechanismGene ontology analysis and KEGG pathway annotation of ONC-differentially expressed genes in the NCI/ADR-RES cell line show interesting terms that allow us to understand how ONC induces cell death.", [["NCI/ADR-RES cell line", "ANATOMY", 199, 220], ["cell", "ANATOMY", 288, 292], ["infection", "DISEASE", 25, 34], ["ONC", "CHEMICAL", 276, 279], ["death", "DISEASE", 293, 298], ["ONC", "GENE_OR_GENE_PRODUCT", 157, 160], ["NCI/ADR-RES cell line", "CELL", 199, 220], ["ONC", "SIMPLE_CHEMICAL", 276, 279], ["cell", "CELL", 288, 292], ["ONC-differentially expressed genes", "DNA", 157, 191], ["NCI/ADR-RES cell line", "CELL_LINE", 199, 220], ["ONC", "PROTEIN", 276, 279], ["Some pathways", "PROBLEM", 0, 13], ["infection", "PROBLEM", 25, 34], ["immunological diseases", "PROBLEM", 38, 60], ["KEGG pathway", "TEST", 130, 142], ["RES cell line", "TREATMENT", 207, 220], ["cell death", "PROBLEM", 288, 298], ["related to", "UNCERTAINTY", 14, 24], ["infection", "OBSERVATION", 25, 34], ["immunological diseases", "OBSERVATION", 38, 60]]], ["These terms are cell proliferation, response to stress, and apoptotic processes (Table 3 ).", [["cell", "ANATOMY", 16, 20], ["cell", "CELL", 16, 20], ["cell proliferation", "PROBLEM", 16, 34], ["stress, and apoptotic processes", "PROBLEM", 48, 79], ["cell proliferation", "OBSERVATION", 16, 34]]], ["In these fields we can find 7 of the 20 most ONC up-regulated genes in NCI/ADR-RES cells ( Table 1 ) that correspond to functionally related transcription regulators: early growth response 1 (EGR1), activating transcription factor 3 (ATF3), growth arrest and DNA-damage-inducible, alpha (GADD45A), thioredoxin interacting protein (TXNIP), cAMP responsive element binding protein 5 (CREB5), and protein phosphatase 1, regulatory subunit 15A (PPP1R15A).", [["NCI/ADR-RES cells", "ANATOMY", 71, 88], ["cAMP", "CHEMICAL", 339, 343], ["cAMP", "CHEMICAL", 339, 343], ["ONC", "GENE_OR_GENE_PRODUCT", 45, 48], ["NCI/ADR-RES cells", "CELL", 71, 88], ["Table 1", "CELL", 91, 98], ["early growth response 1", "GENE_OR_GENE_PRODUCT", 167, 190], ["EGR1", "GENE_OR_GENE_PRODUCT", 192, 196], ["activating transcription factor 3", "GENE_OR_GENE_PRODUCT", 199, 232], ["ATF3", "GENE_OR_GENE_PRODUCT", 234, 238], ["DNA", "CELLULAR_COMPONENT", 259, 262], ["-damage-inducible, alpha", "GENE_OR_GENE_PRODUCT", 262, 286], ["GADD45A", "GENE_OR_GENE_PRODUCT", 288, 295], ["thioredoxin interacting protein", "GENE_OR_GENE_PRODUCT", 298, 329], ["TXNIP", "GENE_OR_GENE_PRODUCT", 331, 336], ["cAMP responsive element binding protein 5", "GENE_OR_GENE_PRODUCT", 339, 380], ["CREB5", "GENE_OR_GENE_PRODUCT", 382, 387], ["protein phosphatase 1", "GENE_OR_GENE_PRODUCT", 394, 415], ["regulatory subunit 15A", "GENE_OR_GENE_PRODUCT", 417, 439], ["PPP1R15A", "GENE_OR_GENE_PRODUCT", 441, 449], ["ONC up-regulated genes", "DNA", 45, 67], ["NCI/ADR-RES cells", "CELL_LINE", 71, 88], ["transcription regulators", "PROTEIN", 141, 165], ["early growth response 1", "PROTEIN", 167, 190], ["EGR1", "PROTEIN", 192, 196], ["activating transcription factor 3", "PROTEIN", 199, 232], ["ATF3", "PROTEIN", 234, 238], ["DNA-damage-inducible, alpha", "PROTEIN", 259, 286], ["GADD45A", "PROTEIN", 288, 295], ["thioredoxin interacting protein", "PROTEIN", 298, 329], ["TXNIP", "PROTEIN", 331, 336], ["cAMP responsive element binding protein 5", "PROTEIN", 339, 380], ["CREB5", "PROTEIN", 382, 387], ["protein phosphatase 1", "PROTEIN", 394, 415], ["regulatory subunit 15A", "PROTEIN", 417, 439], ["PPP1R15A", "PROTEIN", 441, 449], ["activating transcription factor", "TEST", 199, 230], ["growth arrest", "PROBLEM", 241, 254], ["DNA", "PROBLEM", 259, 262], ["damage", "PROBLEM", 263, 269], ["alpha (GADD45A)", "TEST", 281, 296], ["thioredoxin interacting protein", "TEST", 298, 329], ["TXNIP", "TEST", 331, 336], ["cAMP responsive element binding protein", "TEST", 339, 378], ["CREB5", "TEST", 382, 387], ["protein phosphatase", "TEST", 394, 413], ["PPP", "TEST", 441, 444]]], ["Their relationship is depicted in Figure 2 .ONC cytotoxic mechanismATF3 is a member of the ATF/CREB family of transcription factors that transduces signals from various receptors to activate or repress gene expression.", [["mechanismATF3", "GENE_OR_GENE_PRODUCT", 58, 71], ["ATF", "GENE_OR_GENE_PRODUCT", 91, 94], ["CREB", "GENE_OR_GENE_PRODUCT", 95, 99], ["mechanismATF3", "PROTEIN", 58, 71], ["ATF", "PROTEIN", 91, 94], ["CREB family", "PROTEIN", 95, 106], ["transcription factors", "PROTEIN", 110, 131], ["various receptors", "TREATMENT", 161, 178]]], ["Depending on the cell type and context it plays different roles in cancer development [34] .", [["cell", "ANATOMY", 17, 21], ["cancer", "ANATOMY", 67, 73], ["cancer", "DISEASE", 67, 73], ["cell", "CELL", 17, 21], ["cancer", "CANCER", 67, 73], ["cell type", "OBSERVATION_MODIFIER", 17, 26]]], ["Nevertheless, its ectopic expression induces apoptosis in a variety of cancer cells [35, 36] , enhances the ability of different drugs, such as camptothecin, etoposide, curcumin, cisplatin and lovastatin, to induce apoptosis [37] [38] [39] [40] , and even inhibits the invasion and metastasis of cancer cells [41] [42] [43] .", [["cancer cells", "ANATOMY", 71, 83], ["cancer cells", "ANATOMY", 296, 308], ["cancer", "DISEASE", 71, 77], ["camptothecin", "CHEMICAL", 144, 156], ["etoposide", "CHEMICAL", 158, 167], ["curcumin", "CHEMICAL", 169, 177], ["cisplatin", "CHEMICAL", 179, 188], ["lovastatin", "CHEMICAL", 193, 203], ["cancer", "DISEASE", 296, 302], ["camptothecin", "CHEMICAL", 144, 156], ["etoposide", "CHEMICAL", 158, 167], ["curcumin", "CHEMICAL", 169, 177], ["cisplatin", "CHEMICAL", 179, 188], ["lovastatin", "CHEMICAL", 193, 203], ["cancer cells", "CELL", 71, 83], ["camptothecin", "SIMPLE_CHEMICAL", 144, 156], ["etoposide", "SIMPLE_CHEMICAL", 158, 167], ["curcumin", "SIMPLE_CHEMICAL", 169, 177], ["cisplatin", "SIMPLE_CHEMICAL", 179, 188], ["lovastatin", "SIMPLE_CHEMICAL", 193, 203], ["cancer cells", "CELL", 296, 308], ["cancer cells", "CELL_TYPE", 71, 83], ["cancer cells", "CELL_TYPE", 296, 308], ["its ectopic expression", "PROBLEM", 14, 36], ["apoptosis", "PROBLEM", 45, 54], ["cancer cells", "PROBLEM", 71, 83], ["different drugs", "TREATMENT", 119, 134], ["camptothecin", "TREATMENT", 144, 156], ["etoposide", "TREATMENT", 158, 167], ["curcumin", "TREATMENT", 169, 177], ["cisplatin", "TREATMENT", 179, 188], ["lovastatin", "TREATMENT", 193, 203], ["apoptosis", "TEST", 215, 224], ["the invasion", "PROBLEM", 265, 277], ["metastasis of cancer cells", "PROBLEM", 282, 308], ["invasion", "OBSERVATION", 269, 277], ["metastasis", "OBSERVATION", 282, 292]]], ["ATF3 was first described as associated with ONC activity by Altomare et al. [12] .", [["ATF3", "GENE_OR_GENE_PRODUCT", 0, 4], ["ONC", "CANCER", 44, 47], ["ATF3", "PROTEIN", 0, 4]]], ["Our results seem to indicate that it plays a central role in the ONC action because it directly up-regulates the expression of GADD45A [44] and PPP1R15A [45] .", [["ONC", "ANATOMY", 65, 68], ["ONC", "GENE_OR_GENE_PRODUCT", 65, 68], ["GADD45A [44]", "GENE_OR_GENE_PRODUCT", 127, 139], ["PPP1R15A", "GENE_OR_GENE_PRODUCT", 144, 152], ["GADD45A", "PROTEIN", 127, 134], ["the ONC action", "TREATMENT", 61, 75]]], ["Additionally, it can indirectly increase TXNIP expression, since it promotes up-regulation of the Kr\u00fcppel-like factor 6 (KLF6) [44] , a transcription factor whose overexpression in turn increases that of TXNIP [46] .", [["TXNIP", "GENE_OR_GENE_PRODUCT", 41, 46], ["Kr\u00fcppel-like factor 6", "GENE_OR_GENE_PRODUCT", 98, 119], ["KLF6", "GENE_OR_GENE_PRODUCT", 121, 125], ["44", "GENE_OR_GENE_PRODUCT", 128, 130], ["TXNIP", "GENE_OR_GENE_PRODUCT", 204, 209], ["TXNIP", "PROTEIN", 41, 46], ["Kr\u00fcppel-like factor 6", "PROTEIN", 98, 119], ["KLF6", "PROTEIN", 121, 125], ["transcription factor", "PROTEIN", 136, 156], ["TXNIP", "PROTEIN", 204, 209], ["the Kr\u00fcppel-like factor", "TREATMENT", 94, 117], ["a transcription factor", "PROBLEM", 134, 156], ["increase", "OBSERVATION_MODIFIER", 32, 40], ["TXNIP expression", "OBSERVATION", 41, 57]]], ["KLF6 is also up-regulated by ONC, although the fold change is lower than 2.", [["KLF6", "GENE_OR_GENE_PRODUCT", 0, 4], ["ONC", "GENE_OR_GENE_PRODUCT", 29, 32], ["KLF6", "PROTEIN", 0, 4], ["ONC", "PROTEIN", 29, 32], ["KLF6", "TREATMENT", 0, 4], ["fold", "OBSERVATION_MODIFIER", 47, 51], ["change", "OBSERVATION", 52, 58], ["lower", "OBSERVATION_MODIFIER", 62, 67]]], ["Moreover, ATF3 can bind to CREB5 to form a heterodimer [47] .", [["ATF3", "GENE_OR_GENE_PRODUCT", 10, 14], ["CREB5", "GENE_OR_GENE_PRODUCT", 27, 32], ["ATF3", "PROTEIN", 10, 14], ["CREB5", "PROTEIN", 27, 32]]], ["Although the physiological significance of this dimer is not clear, the general view is that its formation can alter DNA binding specificity and transcriptional activity, thus expanding the ability of this transcription factor to regulate gene expression [34] .", [["DNA", "CELLULAR_COMPONENT", 117, 120], ["dimer", "PROTEIN", 48, 53], ["transcription factor", "PROTEIN", 206, 226], ["the general view", "TEST", 68, 84], ["this transcription factor", "PROBLEM", 201, 226]]], ["Finally, it is described that the expression of ATF3 [48] and GADD45A [49] is increased by EGR1 (Figure 2 ).", [["ATF3 [48]", "GENE_OR_GENE_PRODUCT", 48, 57], ["GADD45A [49", "GENE_OR_GENE_PRODUCT", 62, 73], ["EGR1", "GENE_OR_GENE_PRODUCT", 91, 95], ["ATF3", "PROTEIN", 48, 52], ["EGR1", "PROTEIN", 91, 95], ["ATF3", "TEST", 48, 52], ["increased", "OBSERVATION_MODIFIER", 78, 87]]], ["EGR1 is expressed at low levels in several types of cancer [50] [51] [52] , acting as a tumor suppressor and inducing apoptosis of cancer cells in a p53-independent manner [53] .", [["cancer", "ANATOMY", 52, 58], ["tumor", "ANATOMY", 88, 93], ["cancer cells", "ANATOMY", 131, 143], ["cancer", "DISEASE", 52, 58], ["tumor", "DISEASE", 88, 93], ["cancer", "DISEASE", 131, 137], ["EGR1", "GENE_OR_GENE_PRODUCT", 0, 4], ["cancer", "CANCER", 52, 58], ["tumor", "CANCER", 88, 93], ["cancer cells", "CELL", 131, 143], ["p53", "GENE_OR_GENE_PRODUCT", 149, 152], ["EGR1", "PROTEIN", 0, 4], ["cancer cells", "CELL_TYPE", 131, 143], ["p53", "PROTEIN", 149, 152], ["cancer", "PROBLEM", 52, 58], ["a tumor suppressor", "TREATMENT", 86, 104], ["cancer cells", "PROBLEM", 131, 143], ["low levels", "OBSERVATION_MODIFIER", 21, 31], ["cancer", "OBSERVATION", 52, 58], ["cancer cells", "OBSERVATION", 131, 143]]], ["It is interesting to note that ONC exerts its cytotoxicity independently of the p53 phenotype [54] .ONC cytotoxic mechanismGADD45A and PPP1R15A belong to the family of growth arrest and DNA damage (GADD) proteins, which are crucial to cellular stress responses [55] .", [["cellular", "ANATOMY", 235, 243], ["ONC", "CHEMICAL", 31, 34], ["growth arrest", "DISEASE", 168, 181], ["ONC", "CHEMICAL", 31, 34], ["ONC", "SIMPLE_CHEMICAL", 31, 34], ["p53", "GENE_OR_GENE_PRODUCT", 80, 83], ["mechanismGADD45A", "GENE_OR_GENE_PRODUCT", 114, 130], ["PPP1R15A", "GENE_OR_GENE_PRODUCT", 135, 143], ["DNA", "CELLULAR_COMPONENT", 186, 189], ["GADD", "GENE_OR_GENE_PRODUCT", 198, 202], ["cellular", "CELL", 235, 243], ["p53", "PROTEIN", 80, 83], ["ONC", "PROTEIN", 100, 103], ["mechanismGADD45A", "PROTEIN", 114, 130], ["PPP1R15A", "PROTEIN", 135, 143], ["DNA damage (GADD) proteins", "PROTEIN", 186, 212], ["the p53 phenotype", "TEST", 76, 93], ["cytotoxic mechanismGADD45A", "TREATMENT", 104, 130], ["PPP1R15A", "TREATMENT", 135, 143], ["growth arrest", "PROBLEM", 168, 181], ["DNA damage (GADD) proteins", "PROBLEM", 186, 212]]], ["It is known that GADD45A inhibits cell growth through the G 2 /M cell cycle arrest [56, 57] while PPP1R15A plays a vital role in promoting cell death following proteasome inhibition via enhancing protein synthesis to activate mechanisms associated with dead, including ER stress, ROS production, and autophagy formation [58] .", [["cell", "ANATOMY", 34, 38], ["cell", "ANATOMY", 65, 69], ["cell", "ANATOMY", 139, 143], ["GADD45A", "CHEMICAL", 17, 24], ["death", "DISEASE", 144, 149], ["ROS", "CHEMICAL", 280, 283], ["GADD45A", "GENE_OR_GENE_PRODUCT", 17, 24], ["cell", "CELL", 34, 38], ["PPP1R15A", "GENE_OR_GENE_PRODUCT", 98, 106], ["cell", "CELL", 139, 143], ["ER", "GENE_OR_GENE_PRODUCT", 269, 271], ["ROS", "SIMPLE_CHEMICAL", 280, 283], ["GADD45A", "PROTEIN", 17, 24], ["PPP1R15A", "PROTEIN", 98, 106], ["proteasome", "PROTEIN", 160, 170], ["ER", "PROTEIN", 269, 271], ["GADD45A inhibits cell growth", "PROBLEM", 17, 45], ["the G 2 /M cell cycle arrest", "TREATMENT", 54, 82], ["promoting cell death", "PROBLEM", 129, 149], ["proteasome inhibition", "TREATMENT", 160, 181], ["enhancing protein synthesis", "TREATMENT", 186, 213], ["dead", "PROBLEM", 253, 257], ["ER stress", "PROBLEM", 269, 278]]], ["In addition, down-regulation of GADD45A promoted by the NF-\u03baB transcription factor is essential for cancer cell survival [59] .", [["cancer cell", "ANATOMY", 100, 111], ["cancer", "DISEASE", 100, 106], ["GADD45A", "GENE_OR_GENE_PRODUCT", 32, 39], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 56, 61], ["cancer cell", "CELL", 100, 111], ["GADD45A", "PROTEIN", 32, 39], ["NF-\u03baB", "PROTEIN", 56, 61], ["transcription factor", "PROTEIN", 62, 82], ["the NF", "TREATMENT", 52, 58], ["cancer cell survival", "PROBLEM", 100, 120]]], ["In this regard, it is worth mentioning that ONC mediates some of its effects by reducing cellular levels of NF-\u03baB.", [["cellular", "ANATOMY", 89, 97], ["ONC", "CHEMICAL", 44, 47], ["ONC", "SIMPLE_CHEMICAL", 44, 47], ["cellular", "CELL", 89, 97], ["NF-\u03baB.", "GENE_OR_GENE_PRODUCT", 108, 114], ["NF-\u03baB.", "PROTEIN", 108, 114]]], ["In Jurkat cells, ONC induces an arrest of proliferation, accompanied by an altered subcellular distribution and reduced expression of NF-\u03baB [17] .", [["Jurkat cells", "ANATOMY", 3, 15], ["ONC", "ANATOMY", 17, 20], ["subcellular", "ANATOMY", 83, 94], ["Jurkat cells", "CELL", 3, 15], ["ONC", "CELL", 17, 20], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 134, 139], ["Jurkat cells", "CELL_LINE", 3, 15], ["NF-\u03baB [17]", "PROTEIN", 134, 144], ["an arrest of proliferation", "PROBLEM", 29, 55], ["an altered subcellular distribution", "PROBLEM", 72, 107], ["reduced expression of NF", "PROBLEM", 112, 136], ["Jurkat cells", "OBSERVATION", 3, 15], ["arrest", "OBSERVATION", 32, 38], ["proliferation", "OBSERVATION", 42, 55], ["altered", "OBSERVATION_MODIFIER", 75, 82], ["subcellular distribution", "OBSERVATION", 83, 107], ["reduced", "OBSERVATION_MODIFIER", 112, 119]]], ["In addition, in hMM cells ONC inhibits NF-\u03baB nuclear translocation induced by TNF-\u03b1 [60] and produces a down-regulation of the NFKB1 gene, which encodes the NF-\u03baB subunit p50, mediated by the increase in hsa-miR-17* and the decrease in hsa-miR-30c levels [61] .", [["hMM cells", "ANATOMY", 16, 25], ["nuclear", "ANATOMY", 45, 52], ["hMM cells", "CELL", 16, 25], ["ONC", "CELL", 26, 29], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 39, 44], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 78, 83], ["NFKB1", "GENE_OR_GENE_PRODUCT", 127, 132], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 157, 162], ["p50", "GENE_OR_GENE_PRODUCT", 171, 174], ["hsa-miR-17", "GENE_OR_GENE_PRODUCT", 204, 214], ["hsa-miR-30c", "GENE_OR_GENE_PRODUCT", 236, 247], ["hMM cells", "CELL_LINE", 16, 25], ["NF-\u03baB", "PROTEIN", 39, 44], ["TNF", "PROTEIN", 78, 81], ["NFKB1 gene", "DNA", 127, 137], ["NF-\u03baB subunit p50", "PROTEIN", 157, 174], ["hsa", "PROTEIN", 204, 207], ["-miR", "PROTEIN", 207, 211], ["hsa", "PROTEIN", 236, 239], ["-miR", "PROTEIN", 239, 243], ["NF", "TEST", 39, 41], ["TNF", "TEST", 78, 81], ["hsa-miR", "TEST", 204, 211], ["hsa-miR", "TEST", 236, 243], ["increase", "OBSERVATION_MODIFIER", 192, 200], ["decrease", "OBSERVATION_MODIFIER", 224, 232]]], ["It can be expected that, in these cell lines, the inactivation of NF-\u03baB would also lead to the up-regulation of GADD45A.ONC cytotoxic mechanismTXNIP, a protein with multiple functions, plays an important role in redox homeostasis [62] .", [["cell lines", "ANATOMY", 34, 44], ["cell lines", "CELL", 34, 44], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 66, 71], ["GADD45A", "GENE_OR_GENE_PRODUCT", 112, 119], ["mechanismTXNIP", "GENE_OR_GENE_PRODUCT", 134, 148], ["cell lines", "CELL_LINE", 34, 44], ["NF-\u03baB", "PROTEIN", 66, 71], ["GADD45A", "PROTEIN", 112, 119], ["ONC cytotoxic mechanismTXNIP", "PROTEIN", 120, 148], ["these cell lines", "TREATMENT", 28, 44], ["NF-\u03baB", "TREATMENT", 66, 71], ["the up-regulation of GADD45A", "PROBLEM", 91, 119], ["cell lines", "OBSERVATION", 34, 44], ["cytotoxic mechanismTXNIP", "OBSERVATION", 124, 148]]], ["Extensive evidence shows that TXNIP acts as a tumor suppressor [63] [64] [65] [66] [67] [68] [69] .", [["tumor", "ANATOMY", 46, 51], ["tumor", "DISEASE", 46, 51], ["TXNIP", "GENE_OR_GENE_PRODUCT", 30, 35], ["tumor", "CANCER", 46, 51], ["TXNIP", "PROTEIN", 30, 35], ["a tumor suppressor", "TEST", 44, 62]]], ["ONC induces the expression of two ATF3controlled genes whose encoded proteins promote cell cycle arrest at different checkpoints (G2/M in the case of GADD45A and G0/G1 in the case of TXNIP [64, 70] ).", [["cell", "ANATOMY", 86, 90], ["ONC", "SIMPLE_CHEMICAL", 0, 3], ["ATF3controlled", "GENE_OR_GENE_PRODUCT", 34, 48], ["cell", "CELL", 86, 90], ["TXNIP", "GENE_OR_GENE_PRODUCT", 183, 188], ["ONC", "PROTEIN", 0, 3], ["ATF3controlled genes", "DNA", 34, 54], ["GADD45A", "PROTEIN", 150, 157], ["TXNIP", "PROTEIN", 183, 188], ["two ATF3controlled genes", "PROBLEM", 30, 54], ["cell cycle arrest", "TREATMENT", 86, 103], ["cell cycle arrest", "OBSERVATION", 86, 103]]], ["This effect would be in accordance with previous results showing that ONC arrests cell growth of Jurkat and NCI/ ADR-RES cells without altering the percentage of cells in the different cell cycle phases [17, 31] .ONC cytotoxic mechanismONC-regulated genes significantly affect the MAPK signaling pathway (Table 3 ).", [["cell", "ANATOMY", 82, 86], ["Jurkat", "ANATOMY", 97, 103], ["NCI/ ADR-RES cells", "ANATOMY", 108, 126], ["cells", "ANATOMY", 162, 167], ["cell", "ANATOMY", 185, 189], ["ONC", "CHEMICAL", 70, 73], ["ONC", "SIMPLE_CHEMICAL", 70, 73], ["cell", "CELL", 82, 86], ["Jurkat", "CELL", 97, 103], ["NCI/ ADR-RES cells", "CELL", 108, 126], ["cells", "CELL", 162, 167], ["cell", "CELL", 185, 189], ["ONC", "GENE_OR_GENE_PRODUCT", 213, 216], ["mechanismONC", "GENE_OR_GENE_PRODUCT", 227, 239], ["MAPK", "GENE_OR_GENE_PRODUCT", 281, 285], ["Jurkat", "CELL_LINE", 97, 103], ["NCI/ ADR-RES cells", "CELL_LINE", 108, 126], ["ONC cytotoxic mechanismONC-regulated genes", "DNA", 213, 255], ["MAPK", "PROTEIN", 281, 285], ["ONC arrests", "PROBLEM", 70, 81], ["Jurkat", "TEST", 97, 103], ["NCI/ ADR-RES cells", "TEST", 108, 126], ["cytotoxic mechanismONC", "TEST", 217, 239], ["cytotoxic mechanismONC", "OBSERVATION", 217, 239]]], ["In this regard, it is noteworthy that TXNIP, through ASK1 activation [71] , and GADD45A, through its interaction with mitogenactivated protein kinase kinase kinase 4 (MEKK4), are involved in the apoptosis induced by the p38 MAPK/JNK signaling pathway [72] .", [["TXNIP", "GENE_OR_GENE_PRODUCT", 38, 43], ["ASK1", "GENE_OR_GENE_PRODUCT", 53, 57], ["GADD45A", "GENE_OR_GENE_PRODUCT", 80, 87], ["mitogenactivated protein kinase kinase kinase 4", "GENE_OR_GENE_PRODUCT", 118, 165], ["MEKK4", "GENE_OR_GENE_PRODUCT", 167, 172], ["p38 MAPK", "GENE_OR_GENE_PRODUCT", 220, 228], ["JNK", "GENE_OR_GENE_PRODUCT", 229, 232], ["TXNIP", "PROTEIN", 38, 43], ["ASK1", "PROTEIN", 53, 57], ["GADD45A", "PROTEIN", 80, 87], ["mitogenactivated protein kinase kinase kinase 4", "PROTEIN", 118, 165], ["MEKK4", "PROTEIN", 167, 172], ["p38 MAPK", "PROTEIN", 220, 228], ["JNK", "PROTEIN", 229, 232], ["GADD45A", "TEST", 80, 87], ["mitogenactivated protein kinase kinase kinase", "TEST", 118, 163], ["the p38 MAPK", "TEST", 216, 228], ["JNK signaling pathway", "TEST", 229, 250]]], ["At the same time, the activation of p38 MAPK/JNK induces the expression of EGR1 [73, 74] and ATF3 [75] , reinforcing the initial action of ONC thorough the up-regulation of these two genes ( Figure 3 ).", [["p38 MAPK", "GENE_OR_GENE_PRODUCT", 36, 44], ["JNK", "GENE_OR_GENE_PRODUCT", 45, 48], ["EGR1 [73, 74", "GENE_OR_GENE_PRODUCT", 75, 87], ["ATF3", "GENE_OR_GENE_PRODUCT", 93, 97], ["ONC", "GENE_OR_GENE_PRODUCT", 139, 142], ["p38 MAPK", "PROTEIN", 36, 44], ["JNK", "PROTEIN", 45, 48], ["EGR1", "PROTEIN", 75, 79], ["ATF3", "PROTEIN", 93, 97], ["p38 MAPK", "TEST", 36, 44], ["EGR1", "TEST", 75, 79], ["ATF3", "TEST", 93, 97]]], ["Accordingly, ONC is a potent activator of the stress-activated protein kinases JNK1, JNK2 and p38 MAPK in primary and immortalized fibroblasts [18] .ONC cytotoxic mechanismIn this work we show that, in addition to the MAPK pathway, ONC affects the Jak-STAT signaling pathway by altering the expression of different genes.", [["primary", "ANATOMY", 106, 113], ["fibroblasts", "ANATOMY", 131, 142], ["ONC", "CHEMICAL", 13, 16], ["ONC", "SIMPLE_CHEMICAL", 13, 16], ["JNK1", "GENE_OR_GENE_PRODUCT", 79, 83], ["JNK2", "GENE_OR_GENE_PRODUCT", 85, 89], ["p38 MAPK", "GENE_OR_GENE_PRODUCT", 94, 102], ["fibroblasts", "CELL", 131, 142], ["MAPK", "GENE_OR_GENE_PRODUCT", 218, 222], ["ONC", "GENE_OR_GENE_PRODUCT", 232, 235], ["Jak-", "GENE_OR_GENE_PRODUCT", 248, 252], ["STAT", "GENE_OR_GENE_PRODUCT", 252, 256], ["ONC", "PROTEIN", 13, 16], ["stress-activated protein kinases", "PROTEIN", 46, 78], ["JNK1", "PROTEIN", 79, 83], ["JNK2", "PROTEIN", 85, 89], ["p38 MAPK", "PROTEIN", 94, 102], ["primary and immortalized fibroblasts", "CELL_TYPE", 106, 142], ["MAPK", "PROTEIN", 218, 222], ["STAT", "PROTEIN", 252, 256], ["the stress", "TEST", 42, 52], ["activated protein kinases JNK1", "TEST", 53, 83], ["JNK2", "TEST", 85, 89], ["p38 MAPK", "TEST", 94, 102], ["the MAPK pathway", "TEST", 214, 230]]], ["Interestingly, it has been previously described that the cytotoxic effect of ONC on hMM cells is also mediated by the Jak-STAT pathway [12] .", [["hMM cells", "ANATOMY", 84, 93], ["ONC", "CHEMICAL", 77, 80], ["ONC", "CHEMICAL", 77, 80], ["ONC", "SIMPLE_CHEMICAL", 77, 80], ["hMM cells", "CELL", 84, 93], ["Jak-", "GENE_OR_GENE_PRODUCT", 118, 122], ["STAT", "GENE_OR_GENE_PRODUCT", 122, 126], ["hMM cells", "CELL_LINE", 84, 93], ["STAT", "PROTEIN", 122, 126], ["ONC on hMM cells", "TREATMENT", 77, 93], ["cytotoxic", "OBSERVATION_MODIFIER", 57, 66]]], ["Regarding the Jak-STAT signaling, ONC treated NCI/ ADR-RES cells show an increased expression of interleukin 6 (IL6) ( Table 1 and Figure 2 ), previously observed in hMMtreated cells [12] .", [["NCI/ ADR-RES cells", "ANATOMY", 46, 64], ["hMMtreated cells", "ANATOMY", 166, 182], ["ONC", "CHEMICAL", 34, 37], ["RES", "CHEMICAL", 55, 58], ["Jak-", "GENE_OR_GENE_PRODUCT", 14, 18], ["STAT", "GENE_OR_GENE_PRODUCT", 18, 22], ["ONC", "SIMPLE_CHEMICAL", 34, 37], ["NCI/ ADR-RES cells", "CELL", 46, 64], ["interleukin 6", "GENE_OR_GENE_PRODUCT", 97, 110], ["IL6", "GENE_OR_GENE_PRODUCT", 112, 115], ["Table 1", "GENE_OR_GENE_PRODUCT", 119, 126], ["Figure 2", "GENE_OR_GENE_PRODUCT", 131, 139], ["hMMtreated cells", "CELL", 166, 182], ["STAT", "PROTEIN", 18, 22], ["ONC treated NCI/ ADR-RES cells", "CELL_LINE", 34, 64], ["interleukin 6", "PROTEIN", 97, 110], ["IL6", "PROTEIN", 112, 115], ["hMMtreated cells", "CELL_LINE", 166, 182], ["the Jak-STAT signaling", "TEST", 10, 32], ["NCI/ ADR-RES cells", "TEST", 46, 64], ["an increased expression of interleukin 6 (IL6)", "PROBLEM", 70, 116], ["increased", "OBSERVATION_MODIFIER", 73, 82]]], ["IL6 is a pleiotropic cytokine that presents both pro-and anti-inflammatory properties as well as pro-and anti-tumorigenic abilities, depending on the cell type and conditions.", [["cell", "ANATOMY", 150, 154], ["IL6", "GENE_OR_GENE_PRODUCT", 0, 3], ["cell", "CELL", 150, 154], ["IL6", "PROTEIN", 0, 3], ["pleiotropic cytokine", "PROTEIN", 9, 29], ["a pleiotropic cytokine", "PROBLEM", 7, 29], ["pro-and anti-inflammatory properties", "TREATMENT", 49, 85], ["pro-and anti-tumorigenic abilities", "TREATMENT", 97, 131], ["anti-inflammatory properties", "OBSERVATION", 57, 85]]], ["Its overexpression in cancer has been linked to cachexia [77] , a drawback in the therapeutic use of ONC.", [["cancer", "ANATOMY", 22, 28], ["cachexia", "ANATOMY", 48, 56], ["cancer", "DISEASE", 22, 28], ["cachexia", "DISEASE", 48, 56], ["ONC", "CHEMICAL", 101, 104], ["cancer", "CANCER", 22, 28], ["ONC", "SIMPLE_CHEMICAL", 101, 104], ["Its overexpression in cancer", "PROBLEM", 0, 28], ["cachexia", "PROBLEM", 48, 56], ["overexpression", "OBSERVATION_MODIFIER", 4, 18], ["cancer", "OBSERVATION", 22, 28]]], ["Nevertheless, this effect may be partly counterbalanced by the ONC-induced overexpression of myocyte enhancer factor 2C (MEF2C), which is found among the 20 most ONC up-regulated genes ( Table 1) .", [["ONC", "CHEMICAL", 63, 66], ["ONC", "SIMPLE_CHEMICAL", 63, 66], ["myocyte enhancer factor 2C", "GENE_OR_GENE_PRODUCT", 93, 119], ["MEF2C", "GENE_OR_GENE_PRODUCT", 121, 126], ["ONC", "GENE_OR_GENE_PRODUCT", 162, 165], ["myocyte enhancer factor 2C", "PROTEIN", 93, 119], ["MEF2C", "PROTEIN", 121, 126], ["ONC up-regulated genes", "DNA", 162, 184], ["Table 1", "DNA", 187, 194], ["myocyte enhancer factor", "PROBLEM", 93, 116], ["myocyte", "ANATOMY", 93, 100]]], ["MEF2C is a myogenic transcription factor that plays a critical role in skeletal muscle development and differentiation, but is down-regulated in cachexia [78] .", [["skeletal muscle", "ANATOMY", 71, 86], ["cachexia", "ANATOMY", 145, 153], ["cachexia", "DISEASE", 145, 153], ["MEF2C", "GENE_OR_GENE_PRODUCT", 0, 5], ["skeletal muscle", "TISSUE", 71, 86], ["cachexia", "CANCER", 145, 153], ["MEF2C", "PROTEIN", 0, 5], ["myogenic transcription factor", "PROTEIN", 11, 40], ["MEF2C", "TREATMENT", 0, 5], ["a myogenic transcription factor", "PROBLEM", 9, 40], ["cachexia", "PROBLEM", 145, 153], ["skeletal muscle", "ANATOMY", 71, 86]]], ["In addition, ONC overexpression of inteleukin-33 (IL33), together with amphiregulin (AREG) ( Table 1) , may offset the pro-inflammatory properties of IL6 because it has been recently demonstrated that both participate in a pathway of innate immune cell-mediated tissue protection in the intestinal track [79] .", [["immune cell", "ANATOMY", 241, 252], ["tissue", "ANATOMY", 262, 268], ["intestinal", "ANATOMY", 287, 297], ["ONC", "SIMPLE_CHEMICAL", 13, 16], ["inteleukin-33", "GENE_OR_GENE_PRODUCT", 35, 48], ["IL33", "GENE_OR_GENE_PRODUCT", 50, 54], ["amphiregulin", "GENE_OR_GENE_PRODUCT", 71, 83], ["AREG) ( Table 1", "GENE_OR_GENE_PRODUCT", 85, 100], ["IL6", "GENE_OR_GENE_PRODUCT", 150, 153], ["immune cell", "CELL", 241, 252], ["tissue", "TISSUE", 262, 268], ["intestinal", "ORGAN", 287, 297], ["ONC", "PROTEIN", 13, 16], ["inteleukin-33", "PROTEIN", 35, 48], ["IL33", "PROTEIN", 50, 54], ["amphiregulin", "PROTEIN", 71, 83], ["AREG", "PROTEIN", 85, 89], ["IL6", "PROTEIN", 150, 153], ["inteleukin", "TEST", 35, 45], ["amphiregulin (AREG)", "TREATMENT", 71, 90], ["innate immune cell-mediated tissue protection", "TREATMENT", 234, 279], ["intestinal", "ANATOMY", 287, 297]]], ["Finally, ATF3 has been described as being able to epigenetically regulate the EGR1 expression, leading to attenuation of pro-inflammatory chemokines in human enterocytes [80] .The mechanism described for ONC cytotoxicity is cell-line independentSix of the seven ONC differentially expressed genes found in the OVCAR-8 cell line are also differentially expressed in the NCI/ADR-RES cell line (see the Results section).", [["enterocytes", "ANATOMY", 158, 169], ["cell-line", "ANATOMY", 224, 233], ["OVCAR-8 cell line", "ANATOMY", 310, 327], ["NCI/ADR-RES cell line", "ANATOMY", 369, 390], ["ONC", "CHEMICAL", 204, 207], ["ATF3", "GENE_OR_GENE_PRODUCT", 9, 13], ["EGR1", "GENE_OR_GENE_PRODUCT", 78, 82], ["human", "ORGANISM", 152, 157], ["enterocytes", "CELL", 158, 169], ["ONC", "SIMPLE_CHEMICAL", 204, 207], ["cell", "CELL", 224, 228], ["ONC", "GENE_OR_GENE_PRODUCT", 262, 265], ["OVCAR-8 cell line", "CELL", 310, 327], ["NCI/ADR-RES cell line", "CELL", 369, 390], ["ATF3", "PROTEIN", 9, 13], ["EGR1", "PROTEIN", 78, 82], ["pro-inflammatory chemokines", "PROTEIN", 121, 148], ["ONC differentially expressed genes", "DNA", 262, 296], ["OVCAR-8 cell line", "CELL_LINE", 310, 327], ["NCI/ADR-RES cell line", "CELL_LINE", 369, 390], ["human", "SPECIES", 152, 157], ["human", "SPECIES", 152, 157], ["pro-inflammatory chemokines in human enterocytes", "PROBLEM", 121, 169], ["ONC cytotoxicity", "TEST", 204, 220], ["pro-inflammatory chemokines", "OBSERVATION", 121, 148], ["mechanism described for", "UNCERTAINTY", 180, 203], ["8 cell line", "OBSERVATION", 316, 327], ["cell line", "OBSERVATION", 381, 390]]], ["Additionally, in both cell lines, ATF3 and TXNIP are the most ONC up-regulated genes (see the Results section).", [["cell lines", "ANATOMY", 22, 32], ["cell lines", "CELL", 22, 32], ["ATF3", "GENE_OR_GENE_PRODUCT", 34, 38], ["TXNIP", "GENE_OR_GENE_PRODUCT", 43, 48], ["ONC", "GENE_OR_GENE_PRODUCT", 62, 65], ["ATF3", "PROTEIN", 34, 38], ["TXNIP", "PROTEIN", 43, 48], ["ONC up-regulated genes", "DNA", 62, 84], ["both", "ANATOMY_MODIFIER", 17, 21], ["cell lines", "OBSERVATION", 22, 32]]], ["Furthermore, in OVCAR-8 cell line a slight but significant increase in the expression of the rest of the networked transcription regulators differentially expressed in NCI/ADR-RES is observed, with fold change values between 1.8 and 1.5.", [["OVCAR-8 cell line", "ANATOMY", 16, 33], ["NCI", "ANATOMY", 168, 171], ["ADR", "CHEMICAL", 172, 175], ["RES", "CHEMICAL", 176, 179], ["OVCAR-8 cell line", "CELL", 16, 33], ["NCI", "CELL", 168, 171], ["OVCAR-8 cell line", "CELL_LINE", 16, 33], ["transcription regulators", "PROTEIN", 115, 139], ["OVCAR", "TEST", 16, 21], ["fold change values", "PROBLEM", 198, 216], ["cell line", "OBSERVATION", 24, 33], ["slight", "OBSERVATION_MODIFIER", 36, 42], ["significant", "OBSERVATION_MODIFIER", 47, 58], ["increase", "OBSERVATION_MODIFIER", 59, 67]]], ["These results indicate that the effect induced by ONC on both cell lines is similar.", [["cell lines", "ANATOMY", 62, 72], ["ONC", "CHEMICAL", 50, 53], ["ONC", "CHEMICAL", 50, 53], ["ONC", "SIMPLE_CHEMICAL", 50, 53], ["cell lines", "CELL", 62, 72], ["cell lines", "CELL_LINE", 62, 72], ["ONC on both cell lines", "TREATMENT", 50, 72], ["cell lines", "OBSERVATION", 62, 72], ["similar", "OBSERVATION_MODIFIER", 76, 83]]], ["It is also noteworthy that ONC treatment of different hMM cell lines increased the expression of ATF3, GADD45A, and IL6, and involved the MAPK and Jak-STAT signaling pathways [12] , suggesting that the cytotoxic mechanism described here for ONC is not cell-type specific.ONC causes different pleiotropic effects than those observed for PE5ONC and PE5, as RNA-damaging drugs, have pleiotropic effects.", [["hMM cell lines", "ANATOMY", 54, 68], ["cell", "ANATOMY", 252, 256], ["ONC", "CHEMICAL", 27, 30], ["ONC", "CHEMICAL", 271, 274], ["PE5ONC", "CHEMICAL", 336, 342], ["PE5", "CHEMICAL", 347, 350], ["ONC", "CHEMICAL", 27, 30], ["PE5ONC", "CHEMICAL", 336, 342], ["PE5", "CHEMICAL", 347, 350], ["ONC", "SIMPLE_CHEMICAL", 27, 30], ["hMM cell lines", "CELL", 54, 68], ["ATF3", "GENE_OR_GENE_PRODUCT", 97, 101], ["GADD45A", "GENE_OR_GENE_PRODUCT", 103, 110], ["IL6", "GENE_OR_GENE_PRODUCT", 116, 119], ["MAPK", "GENE_OR_GENE_PRODUCT", 138, 142], ["Jak-STAT", "GENE_OR_GENE_PRODUCT", 147, 155], ["ONC", "SIMPLE_CHEMICAL", 241, 244], ["cell", "CELL", 252, 256], ["ONC", "SIMPLE_CHEMICAL", 271, 274], ["PE5ONC", "SIMPLE_CHEMICAL", 336, 342], ["PE5", "SIMPLE_CHEMICAL", 347, 350], ["hMM cell lines", "CELL_LINE", 54, 68], ["ATF3", "PROTEIN", 97, 101], ["GADD45A", "PROTEIN", 103, 110], ["IL6", "PROTEIN", 116, 119], ["MAPK", "PROTEIN", 138, 142], ["STAT", "PROTEIN", 151, 155], ["ONC treatment", "TREATMENT", 27, 40], ["different hMM cell lines", "TREATMENT", 44, 68], ["IL6", "TREATMENT", 116, 119], ["the MAPK", "TEST", 134, 142], ["the cytotoxic mechanism", "PROBLEM", 198, 221], ["different pleiotropic effects", "PROBLEM", 282, 311], ["PE5ONC", "PROBLEM", 336, 342], ["PE5", "TREATMENT", 347, 350], ["damaging drugs", "TREATMENT", 359, 373], ["pleiotropic effects", "PROBLEM", 380, 399], ["hMM cell lines", "OBSERVATION", 54, 68]]], ["Focusing on the NCI/ADR-RES results, the pleiotropic effects caused by these RNases are clearly different.", [["ADR", "CHEMICAL", 20, 23], ["RES", "CHEMICAL", 24, 27], ["RNases", "GENE_OR_GENE_PRODUCT", 77, 83], ["RNases", "PROTEIN", 77, 83]]], ["ONC affects a lower number of genes (11.5fold less) than PE5 [28] .", [["ONC", "PROTEIN", 0, 3], ["lower number", "OBSERVATION_MODIFIER", 14, 26]]], ["Among them, the percentage of up-and down-regulated genes differs between the two RNase treatments.", [["RNase", "GENE_OR_GENE_PRODUCT", 82, 87], ["RNase", "PROTEIN", 82, 87], ["the two RNase treatments", "TREATMENT", 74, 98]]], ["Of the ONC differentially expressed genes, 89% are up-regulated and only 11% are downregulated, while about half of the PE5 differentially expressed genes are up-regulated and half are downregulated [28] .", [["ONC", "CANCER", 7, 10], ["PE5", "GENE_OR_GENE_PRODUCT", 120, 123], ["ONC differentially expressed genes", "DNA", 7, 41], ["PE5 differentially expressed genes", "DNA", 120, 154]]], ["This suggests that the ONC initial action is the activation of gene expression, in agreement with the results previously obtained for ONC-treated hMM cell lines [12] .", [["hMM cell lines", "ANATOMY", 146, 160], ["ONC", "CHEMICAL", 134, 137], ["ONC", "CHEMICAL", 134, 137], ["ONC", "GENE_OR_GENE_PRODUCT", 23, 26], ["ONC", "SIMPLE_CHEMICAL", 134, 137], ["hMM cell lines", "CELL", 146, 160], ["ONC-treated hMM cell lines", "CELL_LINE", 134, 160], ["ONC-treated hMM cell lines", "TREATMENT", 134, 160], ["cell lines", "OBSERVATION", 150, 160]]], ["Interestingly, only the expression of 10 genes was altered by both RNase treatments (see the Results section).", [["RNase", "GENE_OR_GENE_PRODUCT", 67, 72], ["RNase", "PROTEIN", 67, 72], ["both RNase treatments", "TREATMENT", 62, 83]]], ["Among those genes, asparagine synthetase (ASNS) and the phosphoglycerate dehydrogenase (PHGDH) coding genes are worth mentioning.", [["asparagine", "CHEMICAL", 19, 29], ["asparagine", "CHEMICAL", 19, 29], ["phosphoglycerate", "CHEMICAL", 56, 72], ["asparagine synthetase", "GENE_OR_GENE_PRODUCT", 19, 40], ["ASNS", "GENE_OR_GENE_PRODUCT", 42, 46], ["phosphoglycerate dehydrogenase", "GENE_OR_GENE_PRODUCT", 56, 86], ["PHGDH", "GENE_OR_GENE_PRODUCT", 88, 93], ["asparagine synthetase", "PROTEIN", 19, 40], ["ASNS", "PROTEIN", 42, 46], ["phosphoglycerate dehydrogenase (PHGDH) coding genes", "DNA", 56, 107], ["asparagine synthetase (ASNS", "TREATMENT", 19, 46], ["the phosphoglycerate dehydrogenase (PHGDH) coding genes", "PROBLEM", 52, 107]]], ["Both are down-regulated by both RNases and are involved in amino acid metabolism, although we have not found any term related to amino acid metabolism either in gene ontology analysis or in the KEGG pathway annotation.", [["amino acid", "CHEMICAL", 59, 69], ["amino acid", "CHEMICAL", 129, 139], ["amino acid", "CHEMICAL", 59, 69], ["amino acid", "CHEMICAL", 129, 139], ["RNases", "GENE_OR_GENE_PRODUCT", 32, 38], ["amino acid", "AMINO_ACID", 59, 69], ["amino acid", "AMINO_ACID", 129, 139], ["RNases", "PROTEIN", 32, 38], ["amino acid metabolism", "PROBLEM", 59, 80], ["amino acid metabolism", "PROBLEM", 129, 150], ["gene ontology analysis", "TEST", 161, 183], ["down", "OBSERVATION", 9, 13], ["both RNases", "OBSERVATION_MODIFIER", 27, 38]]], ["PE5 down-regulates more genes related to amino acid biosynthesis than the two mentioned above.", [["PE5", "CHEMICAL", 0, 3], ["amino acid", "CHEMICAL", 41, 51], ["amino acid", "CHEMICAL", 41, 51], ["PE5", "GENE_OR_GENE_PRODUCT", 0, 3], ["amino acid", "AMINO_ACID", 41, 51], ["PE5", "PROTEIN", 0, 3], ["PE5", "TEST", 0, 3], ["amino acid biosynthesis", "TREATMENT", 41, 64], ["more genes", "OBSERVATION_MODIFIER", 19, 29]]], ["Its effect is actually to down-regulate this de novo biosynthesis that is significantly increased in cancer cells [28] .", [["cancer cells", "ANATOMY", 101, 113], ["cancer", "DISEASE", 101, 107], ["cancer cells", "CELL", 101, 113], ["cancer cells", "CELL_TYPE", 101, 113], ["cancer cells", "PROBLEM", 101, 113], ["significantly", "OBSERVATION_MODIFIER", 74, 87], ["increased", "OBSERVATION_MODIFIER", 88, 97], ["cancer", "OBSERVATION", 101, 107]]], ["In addition, the most PE5 up-regulated gene, Homeobox containing 1 (HMBOX1), is also found among the 20 most ONC up-regulated genes.", [["PE5", "GENE_OR_GENE_PRODUCT", 22, 25], ["Homeobox containing 1", "GENE_OR_GENE_PRODUCT", 45, 66], ["HMBOX1", "GENE_OR_GENE_PRODUCT", 68, 74], ["ONC", "GENE_OR_GENE_PRODUCT", 109, 112], ["PE5 up-regulated gene", "DNA", 22, 43], ["Homeobox containing 1", "DNA", 45, 66], ["HMBOX1", "DNA", 68, 74], ["ONC up-regulated genes", "DNA", 109, 131], ["Homeobox containing", "TREATMENT", 45, 64]]], ["Very likely, these coincidences are only the result of the pleiotropic effects of both RNases.", [["RNases", "PROTEIN", 87, 93]]], ["Moreover, among the affected gene ontology terms, only five were common between ONC and PE5, and when compared the KEGG pathway annotation, no terms showed coincidence ( [28] and Table 3 ).ONC causes different pleiotropic effects than those observed for PE5The mechanism used by PE5 to kill cancer cells is primarily related to its ability to down-regulate the expression of genes that code for enzymes involved in the metabolic pathways deregulated in the cancer cells.", [["cancer cells", "ANATOMY", 291, 303], ["cancer cells", "ANATOMY", 457, 469], ["ONC", "CHEMICAL", 189, 192], ["PE5", "CHEMICAL", 254, 257], ["PE5", "CHEMICAL", 279, 282], ["cancer", "DISEASE", 291, 297], ["cancer", "DISEASE", 457, 463], ["PE5", "CHEMICAL", 254, 257], ["ONC", "CANCER", 80, 83], ["PE5", "CANCER", 88, 91], ["ONC", "SIMPLE_CHEMICAL", 189, 192], ["PE5", "SIMPLE_CHEMICAL", 279, 282], ["cancer cells", "CELL", 291, 303], ["cancer cells", "CELL", 457, 469], ["ONC", "DNA", 80, 83], ["PE5", "DNA", 88, 91], ["PE5", "PROTEIN", 254, 257], ["PE5", "PROTEIN", 279, 282], ["cancer cells", "CELL_TYPE", 291, 303], ["cancer cells", "CELL_TYPE", 457, 469], ["PE5", "SPECIES", 254, 257], ["the KEGG pathway annotation", "TEST", 111, 138], ["different pleiotropic effects", "PROBLEM", 200, 229], ["PE5", "PROBLEM", 254, 257], ["kill cancer cells", "PROBLEM", 286, 303], ["enzymes", "TEST", 395, 402], ["the cancer cells", "PROBLEM", 453, 469], ["cancer cells", "OBSERVATION", 457, 469]]], ["This decrease in the expression levels of metabolic enzymes is assisted by the down-and up-regulation of several oncogenes and tumor suppressor genes, respectively, that down-regulate the expression of genes coding for these enzymes [28] .", [["tumor", "ANATOMY", 127, 132], ["tumor", "DISEASE", 127, 132], ["tumor", "CANCER", 127, 132], ["metabolic enzymes", "PROTEIN", 42, 59], ["oncogenes", "DNA", 113, 122], ["tumor suppressor genes", "DNA", 127, 149], ["metabolic enzymes", "TEST", 42, 59], ["several oncogenes", "TREATMENT", 105, 122], ["tumor suppressor genes", "TREATMENT", 127, 149], ["these enzymes", "TEST", 219, 232], ["decrease", "OBSERVATION_MODIFIER", 5, 13], ["tumor suppressor genes", "OBSERVATION", 127, 149]]], ["The only link between ONC regulated genes and cell metabolism is through the glucose uptake inhibitory effect of TXNIP and ARRDC4 [82, 83] .ONC causes different pleiotropic effects than those observed for PE5Taken together, our results indicate that the cytotoxic mechanisms exerted by ONC and PE5 on tumor cells are different, which is consistent with their different cellular localization and perhaps with their different RNA targets, cytosolic RNAs, and nuclear RNAs, respectively.", [["cell", "ANATOMY", 46, 50], ["tumor cells", "ANATOMY", 301, 312], ["cellular", "ANATOMY", 369, 377], ["cytosolic", "ANATOMY", 437, 446], ["nuclear", "ANATOMY", 457, 464], ["glucose", "CHEMICAL", 77, 84], ["ONC", "CHEMICAL", 140, 143], ["ONC", "CHEMICAL", 286, 289], ["PE5", "CHEMICAL", 294, 297], ["tumor", "DISEASE", 301, 306], ["glucose", "CHEMICAL", 77, 84], ["ONC", "CHEMICAL", 286, 289], ["PE5", "CHEMICAL", 294, 297], ["ONC", "GENE_OR_GENE_PRODUCT", 22, 25], ["cell", "CELL", 46, 50], ["glucose", "SIMPLE_CHEMICAL", 77, 84], ["TXNIP", "GENE_OR_GENE_PRODUCT", 113, 118], ["ARRDC4", "GENE_OR_GENE_PRODUCT", 123, 129], ["ONC", "SIMPLE_CHEMICAL", 140, 143], ["ONC", "SIMPLE_CHEMICAL", 286, 289], ["PE5", "SIMPLE_CHEMICAL", 294, 297], ["tumor cells", "CELL", 301, 312], ["cellular", "CELL", 369, 377], ["nuclear", "CELLULAR_COMPONENT", 457, 464], ["ONC regulated genes", "DNA", 22, 41], ["TXNIP", "PROTEIN", 113, 118], ["ONC", "PROTEIN", 286, 289], ["tumor cells", "CELL_TYPE", 301, 312], ["RNA targets", "RNA", 424, 435], ["cytosolic RNAs", "RNA", 437, 451], ["nuclear RNAs", "RNA", 457, 469], ["TXNIP", "TEST", 113, 118], ["different pleiotropic effects", "PROBLEM", 151, 180], ["the cytotoxic mechanisms", "PROBLEM", 250, 274], ["PE5 on tumor cells", "PROBLEM", 294, 312], ["cytosolic RNAs, and nuclear RNAs", "PROBLEM", 437, 469], ["cell metabolism", "OBSERVATION", 46, 61], ["tumor cells", "OBSERVATION", 301, 312], ["different", "OBSERVATION_MODIFIER", 317, 326], ["consistent with", "UNCERTAINTY", 337, 352], ["cellular localization", "OBSERVATION", 369, 390], ["cytosolic RNAs", "OBSERVATION", 437, 451], ["nuclear RNAs", "OBSERVATION", 457, 469]]], ["Thus, it is tempting to anticipate a synergistic effect between RNases that exert their action in the cell cytosol and those that do it in the cell nucleus.ONC as antiviral agent beyond its nucleic acids degradation abilityONC has been described as having antiviral activity [25] .", [["cell cytosol", "ANATOMY", 102, 114], ["cell nucleus", "ANATOMY", 143, 155], ["ONC", "CHEMICAL", 156, 159], ["nucleic acids", "CHEMICAL", 190, 203], ["abilityONC", "CHEMICAL", 216, 226], ["RNases", "GENE_OR_GENE_PRODUCT", 64, 70], ["cell cytosol", "CELLULAR_COMPONENT", 102, 114], ["cell nucleus", "CELLULAR_COMPONENT", 143, 155], ["ONC", "SIMPLE_CHEMICAL", 156, 159], ["nucleic acids", "SIMPLE_CHEMICAL", 190, 203], ["RNases", "PROTEIN", 64, 70], ["a synergistic effect between RNases", "PROBLEM", 35, 70], ["antiviral agent", "TREATMENT", 163, 178], ["its nucleic acids degradation", "TREATMENT", 186, 215], ["cell nucleus", "ANATOMY", 143, 155]]], ["Due to the ability of wild type ONC and several ONC variants to cleave different types of RNA [10] [11] [12] [13] [14] [15] , as well as dsRNA [24] , their antiviral properties have been mainly linked to degradation of viral genomes and/ or host-cell nucleic acids needed for viral replication [25, 84] .", [["cell", "ANATOMY", 246, 250], ["[10] [11] [12] [13] [14] [15]", "CHEMICAL", 94, 123], ["nucleic acids", "CHEMICAL", 251, 264], ["ONC", "GENE_OR_GENE_PRODUCT", 32, 35], ["[10] [11] [12] [13] [14] [15]", "SIMPLE_CHEMICAL", 94, 123], ["cell", "CELL", 246, 250], ["viral genomes", "DNA", 219, 232], ["several ONC variants", "TREATMENT", 40, 60], ["dsRNA", "TEST", 137, 142], ["their antiviral properties", "TEST", 150, 176], ["viral genomes", "PROBLEM", 219, 232], ["host-cell nucleic acids", "TREATMENT", 241, 264], ["viral replication", "PROBLEM", 276, 293], ["viral genomes", "OBSERVATION", 219, 232]]], ["However, the finding that ONC cell treatment promotes the up-regulation of ATF3 transcription factor independently of the cell type, leads to the proposal that other mechanisms can strengthen ONC antiviral action.", [["ONC cell", "ANATOMY", 26, 34], ["cell", "ANATOMY", 122, 126], ["ONC", "CHEMICAL", 26, 29], ["ONC cell", "CELL", 26, 34], ["ATF3", "GENE_OR_GENE_PRODUCT", 75, 79], ["cell type", "CELL", 122, 131], ["ONC", "GENE_OR_GENE_PRODUCT", 192, 195], ["ATF3", "PROTEIN", 75, 79], ["transcription factor", "PROTEIN", 80, 100], ["ONC cell treatment", "TREATMENT", 26, 44], ["ATF3 transcription factor", "TREATMENT", 75, 100], ["antiviral action", "TREATMENT", 196, 212]]], ["ATF3 is a transcription factor whose role in cancer is clearly cellular-context dependent, but it seems essential for the maintenance of host defense mechanisms [34] .ONC as antiviral agent beyond its nucleic acids degradation abilityGenomic integration of HPV DNA, occurring in more than 90% of cervical cancers, results in viral E6 protein expression that can interact with a cellular ubiquitin ligase E6-associated protein (E6AP) and target the tumor suppressor p53 for ubiquitin-mediated proteolysis [85] .", [["cancer", "ANATOMY", 45, 51], ["cellular", "ANATOMY", 63, 71], ["cervical cancers", "ANATOMY", 296, 312], ["cellular", "ANATOMY", 378, 386], ["tumor", "ANATOMY", 448, 453], ["cancer", "DISEASE", 45, 51], ["ONC", "CHEMICAL", 167, 170], ["nucleic acids", "CHEMICAL", 201, 214], ["cervical cancers", "DISEASE", 296, 312], ["tumor", "DISEASE", 448, 453], ["ATF3", "GENE_OR_GENE_PRODUCT", 0, 4], ["cancer", "CANCER", 45, 51], ["cellular", "CELL", 63, 71], ["ONC", "SIMPLE_CHEMICAL", 167, 170], ["HPV", "ORGANISM", 257, 260], ["DNA", "CELLULAR_COMPONENT", 261, 264], ["cervical cancers", "CANCER", 296, 312], ["E6", "GENE_OR_GENE_PRODUCT", 331, 333], ["cellular", "CELL", 378, 386], ["E6-associated protein", "GENE_OR_GENE_PRODUCT", 404, 425], ["E6AP", "GENE_OR_GENE_PRODUCT", 427, 431], ["tumor", "CANCER", 448, 453], ["p53", "GENE_OR_GENE_PRODUCT", 465, 468], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 473, 482], ["ATF3", "PROTEIN", 0, 4], ["transcription factor", "PROTEIN", 10, 30], ["HPV DNA", "DNA", 257, 264], ["viral E6 protein", "PROTEIN", 325, 341], ["cellular ubiquitin ligase E6-associated protein", "PROTEIN", 378, 425], ["E6AP", "PROTEIN", 427, 431], ["tumor suppressor p53", "PROTEIN", 448, 468], ["ubiquitin", "PROTEIN", 473, 482], ["HPV", "SPECIES", 257, 260], ["antiviral agent", "TREATMENT", 174, 189], ["its nucleic acids degradation", "TREATMENT", 197, 226], ["HPV DNA", "PROBLEM", 257, 264], ["cervical cancers", "PROBLEM", 296, 312], ["viral E6 protein expression", "PROBLEM", 325, 352], ["the tumor suppressor p53", "TREATMENT", 444, 468], ["ubiquitin-mediated proteolysis", "PROBLEM", 473, 503], ["cancer", "OBSERVATION", 45, 51], ["HPV DNA", "OBSERVATION", 257, 264], ["cervical", "ANATOMY", 296, 304], ["cancers", "OBSERVATION", 305, 312]]], ["ATF3 interaction with viral protein E6 prevents p53 from ubiquitination and degradation, leading to expression of p53-target genes, cell cycle arrest, and apoptotic cell death.", [["cell", "ANATOMY", 132, 136], ["cell", "ANATOMY", 165, 169], ["death", "DISEASE", 170, 175], ["ATF3", "GENE_OR_GENE_PRODUCT", 0, 4], ["E6", "GENE_OR_GENE_PRODUCT", 36, 38], ["p53", "GENE_OR_GENE_PRODUCT", 48, 51], ["p53", "GENE_OR_GENE_PRODUCT", 114, 117], ["cell", "CELL", 132, 136], ["cell", "CELL", 165, 169], ["ATF3", "PROTEIN", 0, 4], ["viral protein E6", "PROTEIN", 22, 38], ["p53", "PROTEIN", 48, 51], ["p53", "PROTEIN", 114, 117], ["target genes", "DNA", 118, 130], ["ATF3 interaction", "PROBLEM", 0, 16], ["viral protein E6", "TREATMENT", 22, 38], ["p53", "TEST", 114, 117], ["cell cycle arrest", "PROBLEM", 132, 149], ["apoptotic cell death", "PROBLEM", 155, 175], ["cell cycle arrest", "OBSERVATION", 132, 149], ["apoptotic cell death", "OBSERVATION", 155, 175]]], ["Thus, ATF3 is a repressor of the oncogenic viral protein E6 and blocks HPV-induced carcinogenesis [86] .", [["carcinogenesis", "DISEASE", 83, 97], ["ATF3", "GENE_OR_GENE_PRODUCT", 6, 10], ["E6", "GENE_OR_GENE_PRODUCT", 57, 59], ["HPV", "ORGANISM", 71, 74], ["ATF3", "PROTEIN", 6, 10], ["oncogenic viral protein E6", "PROTEIN", 33, 59], ["a repressor", "TREATMENT", 14, 25], ["the oncogenic viral protein E6", "TREATMENT", 29, 59], ["blocks HPV", "PROBLEM", 64, 74]]], ["Moreover, the ONC overexpressed gene that codes for protein tyrosine phosphatase receptor type R (PTPRR) has been linked to the inhibition of MAPK signaling through dephosphorylation of p44/42 MAPK, which inhibits AP-1 and the subsequent expression of the E6 and E7 HPV oncoproteins responsible for cervical cancer initiation and progression [87] .ONC as antiviral agent beyond its nucleic acids degradation abilityAfter infection at a portal entry, herpes simplex viruses (HSV) infect sensory nerve endings and are retrograde transported to the neuronal nucleus, where they establish a silent or latent state.", [["cervical cancer", "ANATOMY", 299, 314], ["sensory nerve endings", "ANATOMY", 486, 507], ["neuronal nucleus", "ANATOMY", 546, 562], ["tyrosine", "CHEMICAL", 60, 68], ["cervical cancer", "DISEASE", 299, 314], ["ONC", "CHEMICAL", 348, 351], ["nucleic acids", "CHEMICAL", 382, 395], ["infection", "DISEASE", 421, 430], ["herpes simplex viruses", "DISEASE", 450, 472], ["tyrosine", "CHEMICAL", 60, 68], ["ONC", "GENE_OR_GENE_PRODUCT", 14, 17], ["protein tyrosine phosphatase receptor type R", "GENE_OR_GENE_PRODUCT", 52, 96], ["PTPRR", "GENE_OR_GENE_PRODUCT", 98, 103], ["MAPK", "GENE_OR_GENE_PRODUCT", 142, 146], ["p44/42 MAPK", "GENE_OR_GENE_PRODUCT", 186, 197], ["AP-1", "GENE_OR_GENE_PRODUCT", 214, 218], ["E6", "GENE_OR_GENE_PRODUCT", 256, 258], ["E7", "GENE_OR_GENE_PRODUCT", 263, 265], ["cervical cancer", "CANCER", 299, 314], ["ONC", "SIMPLE_CHEMICAL", 348, 351], ["herpes simplex viruses", "ORGANISM", 450, 472], ["HSV", "ORGANISM", 474, 477], ["nerve endings", "MULTI-TISSUE_STRUCTURE", 494, 507], ["neuronal nucleus", "CELLULAR_COMPONENT", 546, 562], ["ONC overexpressed gene", "DNA", 14, 36], ["protein tyrosine phosphatase receptor type R", "PROTEIN", 52, 96], ["PTPRR", "PROTEIN", 98, 103], ["MAPK", "PROTEIN", 142, 146], ["p44/42 MAPK", "PROTEIN", 186, 197], ["AP-1", "PROTEIN", 214, 218], ["E6 and E7 HPV oncoproteins", "PROTEIN", 256, 282], ["herpes simplex viruses", "SPECIES", 450, 472], ["herpes simplex viruses", "SPECIES", 450, 472], ["HSV", "SPECIES", 474, 477], ["protein tyrosine phosphatase", "TEST", 52, 80], ["MAPK signaling", "TEST", 142, 156], ["dephosphorylation of p44/42 MAPK", "TEST", 165, 197], ["AP", "TEST", 214, 216], ["the E6 and E7 HPV oncoproteins", "PROBLEM", 252, 282], ["cervical cancer", "PROBLEM", 299, 314], ["antiviral agent", "TREATMENT", 355, 370], ["its nucleic acids degradation", "TREATMENT", 378, 407], ["infection", "PROBLEM", 421, 430], ["herpes simplex viruses (HSV) infect sensory nerve endings", "PROBLEM", 450, 507], ["cervical", "ANATOMY", 299, 307], ["cancer", "OBSERVATION", 308, 314], ["infection", "OBSERVATION", 421, 430], ["portal", "ANATOMY", 436, 442], ["simplex viruses", "OBSERVATION", 457, 472], ["nerve", "ANATOMY", 494, 499], ["neuronal nucleus", "ANATOMY", 546, 562], ["latent", "OBSERVATION_MODIFIER", 597, 603]]], ["It is not well known how these virulent viruses remain silent.", [["virulent", "OBSERVATION_MODIFIER", 31, 39], ["viruses", "OBSERVATION", 40, 47]]], ["However, it has recently been described that ATF3 plays a key role in the maintenance of the HSV in this latent state by increasing the expression of a non-coding RNA known as the latencyassociated transcript (LAT) [88] .ONC as antiviral agent beyond its nucleic acids degradation abilityFinally, ONC also inhibits 90-99.9% of human immunodeficiency virus type 1 (HIV-1) replication in H9 leukemia cells over a four-day incubation at concentrations not toxic to uninfected H9 cells [25] .", [["H9 leukemia cells", "ANATOMY", 386, 403], ["H9 cells", "ANATOMY", 473, 481], ["ONC", "CHEMICAL", 221, 224], ["nucleic acids", "CHEMICAL", 255, 268], ["ONC", "CHEMICAL", 297, 300], ["human immunodeficiency virus", "DISEASE", 327, 355], ["leukemia", "DISEASE", 389, 397], ["ONC", "CHEMICAL", 297, 300], ["ATF3", "GENE_OR_GENE_PRODUCT", 45, 49], ["HSV", "ORGANISM", 93, 96], ["LAT", "GENE_OR_GENE_PRODUCT", 210, 213], ["ONC", "SIMPLE_CHEMICAL", 221, 224], ["ONC", "SIMPLE_CHEMICAL", 297, 300], ["human immunodeficiency virus type 1", "ORGANISM", 327, 362], ["HIV-1", "ORGANISM", 364, 369], ["H9 leukemia cells", "CELL", 386, 403], ["H9 cells", "CELL", 473, 481], ["ATF3", "PROTEIN", 45, 49], ["non-coding RNA", "RNA", 152, 166], ["latencyassociated transcript", "PROTEIN", 180, 208], ["LAT", "PROTEIN", 210, 213], ["H9 leukemia cells", "CELL_LINE", 386, 403], ["uninfected H9 cells", "CELL_LINE", 462, 481], ["human immunodeficiency virus type 1", "SPECIES", 327, 362], ["HIV-1", "SPECIES", 364, 369], ["HSV", "SPECIES", 93, 96], ["human immunodeficiency virus type 1", "SPECIES", 327, 362], ["HIV-1", "SPECIES", 364, 369], ["the HSV", "PROBLEM", 89, 96], ["a non-coding RNA", "PROBLEM", 150, 166], ["antiviral agent", "TREATMENT", 228, 243], ["its nucleic acids degradation", "TREATMENT", 251, 280], ["ONC", "TEST", 297, 300], ["human immunodeficiency virus type 1", "PROBLEM", 327, 362], ["H9 leukemia cells", "PROBLEM", 386, 403], ["toxic to uninfected H9 cells", "PROBLEM", 453, 481], ["HSV", "OBSERVATION", 93, 96], ["H9 leukemia cells", "OBSERVATION", 386, 403]]], ["HIV-1 transactivator protein Tat uses CREB to promote IL10 production.", [["HIV-1", "ORGANISM", 0, 5], ["Tat", "GENE_OR_GENE_PRODUCT", 29, 32], ["CREB", "GENE_OR_GENE_PRODUCT", 38, 42], ["IL10", "GENE_OR_GENE_PRODUCT", 54, 58], ["HIV-1 transactivator protein Tat", "PROTEIN", 0, 32], ["CREB", "PROTEIN", 38, 42], ["IL10", "PROTEIN", 54, 58], ["HIV-1", "SPECIES", 0, 5], ["HIV-1", "SPECIES", 0, 5], ["HIV", "PROBLEM", 0, 3], ["IL10 production", "PROBLEM", 54, 69]]], ["Although the importance of this for HIV pathogenesis is not clear, IL10 can inhibit HIV-1 replication in monocytes and macrophages, suggesting that Tat/CREB-induced IL10 production provides a negative feedback signal to prevent excess HIV-1 replication [89] .CONCLUSIONSOur results explain the cytotoxic mechanism induced by ONC in treated cancer cells through a network of different ONC up-regulated genes.", [["monocytes", "ANATOMY", 105, 114], ["macrophages", "ANATOMY", 119, 130], ["cancer cells", "ANATOMY", 340, 352], ["ONC", "CHEMICAL", 325, 328], ["cancer", "DISEASE", 340, 346], ["ONC", "CHEMICAL", 325, 328], ["HIV", "ORGANISM", 36, 39], ["IL10", "GENE_OR_GENE_PRODUCT", 67, 71], ["HIV-1", "ORGANISM", 84, 89], ["monocytes", "CELL", 105, 114], ["macrophages", "CELL", 119, 130], ["Tat", "GENE_OR_GENE_PRODUCT", 148, 151], ["CREB", "GENE_OR_GENE_PRODUCT", 152, 156], ["IL10", "GENE_OR_GENE_PRODUCT", 165, 169], ["HIV-1", "ORGANISM", 235, 240], ["ONC", "SIMPLE_CHEMICAL", 325, 328], ["cancer cells", "CELL", 340, 352], ["ONC", "GENE_OR_GENE_PRODUCT", 384, 387], ["IL10", "PROTEIN", 67, 71], ["monocytes", "CELL_TYPE", 105, 114], ["macrophages", "CELL_TYPE", 119, 130], ["Tat", "PROTEIN", 148, 151], ["CREB", "PROTEIN", 152, 156], ["IL10", "PROTEIN", 165, 169], ["ONC", "PROTEIN", 325, 328], ["treated cancer cells", "CELL_TYPE", 332, 352], ["ONC up-regulated genes", "DNA", 384, 406], ["HIV", "SPECIES", 36, 39], ["HIV-1", "SPECIES", 84, 89], ["HIV-1", "SPECIES", 235, 240], ["HIV", "SPECIES", 36, 39], ["HIV-1", "SPECIES", 84, 89], ["HIV-1", "SPECIES", 235, 240], ["HIV pathogenesis", "PROBLEM", 36, 52], ["HIV", "TEST", 84, 87], ["macrophages", "TEST", 119, 130], ["Tat/CREB", "TEST", 148, 156], ["IL10 production", "PROBLEM", 165, 180], ["excess HIV", "PROBLEM", 228, 238], ["the cytotoxic mechanism", "PROBLEM", 290, 313], ["cancer cells", "PROBLEM", 340, 352]]], ["Among them, ATF3 upregulation plays a central role in the key events triggered by ONC that finally lead to apoptosis.", [["ATF3", "GENE_OR_GENE_PRODUCT", 12, 16], ["ONC", "SIMPLE_CHEMICAL", 82, 85], ["ATF3", "PROTEIN", 12, 16], ["ONC", "PROTEIN", 82, 85], ["apoptosis", "PROBLEM", 107, 116]]], ["This mechanism is cell-type independent.", [["cell", "ANATOMY", 18, 22], ["cell", "CELL", 18, 22]]], ["Up-regulation of ATF3 may also explain the antiviral properties of this RNase.", [["ATF3", "GENE_OR_GENE_PRODUCT", 17, 21], ["RNase", "GENE_OR_GENE_PRODUCT", 72, 77], ["ATF3", "PROTEIN", 17, 21], ["RNase", "PROTEIN", 72, 77], ["Up-regulation of ATF3", "PROBLEM", 0, 21], ["this RNase", "TREATMENT", 67, 77], ["may also explain", "UNCERTAINTY", 22, 38], ["antiviral", "OBSERVATION", 43, 52]]], ["ONCaffected genes are different from those affected by nucleardirected RNases.", [["ONCaffected genes", "DNA", 0, 17], ["nucleardirected RNases", "PROTEIN", 55, 77], ["different", "OBSERVATION_MODIFIER", 22, 31]]], ["The pleiotropic effects of both types of RNases make them attractive as therapeutics to treat either cancer or virus-promoted diseases.ONC expression and purificationConstruction of plasmid expressing ONC (pONC) has been previously described [90] .", [["cancer", "ANATOMY", 101, 107], ["plasmid", "ANATOMY", 182, 189], ["cancer", "DISEASE", 101, 107], ["cancer", "CANCER", 101, 107], ["ONC", "GENE_OR_GENE_PRODUCT", 135, 138], ["ONC", "GENE_OR_GENE_PRODUCT", 201, 204], ["pONC", "GENE_OR_GENE_PRODUCT", 206, 210], ["ONC", "PROTEIN", 135, 138], ["plasmid", "DNA", 182, 189], ["ONC", "PROTEIN", 201, 204], ["pONC", "PROTEIN", 206, 210], ["RNases", "TREATMENT", 41, 47], ["therapeutics", "TREATMENT", 72, 84], ["cancer", "PROBLEM", 101, 107], ["virus", "PROBLEM", 111, 116], ["promoted diseases", "PROBLEM", 117, 134], ["cancer", "OBSERVATION", 101, 107]]], ["Recombinant ONC was produced and purified from Escherichia coli BL21(DE3) cells transformed with pONC essentially as described in [91] .", [["DE3) cells", "ANATOMY", 69, 79], ["ONC", "GENE_OR_GENE_PRODUCT", 12, 15], ["Escherichia coli", "ORGANISM", 47, 63], ["BL21", "ORGANISM", 64, 68], ["DE3) cells", "CELL", 69, 79], ["ONC", "PROTEIN", 12, 15], ["Escherichia coli BL21(DE3) cells", "CELL_LINE", 47, 79], ["Escherichia coli BL21", "SPECIES", 47, 68], ["Escherichia coli BL21", "SPECIES", 47, 68], ["Escherichia coli BL21(DE3) cells", "TREATMENT", 47, 79], ["pONC", "TEST", 97, 101]]], ["The molecular mass of ONC was confirmed by matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry at the Unitat cientificot\u00e8cnica de suport, Institut de Recerca, Hospital Universitari Vall d'Hebron (Barcelona, Spain).", [["ONC", "SIMPLE_CHEMICAL", 22, 25], ["The molecular mass of ONC", "PROBLEM", 0, 25], ["MALDI", "TEST", 103, 108], ["mass spectrometry", "PROBLEM", 114, 131], ["molecular", "OBSERVATION_MODIFIER", 4, 13], ["mass", "OBSERVATION", 14, 18]]], ["ONC concentration was determined by ultraviolet spectroscopy using an extinction coefficient at 280 nm of 10470 M -1 cm -1 , calculated as reported [92] .Cell lines and culture conditionsNCI/ADR-RES human ovarian cancer MDR cell line (formerly MCF-7/ADR) [93] was a generous gift from Dr. Ramon Colomer of the Institut Catal\u00e0 d'Oncologia de Girona, Hospital Universitari de Girona Dr. Josep Trueta (Girona, Spain).", [["Cell lines", "ANATOMY", 154, 164], ["NCI", "ANATOMY", 187, 190], ["ovarian cancer MDR cell line", "ANATOMY", 205, 233], ["MCF-7/ADR", "ANATOMY", 244, 253], ["ONC", "CHEMICAL", 0, 3], ["ADR", "CHEMICAL", 191, 194], ["ovarian cancer", "DISEASE", 205, 219], ["ONC", "SIMPLE_CHEMICAL", 0, 3], ["Cell lines", "CELL", 154, 164], ["NCI", "CELL", 187, 190], ["ADR-RES", "CELL", 191, 198], ["human", "ORGANISM", 199, 204], ["ovarian cancer MDR cell line", "CELL", 205, 233], ["MCF-7/ADR", "CELL", 244, 253], ["RES human ovarian cancer MDR cell line", "CELL_LINE", 195, 233], ["human", "SPECIES", 199, 204], ["human", "SPECIES", 199, 204], ["ultraviolet spectroscopy", "TEST", 36, 60], ["Cell lines", "TREATMENT", 154, 164], ["culture conditions", "TEST", 169, 187], ["ADR", "PROBLEM", 191, 194], ["human ovarian cancer", "PROBLEM", 199, 219], ["MDR cell line", "TREATMENT", 220, 233], ["MCF", "TEST", 244, 247], ["ovarian", "ANATOMY", 205, 212], ["cancer", "OBSERVATION", 213, 219], ["cell line", "OBSERVATION", 224, 233]]], ["The OVCAR-8 human ovarian cancer cell line was obtained from the National Cancer Institute's DCTD tumor repository (Frederick, USA) and was used immediately after thawing.", [["OVCAR-8", "ANATOMY", 4, 11], ["ovarian cancer cell line", "ANATOMY", 18, 42], ["tumor", "ANATOMY", 98, 103], ["ovarian cancer", "DISEASE", 18, 32], ["Cancer", "DISEASE", 74, 80], ["tumor", "DISEASE", 98, 103], ["OVCAR-8", "CELL", 4, 11], ["human", "ORGANISM", 12, 17], ["ovarian cancer cell line", "CELL", 18, 42], ["DCTD tumor", "CANCER", 93, 103], ["OVCAR-8 human ovarian cancer cell line", "CELL_LINE", 4, 42], ["human", "SPECIES", 12, 17], ["human", "SPECIES", 12, 17], ["The OVCAR-8 human ovarian cancer cell line", "TREATMENT", 0, 42], ["ovarian", "ANATOMY", 18, 25], ["cancer", "OBSERVATION", 26, 32], ["cell line", "OBSERVATION", 33, 42], ["Cancer", "OBSERVATION", 74, 80]]], ["NCI/ADR-RES and OVCAR-8 cells were routinely grown at 37\u00baC in a humidified atmosphere of 5% CO 2 in DMEM (Gibco, Germany) containing 1.84 \u00b5M doxorubicin (Tedec-Meiji Farma, Spain) and RPMI (Gibco, Germany), respectively, supplemented with 10% fetal bovine serum (Gibco, Germany), 50 U/ml penicillin, and 50 \u03bcg/ml streptomycin (Gibco, Germany).", [["NCI", "ANATOMY", 0, 3], ["OVCAR-8 cells", "ANATOMY", 16, 29], ["serum", "ANATOMY", 256, 261], ["ADR", "CHEMICAL", 4, 7], ["doxorubicin", "CHEMICAL", 141, 152], ["Tedec-Meiji Farma", "CHEMICAL", 154, 171], ["penicillin", "CHEMICAL", 288, 298], ["streptomycin", "CHEMICAL", 313, 325], ["CO 2", "CHEMICAL", 92, 96], ["doxorubicin", "CHEMICAL", 141, 152], ["penicillin", "CHEMICAL", 288, 298], ["streptomycin", "CHEMICAL", 313, 325], ["ADR-RES", "CELL", 4, 11], ["OVCAR-8 cells", "CELL", 16, 29], ["doxorubicin", "SIMPLE_CHEMICAL", 141, 152], ["bovine", "ORGANISM", 249, 255], ["serum", "ORGANISM_SUBSTANCE", 256, 261], ["Gibco", "ORGANISM_SUBSTANCE", 263, 268], ["penicillin", "SIMPLE_CHEMICAL", 288, 298], ["streptomycin", "SIMPLE_CHEMICAL", 313, 325], ["OVCAR-8 cells", "CELL_LINE", 16, 29], ["bovine", "SPECIES", 249, 255], ["bovine", "SPECIES", 249, 255], ["OVCAR", "TEST", 16, 21], ["a humidified atmosphere", "TREATMENT", 62, 85], ["Gibco", "TEST", 106, 111], ["\u00b5M doxorubicin", "TREATMENT", 138, 152], ["Tedec", "TEST", 154, 159], ["RPMI", "TEST", 184, 188], ["10% fetal bovine serum", "TREATMENT", 239, 261], ["penicillin", "TREATMENT", 288, 298], ["streptomycin", "TREATMENT", 313, 325]]], ["Cells remained free of Mycoplasma and were propagated according to established protocols.Cell proliferation assayNCI/ADR-RES cells (10 4 per well) and OVCAR-8 cells (1.5 x 10 3 per well) were seeded into 96-well plates.", [["Cells", "ANATOMY", 0, 5], ["Cell", "ANATOMY", 89, 93], ["ADR-RES cells", "ANATOMY", 117, 130], ["OVCAR-8 cells", "ANATOMY", 151, 164], ["Cells", "CELL", 0, 5], ["Cell", "CELL", 89, 93], ["ADR-RES cells", "CELL", 117, 130], ["OVCAR-8 cells", "CELL", 151, 164], ["ADR-RES cells", "CELL_LINE", 117, 130], ["OVCAR-8 cells", "CELL_LINE", 151, 164], ["Mycoplasma", "PROBLEM", 23, 33], ["Cell proliferation", "TEST", 89, 107], ["assayNCI", "TEST", 108, 116], ["ADR-RES cells", "TREATMENT", 117, 130], ["OVCAR-8 cells", "TREATMENT", 151, 164], ["Mycoplasma", "OBSERVATION", 23, 33]]], ["After 24 h of incubation, cells were treated for 24, 36, or 48 h with various concentrations of ONC, ranging from 0.001 to 10 \u03bcM.", [["cells", "ANATOMY", 26, 31], ["ONC", "CHEMICAL", 96, 99], ["cells", "CELL", 26, 31], ["ONC", "SIMPLE_CHEMICAL", 96, 99], ["incubation", "TREATMENT", 14, 24], ["ONC", "TEST", 96, 99]]], ["Sensitivity to RNase was determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) method used according to the manufacturer's instructions (Sigma, USA).", [["3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide", "CHEMICAL", 43, 103], ["3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide", "CHEMICAL", 43, 103], ["MTT", "CHEMICAL", 105, 108], ["RNase", "GENE_OR_GENE_PRODUCT", 15, 20], ["3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide", "SIMPLE_CHEMICAL", 43, 103], ["RNase", "PROTEIN", 15, 20], ["RNase", "TEST", 15, 20], ["dimethylthiazol", "TREATMENT", 50, 65], ["diphenyltetrazolium bromide", "TREATMENT", 76, 103]]], ["Data were collected by measuring the absorbance at 570 nm with a Synergy 4 multi-well plate reader (Biotek Instruments, USA).", [["a Synergy", "TREATMENT", 63, 72]]], ["The IC 5 , IC 10 , and IC 15 values represent the concentrations of ONC required to inhibit cell proliferation by 5, 10, and 15%, respectively, and were calculated by interpolation of the obtained growth curves.", [["cell", "ANATOMY", 92, 96], ["ONC", "SIMPLE_CHEMICAL", 68, 71], ["cell", "CELL", 92, 96], ["ONC", "TREATMENT", 68, 71], ["the obtained growth curves", "TEST", 184, 210], ["cell proliferation", "OBSERVATION", 92, 110]]], ["Data were calculated as the mean \u00b1 SD of three independent experiments conducted in triplicates.ONC treatment and RNA isolationNCI/ADR-RES cells (2 x 10 5 per well) and OVCAR-8 cells (5 x 10 4 per well) were seeded into 6-well plates.", [["NCI/ADR-RES cells", "ANATOMY", 127, 144], ["OVCAR-8 cells", "ANATOMY", 169, 182], ["ONC", "CHEMICAL", 96, 99], ["ADR", "CHEMICAL", 131, 134], ["RES", "CHEMICAL", 135, 138], ["ONC", "SIMPLE_CHEMICAL", 96, 99], ["ADR-RES cells", "CELL", 131, 144], ["OVCAR-8 cells", "CELL", 169, 182], ["RES cells", "CELL_LINE", 135, 144], ["OVCAR-8 cells", "CELL_LINE", 169, 182], ["ONC treatment", "TREATMENT", 96, 109], ["RNA isolation", "TEST", 114, 127], ["ADR-RES cells", "TREATMENT", 131, 144], ["OVCAR-8 cells", "TREATMENT", 169, 182]]], ["After 24 h of incubation, cells were treated for 36 h with a concentration of ONC that caused a 10% decrease in cell proliferation (0.5 \u03bcM ONC for NCI/ADR-RES cells and 0.06 \u03bcM ONC for OVCAR-8 cells).", [["cells", "ANATOMY", 26, 31], ["cell", "ANATOMY", 112, 116], ["NCI/ADR-RES cells", "ANATOMY", 147, 164], ["ONC", "ANATOMY", 177, 180], ["OVCAR-8 cells", "ANATOMY", 185, 198], ["ONC", "CHEMICAL", 78, 81], ["RES", "CHEMICAL", 155, 158], ["cells", "CELL", 26, 31], ["ONC", "SIMPLE_CHEMICAL", 78, 81], ["cell", "CELL", 112, 116], ["ADR-RES cells", "CELL", 151, 164], ["OVCAR-8 cells", "CELL", 185, 198], ["RES cells", "CELL_LINE", 155, 164], ["OVCAR-8 cells", "CELL_LINE", 185, 198], ["incubation", "TREATMENT", 14, 24], ["a 10% decrease in cell proliferation", "PROBLEM", 94, 130], ["NCI/ADR", "TEST", 147, 154], ["OVCAR", "TEST", 185, 190], ["cell proliferation", "OBSERVATION", 112, 130]]], ["Cells were then harvested at 400xg for 5 min at 4\u00b0C and washed twice with cold PBS.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["C", "SIMPLE_CHEMICAL", 50, 51], ["cold PBS", "TREATMENT", 74, 82]]], ["Total RNA was extracted using the mirVana miRNA isolation kit (Applied Biosystems/Ambion, USA) according to the manufacturer's instructions and stored at -80\u00b0C. Four independent preparations were performed for each cell line.", [["cell line", "ANATOMY", 215, 224], ["cell line", "CELL", 215, 224], ["cell line", "CELL_LINE", 215, 224], ["Total RNA", "TREATMENT", 0, 9], ["the mirVana miRNA isolation kit", "TREATMENT", 30, 61], ["each cell line", "TREATMENT", 210, 224], ["cell line", "OBSERVATION", 215, 224]]], ["The 260/280 nm absorbance ratio of each sample was checked using a NanoDrop ND-1000 spectrophotometer (Thermo Fisher Scientific, USA).", [["sample", "ANATOMY", 40, 46], ["nm absorbance ratio", "TEST", 12, 31], ["each sample", "TEST", 35, 46], ["a NanoDrop ND", "TREATMENT", 65, 78]]], ["RIN values were used to check RNA integrity using an Agilent 2100 bioanalyzer (Agilent Technologies, USA).", [["RIN values", "TEST", 0, 10], ["an Agilent 2100 bioanalyzer", "TREATMENT", 50, 77]]], ["The RIN value corresponds to the ratio of ribosomal band areas to total area of the electropherogram and the height of the 18S peak [94] .Gene expression microarray analysisGene expression microarray experiments were performed at Bioarray, S.L. (Alacant, Spain) using the SurePrint G3 Human Gene Expression Microarray (Agilent Technologies, USA), a highdensity oligonucleotide microarray that contains 60,000 probes, corresponding to 27,958 Entrez Gene RNAs and 7,419 lncRNAs.", [["ribosomal", "ANATOMY", 42, 51], ["27,958 Entrez Gene RNAs", "RNA", 434, 457], ["7,419 lncRNAs", "DNA", 462, 475], ["Human", "SPECIES", 285, 290], ["The RIN value", "TEST", 0, 13], ["ribosomal band areas", "PROBLEM", 42, 62], ["the electropherogram", "TEST", 80, 100], ["the height", "TEST", 105, 115], ["Gene expression microarray analysis", "TEST", 138, 173], ["Gene expression microarray experiments", "TEST", 173, 211], ["a highdensity oligonucleotide microarray", "TEST", 347, 387], ["ribosomal band", "OBSERVATION", 42, 56], ["total", "OBSERVATION_MODIFIER", 66, 71], ["area", "OBSERVATION_MODIFIER", 72, 76], ["height", "OBSERVATION_MODIFIER", 109, 115], ["peak", "OBSERVATION_MODIFIER", 127, 131]]], ["Sample preparation and microarray processing procedures were done according to the Two-Color Microarray-Based Gene Expression Analysis v. 6.5 (Agilent Technologies, USA).", [["Sample preparation", "TREATMENT", 0, 18], ["microarray processing procedures", "TEST", 23, 55]]], ["Briefly, 200 ng of total RNA were used to synthesize double-stranded cDNA with AffinityScript-Reverse Transcriptase and Oligo dT-Promoter Primer. cDNA was simultaneously amplified and transcribed into cyanine 3-or cyanine 5-labeled cRNA employing T7 RNA polymerase in the presence of cyanine 3-CTP or cyanine 5-CTP.", [["cyanine", "CHEMICAL", 201, 208], ["cyanine", "CHEMICAL", 214, 221], ["cyanine 3-CTP", "CHEMICAL", 284, 297], ["cyanine 5-CTP", "CHEMICAL", 301, 314], ["cyanine", "CHEMICAL", 201, 208], ["cyanine", "CHEMICAL", 214, 221], ["cyanine 3-CTP", "CHEMICAL", 284, 297], ["cyanine", "CHEMICAL", 301, 308], ["5-CTP", "CHEMICAL", 309, 314], ["cyanine 3", "SIMPLE_CHEMICAL", 201, 210], ["cyanine 5-labeled cRNA", "SIMPLE_CHEMICAL", 214, 236], ["cyanine 3-CTP", "SIMPLE_CHEMICAL", 284, 297], ["cyanine 5-CTP", "SIMPLE_CHEMICAL", 301, 314], ["double-stranded cDNA", "DNA", 53, 73], ["AffinityScript-Reverse Transcriptase and Oligo dT-Promoter Primer", "DNA", 79, 144], ["cDNA", "DNA", 146, 150], ["cyanine 3-or cyanine 5-labeled cRNA", "DNA", 201, 236], ["T7 RNA polymerase", "PROTEIN", 247, 264], ["total RNA", "TREATMENT", 19, 28], ["double-stranded cDNA", "TREATMENT", 53, 73], ["AffinityScript", "TREATMENT", 79, 93], ["Reverse Transcriptase and Oligo dT-Promoter Primer", "TREATMENT", 94, 144], ["cyanine", "TEST", 201, 208], ["cyanine", "TREATMENT", 214, 221], ["cyanine", "TEST", 284, 291], ["cyanine", "TREATMENT", 301, 308]]], ["The labeled cRNA (antisense) was purified, evaluated using a NanoDrop ND-1000 spectrophotometer (Thermo Fisher Scientific, USA) and hybridized to the oligonucleotide microarrays at 65\u00b0C for 17 h.", [["cRNA", "CELLULAR_COMPONENT", 12, 16], ["a NanoDrop ND", "TREATMENT", 59, 72], ["the oligonucleotide microarrays", "TREATMENT", 146, 177]]], ["Microarrays were then washed and scanned on a G2565CA microarray scanner upgraded to a resolution of 2 micron (Agilent Technologies, USA).", [["Microarrays", "TEST", 0, 11], ["a G2565CA microarray scanner", "TEST", 44, 72]]], ["Raw microarray data were statistically analyzed using the Marray, pcaMethods, Limma, and RankProd software packages from Bioconductor (www.bioconductor. org), which uses the R statistical environment and programming language.", [["Raw microarray data", "TEST", 0, 19]]], ["In particular, the non-specific signal was removed from the total intensity using the normexp background correction method with an offset of 20 [95] .", [["the non-specific signal", "PROBLEM", 15, 38], ["non-specific", "OBSERVATION_MODIFIER", 19, 31], ["total", "OBSERVATION_MODIFIER", 60, 65], ["intensity", "OBSERVATION_MODIFIER", 66, 75]]], ["Then intra-slide normalization was done using the Loess method [96] to make intensities consistent within each array, and inter-slide normalization was performed employing the quantiles method [97] to achieve consistency between arrays.", [["the Loess method", "TEST", 46, 62], ["inter-slide normalization", "TEST", 122, 147]]], ["After each of these analyses, a quality control analysis of microarray data (RG density plot, MA plot, and M boxplot) was performed.", [["these analyses", "TEST", 14, 28], ["a quality control analysis", "TEST", 30, 56], ["microarray data", "TEST", 60, 75], ["RG density plot", "TEST", 77, 92], ["MA plot", "TEST", 94, 101]]], ["Following normalization, the RankProd method [98] was applied to identify differentially expressed genes.", [["differentially expressed genes", "DNA", 74, 104], ["the RankProd method", "TREATMENT", 25, 44]]], ["Genes were considered differentially expressed when they had a false discovery rate adjusted p-value \u2264 0.05 and a fold change \u2265 2 or \u2264 -2.", [["a fold change", "TREATMENT", 112, 125]]], ["Data have been deposited in NCBI's Gene Expression Omnibus repository [99] (http://www.ncbi.nih. gov/geo) and are available under the accession number: GSE75494.Gene ontology analysis and KEGG pathway annotationIn the NCI/ADR-RES cell line, differentially expressed genes were characterized functionally with a hypergeometric test to find over-represented gene ontology terms in the three main broad ontologies (biological process, molecular function, and cellular component) (www.geneontology.org), and were also mapped to the Kyoto Encyclopedia of Genes and Genomes (KEGG) (www.kegg.jp), which assigns proteins to pathways, to find over-represented pathways.", [["NCI/ADR-RES cell line", "ANATOMY", 218, 239], ["cellular", "ANATOMY", 456, 464], ["NCI/ADR-RES cell line", "CELL", 218, 239], ["cellular", "CELL", 456, 464], ["NCI/ADR-RES cell line", "CELL_LINE", 218, 239], ["Kyoto Encyclopedia of Genes", "DNA", 528, 555], ["Gene ontology analysis", "TEST", 161, 183], ["KEGG pathway", "TEST", 188, 200], ["the NCI", "TEST", 214, 221], ["a hypergeometric test", "TEST", 309, 330], ["cell line", "OBSERVATION", 230, 239]]], ["The analyses were done using the GOstats and RamiGO software packages from Bioconductor (www.bioconductor.org).", [["The analyses", "TEST", 0, 12]]], ["A p-value cutoff of 0.05 was used.", [["A p-value cutoff", "TEST", 0, 16]]], ["The network representation of linkages between ONC-differentially expressed genes was constructed and drawn using the Ingenuity Pathway Analysis (IPA) package available on-line at http://www. ingenuity.com/products/ipa.Quantitative reverse transcription PCR (RT-qPCR)mRNA expression of three ONC up-regulated genes (TXNIP, ATF3, and GADD45A) and two downregulated genes (PHGDH and ASNS) were examined by RT-qPCR.", [["ONC", "GENE_OR_GENE_PRODUCT", 47, 50], ["ONC", "GENE_OR_GENE_PRODUCT", 292, 295], ["TXNIP", "GENE_OR_GENE_PRODUCT", 316, 321], ["ATF3", "GENE_OR_GENE_PRODUCT", 323, 327], ["GADD45A", "GENE_OR_GENE_PRODUCT", 333, 340], ["PHGDH", "GENE_OR_GENE_PRODUCT", 371, 376], ["ASNS", "GENE_OR_GENE_PRODUCT", 381, 385], ["ONC-differentially expressed genes", "DNA", 47, 81], ["ONC up-regulated genes", "DNA", 292, 314], ["TXNIP", "DNA", 316, 321], ["ATF3", "DNA", 323, 327], ["GADD45A", "DNA", 333, 340], ["downregulated genes", "DNA", 350, 369], ["PHGDH", "DNA", 371, 376], ["ASNS", "DNA", 381, 385], ["Analysis (IPA) package", "TREATMENT", 136, 158], ["/ipa", "TREATMENT", 214, 218], ["Quantitative reverse transcription PCR", "TEST", 219, 257], ["RT-qPCR", "TEST", 259, 266], ["mRNA expression", "TEST", 267, 282], ["TXNIP", "TEST", 316, 321], ["ATF3", "TEST", 323, 327], ["two downregulated genes (PHGDH and ASNS", "PROBLEM", 346, 385]]], ["The same RNA samples used for microarrays analysis were used in this analysis.", [["samples", "ANATOMY", 13, 20], ["microarrays analysis", "TEST", 30, 50], ["this analysis", "TEST", 64, 77]]], ["First, RNA samples were digested with DNase to prevent genomic contamination using the RNase-Free DNase Set (Qiagen, Germany) according to the manufacturer's instructions.", [["samples", "ANATOMY", 11, 18], ["DNase", "GENE_OR_GENE_PRODUCT", 38, 43], ["RNase", "GENE_OR_GENE_PRODUCT", 87, 92], ["DNase", "PROTEIN", 38, 43], ["RNase", "PROTEIN", 87, 92], ["RNA samples", "TEST", 7, 18], ["DNase", "TREATMENT", 38, 43], ["genomic contamination", "PROBLEM", 55, 76], ["the RNase", "TREATMENT", 83, 92], ["Free DNase Set (Qiagen, Germany)", "TREATMENT", 93, 125]]], ["They were evaluated using an Agilent 2100 bioanalyzer (Agilent Technologies, USA) and a NanoDrop ND-1000 spectrophotometer (Thermo Fisher Scientific, USA).", [["a NanoDrop ND", "TREATMENT", 86, 99]]], ["Then, for each sample, 0.5 \u03bcg of RNA was used to synthesize single-stranded cDNA with the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, USA) following the manufacturer's instructions.", [["sample", "ANATOMY", 15, 21], ["single-stranded cDNA", "DNA", 60, 80], ["RNA", "TREATMENT", 33, 36]]], ["Gene-specific forward and reverse primers for the selected genes were designed with Primer3 (http://primer3.ut.ee) and checked with NetPrimer (http://www.premierbiosoft.com/netprimer/).", [["forward and reverse primers", "DNA", 14, 41], ["NetPrimer", "DNA", 132, 141], ["reverse primers", "TREATMENT", 26, 41]]], ["Primer sequences for ONC-regulated genes were: TXNIP (F: GCTTGCGGAGTGGCTAAAGT; R: CTCACCTGTTGGCTGGTCTTC), ATF3 (F: AGTGAGT GCTTCTGCCATCGT; R: TGACAAAGGGCGTCAGG www.impactjournals.com/oncotarget TTAG), GADD45A (F: GAGAGCAGAAGACC GAAAGGA; R: CAGGCACAACACCACGTTATC), PHGDH (F: TATTGTTCGCTCTGCCACCA; R: TCATAACCAAGATGCCCTTCC) and ASNS (F: AAAGCCGAGGAGGAGAGTGA, R: GGTGGCAGAG ACAAGTAATAGGA).", [["ONC", "GENE_OR_GENE_PRODUCT", 21, 24], ["TXNIP", "GENE_OR_GENE_PRODUCT", 47, 52], ["F: GCTTGCGGAGTGGCTAAAGT; R: CTCACCTGTTGGCTGGTCTTC", "GENE_OR_GENE_PRODUCT", 54, 103], ["ATF3", "GENE_OR_GENE_PRODUCT", 106, 110], ["Primer sequences", "DNA", 0, 16], ["ONC-regulated genes", "DNA", 21, 40], ["TXNIP", "PROTEIN", 47, 52], ["ATF3", "PROTEIN", 106, 110], ["impactjournals.com", "PROTEIN", 164, 182], ["oncotarget TTAG", "PROTEIN", 183, 198], ["GADD45A", "PROTEIN", 201, 208], ["PHGDH", "PROTEIN", 264, 269], ["ASNS", "PROTEIN", 326, 330], ["Primer sequences", "TEST", 0, 16]]], ["To select a constitutive gene as a reference for normalizing data, the transcription abundances of five genes (ACTB, GUSB, TBP, HPRT1, and ALAS1) were measured for all cDNA samples.", [["samples", "ANATOMY", 173, 180], ["ACTB", "GENE_OR_GENE_PRODUCT", 111, 115], ["GUSB", "GENE_OR_GENE_PRODUCT", 117, 121], ["TBP", "GENE_OR_GENE_PRODUCT", 123, 126], ["HPRT1", "GENE_OR_GENE_PRODUCT", 128, 133], ["ALAS1", "GENE_OR_GENE_PRODUCT", 139, 144], ["constitutive gene", "DNA", 12, 29], ["ACTB", "DNA", 111, 115], ["GUSB", "DNA", 117, 121], ["TBP", "DNA", 123, 126], ["HPRT1", "DNA", 128, 133], ["ALAS1", "DNA", 139, 144], ["the transcription abundances", "TEST", 67, 95], ["ACTB", "TEST", 111, 115], ["GUSB", "TEST", 117, 121], ["TBP", "TEST", 123, 126], ["HPRT1", "TEST", 128, 133], ["all cDNA samples", "TEST", 164, 180]]], ["Primer sequences are described in reference [28] .", [["Primer sequences", "DNA", 0, 16], ["Primer sequences", "TEST", 0, 16]]], ["Among them, TBP showed the highest stability (lower standard deviation of the Ct; results not shown) and it was therefore selected for data normalization.", [["TBP", "GENE_OR_GENE_PRODUCT", 12, 15], ["TBP", "PROTEIN", 12, 15], ["TBP", "TEST", 12, 15], ["the Ct", "TEST", 74, 80], ["highest", "OBSERVATION_MODIFIER", 27, 34], ["stability", "OBSERVATION_MODIFIER", 35, 44]]], ["Real-time PCRs were performed in an optical 96-well plate with an ABI PRISM 7300 Sequence Detector System (Applied Biosystems, USA), using SYBR Green to monitor dscDNA synthesis.", [["dscDNA", "GENE_OR_GENE_PRODUCT", 161, 167], ["dscDNA", "PROTEIN", 161, 167], ["an ABI PRISM", "TEST", 63, 75]]], ["Reactions contained 1x Power SYBR Green PCR Master Mix (Applied Biosystems, USA), 300 nM of gene-specific forward primer, 300 nM of gene-specific reverse primer, and 5 \u03bcl of a 50fold dilution of the previously synthesized cDNA in a final volume of 20 \u03bcl.", [["forward primer", "DNA", 106, 120], ["reverse primer", "DNA", 146, 160], ["cDNA", "DNA", 222, 226], ["a final volume", "TEST", 230, 244]]], ["A dissociation step was performed after amplification to confirm the presence of a single amplicon.", [["A dissociation step", "TEST", 0, 19], ["a single amplicon", "TREATMENT", 81, 98]]], ["To estimate variation in the technique, three technical replicates were carried out for each cDNA sample.", [["the technique", "TEST", 25, 38], ["each cDNA sample", "TEST", 88, 104], ["variation", "OBSERVATION_MODIFIER", 12, 21]]], ["To generate a baseline-subtracted plot of the logarithmic increase in fluorescence signal (\u0394Rn) versus cycle number, baseline data were collected between cycles 3 and 15.", [["the logarithmic increase", "PROBLEM", 42, 66], ["fluorescence signal", "TEST", 70, 89], ["baseline data", "TEST", 117, 130], ["logarithmic", "OBSERVATION_MODIFIER", 46, 57], ["increase", "OBSERVATION_MODIFIER", 58, 66]]], ["All amplification plots were analyzed with an Rn threshold of 0.2 to obtain threshold cycle (Ct) values.", [["All amplification plots", "TEST", 0, 23], ["an Rn threshold", "TEST", 43, 58], ["Ct) values", "TEST", 93, 103]]], ["The amplification efficiency for each gene was calculated based on five dilutions of cDNA ranging from 1 to 3.2x10 -4 and the equation E = 10 (\u22121/slope) .", [["cDNA", "DNA", 85, 89], ["The amplification efficiency", "PROBLEM", 0, 28], ["cDNA", "TEST", 85, 89], ["the equation E", "TEST", 122, 136], ["efficiency", "OBSERVATION_MODIFIER", 18, 28]]], ["The relative transcription abundances (RTA) of ONCtarget genes (TXNIP, ATF3, GADD45A, PHGDH, and ASNS) were calculated as RTA = E \u0394Ct(control-sample) (Target) / E \u0394Ct(control-sample) (Reference) [100] , where control refers to a mix of equal amounts of untreated samples.", [["samples", "ANATOMY", 263, 270], ["ONCtarget", "GENE_OR_GENE_PRODUCT", 47, 56], ["TXNIP", "GENE_OR_GENE_PRODUCT", 64, 69], ["ATF3", "GENE_OR_GENE_PRODUCT", 71, 75], ["GADD45A", "GENE_OR_GENE_PRODUCT", 77, 84], ["PHGDH", "GENE_OR_GENE_PRODUCT", 86, 91], ["ASNS", "GENE_OR_GENE_PRODUCT", 97, 101], ["ONCtarget genes", "DNA", 47, 62], ["TXNIP", "DNA", 64, 69], ["ATF3", "DNA", 71, 75], ["GADD45A", "DNA", 77, 84], ["PHGDH", "DNA", 86, 91], ["ASNS", "DNA", 97, 101], ["E \u0394Ct", "DNA", 128, 133], ["TXNIP", "TEST", 64, 69], ["ATF3", "TEST", 71, 75], ["GADD45A", "TEST", 77, 84], ["PHGDH", "TEST", 86, 91], ["ASNS", "TEST", 97, 101], ["RTA", "TEST", 122, 125]]], ["Fold changes were calculated as the ratio between RTA values obtained for ONC-treated cells and those obtained for untreated cells.", [["cells", "ANATOMY", 86, 91], ["cells", "ANATOMY", 125, 130], ["ONC", "CHEMICAL", 74, 77], ["RTA", "GENE_OR_GENE_PRODUCT", 50, 53], ["ONC", "SIMPLE_CHEMICAL", 74, 77], ["cells", "CELL", 86, 91], ["cells", "CELL", 125, 130], ["RTA", "PROTEIN", 50, 53], ["ONC-treated cells", "CELL_LINE", 74, 91], ["untreated cells", "CELL_TYPE", 115, 130], ["Fold changes", "PROBLEM", 0, 12], ["the ratio", "TEST", 32, 41], ["RTA values", "TEST", 50, 60], ["ONC-treated cells", "TREATMENT", 74, 91], ["untreated cells", "PROBLEM", 115, 130]]], ["The absence of genomic DNA contamination was checked using non-retrotranscriptase controls and the absence of environmental contamination using nontemplate controls.", [["DNA", "CELLULAR_COMPONENT", 23, 26], ["genomic DNA contamination", "PROBLEM", 15, 40], ["non-retrotranscriptase controls", "TREATMENT", 59, 90], ["environmental contamination", "PROBLEM", 110, 137], ["nontemplate controls", "TREATMENT", 144, 164], ["genomic DNA contamination", "OBSERVATION", 15, 40]]]], "bff93017879e66a9094d6965e42fce4499b81646": [["IntroductionCOVID-19 tends to seriously threaten the health and life of people.", [["people", "ORGANISM", 72, 78], ["people", "SPECIES", 72, 78], ["IntroductionCOVID", "TEST", 0, 17]]], ["Some studies have been made on working status, quality of life and psychological status of medical staff in the harder-hit areas like Wuhan [1] , while in the already infected surrounding areas, medical staff face much higher pressure than before due to dense population and mobilization of local medical resources to Wuhan.", [["Some studies", "TEST", 0, 12], ["infected", "OBSERVATION", 167, 175], ["dense", "OBSERVATION_MODIFIER", 254, 259], ["population", "OBSERVATION", 260, 270]]], ["Related studies on that population appear to be helpful for pandemic response in other areas.", [["pandemic response in other areas", "PROBLEM", 60, 92]]], ["Therefore, medical and nonmedical personnel in Anhui province, adjacent to Hubei Province, were selected for this study.Data SourcesCollect data of 248 residents living in Anhui from February 4 to 6 of 2020 through a Network questionnaire survey, among whom 146 are male, 102 are female, ranging from 18 to 75 years old.", [["this study", "TEST", 109, 119]]], ["In the two aspects of gender and age, there was no statistically significant difference (P > 0.05). .", [["P", "TEST", 89, 90], ["no", "UNCERTAINTY", 48, 50], ["statistically", "OBSERVATION_MODIFIER", 51, 64], ["significant", "OBSERVATION_MODIFIER", 65, 76], ["difference", "OBSERVATION_MODIFIER", 77, 87]]], ["CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.Data Sourcesis the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintData SourcesThe copyright holder for this this version posted August 18, 2020.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 128, 131]]], ["The Chinese version of WHOQOL-BREF quality of life measurement scale can generate scores in four fields, physiological, psychological, social relations, and environmental fields.", [["WHOQOL-BREF quality of life measurement scale", "TREATMENT", 23, 68]]], ["The field score was recorded in a positive way, that is, the higher the score, the better the quality of life.Data Sources2.", [["The field score", "TEST", 0, 15]]], ["The anxiety self-rating scale (SAS) is used to assess the subjective feelings of anxious people.", [["anxiety", "DISEASE", 4, 11], ["people", "ORGANISM", 89, 95], ["people", "SPECIES", 89, 95]]], ["It consists of 20 items including 15 items of positive score and 5Data Sourcesitems of negative score.", [["20 items", "OBSERVATION_MODIFIER", 15, 23], ["negative", "OBSERVATION", 87, 95]]], ["The standard threshold was 50 points, with 50-59 being considered mild anxiety, 60-69 moderate anxiety, and 69 above severe anxiety.Data Sources3.", [["anxiety", "DISEASE", 71, 78], ["anxiety", "DISEASE", 95, 102], ["anxiety", "DISEASE", 124, 131], ["mild anxiety", "PROBLEM", 66, 78], ["moderate anxiety", "PROBLEM", 86, 102], ["severe anxiety", "PROBLEM", 117, 131], ["mild", "OBSERVATION_MODIFIER", 66, 70], ["anxiety", "OBSERVATION", 71, 78]]], ["The self-rating depression scale (SDS) is used to assess the subjective feelings of depressed people, including 20 items.", [["depression", "DISEASE", 16, 26], ["depressed", "DISEASE", 84, 93], ["people", "ORGANISM", 94, 100], ["people", "SPECIES", 94, 100]]], ["The scoring method is the same as the anxiety score.", [["anxiety", "DISEASE", 38, 45], ["the anxiety score", "PROBLEM", 34, 51]]], ["The cut-off value of SDS standard score was 53, among which 53-62 were classified as mild depression, 63-72 as moderate depression, and 72 or more as severe depression.Statistical MethodsSPSS 17.0 statistical software was used for data analysis.", [["depression", "DISEASE", 90, 100], ["depression", "DISEASE", 120, 130], ["depression", "DISEASE", 157, 167], ["The cut", "TEST", 0, 7], ["SDS standard score", "TEST", 21, 39], ["mild depression", "PROBLEM", 85, 100], ["moderate depression", "PROBLEM", 111, 130], ["severe depression", "PROBLEM", 150, 167], ["statistical software", "TEST", 197, 217], ["data analysis", "TEST", 231, 244], ["mild", "OBSERVATION_MODIFIER", 85, 89], ["depression", "OBSERVATION", 90, 100], ["moderate", "OBSERVATION_MODIFIER", 111, 119], ["depression", "OBSERVATION", 120, 130], ["severe", "OBSERVATION_MODIFIER", 150, 156], ["depression", "OBSERVATION", 157, 167]]], ["Independent sample ttest was used for comparison of measurement data conforming to normal distribution, while rank sum test was used for comparison of measurement data not conforming to is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintStatistical MethodsThe copyright holder for this this version posted August 18, 2020. . https://doi.org/10.1101/2020.08.15.20158725 doi: medRxiv preprint normal distribution.Chi-square test was used to compare counting data, and P < 0.05 was considered statistically significant.Comparison of scores of each scale between the two groupsThe scores of Zung self-rating scale for depression and Zung self-rating scale for anxiety in the two groups were in line with the normal distribution.", [["depression", "DISEASE", 695, 705], ["anxiety", "DISEASE", 737, 744], ["Independent sample ttest", "TEST", 0, 24], ["measurement data", "TEST", 52, 68], ["rank sum test", "TEST", 110, 123], ["measurement data", "TEST", 151, 167], ["Chi-square test", "TEST", 492, 507], ["counting data", "TEST", 528, 541], ["P", "TEST", 547, 548], ["depression", "PROBLEM", 695, 705], ["Zung self-rating scale", "TREATMENT", 710, 732], ["anxiety", "PROBLEM", 737, 744], ["med", "ANATOMY", 224, 227], ["normal", "OBSERVATION", 472, 478], ["distribution", "OBSERVATION_MODIFIER", 479, 491], ["normal", "OBSERVATION", 785, 791], ["distribution", "OBSERVATION_MODIFIER", 792, 804]]], ["The t-test results indicated that there was no statistically significant difference in the scores of Zung self-rating scale for depression and anxiety in the two groups.", [["depression", "DISEASE", 128, 138], ["anxiety", "DISEASE", 143, 150], ["The t-test", "TEST", 0, 10], ["depression", "PROBLEM", 128, 138], ["anxiety", "PROBLEM", 143, 150], ["no", "UNCERTAINTY", 44, 46], ["significant", "OBSERVATION_MODIFIER", 61, 72], ["difference", "OBSERVATION", 73, 83]]], ["Rank sum test was used for the scores of physiological field, psychological field, social relationship field, and environmental field.", [["Rank sum test", "TEST", 0, 13]]], ["The results indicated that the scores of medical staff were lower than those of nonmedical staff in the four fields, as shown in table 2. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintComparison of scores of each scale between the two groupsThe copyright holder for this this version posted August 18, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintComparison of scores of each scale between the two groupsThe copyright holder for this this version posted August 18, 2020. . https://doi.org/10.1101/2020.08.15.20158725 doi: medRxiv preprint 6 In terms of the impact of public emergencies on the quality of life of the population, previous studies have suggested that different groups are affected differently, and most of them have shown that public emergencies have adverse effects on medical staff, including the decline in the quality of life.", [["medRxiv preprint", "TREATMENT", 701, 717], ["previous studies", "TEST", 807, 823], ["med", "ANATOMY", 176, 179], ["med", "ANATOMY", 432, 435]]], ["[1, 5, 6] This study found that the score of WHOQOL-BREF of medical staff was lower than that of nonmedical staff in physiological, psychological, social relationship, and environmental fields, which was similar to most previous research results.", [["This study", "TEST", 10, 20]]], ["However, Cornelia studies show that these incidents do not have much impact on people's quality of life and the impact is often transient.", [["people", "ORGANISM", 79, 85], ["people", "SPECIES", 79, 85], ["Cornelia studies", "TEST", 9, 25]]], ["[7] Perhaps because studies of Cornelia et al. focused on noncommunicable events in which the studying objects were not subjected to extensive isolation for long periods of time.", [["noncommunicable events", "PROBLEM", 58, 80]]], ["Cong et al. showed that the change of living order and habits during the SARS outbreak in isolation may lead to the decline of life quality and psychological state.", [["SARS", "DISEASE", 73, 77], ["the SARS outbreak", "PROBLEM", 69, 86], ["the decline of life quality and psychological state", "PROBLEM", 112, 163]]], ["[8] During this outbreak, to control the spread of the disease, the government required most people to cancel their work and stay in quarantine at home, while medical staff were responsible for the prevention and control of the epidemic.", [["people", "ORGANISM", 93, 99], ["people", "SPECIES", 93, 99], ["the disease", "PROBLEM", 51, 62], ["the epidemic", "PROBLEM", 224, 236], ["disease", "OBSERVATION", 55, 62]]], ["All these factors may further reduce the quality of life of medical staff.Comparison of scores of each scale between the two groupsPrevious studies have shown that public emergencies have different effects on medical staff of different genders.", [["Previous studies", "TEST", 131, 147], ["public emergencies", "PROBLEM", 164, 182]]], ["The majority of previous studies believe that public emergencies have a greater impact on women's quality of life than men's.", [["women", "ORGANISM", 90, 95], ["men", "ORGANISM", 119, 122], ["women", "SPECIES", 90, 95], ["men", "SPECIES", 119, 122], ["previous studies", "TEST", 16, 32], ["greater", "OBSERVATION_MODIFIER", 72, 79]]], ["[9] [10] [11] Our results suggest that women's quality of life scores were lower than men's in all four areas among medical staff, while there was no statistically significant difference in quality of life between the two genders among nonmedical staff.", [["women", "ORGANISM", 39, 44], ["men", "ORGANISM", 86, 89], ["women", "SPECIES", 39, 44], ["men", "SPECIES", 86, 89]]], ["Previous studies by Mariza and Sergio et al. have shown that overwork, lack of external support, and poor sleep quality are important reasons for the decline of people's quality of life.", [["people", "ORGANISM", 161, 167], ["people", "SPECIES", 161, 167], ["Previous studies", "TEST", 0, 16], ["external support", "TREATMENT", 79, 95], ["poor sleep quality", "PROBLEM", 101, 119]]], ["Such pandemic forced medical staff to cancel the vacation and dedicate to the prevention and treatment work.", [["treatment work", "TREATMENT", 93, 107]]], ["Fatigue may lead to a decline in their quality of life.", [["Fatigue", "DISEASE", 0, 7], ["Fatigue", "PROBLEM", 0, 7], ["a decline", "PROBLEM", 20, 29]]], ["And the situation of women may be more visible than that of men.", [["women", "ORGANISM", 21, 26], ["men", "ORGANISM", 60, 63], ["women", "SPECIES", 21, 26], ["men", "SPECIES", 60, 63], ["more visible", "OBSERVATION_MODIFIER", 34, 46]]], ["In addition, there were no adverse factors such as overwork, lack of family support, and poor sleep quality among nonmedical is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintComparison of scores of each scale between the two groupsThe copyright holder for this this version posted August 18, 2020. . https://doi.org/10.1101/2020.08.15.20158725 doi: medRxiv preprint staff.So men's physical advantages may not show up.", [["men", "ORGANISM", 458, 461], ["men", "SPECIES", 458, 461], ["adverse factors", "PROBLEM", 27, 42], ["no", "UNCERTAINTY", 24, 26], ["med", "ANATOMY", 163, 166]]], ["As a result, the difference in quality of life between men and women is not significant among nonmedical staff.Comparison of scores of each scale between the two groupsIn terms of psychological state, previous studies based on the outbreak of SARS and MERS have shown that public emergencies can lead to an increased risk of anxiety and depression.", [["SARS", "DISEASE", 243, 247], ["anxiety", "DISEASE", 325, 332], ["depression", "DISEASE", 337, 347], ["men", "ORGANISM", 55, 58], ["women", "ORGANISM", 63, 68], ["men", "SPECIES", 55, 58], ["women", "SPECIES", 63, 68], ["previous studies", "TEST", 201, 217], ["SARS", "PROBLEM", 243, 247], ["anxiety", "PROBLEM", 325, 332], ["depression", "PROBLEM", 337, 347], ["increased", "OBSERVATION_MODIFIER", 307, 316], ["anxiety", "OBSERVATION", 325, 332]]], ["For example, the study of Wang showed that the medical staff of SARS in wuhan region did not have obvious psychological emotions of anxiety and depression on the whole, but female medical staff may be more prone to anxiety and depression than men in terms of psychological changes.", [["SARS", "DISEASE", 64, 68], ["anxiety", "DISEASE", 132, 139], ["depression", "DISEASE", 144, 154], ["anxiety", "DISEASE", 215, 222], ["depression", "DISEASE", 227, 237], ["men", "ORGANISM", 243, 246], ["men", "SPECIES", 243, 246], ["the study", "TEST", 13, 22], ["anxiety", "PROBLEM", 132, 139], ["depression", "PROBLEM", 144, 154], ["anxiety", "PROBLEM", 215, 222], ["depression", "PROBLEM", 227, 237], ["psychological changes", "PROBLEM", 259, 280]]], ["Angelina and Imran's research object is the outbreak of the earlier people, respectively, 2 months after the SARS outbreak in China, 1 month after the MERS outbreak in Arab.", [["SARS", "DISEASE", 109, 113], ["people", "ORGANISM", 68, 74], ["people", "SPECIES", 68, 74], ["Angelina", "PROBLEM", 0, 8]]], ["Early in an outbreak, when people know less about new outbreaks, they are prone to changes in their psychological states.Wang's study was conducted four to five months after the SARS outbreak, and at that time people had a certain understanding of SARS; 2.", [["SARS", "DISEASE", 178, 182], ["SARS", "DISEASE", 248, 252], ["people", "ORGANISM", 27, 33], ["people", "ORGANISM", 210, 216], ["people", "SPECIES", 27, 33], ["people", "SPECIES", 210, 216], ["Wang's study", "TEST", 121, 133], ["the SARS outbreak", "PROBLEM", 174, 191]]], ["Although our study was carried out in the early stages of the outbreak, this time the situation was different.", [["our study", "TEST", 9, 18]]], ["After the outbreak of the pandemic, the government and medical institutions promptly organized medical staff to study and strengthened the publicity of knowledge, as previous studies have shown that clear and effective learning measures can alleviate bad emotions.", [["previous studies", "TEST", 166, 182]]], ["[11] The rapid popularization of relevant knowledge reduced the bad mood; 3.", [["bad mood", "DISEASE", 64, 72]]], ["The fatality rate of this COVID-19 is far less than that of SARS and MERS.", [["SARS", "DISEASE", 60, 64], ["COVID-19", "CHEMICAL", 26, 34], ["The fatality rate", "TEST", 0, 17], ["this COVID", "TEST", 21, 31]]], ["[15] In addition, the subjects of this study were mainly concentrated in areas outside Hubei, which made the psychological impact caused by the pandemic smaller.", [["this study", "TEST", 34, 44], ["pandemic", "OBSERVATION_MODIFIER", 144, 152], ["smaller", "OBSERVATION_MODIFIER", 153, 160]]], ["However, it is worth noting that the SDS standard score of women in nonmedical staff has a higher trend than that of men (P=0.097), and it is still necessary to pay attention to women in this group. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintComparison of scores of each scale between the two groupsThe copyright holder for this this version posted August 18, 2020. . https://doi.org/10.1101/2020.08.15.20158725 doi: medRxiv preprint 8 In summary, during the outbreak of COVID 19, different populations were affected differently.", [["women", "ORGANISM", 59, 64], ["men", "ORGANISM", 117, 120], ["women", "ORGANISM", 178, 183], ["women", "SPECIES", 59, 64], ["men", "SPECIES", 117, 120], ["women", "SPECIES", 178, 183], ["COVID", "TEST", 560, 565], ["med", "ANATOMY", 237, 240]]], ["Due to the particularity of work, the quality of life of medical staff in some fields is low, among which the negative impact on female medical staff is more prominent.", [["low", "OBSERVATION_MODIFIER", 89, 92], ["more prominent", "OBSERVATION_MODIFIER", 153, 167]]], ["Timely support and concern may be more conducive to helping medical staff on these areas better face the challenges of the pandemic. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintComparison of scores of each scale between the two groupsThe copyright holder for this this version posted August 18, 2020. . https://doi.org/10.1101/2020.08.15.20158725 doi: medRxiv preprint", [["medRxiv", "TREATMENT", 440, 447], ["med", "ANATOMY", 171, 174]]]], "8e72b28211b8b6509c37085288991ee136476e73": [["To the Editors:As our understanding of the coronavirus disease 2019 (COVID-19) improves through emerging data from the general population affected with COVID-19, there is a paucity of information regarding the management and prognosis of patients with HIV infection who may be at an increased risk for morbidity and mortality.", [["coronavirus disease", "DISEASE", 43, 62], ["HIV infection", "DISEASE", 252, 265], ["coronavirus", "ORGANISM", 43, 54], ["patients", "ORGANISM", 238, 246], ["HIV", "ORGANISM", 252, 255], ["patients", "SPECIES", 238, 246], ["HIV", "SPECIES", 252, 255], ["HIV", "SPECIES", 252, 255], ["the coronavirus disease", "PROBLEM", 39, 62], ["COVID", "TEST", 69, 74], ["COVID", "TEST", 152, 157], ["the management", "TREATMENT", 206, 220], ["HIV infection", "PROBLEM", 252, 265], ["morbidity", "PROBLEM", 302, 311]]], ["1 Here, we describe our experience with the management of COVID-19 in patients with HIV at a health care facility in Newark, the center of the HIV epidemic of New Jersey.", [["COVID-19", "CHEMICAL", 58, 66], ["HIV", "DISEASE", 84, 87], ["patients", "ORGANISM", 70, 78], ["patients", "SPECIES", 70, 78], ["HIV", "SPECIES", 84, 87], ["HIV", "SPECIES", 84, 87], ["HIV", "SPECIES", 143, 146], ["COVID", "TEST", 58, 63], ["HIV", "PROBLEM", 84, 87], ["HIV", "OBSERVATION", 143, 146], ["New", "OBSERVATION_MODIFIER", 159, 162]]], ["2 We included all patients with laboratoryconfirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection defined as a positive result on a reverse transcriptase polymerase chain reaction assay of a specimen collected on a nasopharyngeal swab.To the Editors:We identified 27 patients who had a known history of HIV at the time of presentation.", [["specimen", "ANATOMY", 216, 224], ["nasopharyngeal swab", "ANATOMY", 240, 259], ["acute respiratory syndrome coronavirus", "DISEASE", 59, 97], ["SARS-CoV-2) infection", "DISEASE", 101, 122], ["patients", "ORGANISM", 18, 26], ["SARS-CoV-2", "ORGANISM", 101, 111], ["nasopharyngeal swab", "CANCER", 240, 259], ["patients", "ORGANISM", 292, 300], ["HIV", "ORGANISM", 328, 331], ["reverse transcriptase", "PROTEIN", 157, 178], ["patients", "SPECIES", 18, 26], ["patients", "SPECIES", 292, 300], ["laboratoryconfirmed severe acute respiratory syndrome coronavirus", "SPECIES", 32, 97], ["SARS-CoV-2", "SPECIES", 101, 111], ["HIV", "SPECIES", 328, 331], ["laboratoryconfirmed severe acute respiratory syndrome coronavirus", "PROBLEM", 32, 97], ["SARS-CoV", "TEST", 101, 109], ["infection", "PROBLEM", 113, 122], ["a reverse transcriptase polymerase chain reaction", "PROBLEM", 155, 204], ["a specimen", "TEST", 214, 224], ["a nasopharyngeal swab", "TEST", 238, 259], ["HIV", "PROBLEM", 328, 331], ["severe", "OBSERVATION_MODIFIER", 52, 58], ["acute", "OBSERVATION_MODIFIER", 59, 64], ["respiratory syndrome", "OBSERVATION", 65, 85], ["nasopharyngeal", "ANATOMY", 240, 254]]], ["The median age was 58 years, there were 15 men and 12 women, and 93% (n = 25) were black or African Americans.", [["men", "ORGANISM", 43, 46], ["women", "ORGANISM", 54, 59], ["men", "SPECIES", 43, 46], ["women", "SPECIES", 54, 59]]], ["The top 4 common symptoms at presentation were fever (67%), cough (63%), dyspnea (63%), and fatigue (48%), which had started over a median duration of 3 days before presentation.", [["fever", "DISEASE", 47, 52], ["cough", "DISEASE", 60, 65], ["dyspnea", "DISEASE", 73, 80], ["fatigue", "DISEASE", 92, 99], ["The top 4 common symptoms", "PROBLEM", 0, 25], ["fever", "PROBLEM", 47, 52], ["cough", "PROBLEM", 60, 65], ["dyspnea", "PROBLEM", 73, 80], ["fatigue", "PROBLEM", 92, 99], ["top", "OBSERVATION_MODIFIER", 4, 7]]], ["More than half of the patients had a history of systemic hypertension (59%), and about onethird reported diabetes mellitus (33%) or chronic kidney disease (27%) ( Table 1) .To the Editors:Ambulatory patients were hemodynamically stable at the time of presentation and demonstrated an oxygen saturation of 94-100% on ambient air.", [["kidney", "ANATOMY", 140, 146], ["hypertension", "DISEASE", 57, 69], ["diabetes mellitus", "DISEASE", 105, 122], ["chronic kidney disease", "DISEASE", 132, 154], ["oxygen", "CHEMICAL", 284, 290], ["oxygen", "CHEMICAL", 284, 290], ["patients", "ORGANISM", 22, 30], ["kidney", "ORGAN", 140, 146], ["patients", "ORGANISM", 199, 207], ["oxygen", "SIMPLE_CHEMICAL", 284, 290], ["patients", "SPECIES", 22, 30], ["patients", "SPECIES", 199, 207], ["systemic hypertension", "PROBLEM", 48, 69], ["diabetes mellitus", "PROBLEM", 105, 122], ["chronic kidney disease", "PROBLEM", 132, 154], ["an oxygen saturation", "TEST", 281, 301], ["systemic", "OBSERVATION_MODIFIER", 48, 56], ["hypertension", "OBSERVATION", 57, 69], ["diabetes", "OBSERVATION", 105, 113], ["chronic", "OBSERVATION_MODIFIER", 132, 139], ["kidney", "ANATOMY", 140, 146], ["disease", "OBSERVATION", 147, 154], ["stable", "OBSERVATION", 229, 235], ["oxygen saturation", "OBSERVATION", 284, 301]]], ["They were discharged home with no medical therapy but with the following (2) reported dyspnea requiring a step up in oxygenation therapy to maintain an oxygen saturation between 88% and 94%.To the Editors:Major laboratory markers and immunological data of their HIV status are given in Table 1 .", [["dyspnea", "DISEASE", 86, 93], ["oxygen", "CHEMICAL", 152, 158], ["oxygen", "CHEMICAL", 152, 158], ["oxygen", "SIMPLE_CHEMICAL", 152, 158], ["HIV", "ORGANISM", 262, 265], ["HIV", "SPECIES", 262, 265], ["HIV", "SPECIES", 262, 265], ["medical therapy", "TREATMENT", 34, 49], ["dyspnea", "PROBLEM", 86, 93], ["oxygenation therapy", "TREATMENT", 117, 136], ["an oxygen saturation", "TEST", 149, 169], ["Major laboratory markers", "TEST", 205, 229], ["immunological data", "TEST", 234, 252], ["dyspnea", "OBSERVATION", 86, 93]]], ["The median lymphocyte count was 17%, with a serum d-dimer and procalcitonin of 1.9 ng/mL and 0.26 m/L, respectively.", [["lymphocyte", "ANATOMY", 11, 21], ["serum", "ANATOMY", 44, 49], ["lymphocyte", "CELL", 11, 21], ["serum", "ORGANISM_SUBSTANCE", 44, 49], ["d-dimer", "GENE_OR_GENE_PRODUCT", 50, 57], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 62, 75], ["serum d-dimer", "PROTEIN", 44, 57], ["The median lymphocyte count", "TEST", 0, 27], ["a serum d-dimer", "TEST", 42, 57], ["procalcitonin", "TEST", 62, 75], ["median lymphocyte count", "OBSERVATION", 4, 27]]], ["Patients reported a median CD4 count of 551, and the viral load was ,120 in 96% (n = 26) of the patients.", [["Patients", "ORGANISM", 0, 8], ["patients", "ORGANISM", 96, 104], ["CD4", "PROTEIN", 27, 30], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 96, 104], ["a median CD4 count", "TEST", 18, 36], ["the viral load", "TEST", 49, 63]]], ["Data on antiretroviral regimen before presentation were unavailable in 15% (n = 4) of the patients.", [["patients", "ORGANISM", 90, 98], ["patients", "SPECIES", 90, 98], ["antiretroviral regimen", "TREATMENT", 8, 30]]], ["Among those with full data, integrase-based regimen was used in 33% (n = 9), nonnucleoside reverse transcriptase inhibitor (NNRTI) in 19% (n = 7), protease inhibitor (PI) + integrase in 19% (n = 7), NNRTI + integrase in 7% (n = 3), and PI based in only 1 patient.To the Editors:Of the hospitalized patients, 26% (n = 7) received hydroxychloroquine and 30% (n = 6) were managed with empiric antibiotics for suspected community-acquired pneumonia.", [["nonnucleoside reverse transcriptase inhibitor", "CHEMICAL", 77, 122], ["hydroxychloroquine", "CHEMICAL", 329, 347], ["pneumonia", "DISEASE", 435, 444], ["hydroxychloroquine", "CHEMICAL", 329, 347], ["nonnucleoside reverse transcriptase", "GENE_OR_GENE_PRODUCT", 77, 112], ["protease inhibitor", "GENE_OR_GENE_PRODUCT", 147, 165], ["PI", "SIMPLE_CHEMICAL", 167, 169], ["NNRTI + integrase", "GENE_OR_GENE_PRODUCT", 199, 216], ["patient", "ORGANISM", 255, 262], ["patients", "ORGANISM", 298, 306], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 329, 347], ["nonnucleoside reverse transcriptase", "PROTEIN", 77, 112], ["patient", "SPECIES", 255, 262], ["patients", "SPECIES", 298, 306], ["integrase-based regimen", "TREATMENT", 28, 51], ["nonnucleoside reverse transcriptase inhibitor", "TREATMENT", 77, 122], ["NNRTI", "TEST", 124, 129], ["protease inhibitor", "TREATMENT", 147, 165], ["integrase", "TEST", 173, 182], ["NNRTI + integrase", "TREATMENT", 199, 216], ["PI", "TREATMENT", 236, 238], ["hydroxychloroquine", "TREATMENT", 329, 347], ["empiric antibiotics", "TREATMENT", 382, 401], ["acquired pneumonia", "PROBLEM", 426, 444], ["pneumonia", "OBSERVATION", 435, 444]]], ["Antiretroviral therapy was held during hospitalization.", [["Antiretroviral therapy", "TREATMENT", 0, 22]]], ["None of the patients had a superimposed infection, defined as an isolated organism in a positive sputum, urine, or blood culture.", [["sputum", "ANATOMY", 97, 103], ["urine", "ANATOMY", 105, 110], ["blood", "ANATOMY", 115, 120], ["infection", "DISEASE", 40, 49], ["patients", "ORGANISM", 12, 20], ["urine", "ORGANISM_SUBSTANCE", 105, 110], ["blood", "ORGANISM_SUBSTANCE", 115, 120], ["patients", "SPECIES", 12, 20], ["a superimposed infection", "PROBLEM", 25, 49], ["an isolated organism", "PROBLEM", 62, 82], ["a positive sputum, urine", "TEST", 86, 110], ["blood culture", "TEST", 115, 128], ["superimposed", "OBSERVATION_MODIFIER", 27, 39], ["infection", "OBSERVATION", 40, 49]]], ["After a median hospital course of 10 days, 3 patients required intensive unit level of care and 2 of them had died.", [["patients", "ORGANISM", 45, 53], ["patients", "SPECIES", 45, 53], ["intensive unit level of care", "TREATMENT", 63, 91]]], ["The deceased subjects were elderly patients, with multiple coexisting conditions whose course was complicated by septic shock and multiorgan dysfunction syndrome.", [["multiorgan", "ANATOMY", 130, 140], ["septic shock", "DISEASE", 113, 125], ["multiorgan dysfunction syndrome", "DISEASE", 130, 161], ["subjects", "ORGANISM", 13, 21], ["patients", "ORGANISM", 35, 43], ["patients", "SPECIES", 35, 43], ["multiple coexisting conditions", "PROBLEM", 50, 80], ["septic shock", "PROBLEM", 113, 125], ["multiorgan dysfunction syndrome", "PROBLEM", 130, 161], ["septic shock", "OBSERVATION", 113, 125], ["multiorgan dysfunction syndrome", "OBSERVATION", 130, 161]]], ["There were no cases of hospital admission for patients who were managed in the ambulatory setting.To the Editors:In this series of HIV patients with COVID-19, we found a similarity in presentation with what has been reported for the general population.", [["patients", "ORGANISM", 46, 54], ["HIV", "ORGANISM", 131, 134], ["patients", "ORGANISM", 135, 143], ["patients", "SPECIES", 46, 54], ["HIV", "SPECIES", 131, 134], ["patients", "SPECIES", 135, 143], ["HIV", "SPECIES", 131, 134], ["COVID", "TEST", 149, 154]]], ["Half of the patients were managed in the ambulatory setting with no reported mortality or morbidity.", [["patients", "ORGANISM", 12, 20], ["patients", "SPECIES", 12, 20], ["morbidity", "PROBLEM", 90, 99]]], ["Inhospital survival was 85% and 23% required intensive care unit admission.", [["Inhospital survival", "TEST", 0, 19]]], ["Of note, all 27 patients had well-controlled HIV infection evidenced by elevated CD4 count levels and low viral loads.", [["HIV infection", "DISEASE", 45, 58], ["patients", "ORGANISM", 16, 24], ["HIV", "ORGANISM", 45, 48], ["CD4", "GENE_OR_GENE_PRODUCT", 81, 84], ["CD4", "PROTEIN", 81, 84], ["patients", "SPECIES", 16, 24], ["HIV", "SPECIES", 45, 48], ["well-controlled HIV infection", "PROBLEM", 29, 58], ["elevated CD4 count levels", "PROBLEM", 72, 97], ["low viral loads", "PROBLEM", 102, 117], ["infection", "OBSERVATION", 49, 58], ["elevated", "OBSERVATION_MODIFIER", 72, 80], ["CD4 count", "OBSERVATION", 81, 90], ["low", "OBSERVATION_MODIFIER", 102, 105], ["viral loads", "OBSERVATION", 106, 117]]], ["As the challenge involving the management of COVID-19 evolves, large-scale studies are necessary to better understand the management and prognosis of patients with HIV who present with COVID-19.", [["HIV", "DISEASE", 164, 167], ["patients", "ORGANISM", 150, 158], ["HIV", "ORGANISM", 164, 167], ["patients", "SPECIES", 150, 158], ["HIV", "SPECIES", 164, 167], ["HIV", "SPECIES", 164, 167], ["COVID", "TEST", 45, 50], ["large-scale studies", "TEST", 63, 82], ["HIV", "PROBLEM", 164, 167], ["COVID", "TEST", 185, 190]]]], "PMC7273096": [["IntroductionSystems of stroke care in India have been evolving at a rapid pace in recent years to meet the stroke burden, with remarkable advances made in stroke awareness, prevention, rapid triage, treatment, and rehabilitation.", [["stroke", "DISEASE", 23, 29], ["stroke", "DISEASE", 107, 113], ["stroke", "DISEASE", 155, 161], ["stroke care", "TREATMENT", 23, 34], ["the stroke burden", "PROBLEM", 103, 120], ["stroke awareness", "PROBLEM", 155, 171], ["treatment", "TREATMENT", 199, 208], ["rehabilitation", "TREATMENT", 214, 228], ["stroke", "OBSERVATION", 23, 29]]], ["Yet, acute stroke care and poststroke rehabilitation in the country have limitations owing to the economic constraints and poor access to healthcare, burdening a large section of the population.1It is not surprising that the health impact of the SARS\u2010CoV\u20102/COVID\u201019 pandemic sweeping the world has created challenges for stroke care in India, which are distinct from those faced by the developed world.IntroductionWe conducted a survey of stroke experts from 13 established stroke centers in India using a brief questionnaire aimed at capturing the impact of the COVID\u201019 pandemic and the nationwide lockdown on acute stroke care services.", [["stroke", "DISEASE", 11, 17], ["SARS", "DISEASE", 246, 250], ["CoV\u20102", "CHEMICAL", 251, 256], ["stroke", "DISEASE", 321, 327], ["stroke", "DISEASE", 439, 445], ["stroke", "DISEASE", 474, 480], ["acute stroke", "DISEASE", 612, 624], ["acute stroke care", "TREATMENT", 5, 22], ["poststroke rehabilitation", "TREATMENT", 27, 52], ["a large section of the population", "TREATMENT", 160, 193], ["CoV\u20102/COVID\u2010", "TREATMENT", 251, 263], ["stroke care", "TREATMENT", 321, 332], ["stroke", "PROBLEM", 439, 445], ["the COVID\u2010", "TREATMENT", 559, 569], ["acute stroke care services", "TREATMENT", 612, 638], ["acute", "OBSERVATION_MODIFIER", 5, 10], ["stroke", "OBSERVATION", 11, 17], ["large", "OBSERVATION_MODIFIER", 162, 167], ["not surprising", "UNCERTAINTY", 201, 215]]], ["In this report here, we, stroke neurologists from high\u2010volume stroke centers in India, identify the weak links in acute stroke care, poststroke rehabilitation, and care of stroke survivors during the COVID\u201019 outbreak, and suggest remedial measures with a special focus on telemedicine.The SARS\u2010CoV\u20102 outbreak in India and impact on health careIndia is home to 1.37 billion people, nearly one fifth of the world's population.2The first case of COVID\u201019 in India was reported on January 30, 2020 and rapid escalation of cases was noted in mid\u2010March, with confirmed cases crossing 70,756 as of May 12, 2020.", [["stroke", "DISEASE", 25, 31], ["high\u2010volume stroke", "DISEASE", 50, 68], ["stroke", "DISEASE", 120, 126], ["stroke", "DISEASE", 172, 178], ["SARS", "DISEASE", 290, 294], ["COVID", "DISEASE", 444, 449], ["people", "ORGANISM", 374, 380], ["people", "SPECIES", 374, 380], ["acute stroke care", "TREATMENT", 114, 131], ["poststroke rehabilitation", "TREATMENT", 133, 158], ["stroke survivors", "PROBLEM", 172, 188], ["remedial measures", "TREATMENT", 231, 248], ["acute", "OBSERVATION_MODIFIER", 114, 119], ["stroke", "OBSERVATION", 120, 126], ["mid", "ANATOMY_MODIFIER", 538, 541]]], ["A nationwide lockdown in India was imposed on March 25, 2020, which brought to a standstill nearly all travel and commercial human activities across the country.3The swift and strict restrictive measures adopted have at least temporarily halted the flooding of the health services with COVID\u201019 cases, though current epidemiological models project the peak of the curve for hospital admissions to be in June or July 2020.3,4", [["human", "ORGANISM", 125, 130], ["human", "SPECIES", 125, 130], ["human", "SPECIES", 125, 130], ["The swift", "TREATMENT", 162, 171], ["strict restrictive measures", "TREATMENT", 176, 203], ["strict restrictive", "OBSERVATION_MODIFIER", 176, 194]]]], "PMC7173584": [["Expression of Genetic InformationAs described in Chapter 1, no virus yet discovered has the genetic information that encodes the tools necessary for the generation of metabolic energy or for protein synthesis (ribosomes).", [["Chapter 1", "GENE_OR_GENE_PRODUCT", 49, 58], ["ribosomes", "CELLULAR_COMPONENT", 210, 219], ["virus", "PROBLEM", 63, 68], ["protein synthesis (ribosomes", "TREATMENT", 191, 219]]], ["So all viruses are dependent on their host cells for these functions, but the way in which viruses persuade their hosts to express their genetic information for them varies considerably.", [["cells", "ANATOMY", 43, 48], ["host cells", "CELL", 38, 48], ["host cells", "CELL_TYPE", 38, 48], ["all viruses", "PROBLEM", 3, 14], ["viruses", "OBSERVATION", 7, 14]]], ["Patterns of virus replication are determined by tight controls on virus gene expression.", [["virus replication", "PROBLEM", 12, 29], ["virus gene expression", "TREATMENT", 66, 87], ["virus replication", "OBSERVATION", 12, 29]]], ["There are fundamental differences in the control mechanisms of these processes in prokaryotic and eukaryotic cells, and these differences inevitably affect the viruses that use them as hosts.", [["cells", "ANATOMY", 109, 114], ["eukaryotic cells", "CELL", 98, 114], ["prokaryotic and eukaryotic cells", "CELL_TYPE", 82, 114], ["fundamental differences", "PROBLEM", 10, 33], ["prokaryotic and eukaryotic cells", "PROBLEM", 82, 114], ["the viruses", "PROBLEM", 156, 167], ["fundamental", "OBSERVATION_MODIFIER", 10, 21], ["differences", "OBSERVATION_MODIFIER", 22, 33], ["eukaryotic cells", "OBSERVATION", 98, 114], ["viruses", "OBSERVATION", 160, 167]]], ["In addition, the relative simplicity and compact size of most virus genomes (compared with those of cells) creates further limits.", [["cells", "ANATOMY", 100, 105], ["cells", "CELL", 100, 105], ["the relative simplicity", "PROBLEM", 13, 36], ["most virus genomes", "PROBLEM", 57, 75], ["simplicity", "OBSERVATION_MODIFIER", 26, 36], ["compact", "OBSERVATION_MODIFIER", 41, 48], ["size", "OBSERVATION_MODIFIER", 49, 53], ["most", "OBSERVATION_MODIFIER", 57, 61], ["virus genomes", "OBSERVATION", 62, 75]]], ["Cells have evolved varied and complex mechanisms for controlling gene expression by using their extensive genetic capacity.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["varied", "OBSERVATION_MODIFIER", 19, 25]]], ["Viruses have had to achieve highly specific quantitative, temporal, and spatial control of expression with much more limited genetic resources.", [["Viruses", "PROBLEM", 0, 7]]], ["Viruses have counteracted their genetic limitations by the evolving of a range of solutions to these problems.", [["Viruses", "PROBLEM", 0, 7], ["these problems", "PROBLEM", 95, 109]]], ["These mechanisms include:\u25aaPowerful positive and negative signals that promote or repress gene expression\u25aaHighly compressed genomes in which overlapping reading frames are common\u25aaControl signals that are frequently nested within other genes\u25aaStrategies that allow multiple polypeptides to be created from a single messenger RNA", [["overlapping reading frames", "DNA", 140, 166], ["messenger RNA", "RNA", 312, 325], ["Highly compressed genomes", "PROBLEM", 105, 130], ["multiple polypeptides", "TREATMENT", 262, 283], ["a single messenger RNA", "TREATMENT", 303, 325], ["compressed", "OBSERVATION_MODIFIER", 112, 122], ["genomes", "OBSERVATION", 123, 130]]]], "PMC7326392": [["IntroductionThe World Health Organization declared the 2019\u20132020 coronavirus disease (COVID-19) outbreak a Public Health Emergency of International Concern on 30 January 2020 and a pandemic on 11 March 2020 [1, 2].", [["coronavirus disease", "DISEASE", 65, 84], ["2019\u20132020 coronavirus", "SPECIES", 55, 76], ["coronavirus disease", "PROBLEM", 65, 84], ["coronavirus disease", "OBSERVATION", 65, 84]]], ["In Italy, the first cluster of SARS-CoV-2-positive patients was reported in Lombardy, a region of northern Italy, on 21 February, and after entering, COVID-19 has been spreading fast [3\u20137].", [["SARS", "DISEASE", 31, 35], ["SARS-CoV-2", "ORGANISM", 31, 41], ["patients", "ORGANISM", 51, 59], ["patients", "SPECIES", 51, 59], ["SARS-CoV", "SPECIES", 31, 39], ["SARS", "TEST", 31, 35], ["CoV", "TEST", 36, 39], ["COVID", "TEST", 150, 155]]], ["The outbreak has caused the Italian government to take severe protective measures: on 9 March, a national quarantine was imposed, restricting population movement, whereas on 21 March, a further enlargement of the \u201clockdown\u201d was announced, shutting down all unnecessary businesses and industries [8\u201310].IntroductionIn this scenario, delivering healthcare is extremely challenging given the competing risks of death from acute/subacute diseases, such as cancer or cardiovascular diseases, with death from COVID-19 infection [11].", [["cancer", "ANATOMY", 452, 458], ["cardiovascular", "ANATOMY", 462, 476], ["death", "DISEASE", 408, 413], ["cancer", "DISEASE", 452, 458], ["cardiovascular diseases", "DISEASE", 462, 485], ["death", "DISEASE", 492, 497], ["COVID-19", "CHEMICAL", 503, 511], ["infection", "DISEASE", 512, 521], ["cancer", "CANCER", 452, 458], ["cardiovascular", "ANATOMICAL_SYSTEM", 462, 476], ["severe protective measures", "TREATMENT", 55, 81], ["a national quarantine", "TREATMENT", 95, 116], ["a further enlargement", "PROBLEM", 184, 205], ["death", "PROBLEM", 408, 413], ["acute/subacute diseases", "PROBLEM", 419, 442], ["cancer", "PROBLEM", 452, 458], ["cardiovascular diseases", "PROBLEM", 462, 485], ["death", "PROBLEM", 492, 497], ["COVID-19 infection", "PROBLEM", 503, 521], ["enlargement", "OBSERVATION", 194, 205], ["acute", "OBSERVATION_MODIFIER", 419, 424], ["subacute", "OBSERVATION_MODIFIER", 425, 433], ["diseases", "OBSERVATION", 434, 442], ["cardiovascular", "ANATOMY", 462, 476]]], ["To ensure both healthcare worker (HCW) and patient safety, long-term sustainability of services and resource availability were shifted to patients critically ill with COVID-19, delaying non-emergency procedures [4, 12].", [["patient", "ORGANISM", 43, 50], ["patients", "ORGANISM", 138, 146], ["patient", "SPECIES", 43, 50], ["patients", "SPECIES", 138, 146], ["COVID", "TREATMENT", 167, 172]]], ["However, efforts should be made not to compromise the prognosis of patients with high-risk acute/subacute diseases, still requiring a high standard of care.", [["patients", "ORGANISM", 67, 75], ["patients", "SPECIES", 67, 75], ["high-risk acute/subacute diseases", "PROBLEM", 81, 114], ["a high standard of care", "TREATMENT", 132, 155], ["acute", "OBSERVATION_MODIFIER", 91, 96], ["subacute", "OBSERVATION_MODIFIER", 97, 105], ["diseases", "OBSERVATION", 106, 114]]], ["Furthermore, hospital organizations need to protect healthcare personnel from the risk of infection and limit the possibility for HCWs to transmit the disease [13].IntroductionInterventional radiology (IR) has a critical role in the management of patients within the healthcare system, being involved in the treatment of both urgent and chronic diseases and having a pivotal role within the therapeutic pathway of many oncologic patients, also during a pandemic [14].", [["infection", "DISEASE", 90, 99], ["patients", "ORGANISM", 247, 255], ["patients", "ORGANISM", 429, 437], ["patients", "SPECIES", 247, 255], ["patients", "SPECIES", 429, 437], ["infection", "PROBLEM", 90, 99], ["chronic diseases", "PROBLEM", 337, 353], ["infection", "OBSERVATION", 90, 99], ["chronic", "OBSERVATION_MODIFIER", 337, 344], ["diseases", "OBSERVATION", 345, 353]]], ["On the other hand, the risk of transmission is related to the degree of contact between patients and HCWs.", [["patients", "ORGANISM", 88, 96], ["patients", "SPECIES", 88, 96]]], ["Therefore, certain subspecialties like IR entail a greater risk of acquiring and transmitting infection due to the close patient contact and invasive patient care these services provide [15\u201317].IntroductionThis makes it imperative to develop and set up guidelines in order to limit transmission, while optimizing resources, rearranging work site and health force, and enforcing segregation and disinfection parameters [18].IntroductionThe primary aims of our study were to perform a descriptive analysis and longitudinal study of IR activity performed in our metropolitan tertiary care hospital during the COVID-19 pandemic, and compare the number and characteristics of IR procedures we carried out with those performed in the same period of 2019.", [["infection", "DISEASE", 94, 103], ["patient", "ORGANISM", 121, 128], ["patient", "ORGANISM", 150, 157], ["patient", "SPECIES", 121, 128], ["patient", "SPECIES", 150, 157], ["transmitting infection", "PROBLEM", 81, 103], ["our study", "TEST", 455, 464], ["a descriptive analysis", "TEST", 481, 503], ["longitudinal study", "TEST", 508, 526], ["IR activity", "TEST", 530, 541], ["the COVID", "TEST", 602, 611], ["IR procedures", "TEST", 671, 684]]], ["The secondary objective was to describe how to reorganize IR activity to effectively deal with the COVID-19 spread.Study design and setting ::: Materials and methodsThis is a retrospective observational study conducted in a large tertiary-care 1526-bed teaching hospital in Rome (Italy).", [["the COVID", "TEST", 95, 104], ["a retrospective observational study", "TEST", 173, 208]]], ["Our center is a hub for emergency medicine, adult/pediatric traumas, and oncological and cardiovascular diseases, as well as neurovascular and body interventional radiology.", [["cardiovascular", "ANATOMY", 89, 103], ["neurovascular", "ANATOMY", 125, 138], ["body", "ANATOMY", 143, 147], ["traumas", "DISEASE", 60, 67], ["cardiovascular diseases", "DISEASE", 89, 112], ["neurovascular", "MULTI-TISSUE_STRUCTURE", 125, 138], ["body", "ORGANISM_SUBDIVISION", 143, 147], ["emergency medicine", "TREATMENT", 24, 42], ["cardiovascular", "ANATOMY", 89, 103], ["diseases", "OBSERVATION", 104, 112]]], ["Our center was also designated as a hub even for COVID-19 infection treatment.Study design and setting ::: Materials and methodsAll consecutive patients admitted to our department to undergo an interventional radiology procedure between January 30 and April 8, 2020, were included (COVID-era group).", [["COVID-19", "CHEMICAL", 49, 57], ["infection", "DISEASE", 58, 67], ["patients", "ORGANISM", 144, 152], ["patients", "SPECIES", 144, 152], ["COVID-19 infection treatment", "TREATMENT", 49, 77], ["an interventional radiology procedure", "TREATMENT", 191, 228], ["infection", "OBSERVATION", 58, 67]]], ["This IR activity was compared with that performed in the same time range of the previous year (2019; non-COVID-era group).Study design and setting ::: Materials and methodsFor each included patient, demographic and clinical characteristics as well as procedural data were retrospectively recorded by reviewing the patient\u2019s charts and electronic medical records and analyzed.", [["patient", "ORGANISM", 190, 197], ["patient", "ORGANISM", 314, 321], ["patient", "SPECIES", 190, 197], ["patient", "SPECIES", 314, 321], ["procedural data", "TEST", 251, 266]]], ["Demographic, clinical, and procedural variables are shown in Table 1.Study design and setting ::: Materials and methodsFor the COVID-era group, COVID-19 status (negative/low risk, suspected/intermediate-to-high risk, positive) was also registered before the procedure and during the admission (in case of a late positive result), based on clinical/laboratory data and SARS-CoV-2 culture test (Table 1).Study design and setting ::: Materials and methodsA further analysis was also performed considering two subgroups of patients, based on a temporal criterion (before and after 11 March): the so-called pre-lockdown period subgroup (pre-LDP\u201430 January\u201310 March) and lockdown period subgroup (LDP\u201411 March\u20138 April, 2020); these subgroups of patients were also compared with those in a similar period of 2019.Study design and setting ::: Materials and methodsThis study followed the protocol and the principles of the Declaration of Helsinki, in accordance with the International Conference on Harmonization Tripartite Guideline for Good Clinical Practice, and was approved by our local Institutional Review Board.", [["patients", "ORGANISM", 519, 527], ["patients", "ORGANISM", 739, 747], ["patients", "SPECIES", 519, 527], ["patients", "SPECIES", 739, 747], ["COVID", "TEST", 144, 149], ["the procedure", "TREATMENT", 254, 267], ["clinical/laboratory data", "TEST", 339, 363], ["SARS", "TEST", 368, 372], ["CoV", "TEST", 373, 376], ["culture test", "TEST", 379, 391], ["methodsA further analysis", "TEST", 445, 470], ["This study", "TEST", 856, 866], ["the protocol", "TREATMENT", 876, 888]]], ["Written informed consent was obtained from all subjects prior to any treatment.IR activity reorganization to reduce virus spread ::: Materials and methodsTo comply with government directives, on 11 March 2020, our department has implemented organizational changes to modulate the elective IR activity.", [["any treatment", "TREATMENT", 65, 78], ["the elective IR activity", "TREATMENT", 276, 300]]], ["One angiography suite has been dedicated to COVID-19 patients whereas the other has been dedicated to elective IR for about 6 h a day with an on-call activity for emergencies in the remaining 18 h of each day.", [["patients", "ORGANISM", 53, 61], ["patients", "SPECIES", 53, 61], ["One angiography", "TEST", 0, 15]]], ["Only one weekly slot for CT-guided activity has been planned whereas dedicated US-guided slots, usually performed in ultrasound rooms, were canceled.", [["CT", "TEST", 25, 27], ["dedicated US", "TEST", 69, 81]]], ["In detail, during LDP, US-guided procedures were performed bedside, to reduce contamination, or in the angiography suite whenever possible, to reduce contamination and the number of IR consultants in the hospital.", [["US", "TEST", 23, 25], ["guided procedures", "TEST", 26, 43], ["contamination", "PROBLEM", 78, 91]]], ["Based on these organizational changes, one IR consultant was actively dedicated to IR angiographic or CT slots in the morning with another one on-call for emergency in the remaining hours of the day.", [["CT slots", "TEST", 102, 110]]], ["Access to residents in the angio-suite has been reduced as much as possible and video consultations were offered to patients and clinicians.", [["patients", "ORGANISM", 116, 124], ["patients", "SPECIES", 116, 124]]], ["Furthermore, access to our department has been restricted to visitors, students, external colleagues, and specialists.IR activity reorganization to reduce virus spread ::: Materials and methodsTo reduce virus diffusion through infected patients, each patient has been equipped with a surgical mask, regardless of risk factors.", [["patients", "ORGANISM", 236, 244], ["patient", "ORGANISM", 251, 258], ["patients", "SPECIES", 236, 244], ["patient", "SPECIES", 251, 258], ["virus diffusion", "PROBLEM", 203, 218], ["a surgical mask", "TREATMENT", 282, 297], ["risk factors", "PROBLEM", 313, 325], ["virus", "OBSERVATION", 203, 208], ["infected", "OBSERVATION_MODIFIER", 227, 235]]], ["Patients who would benefit from a bedside procedure have been treated in their ward in order to limit their movement.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["a bedside procedure", "TREATMENT", 32, 51]]], ["Any effort has been put in place to reduce waiting time in preoperative holding areas.IR activity reorganization to reduce virus spread ::: Materials and methodsAll patients admitted to our hospital to undergo IR elective procedures always performed accurate triage, chest X-ray, and a rhino-pharyngeal swab, regardless of symptoms and risk factors, to avoid room contamination and unprotected HCWs exposure; testing all patients allowed us to create three different dedicated routes, for negative, doubt/unknown waiting for results, and positive patients.IR activity reorganization to reduce virus spread ::: Materials and methodsTo avoid useless waste, the use of personal protective equipment was optimized, based on patient risk, as previously defined, or procedure type: standard precautions (surgical cap, surgical mask, goggles, work uniform, and latex gloves) for low-risk patients, airborne precautions (disposable surgical cap, medical protective mask FFP2/N95, work uniform, disposable latex gloves, water-resistant disposable medical protective uniform, and full-face protective device) for intermediate- or high-risk patients, as well as for COVID-positive patients, since the need of endotracheal intubation could be surely excluded, for potential intraprocedural complication.", [["chest", "ANATOMY", 267, 272], ["pharyngeal swab", "ANATOMY", 292, 307], ["endotracheal", "ANATOMY", 1198, 1210], ["patients", "ORGANISM", 165, 173], ["patients", "ORGANISM", 421, 429], ["patients", "ORGANISM", 547, 555], ["patient", "ORGANISM", 720, 727], ["patients", "ORGANISM", 881, 889], ["patients", "ORGANISM", 1130, 1138], ["patients", "ORGANISM", 1170, 1178], ["patients", "SPECIES", 165, 173], ["patients", "SPECIES", 421, 429], ["patients", "SPECIES", 547, 555], ["patient", "SPECIES", 720, 727], ["patients", "SPECIES", 881, 889], ["patients", "SPECIES", 1130, 1138], ["patients", "SPECIES", 1170, 1178], ["IR elective procedures", "TREATMENT", 210, 232], ["accurate triage", "TEST", 250, 265], ["chest X-ray", "TEST", 267, 278], ["a rhino-pharyngeal swab", "TEST", 284, 307], ["symptoms", "PROBLEM", 323, 331], ["risk factors", "PROBLEM", 336, 348], ["room contamination", "PROBLEM", 359, 377], ["useless waste", "TREATMENT", 640, 653], ["personal protective equipment", "TREATMENT", 666, 695], ["standard precautions", "TREATMENT", 776, 796], ["surgical cap", "TREATMENT", 798, 810], ["surgical mask", "TREATMENT", 812, 825], ["goggles", "TREATMENT", 827, 834], ["latex gloves", "TREATMENT", 854, 866], ["airborne precautions", "TREATMENT", 891, 911], ["disposable surgical cap", "TREATMENT", 913, 936], ["medical protective mask FFP2", "TREATMENT", 938, 966], ["disposable latex gloves", "TREATMENT", 986, 1009], ["full-face protective device", "TREATMENT", 1070, 1097], ["endotracheal intubation", "TREATMENT", 1198, 1221], ["potential intraprocedural complication", "PROBLEM", 1252, 1290], ["chest", "ANATOMY", 267, 272], ["pharyngeal", "ANATOMY", 292, 302]]], ["It is mandatory to highlight that there are no IR aerosol-generating procedures (AGP), but for procedures like lung biopsy, pleural drainage, lung ablation, or bronchial artery embolization, patients could experience hemoptysis during the procedures which can incite violent coughing and aerosolization; hence, it may be considered an AGP.\u201cSafety\u201d healthcare worker analysis ::: Materials and methodsTest was only performed in symptomatic HCWs or after unprotected exposure to a patient with confirmed or suspected COVID-19 regardless of symptoms [19]; in detail, no widespread testing was used in our hospital for HCWs.\u201cSafety\u201d healthcare worker analysis ::: Materials and methodsThe number of IR team components (composed of 9 IRs, 9 technicians, 10 nurses, and 2 administrative personnel) who experienced symptoms suspected for COVID-19 or underwent COVID-19 test, or underwent preventive quarantine, or was COVID-19 positive or hospitalized for COVID-19 was registered.\u201cSafety\u201d healthcare worker analysis ::: Materials and methodsGiven that the presumed potential time lag between exposure to coronavirus and clinical infection is up to about 14 days, data were recorded till April 22 in order not to miss late healthcare worker or patient infections derived from exposures up to April 8.Statistical analysis ::: Materials and methodsDemographic, clinical, and procedural characteristics of all patients for both the non-COVID era and the COVID era were collected.", [["lung", "ANATOMY", 111, 115], ["pleural", "ANATOMY", 124, 131], ["lung", "ANATOMY", 142, 146], ["bronchial artery", "ANATOMY", 160, 176], ["hemoptysis", "DISEASE", 217, 227], ["coughing", "DISEASE", 275, 283], ["coronavirus", "DISEASE", 1097, 1108], ["infection", "DISEASE", 1122, 1131], ["infections", "DISEASE", 1244, 1254], ["lung biopsy", "MULTI-TISSUE_STRUCTURE", 111, 122], ["pleural", "MULTI-TISSUE_STRUCTURE", 124, 131], ["lung", "ORGAN", 142, 146], ["bronchial artery", "MULTI-TISSUE_STRUCTURE", 160, 176], ["patients", "ORGANISM", 191, 199], ["AGP", "GENE_OR_GENE_PRODUCT", 335, 338], ["patient", "ORGANISM", 479, 486], ["coronavirus", "ORGANISM", 1097, 1108], ["patient", "ORGANISM", 1236, 1243], ["patients", "ORGANISM", 1399, 1407], ["AGP", "PROTEIN", 335, 338], ["patients", "SPECIES", 191, 199], ["patient", "SPECIES", 479, 486], ["patient", "SPECIES", 1236, 1243], ["patients", "SPECIES", 1399, 1407], ["IR aerosol", "TREATMENT", 47, 57], ["procedures", "TEST", 95, 105], ["lung biopsy", "TEST", 111, 122], ["pleural drainage", "TREATMENT", 124, 140], ["lung ablation", "TREATMENT", 142, 155], ["bronchial artery embolization", "TREATMENT", 160, 189], ["hemoptysis", "PROBLEM", 217, 227], ["the procedures", "TREATMENT", 235, 249], ["violent coughing", "PROBLEM", 267, 283], ["aerosolization", "TREATMENT", 288, 302], ["an AGP", "PROBLEM", 332, 338], ["Test", "TEST", 400, 404], ["COVID", "TEST", 515, 520], ["symptoms", "PROBLEM", 538, 546], ["widespread testing", "TEST", 567, 585], ["symptoms", "PROBLEM", 808, 816], ["COVID", "TEST", 831, 836], ["COVID", "TEST", 853, 858], ["preventive quarantine", "TREATMENT", 881, 902], ["COVID", "TEST", 911, 916], ["COVID", "TEST", 949, 954], ["coronavirus", "PROBLEM", 1097, 1108], ["clinical infection", "PROBLEM", 1113, 1131], ["patient infections", "PROBLEM", 1236, 1254], ["lung", "ANATOMY", 111, 115], ["biopsy", "OBSERVATION", 116, 122], ["pleural", "ANATOMY", 124, 131], ["drainage", "OBSERVATION", 132, 140], ["lung", "ANATOMY", 142, 146], ["ablation", "OBSERVATION", 147, 155], ["bronchial artery", "ANATOMY", 160, 176], ["embolization", "OBSERVATION", 177, 189], ["hemoptysis", "OBSERVATION", 217, 227], ["coronavirus", "OBSERVATION", 1097, 1108]]], ["A univariable analysis was conducted to compare demographics, clinical, and procedural characteristics of the two periods.", [["A univariable analysis", "TEST", 0, 22]]], ["For continuous variables, means, medians, interquartile ranges (IQR), and standard deviations (SD) are presented and p values calculated with t test or Wilcoxon rank-sum depending on normality distribution (tested with Shapiro Wilk\u2019s).", [["p values", "TEST", 117, 125], ["t test", "TEST", 142, 148], ["Wilcoxon rank", "TEST", 152, 165], ["normality distribution", "PROBLEM", 183, 205]]], ["For categorical measures, frequencies and percentages are presented and p values calculated with Fisher\u2019s exact test or \u03c72 as appropriate.", [["categorical measures", "TEST", 4, 24]]], ["No adjustments were made for multiple comparisons.", [["multiple comparisons", "TEST", 29, 49]]], ["Statistical significance threshold was set at 5%.", [["Statistical significance threshold", "PROBLEM", 0, 34]]], ["The statistical analysis has been performed using STATA 15.1 (StataCorp LLC).Subgroup analysis: pre-lockdown period (pre-LDP) ::: ResultsIn the pre-LDP (30 Jan\u201310 Mar), a total of 945 procedures were analyzed: 462 in 2019 and 483 in 2020 with a relative increase of 4.5%.", [["The statistical analysis", "TEST", 0, 24], ["STATA", "TEST", 50, 55], ["Subgroup analysis", "TEST", 77, 94], ["increase", "OBSERVATION_MODIFIER", 254, 262]]], ["Patients\u2019 clinical, radiological, and procedural characteristics are shown in Table 3.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8]]], ["CT and US + fluoroscopic guidance were more frequently used in 2019 while US, US + CT, and fluoroscopic guidance were more frequently used in 2020 (p = .006).", [["CT", "TEST", 0, 2], ["US", "TEST", 7, 9], ["fluoroscopic guidance", "TEST", 12, 33], ["US", "TEST", 74, 76], ["US", "TEST", 78, 80], ["CT", "TEST", 83, 85], ["fluoroscopic guidance", "TEST", 91, 112]]], ["Head, abdomen and bone procedures were more frequent in 2020 (p = .013), with no bedside procedures performed during 2020 (vs 12/483, 2.6%; p < .001).Subgroup analysis: lockdown period (pre-LDP) ::: ResultsWhen considering the lockdown period (11 Mar\u20138 Apr), a total of 551 procedures were analyzed: 363 in 2019 and 188 in 2020 with a 48.2% relative decrease.", [["abdomen", "ANATOMY", 6, 13], ["bone", "ANATOMY", 18, 22], ["abdomen", "ORGAN", 6, 13], ["bone", "TISSUE", 18, 22], ["Head, abdomen and bone procedures", "TEST", 0, 33], ["bedside procedures", "TEST", 81, 99], ["vs", "TEST", 123, 125], ["abdomen", "ANATOMY", 6, 13], ["bone", "ANATOMY", 18, 22], ["decrease", "OBSERVATION_MODIFIER", 350, 358]]], ["Patients\u2019 clinical, radiological, and procedural characteristics are shown in Table 4 and Table 5.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8]]], ["Demographics and procedural characteristics were comparable, except for ward of provenance: emergency departments (15.15% vs 10.11%), intensive care units (0.55% vs 2.13%), and outpatients (6.06% vs 3.19%) (p = .048); also, oncological setting differed between the two periods, with a decreasing of non-oncologic patients (43.25% vs 28.19%) and an increasing of both procedures in oncologic patients (38.02% vs 48.94%) and oncologic treatments (18.73% vs 22.87%) (p = .003).", [["patients", "ORGANISM", 313, 321], ["patients", "ORGANISM", 391, 399], ["patients", "SPECIES", 313, 321], ["patients", "SPECIES", 391, 399], ["oncologic treatments", "TREATMENT", 423, 443], ["increasing", "OBSERVATION_MODIFIER", 348, 358]]], ["Bedside procedures were more common during 2020 than 2019 (2.13% vs 0%; p = .01).Suspected or COVID-19-positive patients ::: ResultsAll patients referring to our emergency department underwent nasopharyngeal swab for SARS-CoV-2 culture test; all patients, regardless of the risk class, were equipped with a surgical mask.Suspected or COVID-19-positive patients ::: ResultsDuring the whole COVID era, nine patients (9/671, 1.34%) were classified as suspected while one patient (1/671, 0.15%) was COVID-19 positive; considering the sole lockdown period, we had 7 suspected patients (7/188, 3.72%) and one COVID-19-positive patient (1/188, 0.53%).\u201cSafety\u201d healthcare workers analysis ::: ResultsCOVID-19 testing was performed only in 2 nurses and 2 technicians (4/30, 13.3%); all of them were asymptomatic so no one experienced a preventive quarantine.", [["nasopharyngeal swab", "ANATOMY", 193, 212], ["COVID-19", "GENE_OR_GENE_PRODUCT", 94, 102], ["patients", "ORGANISM", 112, 120], ["patients", "ORGANISM", 136, 144], ["patients", "ORGANISM", 246, 254], ["COVID-19", "GENE_OR_GENE_PRODUCT", 334, 342], ["patients", "ORGANISM", 352, 360], ["patients", "ORGANISM", 405, 413], ["patient", "ORGANISM", 468, 475], ["patients", "ORGANISM", 571, 579], ["COVID-19", "GENE_OR_GENE_PRODUCT", 603, 611], ["patient", "ORGANISM", 621, 628], ["patients", "SPECIES", 112, 120], ["patients", "SPECIES", 136, 144], ["patients", "SPECIES", 246, 254], ["patients", "SPECIES", 352, 360], ["patients", "SPECIES", 405, 413], ["patient", "SPECIES", 468, 475], ["patients", "SPECIES", 571, 579], ["patient", "SPECIES", 621, 628], ["Bedside procedures", "TEST", 0, 18], ["p", "TEST", 72, 73], ["COVID", "TEST", 94, 99], ["nasopharyngeal swab", "TEST", 193, 212], ["SARS", "PROBLEM", 217, 221], ["CoV-2 culture test", "TEST", 222, 240], ["a surgical mask", "TREATMENT", 305, 320], ["COVID", "TEST", 334, 339], ["COVID", "TEST", 495, 500], ["COVID", "TEST", 603, 608], ["ResultsCOVID", "TEST", 685, 697], ["nasopharyngeal", "ANATOMY", 193, 207]]], ["Test was negative in all HCWs.", [["Test", "TEST", 0, 4]]], ["No HCWs of our team was hospitalized for COVID-19.DiscussionThe coronavirus disease worldwide outbreak has led to a dramatic challenge for all healthcare systems [20].", [["coronavirus disease", "DISEASE", 64, 83], ["COVID-19", "CHEMICAL", 41, 49], ["coronavirus", "ORGANISM", 64, 75], ["COVID", "TEST", 41, 46], ["The coronavirus disease", "PROBLEM", 60, 83], ["coronavirus disease", "OBSERVATION", 64, 83]]], ["IR services would be prepared to adequately perform elective or emergency procedures also under these extreme circumstances.", [["emergency procedures", "TREATMENT", 64, 84]]], ["The main issue is related to the protection of patients and healthcare workers (HCW) from being contaminated or infected, while providing safe IR care for patients [15, 18].", [["patients", "ORGANISM", 47, 55], ["patients", "ORGANISM", 155, 163], ["patients", "SPECIES", 47, 55], ["patients", "SPECIES", 155, 163], ["main", "OBSERVATION_MODIFIER", 4, 8]]], ["However, to date, there are no published data regarding the real impact of COVID-19 pandemic emergency on IR activity, in particular showing if measures and challenges applied were able to obtain clinical results in terms of safety for both patients and HCW.DiscussionBased on this attempt, our retrospective study was performed analyzing our activity from January 30 to April 8, 2020 (COVID era), compared with the same activity obtained in 2019 (non-COVID era).", [["patients", "ORGANISM", 241, 249], ["patients", "SPECIES", 241, 249], ["COVID", "TEST", 75, 80], ["IR activity", "TREATMENT", 106, 117], ["our retrospective study", "TEST", 291, 314]]], ["We also compared two subgroups of patients treated before or after March 11, when a lockdown, provided by government after World Health Organization\u2019s pandemic declaration, was imposed.", [["patients", "ORGANISM", 34, 42], ["patients", "SPECIES", 34, 42]]], ["It became mandatory to postpone outpatient activity and elective procedures, in particular for benign diseases, especially in older patients and those with comorbidities [22].DiscussionHowever, all procedures with a survival benefit needed to be maintained and prioritized whenever possible.", [["patients", "ORGANISM", 132, 140], ["patients", "SPECIES", 132, 140], ["elective procedures", "TREATMENT", 56, 75], ["benign diseases", "PROBLEM", 95, 110], ["all procedures", "TREATMENT", 194, 208], ["a survival benefit", "TREATMENT", 214, 232]]], ["For all these procedures that could not be postponed, accurate selection/stratification of patients is mandatory to avoid unprotected accidental contamination of angio-suite and healthcare workers.DiscussionOur data confirmed that IR activity was significantly reduced in the overall COVID era by 20%.", [["patients", "ORGANISM", 91, 99], ["patients", "SPECIES", 91, 99], ["all these procedures", "TEST", 4, 24], ["DiscussionOur data", "TEST", 197, 215]]], ["These results highlighted that variations in procedure numbers were only due to the lockdown secondary to COVID emergency, and not to year-on-year variability, as demonstrated by the relative slight increase (4.5%) obtained in the pre-LDP.", [["COVID", "DISEASE", 106, 111], ["procedure numbers", "TEST", 45, 62], ["slight", "OBSERVATION_MODIFIER", 192, 198], ["increase", "OBSERVATION_MODIFIER", 199, 207]]], ["In detail, data collected in pre-LDP showed similar trend in terms of oncological classes (procedures performed in non-oncologic or oncologic patients).DiscussionOur activity was also almost homogeneous when considering the overall period; in detail, demographics and procedural characteristics were almost comparable for the two groups in terms of type (therapeutic for more than 80% of them), rate of emergency (33.3% vs 30.1%), indication, and oncological setting.", [["patients", "ORGANISM", 142, 150], ["patients", "SPECIES", 142, 150]]], ["Interesting results were obtained when considering the LDP only, in which we obtained significant differences for oncological setting, with about 72% of procedures performed in oncologic patients (versus 57%), prioritizing procedure for life-threatening conditions, non-deferrable oncologic treatments, and organ-saving procedures, with the same mean number of elective procedures for session in oncologic patients when compared to the same period in 2019.DiscussionUnfortunately, the effects of COVID-19 are not solely limited to the treatment of patients with cancer, but will also hit the entire healthcare community, with consequences for prevention/screening programs and early diagnosis of diseases, management of cardiovascular pathologies, scheduled operations, appointments/consultations that were postponed to prioritize hospital beds and care for COVID-19 pandemic.", [["organ", "ANATOMY", 307, 312], ["cancer", "ANATOMY", 562, 568], ["cardiovascular", "ANATOMY", 720, 734], ["cancer", "DISEASE", 562, 568], ["cardiovascular pathologies", "DISEASE", 720, 746], ["COVID-19", "CHEMICAL", 496, 504], ["patients", "ORGANISM", 187, 195], ["organ", "ORGAN", 307, 312], ["patients", "ORGANISM", 406, 414], ["patients", "ORGANISM", 548, 556], ["cancer", "CANCER", 562, 568], ["cardiovascular", "ANATOMICAL_SYSTEM", 720, 734], ["patients", "SPECIES", 187, 195], ["patients", "SPECIES", 406, 414], ["patients", "SPECIES", 548, 556], ["the LDP", "TEST", 51, 58], ["procedures", "TEST", 153, 163], ["prioritizing procedure", "TREATMENT", 210, 232], ["life-threatening conditions", "PROBLEM", 237, 264], ["oncologic treatments", "TREATMENT", 281, 301], ["organ-saving procedures", "TREATMENT", 307, 330], ["elective procedures", "TREATMENT", 361, 380], ["COVID", "TEST", 496, 501], ["cancer", "PROBLEM", 562, 568], ["diseases", "PROBLEM", 696, 704], ["cardiovascular pathologies", "PROBLEM", 720, 746], ["COVID", "TEST", 858, 863], ["pandemic", "PROBLEM", 867, 875], ["cancer", "OBSERVATION", 562, 568]]], ["Furthermore, COVID-19 also deeply influenced patients\u2019 perception of medical priorities and risk of contagion: patients could be afraid of coming to the hospital and some of them could have decided to stay at home even if their conditions deserved urgent evaluation.", [["patients", "ORGANISM", 45, 53], ["patients", "ORGANISM", 111, 119], ["patients", "SPECIES", 45, 53], ["patients", "SPECIES", 111, 119], ["urgent evaluation", "TEST", 248, 265]]], ["The long-term consequences of this scenario are difficult to estimate, as a long follow-up duration will be required to reveal the effects of delayed diagnosis and management/treatment of diseases.DiscussionIt is interesting to highlight that even if our Hospital was highly exposed to COVID patients, among all treated patients during COVID-period, only 1.5% of them were suspected or COVID-positive.", [["COVID", "DISEASE", 286, 291], ["patients", "ORGANISM", 292, 300], ["patients", "ORGANISM", 320, 328], ["patients", "SPECIES", 292, 300], ["patients", "SPECIES", 320, 328], ["management", "TREATMENT", 164, 174], ["treatment", "TREATMENT", 175, 184], ["diseases", "PROBLEM", 188, 196], ["long-term consequences", "OBSERVATION_MODIFIER", 4, 26], ["positive", "OBSERVATION", 392, 400]]], ["This data confirmed that COVID-positive patients do not require an excessive burden of IR procedures, highlighting the aim of preserving a regular activity for non-COVID patients being able to protect both patients and healthcare workers.", [["COVID", "GENE_OR_GENE_PRODUCT", 25, 30], ["patients", "ORGANISM", 40, 48], ["patients", "ORGANISM", 170, 178], ["patients", "ORGANISM", 206, 214], ["patients", "SPECIES", 40, 48], ["patients", "SPECIES", 170, 178], ["patients", "SPECIES", 206, 214], ["This data", "TEST", 0, 9], ["IR procedures", "TREATMENT", 87, 100], ["non-COVID patients", "TREATMENT", 160, 178]]], ["For this attempt, it is mandatory to follow procedural approaches for the IR workflow, creating different dedicated routes and facilities to reduce contamination, performing when possible bedside US-guided procedures to avoid moving and transporting suspected/positive patients out of their room/area [23], optimizing the use of appropriate personal protective equipment [24\u201326].DiscussionStrict adoption of safe procedures allowed us to have until now no incidents of cross-infection of non-infected from infected patients and no evidence of COVID-19 infection of HCWs in the IR service up to now [27].", [["cross-infection of non-infected from infected", "DISEASE", 469, 514], ["infection", "DISEASE", 552, 561], ["patients", "ORGANISM", 269, 277], ["patients", "ORGANISM", 515, 523], ["patients", "SPECIES", 269, 277], ["patients", "SPECIES", 515, 523], ["the IR workflow", "TEST", 70, 85], ["bedside US", "TEST", 188, 198], ["guided procedures", "TREATMENT", 199, 216], ["appropriate personal protective equipment", "TREATMENT", 329, 370], ["safe procedures", "TREATMENT", 408, 423], ["cross-infection", "PROBLEM", 469, 484], ["COVID", "TEST", 543, 548], ["no evidence of", "UNCERTAINTY", 528, 542], ["infection", "OBSERVATION", 552, 561]]], ["It needs to be highlighted that a main role for obtaining these results were played by rhino-pharyngeal swabs performed to all patients admitted to our hospital to undergo IR elective procedures.", [["pharyngeal swabs", "ANATOMY", 93, 109], ["patients", "ORGANISM", 127, 135], ["patients", "SPECIES", 127, 135], ["IR elective procedures", "TREATMENT", 172, 194], ["pharyngeal", "ANATOMY", 93, 103]]], ["Testing patients for COVID allowed us to avoid incidental room contamination and unprotected HCW exposure, creating three different dedicated routes for negative, doubt/unknown waiting for results, and positive patients.DiscussionThe main limitation of our study is represented by its retrospective and monocentric nature.", [["patients", "ORGANISM", 8, 16], ["patients", "ORGANISM", 211, 219], ["patients", "SPECIES", 8, 16], ["patients", "SPECIES", 211, 219], ["incidental room contamination", "PROBLEM", 47, 76], ["unprotected HCW exposure", "PROBLEM", 81, 105], ["our study", "TEST", 253, 262], ["main", "OBSERVATION_MODIFIER", 234, 238]]], ["However, our aim was not to suggest guidelines or measures to be applied everywhere, but only to perform a descriptive analysis and longitudinal study of IR activity in a tertiary care hospital during the COVID-19 pandemic.", [["a descriptive analysis", "TEST", 105, 127], ["longitudinal study", "TEST", 132, 150], ["the COVID", "TEST", 201, 210], ["pandemic", "PROBLEM", 214, 222]]], ["To the best of our knowledge, our study is the first work focused on analyzing real impact of COVID-related changes on IR service activity.", [["our study", "TEST", 30, 39]]], ["It is mandatory to underline that, in our experience, reduction of activity was most pronounced in the non-oncologic patient group: the long-term effects of this on the population remain to be seen, and may be the subject of future study.DiscussionIt is well known that there is no universal solution to healthcare during this crisis.", [["patient", "ORGANISM", 117, 124], ["patient", "SPECIES", 117, 124], ["future study", "TEST", 225, 237], ["universal solution", "TREATMENT", 282, 300], ["this crisis", "PROBLEM", 322, 333], ["long-term effects", "OBSERVATION_MODIFIER", 136, 153]]], ["However, IR services face the need to preserve the care for patients, as the duration of this pandemic is hard to predict [28].", [["patients", "ORGANISM", 60, 68], ["patients", "SPECIES", 60, 68]]], ["In this scenario, protection of patients and physicians is mandatory in order to keep providing the best service in a safe way, in particular when dealing with oncologic patients, which are frail and at high risk for infections.DiscussionIn conclusion, our study confirmed the high impact of coronavirus disease pandemic on the interventional radiology activity performed in our metropolitan tertiary-care hospital, with a significant reduction of IR procedures due to organizational changes implemented to comply with government directives.", [["infections", "DISEASE", 217, 227], ["coronavirus disease pandemic", "DISEASE", 292, 320], ["patients", "ORGANISM", 32, 40], ["patients", "ORGANISM", 170, 178], ["coronavirus", "ORGANISM", 292, 303], ["patients", "SPECIES", 32, 40], ["patients", "SPECIES", 170, 178], ["infections", "PROBLEM", 217, 227], ["our study", "TEST", 253, 262], ["coronavirus disease", "PROBLEM", 292, 311], ["IR procedures", "TREATMENT", 448, 461], ["organizational changes", "PROBLEM", 469, 491], ["infections", "OBSERVATION", 217, 227], ["coronavirus disease", "OBSERVATION", 292, 311], ["significant", "OBSERVATION_MODIFIER", 423, 434], ["reduction", "OBSERVATION_MODIFIER", 435, 444]]], ["However, our experience confirms that the interventional radiology continuum of care is needed and can be safely performed also during the pandemic emergency, following defined measures and protocols, taking care of all patients with disease, mainly represented, not just those affected by coronavirus disease.", [["coronavirus disease", "DISEASE", 290, 309], ["patients", "ORGANISM", 220, 228], ["coronavirus", "ORGANISM", 290, 301], ["patients", "SPECIES", 220, 228], ["protocols", "TREATMENT", 190, 199], ["disease", "PROBLEM", 234, 241], ["coronavirus disease", "PROBLEM", 290, 309], ["coronavirus", "OBSERVATION", 290, 301]]]]}